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Nuts and Dried Fruits: An Update of Their Beneficial Effects on Type 2 Diabetes








Christina M. Gant, S. Heleen Binnenmars, Else van den Berg, Stephan J. L. Bakker,
Gerjan Navis and Gozewijn D. Laverman
Integrated Assessment of Pharmacological and Nutritional Cardiovascular Risk Management:
Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente (DIALECT)
doi: 10.3390/nu9070709 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264
Charlotte E. Pelgrim, Bart A. A. Franx, Jessica Snabel, Robert Kleemann, Ilse A. C. Arnoldussen
and Amanda J. Kiliaan
Butyrate Reduces HFD-Induced Adipocyte Hypertrophy and Metabolic Risk Factors in
Obese LDLr-/-.Leiden Mice














About the Special Issue Editors
Peter Pribis, Dr., M.D., DR.P.H., is an Associate Professor of Nutrition and Dietetics in the Department
of Individual, Family & Community Education at the University of New Mexico. He graduated from
the School of Medicine at King Charles University in Prague, Czech Republic and from Loma Linda
University, School of Public Health with Dr. P.H. He is a Registered Dietitian and a member of the
Academy of Nutrition and Dietetics. He worked for nine years as the Director of the Master of Science
Program in Nutrition and Wellness at Andrews University in Michigan before moving to New Mexico.
Dr. Pribis has authored more than 20 articles for different health publications, one book chapter
for a nutrition book, 12 research articles for scholarly peer-reviewed journals, and co-authored two
cookery books. His research expertise is studying the potential of plant-based diets in preventing
chronic diseases and nutritional neuroscience. He is an enthusiastic speaker on the benefits of healthy
nutrition and a promoter of evidence-based lifestyle medicine.
Hana Kahleova, Dr., M.D., Ph.D., is a medical doctor specializing in internal medicine and
endocrinology and has a PhD in nutrition and diabetes. She has done several research studies on the
beneficial effects of plant-based diets in type 2 diabetes. Dr. Kahleova enjoys studying how metabolic
function works in regard to diet composition, meal timing, and frequency. She is the director of clinical














Preface to ”Nutrition and Diet Factors in Type
2 Diabetes”
Diabetes can be rightly called the new plague of the 21st century. It follows the pandemic of obesity,
usually with a delay of 5–10 years. Approximately seven million people develop diabetes in both
developed and developing countries every year, with the most dramatic increases occurring in Type
2 Diabetes (DM2). Global prevalence of DM2 is approximately 8% presently, and it is likely to grow
substantially in the next few decades. Especially alarming, is the rising incidence of DM2 in obese
children before puberty. Diabetes mellitus has become a major global public health problem. In April
2017, a Special Issue of Nutrients entitled “Nutrition and Diet Factors in Type 2 Diabetes” closed with
19 published papers—eight original studies on humans, five on animals, one brief report and five
reviews. The focus of the issue was on nutrition, diet factors, whole foods, broad dietary and lifestyle
strategies, dietary patterns, intensive personalized treatments, nutritional prevention programs, and
food policies that can be used in the development, treatment, and prevention of DM2.
The five animal studies presented covered a wide array of topics. Xiao et al. provided novel
evidence that maternal low-protein diet may be associated with chronic inflammation in the offspring.
Pelgrim et al. suggested that butyrate, Liu et al. suggested that leucine, and Almomen et al. suggested
that grape powder might be beneficial and attenuate diabetes risk factors. Burgeiro et al. described the
liver glucose and lipid dysmetabolism in an animal prediabetes model induced by high-sucrose diet.
As for the human studies: Jablonska et al.‘s study suggests that selenium may affect glycemic
control at different levels of gene regulation, linked to insulin signaling, glycolysis and pyruvate
metabolism. Jacobo-Cejudo et al. reported that n-3 PUFA supplementation had a beneficial effect on
some selective DM2 risk factors. A descriptive study of Canadians by Bertinato et al. discovered that a
substantial portion of the population is hypomagnesaemic which can be negatively associated with
diabetes, glycemic control and insulin resistance.
Simple interventions such as the inclusion of fiber-rich functional bread into the diet (Tessari et al.)
or avoidance of large amounts of carbohydrates from high-glycemic index sources in the evening
(Diederichs et al.), as reported by the DONALD study, should be considered as preventive dietary
strategies. Studying the black South African population, Chikowore et al. concluded that plant driven
nutrient patterns are associated with low fasting glucose and glycated hemoglobin levels. Veleba
et al.‘s study suggests that in DM2 patients, a vegetarian diet led to more effective improvement in
physical fitness than a conventional diet.
There are two reports from large European-based cohorts. Fogelholm et al. described the design,
methodology and baseline characteristics of the PREVIEW project that was initiated to find the most
effective lifestyle for the prevention of DM2; while Gant at al. reported results from the DIALECT
project that suggest that incorporating nutrition management in routine care would greatly improve
the treatment quality.
As for the five reviews: Fang et al. concluded that combined data support the role for magnesium
in reducing risk of DM2; Luo et al. concluded that there is evidence for an association between vitamin
D deficiency and an increased risk of diabetic retinopathy in DM2 patients; and Hernández-Alonso et
al. suggest that nuts and dried fruits could play a significant role in the prevention and treatment of
insulin resistance and DM2; Kosinski et al. discussed the role and safety of ketogenic diets in animals









Nutrition and Diet Factors in Type 2 Diabetes is written for clinical and academic nutritionists,
for registered dietitians, health professionals, graduate students, and for everybody with a deeper
interest in diabetes care. Studies and reviews presented here demonstrate that diabetes research is
extensive and vibrant and the prevention, treatment and reversal of diabetes are achievable, economical,
powerful, and possible.























“A Vegetarian vs. Conventional Hypocaloric Diet:
The Effect on Physical Fitness in Response to Aerobic
Exercise in Patients with Type 2 Diabetes.” A Parallel
Randomized Study
Jiri Veleba 1, Martin Matoulek 2, Martin Hill 3, Terezie Pelikanova 1 and Hana Kahleova 1,*
1 Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague, Czech Republic;
jivb@ikem.cz (J.V.); tepe@ikem.cz (T.P.)
2 General University Hospital, 3rd Internal Clinic of Endocrinology and Metabolism,
12808 Prague, Czech Republic; mmato@vstj.cz
3 Institute of Endocrinology, Narodni 8, 11394 Prague, Czech Republic; mhill@endo.cz
* Correspondence: hana.kahleova@gmail.com; Tel.: +420-261-362-150; Fax: +420-261-362-820
Received: 26 July 2016; Accepted: 17 October 2016; Published: 26 October 2016
Abstract: It has been shown that it is possible to modify macronutrient oxidation, physical fitness
and resting energy expenditure (REE) by changes in diet composition. Furthermore, mitochondrial
oxidation can be significantly increased by a diet with a low glycemic index. The purpose of
our trial was to compare the effects of a vegetarian (V) and conventional diet (C) with the same
caloric restriction (−500 kcal/day) on physical fitness and REE after 12 weeks of diet plus aerobic
exercise in 74 patients with type 2 diabetes (T2D). An open, parallel, randomized study design
was used. All meals were provided for the whole study duration. An individualized exercise
program was prescribed to the participants and was conducted under supervision. Physical fitness
was measured by spiroergometry and indirect calorimetry was performed at the start and after
12 weeks Repeated-measures ANOVA (Analysis of variance) models with between-subject (group)
and within-subject (time) factors and interactions were used for evaluation of the relationships
between continuous variables and factors. Maximal oxygen consumption (VO2max) increased by
12% in vegetarian group (V) (F = 13.1, p < 0.001, partial η2 = 0.171), whereas no significant change
was observed in C (F = 0.7, p = 0.667; group × time F = 9.3, p = 0.004, partial η2 = 0.209). Maximal
performance (Watt max) increased by 21% in V (F = 8.3, p < 0.001, partial η2 = 0.192), whereas it did not
change in C (F = 1.0, p = 0.334; group × time F = 4.2, p = 0.048, partial η2 = 0.116). Our results indicate
that V leads more effectively to improvement in physical fitness than C after aerobic exercise program.
Keywords: insulin sensitivity; maximal oxygen consumption; maximal performance; physical fitness;
type 2 diabetes; vegetarian diet
1. Introduction
Dietary intervention and physical exercise are both cornerstones in the treatment of type 2 diabetes
(T2D) patients [1]. A vegetarian diet is a promising way to reduce energy intake by consuming foods
with a low energy density, with a fair degree of patient adherence [2,3].
The superior effects of a vegetarian diet on body weight, glycemic control, blood lipids, insulin
sensitivity and oxidative stress markers compared with a conventional diet have been shown by us
and others previously [2–4]. A vegetarian diet was also reported to reduce the content of intramuscular
lipids [5].
Physical activity combats insulin resistance by several different mechanisms: by influencing
changes in body composition such as reducing fat mass and volume of visceral fat and increasing
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fat-free mass, by enhancing insulin-stimulated glucose disposal in skeletal muscle, morphological
changes in muscle, and by decreased glucose production in the liver [6]. To the best of our knowledge,
a direct comparison between the effect of a vegetarian diet and a conventional hypocaloric diet on
physical fitness and resting energy expenditure (REE) in subjects with T2D during aerobic exercise
training has not yet been performed.
It has been shown that it is possible to modify macronutrient oxidation, physical fitness and resting
energy expenditure (REE) by changes in diet composition. Furthermore, mitochondrial oxidation can
be significantly increased by a diet with a low glycemic index. The aim of this secondary analysis
was to compare the effects of vegetarian (V) and conventional diabetic diet (C) with the same caloric
restriction (−500 kcal/day) on physical fitness and REE after 12 weeks of diet plus aerobic exercise in
patients with type 2 diabetes (T2D).
2. Experimental Section
The characteristics of our study population and the methods can be found elsewhere [3].
Briefly: In the context of a randomized, open, parallel design, 74 patients with T2D treated by oral
hypoglycemic agents, both men (47%) and women (53%) were randomly assigned either into the
vegetarian group (V, n = 37) or the control group (C, n = 37) treated by conventional diet. Both diets were
calorie-restricted (−500 kcal/day) according to the indirect calorimetry measurement [7]. The dietary
interventions were combined with aerobic exercise for 12 weeks, performed under professional
supervision. All meals were provided for the whole study duration. The study protocol was
approved by the Institutional Ethics Committee of the Thomayer Hospital and Institute for Clinical
and Experimental Medicine, Prague, Czech Republic. (The approval code is G-08-08-22.)
2.1. Diet
The vegetarian diet (~60% of energy from carbohydrates, 15% protein, and 25% fat) was based
on whole plant foods (whole grains, legumes, vegetables, fruits and nuts). Animal products were
rectricted to one portion of low-fat dairy a day. The composition of the conventional diabetic diet met
the dietary guidelines of the Diabetes and Nutrition Study Group (DNSG) of the European Association
for the Study of Diabetes (EASD) [8]. It derived 50% of energy from carbohydrates, 20% protein,
less than 30% fat (≤7% energy from saturated fat, less than 200 mg/day of cholesterol/day).
2.2. Exercise
An individualized exercise program was prescribed to the participantsbased on previous physical
activity and spiroergometry. Aerobic exercise was performed twice a week at 60% of maximal heart
rate for 1 h under professional supervision at the sports center, and the third weekly session took place
either at the sports center or at home. The participants used a sport-tester and a pedometer.
2.3. Medication
No changes in medication use were made, except for the case of repeated hypoglycemia (plasma
glucose determined at the laboratory <4.4 mmol·L−1 or capillary glucose reading <3.4 mmol·L−1
accompanied by hypoglycemic symptoms). In this case, medications were reduced by a study
physician following a standard protocol. All participants used an Accu-Chek Go glucometer (Roche,
Basel, Switzerland).
2.4. Adherence
All visits to pick up meals were recorded. Three-day dietary records (two weekdays and one
weekend day) were completed by each participant at baseline and at week 12, and analyzed by
a registered dietician. High adherence was defined as the average daily energy intake being no
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Additional criteria for high adherence to vegetarian diet were the average daily cholesterol intake
≤50 mg, for medium adherence less than 100 mg. In the control group, the average daily cholesterol
limit was ≤200 mg for high adherence, and less than 300 mg for medium adherence.
Adherence to the exercise program was defined as more than 75% of prescribed visits at the sports
center (18/24).
2.5. Hunger and Depressive Symptoms
Hunger and depressive symptoms were assessed using the Three-Factor Eating Questionnaire [9]
and the Beck Depression Inventory [10], respectively.
2.6. Statistical Analysis
The intention-to-treat analysis was used, and all participants were included. To eliminate skewed
data distribution and heteroscedasticity, the original data was transformed to a Gaussian distribution
before further processing by a power transformation using the statistical software Statgraphics
Centurion, version XV from Statpoint Inc. (Herndon, Virginia, VA, USA). Non-homogeneities in
the data were detected using residual analysis. Repeated-measures ANOVA (Analysis of variance)
models with between-subject (group) and within-subject (time) factors and interactions were used.
Factors of treatment group, subject and time were included in the model. Interactions between group
and time (group × time) were calculated for each variable.
Paired t-tests were calculated within each group, to check the significance of changes from
baseline. Bonferroni post-hoc correction for seven variables implies that p-values < 0.007 can be
considered significant.
3. Results
Data are presented as means with 95% confidence intervals. Maximal performance (Watt max)
increased by 21% in vegetarian group (V) (F = 8.3, p < 0.001, partial η2 = 0.192), whereas it did not
change in control group (C) (F = 1.0, p = 0.334; group × time F = 4.2, p = 0.048, partial η2 = 0.116;
Figure 1A). Maximal oxygen consumption (VO2max) increased by 12% in V (F = 13.1, p < 0.001, partial
η2 = 0.171), whereas it did not change significantly in C (F = 0.7, p = 0.667; group × time F = 9.3,
p = 0.004, partial η2 = 0.209; Figure 1B). REE remained constant in V (F = 0.6, p = 0.556), whereas
it decreased in C (F = 4.1, p = 0.032, partial η2 = 0.113; group × time F = 2.8, p = 0.067; Figure 1C).
The respiratory quotient did not change significantly in either group (F = 2.7, p = 0.0673 for V, and
F = 1.5, p = 0.224 for C; group × time F = 0.4, p = 0.666; Figure 1D). No change in fasting oxidation of fat
was observed in either group (F = 0.3, p = 0.742 for V, and F = 1.1, p = 0.318 for C; group × time F = 0.4,
p = 0.658; Figure 1E). Fasting oxidation of carbohydrates decreased in C by 89% (F = 3.8, p = 0.01, partial
η2 = 0.029), while it did not change in V (F = 0.2, p = 0.865; group × time F = 4.0, p = 0.024; partial
η2 = 0.139; Figure 1F). Fasting oxidation of protein did not change in either group (F = 0.3, p = 0.742 for
V, and F = 1.4, p = 0.259 for C; group × time F = 2.6, p = 0.082; Figure 1G).
Adherence
The diet adherence was high among 55% of participants in V and 32% in C, medium among 22.5%
in V and 39% in C, and low among 22.5% in V and 29% in C. Adherence to the exercise program was
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Figure 1. Changes in physical fitness in response to a vegetarian (V, full line and full circles) and
conventional diet (C, dashed line and empty circles). Data are means ± 95% confidence intervals.
Significant changes from baseline to 12 weeks within groups assessed by paired comparison t-tests are
indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001. p-values for the interaction between
factors group (vegetarian and control group) and time (0 and 12 weeks) assessed by repeated measures.
ANOVA are: p = 0.048 for maximal performance (A), p = 0.004 for maximal oxygen consumption,
VO2max (B), p = 0.067 for resting energy expenditure (C), p = 0.666 for respiratory quotient (D), p = 0.793
for fasting oxidation of fats (E), p = 0.024 for fasting oxidation of carbohydrates (F), and p = 0.082 for
fasting oxidation of protein (G).
4. Discussion
Our results show a slight improvement in physical fitness after a 12-week aerobic training program
with a vegetarian diet compared with a conventional hypocaloric diet. David Nieman demonstrated
in his review in 1999 [11] that vegetarianism and veganism do not diminish physical fitness. Several
studies showed that endurance athletes and marathon runners might benefit from plant-based diets
with an emphasis on high-carbohydrate and antioxidant-rich foods such as pasta, grains, cereals,
legumes, vegetables, and dried fruits [12,13].
Numerous comparative studies reveal no fundamental differences in morphological or enzymatic
equipment of skeletal muscle in vegetarians/vegans compared to omnivores [14,15]. In our study,
we showed that visceral fat decreased more in V compared to C [3]. This might suggest the possible
decrease of ectopic fat in the muscle, potentially related to improved physical fitness. Several studies
reported lower levels of intramyocellular fat in vegetarians/vegans, implying their improved insulin
sensitivity. However, the impact of this finding on physical fitness is unclear. Given the described
athlete's paradox [6], where trained athletes have more intramyocellular fat than healthy subjects, and
even more than those with type 2 diabetes, it is questionable if lower intramyocellular fat content can
be expected to be related to better fitness.
Abete et al. showed that a diet with a lower glycemic index increases mitochondrial oxidation [16],
which corresponds with our findings. Plant-based diets with an emphasis on whole plant foods have
a low glycemic index due to the high fiber content [17]. In addition, it seems that participants in V
were able to better utilize carbohydrates compared to the control group. Together with the increased
insulin sensitivity demonstrated previously [3], these are markers of improved metabolic flexibility,
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Besides physiological mechanisms, we need to mention the potential role of psychological factors.
We observed reduced hunger and a reduced Beck depressive score in V [18], pointing to a higher
executive potential including a positive attitude toward exercise. This hypothesis is also supported by
lower levels of leptin in V [3], which may potentiate readiness for physical activity through the central
nervous system [19].
The strengths of the study are represented by the randomized, parallel design, providing all meals,
and exercising under professional supervision. The study duration was reasonably long, allowing
sufficient time for tracking the changes in response to the diet and exercise. However, the number
of subjects and study duration preclude generalizing our study for free-living conditions. Further
larger-scale, long-term studies are essential before offering recommendations in terms of vegetarian
diet during aerobic exercise.
5. Conclusions
In conclusion, our results indicate that V leads more effectively to improvement in physical
fitness than C after an aerobic exercise program. We have also observed a decrease in REE only in
C in response to aerobic exercise. The lower glycemic index of V, the higher fasting oxidation of
carbohydrates, and the possible increase in mitochondrial oxidation may be partly responsible for
a trend toward greater REE with V after aerobic exercise. V might be a more convenient alternative in
the nutritional treatment of T2D during an aerobic exercise program.
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Abstract: The epidemiological evidence for a dose-response relationship between magnesium intake
and risk of type 2 diabetes mellitus (T2D) is sparse. The aim of the study was to summarize
the evidence for the association of dietary magnesium intake with risk of T2D and evaluate the
dose-response relationship. We conducted a systematic review and meta-analysis of prospective
cohort studies that reported dietary magnesium intake and risk of incident T2D. We identified
relevant studies by searching major scientific literature databases and grey literature resources from
their inception to February 2016. We included cohort studies that provided risk ratios, i.e., relative
risks (RRs), odds ratios (ORs) or hazard ratios (HRs), for T2D. Linear dose-response relationships
were assessed using random-effects meta-regression. Potential nonlinear associations were evaluated
using restricted cubic splines. A total of 25 studies met the eligibility criteria. These studies comprised
637,922 individuals including 26,828 with a T2D diagnosis. Compared with the lowest magnesium
consumption group in the population, the risk of T2D was reduced by 17% across all the studies;
19% in women and 16% in men. A statistically significant linear dose-response relationship was
found between incremental magnesium intake and T2D risk. After adjusting for age and body
mass index, the risk of T2D incidence was reduced by 8%–13% for per 100 mg/day increment in
dietary magnesium intake. There was no evidence to support a nonlinear dose-response relationship
between dietary magnesium intake and T2D risk. The combined data supports a role for magnesium
in reducing risk of T2D, with a statistically significant linear dose-response pattern within the
reference dose range of dietary intake among Asian and US populations. The evidence from Europe
and black people is limited and more prospective studies are needed for the two subgroups.
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1. Introduction
Type 2 diabetes mellitus (T2D) represents a growing public health burden across the world and
is a leading cause of death. In 2013, an estimated 340 million people worldwide had T2D and this
number is expected to increase to 400 million or more by 2030 [1,2]. Obesity and diet are widely
believed to play an important role in the development of T2D [3,4]. Magnesium is the most abundant
divalent intracellular cation, the second most abundant cellular ion next to potassium and the fourth
cation in general in the human body. Of the 21–28 g of magnesium present in the adult human
body, 99% is distributed in the intracellular compartment, and only 1% in the extracellular fluid [5].
Magnesium has received considerable interest for its potential in improving insulin sensitivity and
preventing diabetes [6–9]. T2D is often accompanied by altered magnesium status. An increased
prevalence of magnesium deficit has been identified in T2D patients, especially in those with poorly
controlled glycemic profiles, longer duration of disease and the presence of micro- and macro-vascular
chronic complications [10–12]. A number of prospective cohort studies of magnesium intake and
diabetes incidence have been conducted [7,13–24] and statistically significant negative associations
between magnesium intake and risk of T2D were reported in previous meta-analyses [25–27]. However,
these meta-analyses did not examine whether the association was confounded by other established
risk factors such as being overweight and other factors highly associated with magnesium intake,
such as amount of cereal fiber, and whether the relationship is linear.
During the past few years, the number of studies on this topic has increased. With mounting
evidence, we conducted a meta-analysis of prospective cohort studies for the following purpose:
(1) to update the epidemiological evidence on the association between magnesium intake and T2D
risk; (2) to evaluate the association according to characteristics of study designs and population;
and (3) to examine the linear and nonlinear dose-response pattern of magnesium intake and T2D risk.
2. Materials and Methods
The protocol for this systematic review was registered in the PROSPERO database of prospectively
registered systematic reviews in February 2016 (www.crd.york.ac.uk/PROSPERO; CRD42016033519).
The completed review conforms to the standard criteria PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analysis) and MOOSE (Meta-analysis of Observational Studies in
Epidemiology) [28,29].
2.1. Data Sources and Searches
We conducted a systematic review for all population-based studies that evaluated the association
of magnesium intake with T2D. We searched Pubmed (http://www.ncbi.nlm.nih.gov/), Web of
Science (http://webofscience.com/), ScienceDirect (http://www.sciencedirect.com/) and China
Knowledge Resource Integrated Database (http://oversea.cnki.net/kns55/default.aspx) and the
Cochrane Library (http://www.cochranelibrary.com/) from their inception to 29 February, 2016.
The later cut-off date to 30 June 2016 was subsequently revised to include the latest published
studies. To avoid publication bias, we also used the National Library of Medicine Gateway
(https://gateway.nlm.nih.gov/), Virtual Health Library (http://pesquisa.bvsalud.org/portal/),
the System for Information on Grey Literature in Europe (http://www.opengrey.eu/), the National
Academic Research and Collaborations Information System (http://www.narcis.nl/?Language=en)
and Grey Literature Report (www.greylit.org) to find potential unpublished relevant studies.
Key search terms included magnesium intake, type 2 diabetes, diabetes mellitus, prospective study,
longitudinal study, cohort study, and nested case-control study, combined with incidence or risk.
These searches were supplemented by hand-searching of the reference lists of identified research
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2.2. Inclusion Criteria
We only included original research in this meta-analysis. Reviews, editorials, commentaries
and letters were not eligible. All population-based cohort studies (including nested case-control
studies) were included if they fulfilled the following criteria: (1) had a prospective study design;
(2) the doses of magnesium intake (dietary and supplemental) were reported; (3) the endpoint of
interest was incidence of T2D; (4) the risk ratio was reported such as relative risk (RR), odds ratio (OR)
or hazard ratio (HR), as well as the associated 95% confidence interval (CI) or other data to estimate the
variance or accuracy (standard deviation or standard error) were reported; (5) the risk assessment had
to be adjusted for potential confounding factors or by other forms of standardization (if applicable).
For multiple studies using the same population, only the study with the largest number of events or
with adjustment for additional potential confounders was included. Studies were excluded if they:
(1) focused on the populations with disrupted mineral homeostasis (such as patients with heart failure
or kidney disease); (2) were narrative reviews, editorial papers, methodological papers, experimental
studies, case control or cross-sectional; (3) assessed type 1 diabetes; (4) identified a dietary pattern
that did not fit into healthy or unhealthy dietary pattern categories; (5) evaluated magnesium only in
drinking water or had no reliable magnesium estimates. For included studies only in abstract form,
we tried to contact authors to obtain the necessary estimates or risks and relevant accuracy.
2.3. Quality Assessment and Data Extraction
Computerized bibliographic searches of pre-determined literature databases used an optimized
version of the Cochrane Collaboration search strategy [30]. Three investigators (X.F., C.L. and M.L.)
screened all the identified titles and abstracts for relevance (n = 2858). Full papers were downloaded
for all the abstracts judged potentially relevant (n = 60). No new studies were identified among the
cited references of all included articles. Of 60 full-text articles reviewed independently, we excluded
35 studies for the following reasons: they were not prospective studies (n = 14); outcomes were not
T2D (n = 9); did not report dietary magnesium (n = 7); did not assess the risk (n = 3); or duplicated
another study (n = 1). All papers identified through the screening process were assessed for relevance
independently by two investigators (C.L. and M.L.) using standardized study assessment and a sorting
form. The studies were evaluated and scored based on the guidelines adapted from the tools for
assessing quality and susceptibility to bias in observational studies in epidemiology [31]. Inter-rater
agreement was substantial (Cohen κ > 0.6) [32]. No studies were excluded by the quality assessment.
In total, 25 studies met the inclusion criteria and were included in the meta-analysis.
Full papers were obtained for all abstracts judged potentially relevant. Data extraction was
conducted independently by two investigators (X.F. and M.L.) with the use of a standardized electronic
form in Microsoft Excel. The following data were extracted from each study: first author’s surname;
study design; location; year the study started, finished and was published; age; sex; ethnicity; sample
size (number of those with T2D and the total number of participants); diseases present at baseline
(hypertension or hypercholesterolemia, etc.); magnesium intake modes (dietary or supplemental)
and dose; as well as covariates adjusted for in the multivariable analysis. For magnesium intake,
data on assessment method used (food frequency questionnaire, dietary recall, other) and whether the
data were energy-adjusted (yes, no) were obtained. For each study, the median magnesium intake
for each quantile (tertile, quartile or quintile) of magnesium intake was assigned as the representative
dose. When the median intake per quantile was not provided, we assigned the midpoint of lower
and upper boundaries in each quantile as the average intake. If the lower or upper boundary for the
lowest or highest quantile, respectively, was not reported, we assumed that the boundary has the same
amplitude as the closest quantile. The increment of dietary magnesium intake was calculated as the
difference between the representative dose of the higher quantiles and the representative dose of the
control quantile.
For each dose quantile, we extracted RR, OR or HR with their measure of uncertainty (standard
error) or variance (95% CI). Risk estimates for continuous exposure were also extracted. If estimates
were presented for more than one multivariate model, we only extracted estimates from the model
maximally adjusted for potential confounding variables to ensure a conservative conclusion. Because
there are studies based on the same cohort but conducted at different times, they shared the T2D
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2.4. Statistical Analysis
We used OR and HR as RR in our pooled analysis because when event rates are small, the OR,
HR and RR approximate one another [33]. We estimated a pooled risk with 95% CI for a 100 mg/day
increase in daily magnesium intake for the studies. To maximize all the data for calculating the
pooled dose-response, the restricted maximum likelihood (REML) approach proposed by Harbord [34],
which provides improved estimation of the between-study variance, was used to compute the linear
trend of the log transformed risk estimates across magnesium intake doses. We also performed
subgroup analysis by level of magnesium intake increment, sex, geographic area and adjustment.
The Higgins’s I2 statistic, a quantitative measure of inconsistency, was calculated to evaluate
the statistical heterogeneity across the studies [35]. I2 > 30% was considered as at least moderate
heterogeneity. In view of substantial heterogeneity being detected, we presented the pooled estimates
based on the random-effects model.
Potential publication bias was assessed by Egger’s test [36]. Because the sample sizes of reference
groups and comparative groups were balanced in all the studies, we used Harbord’s modification to
Egger’s test to reduce the false-positive rate [37]. The results were also confirmed by Begg’s test [38]
and Peters’s test [39].
Potential nonlinear associations were assessed using restricted cubic splines; we used four knots
at fixed percentiles 5%, 35%, 65% and 95% of the distribution [40]. The study-specific estimates were
pooled by using the REML method in a random-effects meta-analysis [41].
We also conducted a sensitivity analysis to investigate the influence of a single study on the
overall risk estimate by dropping one study in each turn. We performed all analyses in Stata
(version 14.1; Stata Corp., College Station, TX, USA). A p value < 0.05 was considered statistically
significant, except where otherwise specified.
3. Results
3.1. Eligible Studies and Characteristics
Our literature search identified 25 studies from 17 cohorts that met the eligibility criteria
(Figure 1). These studies were published between 1997 and 2014 and comprised 637,922 individuals
and 26,828 T2D cases after excluding duplicated cohorts (Table 1). There were 16 studies conducted in
the U.S. (including Hawaii), two in Europe (Italy and Germany), and seven in Asia (five in Japan and
two in China). Studies treated dietary calcium [42–44], red/processed meat [45,46], whole grain [47],
fiber [14,15,48], vitamin D [43,44], carbohydrates [14], coffee [49] or glycemic load [15,48,50] as main
exposures, but also reported dietary magnesium intakes which were included in our meta-analysis.
The main endpoints of two studies were impaired insulin metabolism [7] and insulin resistance [22],
but both studies also reported the incidence of T2D. Participants were predominately middle-aged at
baseline, with a mean age of 51.2 years and a mean BMI of 25.0 kg/m2 across the studies. The length
of the follow-up period ranged from four to 20 years.
Dietary intake of magnesium was evaluated by food frequency questionnaires (FFQs) in all the
studies and 13 studies indicated that the questionnaires were validated. The median magnesium
intake of the different dose groups ranged from 115 mg/day in U.S. black women [18] (much lower
than the US Recommended Dietary Allowance of 400 mg/day for men and 310 magnesium for
women >30 years [51]) to 478 mg/day in a U.S. population [22]. T2D was ascertained by self-report
and 21 studies indicated that the self-reported diagnoses were validated.
For the 16 studies with the magnesium as the main exposure, although the degree of covariate and
confounder adjustment varied in the multivariate models, most studies adjusted for age, body mass
index (BMI), total energy intake, smoking, physical activity, family history of diabetes and hypertension;
fewer studies adjusted for intake of calcium or other nutrition supplement and education attainment.
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Figure 1. Screening and selection of articles on dietary magnesium intake and risk of type 2
diabetes mellitus.
3.2. Dietary Magnesium Intake and Type 2 Diabetes Mellitus (T2D) Incidence
We divided the increment of dietary magnesium intake into four categories, i.e., <50 mg/day,
50–99 mg/day, 100–149 mg/day and ≥150 mg/day, by subtracting the reference doses from the
compared doses. Heterogeneity was found by Higgins’s test, with I2 = 73.3% (p < 0.001) for all
compared doses, and 67.2% (p < 0.001), 75.0% (p < 0.001), 52.3% (p = 0.005) and 54.5% (p = 0.031) for
four increment categories, respectively. However, the approximately symmetric funnel plot of all
but four doses suggests a moderate homogeneity among the studies (Figure 2). Although there is
evidence of publication bias among all compared doses for Egger’s test (p = 0.002), Begg’s, Harbord’s
and Peters’s tests show no evidence of publication bias (p = 0.170, 0.401 and 0.105, respectively).
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The overall combined RR for T2D incidence is 0.83 (95% CI: 0.80, 0.86; p < 0.001) for all compared
doses. The results of subgroup analysis are presented in Table 2. A statistically significant negative
association between dietary magnesium and risk of T2D incidence was observed across sexes and
the pooled RRs are 0.81 (95% CI: 0.77, 0.86) for women, 0.84 (95% CI: 0.80, 0.88) for men, and 0.85
(95% CI: 0.78, 0.94) for the studies that only reported sex-combined risk estimates. The association
was statistically significant in all the study areas and the largest magnitude association was found
among U.S. studies (pooled RR = 0.82 in U.S. vs. 0.86 in Europe and 0.85 in Asia), compared with the
unadjusted associations (pooled RR = 0.81; 95% CI: 0.74, 0.88), with lower magnitude after adjustment
(pooled RR = 0.83; 95% CI: 0.81, 0.86). Two studies investigated the association specially in black people
and showed a statistically significant association (pooled RR = 0.82; 95% CI: 0.71, 0.94), however, it
seems this is mainly observed among black women [18] rather than black men [13].
Table 2. Pooled RRs * for T2D incidence of increased dietary magnesium intake by sex, area
and adjustment.
Subgroup
No. of Studies (Dose
Quantiles)
RR (95% CI) I2 (%) Heterogeneity-p
Sex
Women 17 (58) 0.814 (0.774, 0.856) 82.4 <0.001
Men 7 (25) 0.838 (0.803, 0.876) 25.7 0.120
Both 7 (26) 0.854 (0.775, 0.941) 46.7 0.005
Area
U.S. 16 (67) 0.817 (0.780, 0.857) 81.7 <0.001
Europe 2 (5) 0.858 (0.774, 0.951) 0 0.498
Asia 7 (37) 0.846 (0.811, 0.883) 10.2 0.294
Adjustment
Adjusted † 16 (76) 0.830 (0.806, 0.855) 39.6 <0.001
Crude ‡ 9 (33) 0.808 (0.741, 0.881) 87.8 <0.001
Black people 2 (7) 0.815 (0.711, 0.935) 59.3 0.022
* Random-effects model was used; † Adjusted for age, BMI, energy intake, smoking, alcohol, physical
activity, calcium, sugar, soft drink, red meat family and/or other dietary intakes, and/or family history,
sociodemographic factors; ‡ Simple risk ratio without any adjustment.
The dose-category-specific pooled RRs for T2D incidence from the included studies are shown
in Figure 3a–d, which are 0.88 (95% CI: 0.85, 0.92), 0.81 (95% CI: 0.76, 0.86), 0.77 (95% CI: 0.70,
0.83) and 0.72 (95% CI: 0.61, 0.84) for increment <50 mg/day, 50–99 mg/day, 100–149 mg/day
and ≥150 mg/day, respectively. In general, the RR decreases 4% to 7% per 50 mg/day increment
(equivalent to 8% to 14% per 100 mg/day increment) in dietary magnesium intake.
3.3. Linear Dose-Response Relationship
After adjusting for age and BMI in random-effects meta-regression models, a statistically
significant linear dose-response relationship between incremental dietary magnesium intake and
T2D incidence was found across all the studies (see Table 3 and Figure 4). The RRs (95% CI) for the
association of a 100 mg/day increment in dietary magnesium intake with T2D incidence are 0.92
(95% CI: 0.85, 0.99) and 0.88 (0.80, 0.97) for including and excluding one extreme dose, respectively.
The statistically significant linear dose-response relationship was also found for men (RR = 0.87; 95%
CI: 0.77, 0.98) but not for women (RR = 0.88; 95% CI = 0.76, 1.02). Regarding study areas, significantly
linear dose-response relationship was only found in Asia (RR = 0.87; 95% CI: 0.77, 0.98). No significant
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Figure 3. Relative risks (RRs) for risk of T2D incidence for different dietary magnesium increment
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Table 3. Estimated RRs for T2D incidence per 100 mg/day increment in dietary magnesium intake,
adjusted for age and BMI.
No. of Studies (Doses) I2 (%) RR (95% CI) p-Value
All studies 25 (105) 69.72 0.916 (0.852,0.985) 0.018
All studies * 24 (104) 69.13 0.882 (0.803,0.969) 0.010
Sex
Women 17 (56) 78.87 0.879 (0.756,1.023) 0.094
Men 7 (23) 0 0.865 (0.767,0.975) 0.020
Both 7 (26) 26.51 0.935 (0.853,1.026) 0.148
Both * 6 (25) 29.00 0.857 (0.695,1.057) 0.141
Area
U.S. 16 (63) 79.09 0.910 (0.796,1.042) 0.169
Europe 2 (5) 0 1.071 (0.264,4.351) 0.644
Europe * 1 (4) - - -
Asia 7 (37) 0 0.867 (0.768,0.978) 0.022
Adjustment
Adjusted 16 (72) 25.73 0.911 (0.864,0.961) 0.001
Adjusted * 15 (71) 24.09 0.885 (0.830,0.944) <0.001
Crude 9 (33) 85.14 0.653 (0.462,0.924) 0.018
Black people 2 (7) 0 0.747 (0.232,2.409) 0.486








Nutrients 2016, 8, 739
Figure 4. Dose-response relationship between risk of T2D incidence and incremental dietary
magnesium intake (excluding one extreme dose). The size of the bubble reflects the study-specific
analytical weight, i.e., the inverse of the variance.
In general, the risk of T2D incidence decreases by 8% (across all studies) to 13% (in the Asian
population) per 100 mg/day increment in dietary magnesium intake, which is consistent with the
result from dose-category-specific analysis.
3.4. Nonlinear Dose-Response Relationship
We found no evidence of nonlinear associations between dietary magnesium intake and T2D
incidence across all the studies with (p = 0.665) or without (p = 0.980) one extreme dose (Figure 5),
adjusting for age and BMI. For subgroup analysis, no evidence of nonlinear association was found
for women (p = 0.637), men (p = 0.790), sex-combined (p = 0.987), black people (p = 0.787), U.S.
population (p = 0.686), Asian population (p = 0.519), adjusted RRs (p = 0.663) and crude RRs (p = 0.250),
which suggested that pooling the dose-response estimates from linear trend estimation for dietary
magnesium intake and T2D incidence was appropriate. Because of insufficient dose observations,
no nonlinear association was evaluated for European studies.
Figure 5. Examination of nonlinear association between increment in dietary magnesium intake and
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3.5. Sensitivity Analysis
Regarding the combined risk of T2D incidence for all studies, the sensitivity analysis omitting
one study at a time yielded statistically significant RRs within a very narrow range from 0.82 (95% CI:
0.79, 0.84) to 0.84 (95% CI: 0.81, 0.87). The subgroup analyses also showed robust results for women
(RR range: 0.80, 0.84), men (RR range: 0.83, 0.85), sex-combined (RR range: 0.79, 0.88), U.S. population
(RR range: 0.80, 0.84), Asian population (RR range: 0.83, 0.85), adjusted RRs (RR range: 0.82, 0.84)
and crude RRs (RR range: 0.78, 0.86). However, because of a limited number of studies in Europe
and black people, the sensitivity analysis generated relatively wide ranges for these two subgroups.
The RR ranges were from 0.73 (95% CI: 0.51, 1.04) to 0.87 (95% CI: 0.78, 0.97) and from 0.76 (95% CI:
0.67, 0.85) to 1.17 (95% CI: 0.88, 1.54) for European studies and black people, respectively.
The sensitivity analyses for linear and nonlinear dose-response relationships between incremental
dietary magnesium intake and the risk of T2D incidence show similar results. The RRs of linear
dose-response relationship across all the studies are statistically significant and range from 0.88
(95% CI: 0.80, 0.97) to 0.93 (95% CI: 0.87, 1.00) when omitting one study at a time. The p-values for
a nonlinear dose-response relationship across all studies range from 0.52 to 0.96 when omitting one
study at a time. The results for subgroup analysis also change little except for European studies and
black people (data not show). Overall, the results from sensitivity analyses indicate the robustness of
our findings.
4. Discussion
This meta-analysis of 25 prospective studies showed a statistically significant negative association
between dietary magnesium intake and T2D incidence. Compared with the lowest dietary magnesium
consumption groups in the populations, the risk of T2D could be reduced by 19% in women and 16% in
men (Table 2). The largest reduction of risk was observed for the U.S. population (18%). A statistically
significant linear dose-response relationship was found between incremental dietary magnesium
intake and T2D incidence across all the studies, in male and Asian populations, adjusting for age
and BMI. The risk of T2D was associated with a reduction of 8%–13% per 100 g/day increment in
dietary magnesium intake. After adjusting for age and BMI, we did not find a statistically significant
nonlinear dose-response relationship of incremental dietary magnesium intake with T2D risk.
The present systematic review, which includes a total of 637,922 participants and 26,828 T2D cases,
provides the most robust evidence to date of the linear dose-response relationship between incremental
dietary magnesium intake across its physiological range and risk of T2D.
4.1. Dose-Response Association of Dietary Magnesium Intake with T2D Incidence
A putative protective effect of magnesium intake against T2D incidence has been reported
previously [13,14]. The negative association between magnesium intake and T2D incidence is
biologically plausible and may be partially explained by its influence on glucose metabolism, insulin
sensitivity and insulin action [5,6]. However, there is no conclusive evidence for the beneficial dose
of dietary magnesium. For example, a meta-analysis indicated that 300 mg/day of magnesium
intake was the essential dose for preventing T2D [27]. A cross-sectional study concluded that
more than 300 mg/day of magnesium intake might not improve insulin sensitivity and have no
influence [55]. Evidence from a prospective study showed that increased intake of magnesium might
provide more benefit to participants with magnesium deficiency, as magnesium deficiency and
hypomagnesaemia have been associated with the development of insulin resistance [18]. Meta-analyses
of magnesium supplementation have also revealed conflicting results. A review including 12 randomized
controlled trials (RCTs) assessing the efficacy of magnesium supplementation on insulin sensitivity
and glucose levels included studies yielding inconsistent results [56]. However, concerning the effect
of dietary magnesium intake on T2D incidence, the previous meta-analyses appeared to reach a
consensus [19,25,27]. A meta-analysis of eight cohort studies showed a significant negative association
(RR = 0.77; 95% CI: 0.72, 0.84). Another meta-analysis of 13 prospective cohort studies detected
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0.73, 0.84). A more recent meta-analysis with a total of 539,735 participants and 25,252 incident
diabetes cases also indicated that magnesium intake was associated with a significant lower risk of
T2D (RR = 0.77; 95% CI: 0.71, 0.82). However, there is less conclusive evidence of dose-response
relationship between dietary magnesium intake and risk of T2D incidence [26]. By combining results
of seven cohort studies, Larsson et al. observed a statistically significant lower risk of T2D for
100 mg/day increase in magnesium intake (RR = 0.85; 95% CI: 0.79, 0.92). Dong et al. also found a
linear dose-response relationship for every 100 mg/day increment in magnesium intake (RR = 0.86;
95% CI: 0.82, 0.89) [25]. In contrast, a nonlinear relationship (p = 0.003) between magnesium intake and
type 2 diabetes was reported by Xu et al. [27].
Our meta-analysis with a larger number of people with T2D did support existence of a statistically
significant linear dose-response relationship between increased dose of dietary magnesium intake and
T2D incidence among all the participants, especially in males and in Asian populations. In addition,
we found no evidence of nonlinear associations between dietary magnesium intake and T2D incidence
across all the studies (p = 0.665). The magnitude of the effect for 100 mg/day increment in magnesium
intake in this meta-analysis (8%–13% reduction in risk of T2D) is comparable to those from other
meta-analyses (8%–21% reduction in risk of T2D).
The discrepant findings between women and men might be due to the influence of other factors
than magnesium intake. For example, the influence of magnesium on T2D incidence in women may be
potentially attenuated by changed endogenous sex hormones in postmenopausal women [57,58];
which could accelerate T2D development and counteract the potentially protective influence of
magnesium. The discrepancy between the Asian population and non-Asian population needs further
research. However, because of the limited number of the included studies in Europe, the discrepancy
may have been accidental and a chance finding cannot be ruled out.
It should be noted that our sensitivity analysis revealed robust associations for linear and nonlinear
dose-response analyses among all the participants.
4.2. Implication for Practice
Magnesium is mainly consumed through diet, and low magnesium consumption is common
worldwide. It has been estimated that magnesium intake in a normal Western diet is often inadequate
for the body’s needs; in the United States, 67% of women and 64% of men consume inadequate
amounts of magnesium [59]. For people aged more than 30, the recommended dietary allowance
(RDA) of magnesium for men and women is 350 mg/day and 420 mg/day, respectively [51]. On the
basis of the studies we have reviewed, current evidence from population-based prospective cohort
studies support the recommendation for increasing dietary magnesium intake.
4.3. Strengths and Limitations
The population-based evidence on whether increased magnesium intake may reduce T2D
incidence is still sparse. To our knowledge, this study is the largest meta-analysis that investigated the
dose-response relationship between dietary magnesium intake and T2D risk. It has several strengths.
First, our data providing a systematic review of prospective studies represent the best available
evidence of how dietary magnesium intake may influence risk of T2D incidence. Because of the lagged
and cumulative effects of exposure on outcome of chronic diseases, the dose-response relationship
without reversed causality would be revealed only by prospective studies rather than cross-sectional
or retrospective studies. In addition, the prospective studies also minimized recall and selection bias.
Second, by combining all available doses in included studies across a wide range of exposure, we
increased the validity of the dose-response estimates. Our studies included 141 dietary magnesium
doses and 108 risk estimates, which enabled us to estimate both linear and nonlinear dose-response
relationship with a high statistical power. Third, age and BMI were adjusted for in our meta-regression
model and stratified analyses were used for sex, study areas and adjustment, which reduced the
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considered the heterogeneity among studies, which resulted in a relatively conservative conclusion
rather than an exaggerated one.
However, some limitations warrant consideration. First, although the majority of the studies
adjusted for known risk factors for T2D incidence, such as age, BMI, smoking status, education,
physical activity level and alcohol consumption, we could only retrieve age and BMI for all the
studies and adjust only for them in our final model. The possible bias from residual confounders
remained. Subgroup analyses that distinguish the studies with and without adjustment for these
confounders would be informative. For example, we conducted the subgroup analysis for the studies
adjusting for intake of cereal fiber; however, the overall RRs changed little, which were 0.892 (95% CI:
0.834, 0.954) and 0.916 (95% CI: 0.852, 0.985) for adjusted and unadjusted studies, respectively. Second,
the magnesium intake in these studies were only assessed by FFQ, which do not capture the magnesium
intake from drinking water and nutritional supplementation, and thereby might underestimate total
magnesium intake and result in potential misclassification. However, the misclassification would
most likely lead to an underestimated association. Third, influence of other nutrients or dietary
components such as coffee [49], red meat [45], calcium [43] and fiber [14,19] that are correlated
with dietary magnesium could not be excluded; other nutrients may have been responsible for the
observed association partly or completely. Finally, publication bias may be a problem in our pooling
analysis. Although we tried as much as possible to search for potential unpublished studies, no valid
studies were identified from the available grey literature resources. However, the evidence (Harbord’s
p = 0.401) did not indicate notable publication bias in our meta-analysis.
5. Conclusions
In conclusion, results from this meta-analysis indicate that dietary magnesium intake is associated
with a reduced risk of type 2 diabetes (T2D). The greatest magnitude in risk reduction was found in
the US population. A statistically significant linear dose-response relationship was identified across all
the studies, and the largest magnitude association was found in the Asian population. A 100 mg/day
increment in dietary magnesium intake was associated with an 8%–13% reduction in risk of T2D.
No nonlinear dose-response relationship was found between incremental dietary magnesium intake
and T2D incidence. Regarding the dose-response relationship between dietary magnesium intake and
T2D in populations in Africa and Europe, more evidence is needed.
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Abstract: The aim of the study was to evaluate the effect of selenium supplementation on the
expression of genes associated with glucose metabolism in humans, in order to explain the unclear
relationship between selenium and the risk of diabetes. For gene expression analysis we used archival
samples of cDNA from 76 non-diabetic subjects supplemented with selenium in the previous study.
The supplementation period was six weeks and the daily dose of selenium was 200 μg (as selenium
yeast). Blood for mRNA isolation was collected at four time points: before supplementation, after two
and four weeks of supplementation, and after four weeks of washout. The analysis included 15 genes
encoding selected proteins involved in insulin signaling and glucose metabolism. In addition,
HbA1c and fasting plasma glucose were measured at three and four time points, respectively.
Selenium supplementation was associated with a significantly decreased level of HbA1c but not
fasting plasma glucose (FPG) and significant down-regulation of seven genes: INSR, ADIPOR1, LDHA,
PDHA, PDHB, MYC, and HIF1AN. These results suggest that selenium may affect glycemic control
at different levels of regulation, linked to insulin signaling, glycolysis, and pyruvate metabolism.
Further research is needed to investigate mechanisms of such transcriptional regulation and its
potential implication in direct metabolic effects.
Keywords: selenium; gene expression; insulin signaling; glucose metabolism; glycolysis; pyruvate
metabolism; energy metabolism; glycated hemoglobin; fasting plasma glucose
1. Introduction
Selenium (Se) is a trace element with multiple biological functions. The majority of studies
related to this nutrient and human health were devoted to its potential anticancer activity and
chemoprevention based on Se supplementation [1–3]. However recent scientific focus has been
switched towards possible harmful effects of Se supplementation, especially in terms of its unclear
link with glucose metabolism and diabetes [4–6]. The increased risk of diabetes type II (T2DM)
in humans associated with elevated Se status has been suggested for the first time on the basis of
reanalysis of a placebo-controlled randomized trial (NPC, Nutritional Prevention of Cancer) conducted
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in the USA in the years 1983–1991 in a group of 1312 subjects. In that study, there was a significant
increase in the risk of diabetes among Se-supplemented subjects who had the highest Se status
(plasma concentration >121.6 ng/mL) before supplementation (Risk Ratio (RR) = 2.40; p = 0.01) [7].
In another American study (SELECT, Selenium and Vitamin E Cancer Prevention Trial) conducted in
35,533 individuals, there was a non-significant increase in the risk of diabetes among Se- supplemented
arm (RR = 1.07%, p = 0.16) [8]. Results of this large and well-designed, randomized, placebo-controlled
trial generated much controversy and up to now, no clear conclusion have been made with respect to the
potentially diabetogenic properties of Se. Several observational studies, as well as Se supplementation
trials, in which the association between Se status/Se intake and the risk of diabetes or markers of
glucose metabolism has been investigated, generated inconsistent results [4,9–12]. On the other hand,
animal studies indicated that Se supplementation may lead to hyperinsulinemia, insulin resistance,
and glucose intolerance [13]. To complicate this, previous in vivo studies indicated protective role of
Se in diabetes [14,15]. The link between Se and glucose seems very complex and is supposed to be
reflected by a non-linear U-shaped dose-response relationship [16].
The insights from experimental studies in animals indicate that Se is involved in glucose
metabolism via Se-dependent proteins (selenoproteins), which possess redox properties. It is assumed
that they may influence the insulin-dependent metabolic pathways, because both insulin release and
insulin signaling are regulated by the cellular redox potential [17]. In particular, the essential role in
the regulation of both processes is attributed to hydrogen peroxide, which is one of the reactive oxygen
species produced inter alia by dismutation of superoxide anion radical (catalyzed by superoxide
dismutase, SOD). Hydrogen peroxide is reduced to water with the participation of enzymes, such as
Se-dependent glutathione peroxidase (GPx) and catalase (CAT). The role of GPx in the metabolism
of insulin appears to be significant and complex, which is reflected by a relatively low expression of
mRNA for GPx1 and its low enzymatic activity in the pancreas (1%–5% of the value observed in the
liver; the study in mice) [18]. Moreover, it was shown that global overexpression of GPx1 mRNA in
mice fed with a normal Se diet (0.4 mg/kg) was associated with hyperglycemia, hyperinsulinemia,
and an increase in plasma leptin concentrations [19]. Another selenoprotein potentially important
in the etiology of diabetes is selenoprotein P (Sepp1) which is produced mainly in the liver and
secreted into plasma, acting as a Se transporter, and having also antioxidant properties. Misu et al.
observed a positive correlation between the level of Sepp1 mRNA and insulin resistance in humans [20].
The same authors also demonstrated in vitro that cells stimulated exogenously with purified Sepp1
were characterized by impaired insulin signaling and impaired glucose metabolism [20]. Recently it has
been also observed that serum concentration of Sepp1 was positively correlated with fasting plasma
glucose (FPG) concentration (r = 0.35, p = 0.037) and negatively correlated with serum adiponectin
levels (r = −0.355, p = 0.034; r = −0.367, p = 0.028) in patients with T2DM [21].
Altogether, mechanisms of action of Se in humans at the level of glucose metabolism and its
potential role in the etiology of diabetes are unknown and point to the need for more studies relevant
to human metabolism. The aim of this study was to assess the effect of Se supplementation on the
expression of genes related to glucose metabolism, including genes encoding hormones responsible for
glycemic control (insulin, glucagon, leptin, and adiponectin), receptors for these hormones, enzymes
involved in glycolysis, as well as key transcription factors involved in the regulation of glycolysis.
To our knowledge this is the first study conducted in humans, which aimed to investigate more
in-depth molecular effects of Se with respect to glucose homeostasis.
2. Materials and Methods
2.1. Study Design
For the purpose of this study we used archival samples of cDNA obtained from subjects who
were supplemented with Se during the trial conducted by us previously. Details of the trial, as well
as subjects’ exclusion criteria, were described elsewhere [22]. The exclusion criteria for subjects’
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non-smoking and non-diabetic individuals were supplemented with 200 μg of Se/day (in the form of
Se yeast) for six weeks and fasting blood was collected at four time points: at baseline, after two weeks
of supplementation, after six weeks of supplementation, and after four weeks of washout. In the
present study, gene expression analysis was performed with the use of cDNA obtained from 76 subjects,
randomly selected out of the entire study group, including 36 males and 40 females. Table 1 presents
basic characteristics of the subjects. Plasma Se concentration was measured previously (as described
in [22]) and mean plasma Se levels calculated for 76 subjects at each time points are presented also
in Table 1.
Written informed consent was obtained from all the study participants and the study was
approved by the Local Ethics Committee (Ethical Institutional Review Board at the Nofer Institute of
Occupational Medicine, Lodz, Poland, Resolution No. 3/2010).
Table 1. Basic characteristics of the study group (76 subjects supplemented with selenium).
Variable All (n = 76) Males (n = 36) Females (n = 40) p (Males vs. Females)
Age (years) 34.8 ± 10.4 35 ± 18 36 ± 18 0.7549 a
BMI (kg/m2) 24.0 ± 2.9 25.0 ± 2.7 23.0 ± 2.9 0.0009 a
Smoking, n (%)
Current 0 (0) 0 (0) 0 (0)
Ever 18 (24) 8 (23) 10 (24)
Never 58 (76) 27 (77) 31 (76) ns
Use of Se-containing supplements in the past 6 months, n (%)
Yes 5 (7) 3 (9) 2 (5)
No 71 (93) 32 (91) 39 (95) ns
Mean plasma Se ± SD (μg/L)
Baseline 65.2 ± 16.5 65.2 ± 16.6 65.3 ± 16.5 0.9729 b
After two weeks 101.1 ± 24.5 98.7 ± 22.8 103.3 ± 26.1 0.3907 a
After six weeks 99.1 ± 20.3 95.0 ± 16.9 102.7 ± 22.4 0.0928 b
After four weeks of washout 76.5 ± 15.6 75.3 ± 15.3 77.6 ± 16.1 0.7777 b
p (ANOVA) <0.0001 <0.0001 <0.0001
a—Mann-Whitney U test; b—Student’s t-test. Significant p values are in bold.
2.2. Gene Expression Experiment
mRNA for gene expression analysis was isolated from white blood cells (WBC). The description
of material preservation, mRNA isolation, quantification, and quality assessment were described
previously [22]. For reverse transcription we used a QuantiTect Kit (Qiagen, Hilden, Germany).
Gene expression was analyzed by means of qPCR and conducted on a QuantStudioTM 12K Flex
Real-Time PCR System (Thermo Fisher Scienific, Waltham, MA, USA), using Custom Taqman® array
cards and TaqMan® Universal Master Mix (Thermo Fisher Scienific, Waltham, MA, USA). For each
array card 6 μg of cDNA was taken. Reaction conditions were as follows: 95 ◦C of initial denaturation
for 10 min followed by 50 cycles of 95 ◦C for 15 s and 60 ◦C for 60 s. The analysis included 15 genes
encoding selected proteins involved in insulin signaling and glucose metabolism. The expression
was normalized against GAPDH. The list of all targets is presented in Table 2. The genes were
divided into four groups according to the type of encoded protein: (1) hormones: insulin (INS),
glucagon (GCG), adiponectin (ADIPOQ), and leptin (LEP); (2) hormone receptors: insulin receptor
(INSR), glucagon receptor (GCGR), adiponectin receptors (ADIPOR1, ADIPOR2), and leptin receptor
(LEPR); (3) enzymes involved in pyruvate metabolism: lactic acid dehydrogenase (LDHA), pyruvate
dehydrogenase, alpha subunit (PDHA1) and beta subunit (PDHB); (4) transcription factors or their
inhibitors driving glycolysis: transcription factor HIF1 (HIF1A), HIF1A inhibitor (HIF1AN), and nuclear
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Table 2. Genes of interest selected for the study.






INSR 19p13.3-p13.2 insulin receptor
hormone receptors
GCGR 17q25 glucagon receptor
ADIPOR1 1q32.1 adiponectin receptor 1
ADIPOR2 12p13.31 adiponectin receptor 2
LEPR 7q31.3 leptin receptor
LDHA 11p15.4 lactate dehydrogenase enzymes involved in
pyruvate metabolismPDHA1 Xp22.1 pyruvate dehydrogenase (lipoamide) alpha 1 subunit
PDHB 3p21.1-p14.2 pyruvate dehydrogenase (lipoamide) beta subunit
HIF1A 14q23.2 hypoxia inducible factor 1, alpha subunit transcription factors and their
inhibitors, involved in the
regulation of glycolysis
HIF1AN 10q24 hypoxia inducible factor 1, alpha subunit inhibitor
MYC 8q24.21 v-myc avian myelocytomatosis viral oncogene homolog
2.3. HbA1c, Fasting Plasma Glucose
Levels of HbA1c (glycated hemoglobin) were determined in 10 μL of whole blood (heparinized tube)
immediately after the blood was collected. The analysis was performed commercially in the
certified laboratory of clinical diagnostics, using immunoturbidimetric assay on an INTEGRA 400
system (Roche Diagnostics, Rotkreuz, Switzerland). The enzymic colorimetric method was based
on an oxidase/peroxidase method and the respective commercial kit (Alpha Diagnostics, Warsaw,
Poland) was used to analyze FPG. All absorbance values were measured on a UV4 Unicam UV-VIS
spectrophotometer (Cambridge, UK). Intra- and inter-assay coefficients of variation for FPG analyses
were 2.52% (n = 10) and 4.57% (n = 32), respectively.
2.4. Statistical Analysis
The analysis on gene expression data was performed on the log-transformed values in order to
have a normal distribution. Repeated measures analysis of variance (MANCOVA) with an unstructured
covariance matrix was carried out to test the effects of time on FPG, HbA1c, and gene expression.
With this analysis, markers (FPG, HbA1c, gene expression) at different time points were considered as
dependent variables, while covariates (age, sex, BMI, and baseline Se) were included in the models
as independent variables. The possible correlation between variation of Se and of gene expression
values at different time points was investigated by a linear regression model with the difference of
gene expression at two time points as the dependent variable, and the difference of Se, age, sex, BMI,
baseline Se, and baseline gene expression as independent variables. All of the analyses were carried
out in the whole group of subjects and separately in women and men. Post-hoc comparisons between
pairwise time points were performed by contrast tests, using Bonferroni correction. All of the other
statistical tests were performed at a significance level of α = 0.05. To adjust the results for multiple
comparisons, we performed a false discovery rate (FDR) analysis. Statistical analyses were conducted
using SAS software, version 9.2 (SAS Institute, Cary, NC, USA).
3. Results
3.1. The Effect of Se Supplementation on HbA1c and Fasting Plasma Glucose
Significant changes in HbA1c levels were observed upon Se supplementation (p < 0.0001), with
post hoc tests indicating a significant decrease both after six weeks of supplementation and after
four weeks of washout (p < 0.0001 and p = 0.02 vs. baseline, respectively) (Table 3). On the contrary,
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Table 3. The effect of Se supplementation on fasting plasma glucose concentration, HbA1c levels and




Baseline Two Weeks Six Weeks Washout
FPG (mg/dL) 91.96 ± 13.94 90.55 ± 14.07 91.00 ± 14.15 91.56 ± 13.79 0.55
HbA1c (%) 4.74 ± 0.80 na 4.44 ± 0.63 c 4.57± 0.65 a <0.05
INSR 1.23 ± 0.67 0.98 ± 0.25 b 1.02 ± 0.27 b 0.95 ± 0.25 c 0.005
ADIPOR1 2.05 ± 0.23 2.00 ± 0.18 a 2.07 ± 0.21 2.04 ± 0.23 0.002
ADIPOR2 1.88 ± 0.23 1.84 ± 0.18 1.84 ± 0.19 1.80 ± 0.19 0.08
LEPR 0.87 ± 0.35 0.80 ± 0.34 0.80 ± 0.29 0.82 ± 0.38 0.26
LDHA 2.74 ± 0.30 2.59 ± 0.26 c 2.49 ± 0.21 c 2.51 ± 0.27 c <0.0001
PDHA 2.03 ± 0.29 1.93 ± 0.24 a 1.90 ± 0.20 c 1.90 ± 0.26 b 0.0002
PDHB 1.92 ± 0.25 1.86 ± 0.20 1.81 ± 0.18 c 1.81 ± 0.21 b 0.0008
HIF1A 2.37 ± 0.26 2.29 ± 0.23 2.29 ± 0.24 2.30 ± 0.27 0.16
HIF1AN 1.71 ± 0.32 1.61 ± 0.19 b 1.70 ± 0.20 1.67 ± 0.21 0.0001
MYC 2.31 ± 0.29 2.22 ± 0.26 a 2.14 ± 0.22 c 2.18 ± 0.25 a <0.0001
Values significantly different as compared to baseline are in bold, a—p < 0.05, b—p < 0.01, c—p < 0.001;
*—Multivariate analysis of covariance, model included age, sex, BMI and baseline selenium; na—not analyzed
(HbA1c was not analyzed after two weeks of supplementation).
3.2. The Effect on Gene Expression
In the first step of analysis, we excluded genes which were not expressed or which had very
low expression. These were five genes: INS, GCG, GCGR, ADIPOQ, and LEP. Further analysis of the
remaining 10 genes indicated a significant reduction in mRNA expression of seven targets, including
INSR, ADIPOR1, LDHA, PDHA, PDHB, MYC, and HIF1AN. In the case of INSR, LDHA, PDHA, and
MYC, a significant decrease was observed at all measurement points as indicated by contrast tests
(during supplementation and the washout period). For genes ADIPOR2, LEPR, and HIF1A there was
no statistically significant changes over time (Table 3).
Further analysis aimed to test whether the variation of gene expression depended on the variation
of Se. We conducted this analysis for all 10 genes and all time points regardless of the fact whether the
overall effect was significant or not. Significant correlations between Se status and gene expression
were found in the case of ADIPOR1 after six weeks of supplementation (p = 0.012) and in the case of
HIF1AN after two weeks (p = 0.045) and six weeks (p = 0.002) of supplementation. All data are shown
in Table S3.
3.3. Sex Differences
At baseline, males had significantly higher levels of FPG (p = 0.01) as compared to females,
however, both sexes did not differ significantly in the level of HbA1c (p = 0.175). No modifying effect of
sex was observed at the level of both markers upon time (during supplementation and after washout
period, as assessed in the MANCOVA model; p = 0.55 and p = 0.09 for time interaction with sex for
FPG and HbA1c, respectively). Data on FPG, HbA1c, and on gene expression analyzed separately for
males and females are presented in the supplementary materials (Tables S1 and S2). The results of
analysis stratified by sex were less powered and some p-values were no more significant. However,
general trends were similar. Analogically to the analyses conducted in the whole group, we tested
the correlation between variations in plasma Se levels and in gene expression. In males significant
correlation was found for HIF1AN after six weeks of supplementation (p = 0.038). In females significant
correlations were observed for four genes after six weeks of supplementation: ADIPOR1 (p = 0.047),
PDHB (p = 0.034), HIF1AN (p = 0.035), and MYC (p = 0.048). Regression analysis data are shown in
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3.4. False Discovery Rate Analysis
P-values for the effect on gene expression (Table 3, Tables S1 and S2) were still statistically
significant after FDR adjustment for multiple comparisons, except for two genes in women: ADIPOR1
and HIF1AN (in both cases the FDR-adjusted p-value was 0.06).
4. Discussion
In this study we observed that six weeks of supplementation with 200 μg of Se in the form of
Se yeast had significantly decreased the level of HbA1c in the subjects with relatively low baseline
Se status. On the other hand we did not observe any changes at the level of FPG. However, FPG
reflects the glycemic status at the time of measurement. HbA1c is regarded as a more reliable marker
since it indicates long-term changes in the glycemic control. Thus, the impact of Se supplementation
on HbA1c levels observed in this study confirms that Se is involved in the metabolism of glucose.
Moreover, significant decrease in HbA1c levels was maintained four weeks after supplementation
discontinuation, which clearly shows that the effect of Se on the glycemic control was relatively strong.
There are only a few other studies reporting the effect of Se supplementation on glucose homeostasis in
humans. Three of them, being all randomized, placebo-controlled trials (RCTs), have shown beneficial
effect of short-term Se supplementation in specific groups of women. In the first study, 70 women
with gestational diabetes were supplemented with Se at a dose of 200 μg per day for six weeks.
Improved glucose homeostasis was observed as reflected by decreased levels of FPG and serum insulin
as well as decreased HOMA-IR values (homeostasis model of assessment of insulin resistance) [23].
The second study was conducted in 70 women with polycystic ovary syndrome. After eight weeks of
supplementation with Se at 200 μg per day, there was a significant decrease in serum insulin levels,
HOMA-IR, HOMA-B (homeostatic model of assessment of beta-cell function) values, and an increase
in QUICKI (quantitative insulin sensitivity check index), whereas FPG remained unchanged [24].
The last study investigated the effect of Se supplementation in women with central obesity. After six
weeks of Se supplementation (200 μg/day), significant decrease in serum insulin levels and HOMA-IR
values was observed [25]. Another study which was conducted in 60 subjects of both sexes (20 males
and 40 females) diagnosed with T2DM and coronary heart disease also showed beneficial effects of Se
supplementation (200 μg/day for eight weeks) in terms of decreased insulin, HOMA-IR, HOMA-B
parameters, and increased QUICKI [26]. On the contrary, only one RCT, conducted in patients with
T2DM (n = 60, including 34 males and 26 females), indicated that three months of Se supplementation
(200 μg/day) led to the increased FPG levels [27]. To compare with short term supplementation,
long-term RCTs did not indicate any effects on glucose homeostasis upon Se supplementation, as
shown at the level of serum glucose concentration in 140 men with prostate cancer (supplemented with
Se at dose 200 μg/day for five years) or at the level of FPG in 3146 participants of the SU.VI.MAX trial
(supplemented with 100 μg of Se in combination with zinc (Zn) and vitamins C, E, and beta-carotene,
for 7.5 years) [28,29]. Overall, the inconsistent results of the above RCTs coincide with a lack of
compliance in the observational studies investigating the link between Se and diabetes. These studies
also suggest that Se-induced effects may largely depend on specific health conditions (notably none
of them has been conducted in the general population). A similar conclusion has been drawn from
recent studies in mice, which were fed with a high-fat diet in order to induce insulin resistance [30].
It was observed that pre-treatment with Se protected animals against developing insulin resistance,
whereas post-treatment with Se exacerbated this metabolic disorder. The effects of pre-treatment
and post-treatment with Se were different in the context of adipogenesis and lipolysis, showing
increased adipocyte differentiation and fat accumulation in adipose tissue in pre-treated mice, whereas
post-treated mice were characterized by increased lipolysis and ectopic lipid deposition [30]. The above
study clearly shows that Se exerts differential effects under different health conditions.
Along with HbA1c decrease upon Se supplementation, we have observed in this study
a significant decrease of leukocyte mRNA levels for seven genes involved in different steps of glucose
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endocrine hormones: insulin and adiponectin, which are key players in insulin signaling responsible
for cellular glucose uptake. Suppressive effects of Se on insulin receptors was observed previously
in a study of gestating rats and their offspring [31]. In that experiment, decreased mRNA expression
for Insr, as well as other insulin signaling genes, including Irs-1 (insulin receptor substrate 1), Irs-2
(insulin receptor substrate 2), and Akt2 (serine/threonine protean kinase 2), was observed in the liver
of dams supplemented with 3 mg Se/kg diet (as compared to dams fed basal diet). Importantly,
similar changes in the liver, additionally accompanied by decreased protein levels of insulin receptors,
were observed in the offspring of dams also receiving a high Se diet. At the same time, high
Se diet was associated in both dams and the offspring with hyperinsulinemia, insulin resistance
and glucose intolerance [31]. The impact of a high Se diet on protein levels for insulin receptors
was also investigated in pigs, showing tissue-specific changes, with up-regulation in the liver and
down-regulation in the muscle. However, no changes in both tissues were observed for insulin
receptors at the level of mRNA [32]. Similarly, another study conducted in pigs also failed to show
any effect of supranutritional intake of Se on insulin receptor mRNA levels, analyzed in liver, muscle,
and visceral adipose tissue [33]. Significant reduction of mRNA expression for the adiponectin
receptor, ADIPOR1, observed in our study after two weeks of supplementation, was accompanied by a
borderline significant decrease in ADIPOR2 (p = 0.08). AdipoR2 is expressed mainly in the liver; thus,
in blood leukocytes it was more probable to observe a significant effect in the case of AdipoR1, which
is expressed ubiquitously [34]. Both receptors bind adiponectin, a hormone produced by adipocytes
and involved in glucose metabolism via modulating insulin sensitivity [34]. Though our study may
suggest some effect of Se on adiponectin signaling, two supplementation trials failed to show any effect
of Se administration on plasma adiponectin levels in humans [35,36]. Nevertheless, the suppressive
effect on INSR and ADIPOR1 indicated in this study deserves further research, as decreased expression
of mRNA levels for these receptors has been linked to insulin resistance and diabetes in humans
and animals [37–39]. Decreased expression of essential genes involved in glucose metabolism, such
as those encoding receptors for insulin and adiponectin, may indicate rather detrimental effects of
Se supplementation in the study group. On the other hand, the effect at the level of HbA1c was
somewhat positive. The hypothetical explanation for these contradictory observations may be that
the potentially beneficial decrease in HbA1c level reflects an adaptive response which counteracts the
adverse effects of the metalloid on glucose homeostasis and that this response is rather short-term.
This adaptive mechanism when induced in a constant manner (by introducing the factor day by
day for several weeks) may be strong enough to influence the level of HbA1c, however, not in the
long-term. The hypothesis about short-term adaptive response is in line with overall observations
from Se supplementation trials, indicating mainly beneficial effects of Se on glucose metabolism in
the case of short-term administration and, on the other hand, null or negative effects upon long-term
supplementation with this nutrient. Alternative explanation for decreased levels of HbA1c upon Se is
the possibility that Se may prevent the process of hemoglobin glycation. This may be suggested on
the basis of a recent study by Yu and colleagues, showing Se nanoparticles prevent protein glycation
in vitro [40]. Nevertheless, it is not clear whether changes observed in our study at the level of
leukocyte gene expression reflect changes in insulin-sensitive tissues. If they do, down-regulation of
INSR and ADIPOR1 in blood leukocytes could serve as an early biomarker of adverse health effects of
Se supranutrition in humans, leading to impaired glucose homeostasis.
The second group of down-regulated genes in this study included LDH, PDHA, and PDHB,
all three encoding enzymes involved in pyruvate metabolism. Pyruvate is the end product of glycolysis
and its further metabolism depends on cellular oxygen concentration. Under anaerobic conditions,
it is transformed by lactate dehydrogenase (LDH) to lactic acid whereas, under normal aerobic
conditions, it is metabolized by pyruvate dehydrogenase complex (PDC) to acetyl coenzyme A
(acetyl CoA). The latter reaction links glycolysis to the Krebs cycle. Importantly, pyruvate recycling
(occurring across mitochondrial membranes) is an important regulator of insulin secretion due to
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pivotal molecule required for insulin granule exocytosis in beta cells [41]. Pyruvate metabolism was
shown to be implicated in diabetes, as reflected by increased activity of pyruvate dehydrogenase
kinase (PDK) in diabetic subjects (PDK plays significant role in glucose disposal as it decreases the
activity of PDC) [42]. In general, glycolytic pathway was shown to be dysregulated in diabetes [43].
A study in rats showed, for example, that an alloxan-induced diabetic state significantly altered the
activities of glycolytic enzymes in lymphocytes [44]. Importantly, recent animal studies suggest
that Se interferes with glycolytic targets and pyruvate metabolism, supporting our observation.
Pigs fed with a supranutritional dose of Se exhibited decreased expression of mRNA for pyruvate
kinase (enzyme responsible for pyruvate synthesis in the last step of glycolysis) [33]. Interestingly,
increased pyruvate levels in the liver and increased expression of pyruvate metabolizing enzymes
(pyruvate carboxylase (Pcx) and pyruvate dehydrogenase (Pdh)) were shown in mice with a knocked
out gene for selenocysteine lyase (SCLY, the enzyme catalyzing conversion of selenocysteine into
alanine and selenide, an important step in Se metabolism, as selenide is a substrate for selenoprotein
biosynthesis) [45]. Recently it has been also shown that Se affects glycolysis in cancer cells, suggesting
that down-regulation of glycolytic enzymes is a novel mechanism of Se toxicity in cancer and that
this mechanism targets the well-known metabolic hallmark of cancer cells associated with enhanced
glycolysis, which is called the Warburg effect [46]. In our study we have observed, additionally
that Se may affect also transcriptional regulation of glycolysis, leading to significantly decreased
expression of MYC. c-MYC protein, encoded by MYC gene, is responsible for transcriptional regulation
of all glycolytic targets, including pyruvate kinase, pyruvate kinase dehydrogenase and lactate
dehydrogenase [47]. Importantly, it was also shown to regulate the expression of glucose transporter
2 (GLUT2) and 4 (GLUT4) [47]. mRNA expression of the second major transcriptional regulator
of glycolytic targets, HIF1 [47] was not affected upon Se supplementation in our study, whereas a
significant decrease was observed for its inhibitor (but only after two weeks of supplementation).
Altogether, these results suggest the need for a more in-depth investigation of the link between Se and
glycolysis in humans.
We were not able to detect the expression of genes encoding: insulin (INS), glucagon (GCG),
adiponectin (ADIPOQ), and leptin (LEP) in leukocytes. This was not surprising as all of these hormones
are produced either by pancreas (insulin, glucagon) or by adipocytes (adiponectin, leptin). Similarly,
GCGR levels were not detectable in leukocytes, which was also expected, as the glucagon receptor is
expressed mainly in the liver, in which it mediates glucagon effects: glycogen breakdown and glucose
release into the bloodstream.
The last analysis in this study concerned the correlation between the variation in gene expression
and variation in plasma Se concentrations at a particular time point. There were only a few significant
correlations and those that were significant were very small, indicating that changes in gene expression
were not high enough to correlate with changes in Se.
Since this report presents secondary outcomes of the supplementation trial, it has several
weaknesses. First of all, due to the short-term supplementation (six weeks) we were not able to
assess changes in HbA1c levels after the whole life span of erythrocytes (which is about 120 days).
HbA1c levels reflect the cumulative history of glycemic control in the past two to three months [48].
After this period the measurement of HbA1c levels is most indicative. However it is possible to
observe changes earlier, as shown by studies investigating the effects of glucose-lowering drugs [49].
Since erythrocytes are produced constantly (meaning that the whole pool of erythrocytes contains
cells of different ages) the effect observed in our study resulted from HbA1c reduction in the youngest
erythrocytes. Nevertheless, one could speculate that these changes might have occurred due to some
potential confounders present in the study during several weeks before the beginning of the trial,
such as pharmacological or dietary factors. However, none of the supplemented subjects declared
to be taking any drugs or supplements that could affect glucose metabolism (we asked all subjects
about their use of glucose-lowering drugs or supplements before and during the trial). As for the
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The second major weakness of this study is attributable to the fact that the trial was not randomized
(subjects were selected for the study according to genotype) and not placebo controlled (for details
see [22]). Since no separate control group was investigated, we compared all data with respect to
baseline values, measured on the first day of the trial, before taking the first pill with the supplement.
Finally, gene expression was analyzed in this study in blood leukocytes and it is not clear whether
these changes reflect general reactions to Se at the molecular level in humans or if they are tissue
specific. In addition we did not analyze the protein levels for genes of interest; thus, we were unable to
show any correspondence between transcriptomic and proteomic expression and elucidate whether
observed subtle changes in mRNA have any further consequences.
To conclude, results of this study suggest that Se may affect glycemic control at different levels
of regulation, linked not only to insulin signaling, but also to glycolytic pathway and pyruvate
metabolism. Further research is needed to investigate mechanisms of negative transcriptional
regulation in blood leukocytes upon Se treatment, its relevance to other tissues, correspondence
to protein levels and, finally, potential implications in direct metabolic and cellular effects. Overall,
findings of this study added more insight into the controversial topic of possible diabetogenic effects of
Se supplementation in humans. What is the exact impact of Se supplementation on glucose homeostasis
and the risk of diabetes remains still an open question. The answer will not be obtained without studies
unraveling the underlying mechanisms, as well as factors which may modify Se effects with respect
to glucose homeostasis, in addition to these already suggested, such as sex and genotype [50,51],
as well as Se speciation [52,53]. Explaining the link between Se, glucose metabolism, and diabetes
is currently one of the priority goals in Se research because it will determine the further direction of
studies focusing on Se as a potential chemopreventive agent.
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concentration, HbA1c levels and gene expression. Data for female subjects (n = 40); Table S3: Correlation between
changes in Se and changes in gene expression measured between two different time points. Data for all subjects
(n = 76); Table S4: Correlation between changes in Se and changes in gene expression measured between two
different time points in male subjects (calculated only for genes which were shown to be significantly changed
upon Se supplementation). Data for male subjects (n = 36); Table S5: Correlation between changes in Se and
changes in gene expression measured between two different time points in all subjects (calculated only for genes
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Abstract: Type 2 diabetes (T2D) burden is increasing globally. However, evidence regarding nutrient
patterns associated with the biomarkers of T2D is limited. This study set out to determine the
nutrient patterns associated with fasting glucose and glycated haemoglobin the biomarkers of T2D.
Factor analysis was used to derive nutrient patterns of 2010 participants stratified by urban/rural
status and gender. Principal Component Analysis (PCA) was applied to 25 nutrients, computed from
the quantified food frequency questionnaires (QFFQ). Three nutrient patterns per stratum, which
accounted for 73% of the variation of the selected nutrients, were identified. Multivariate linear
regression models adjusted for age, BMI, smoking, physical activity, education attained, alcohol
intake, seasonality and total energy intake were computed. Starch, dietary fibre and B vitamins
driven nutrient pattern was significantly associated with fasting glucose (β = −0.236 (−0.458; −0.014);
p = 0.037) and glycated haemoglobin levels (β = −0.175 (−0.303; −0.047); p = 0.007) in rural women.
Thiamine, zinc and plant protein driven nutrient pattern was associated with significant reductions in
glycated haemoglobin and fasting glucose ((β = −0.288 (−0.543; −0.033); p = 0.027) and (β = −0.382
(−0.752; −0.012); p = 0.043), respectively) in rural men. Our results indicate that plant driven nutrient
patterns are associated with low fasting glucose and glycated haemoglobin levels.
Keywords: plant based; fasting glucose and glycated haemoglobin; T2D; dietary patterns
1. Introduction
Type 2 diabetes (T2D) prevalence and the burden it places on populations is increasing globally,
thereby making it a public health challenge which requires urgent attention [1]. For instance, the
global prevalence of T2D among women increased from 5% to 7.9% from 1980 to 2014 [2]. The diabetes
prevalence in Africa is projected to have the largest increase of 109% compared to other regions in the
world by 2035 [3]. Urban black South Africans have not been spared from the T2D burden. The highest
prevalence of T2D in Sub Saharan Africa was reported among urban black South Africans, with 60% of
these cases being reported amongst women [4]. Black South African women also have the highest
prevalence of obesity, which has been reported to be rising together with T2D in this population [5].
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The adoption of Westernised lifestyles by urban dwellers is suggested to be among the leading
factors resulting in the increase in non-communicable diseases (NCDs) such as T2D in developing
countries [6]. The migration of populations from rural to urban areas has been accompanied by
an increase in meat consumption as well as an increase in the consumption of sugary foods in
South Africa [7]. Both of these foods are recognised as dietary risk factors for T2D [6]. However,
improvements in micronutrient intake among black South African women in urban areas is suggested
to be a result of the increased consumption of fruits and vegetables which are protective of T2D
risk [8–10]. Thus, the role of diet as a risk factor for T2D is complex among the black South African
women. In addition, people eat meals with a variety of nutrients which have interactive and synergistic
effects on health [11]. Therefore, it is difficult to determine the separate effect of a food or nutrient
on disease development as it is highly interrelated with other nutrients [11]. There is need of dietary
pattern analysis methods which are able to evaluate the diet as a whole and clarify the effects of
the consumption of sugary foods and meat products, together with improved intakes of fruits and
vegetables, related to T2D risk amongst this population group.
Dietary pattern (or food pattern) approaches comprise data driven methods such as factor analysis,
which allow the dietary information (or food intake) at hand to determine the unique dietary pattern
for the population group being evaluated [10]. Although dietary patterns have been associated
with disease risk, their effect is considered to be through nutrient intake; therefore, it is pivotal to
determine nutrient patterns that are associated with T2D risk [12]. This information will aid in the
understanding of the aetiology of T2D. The foods that people eat are governed by their cultural norms
and beliefs, which vary amongst ethnic groups, making dietary patterns limited and not applicable
across divergent population groups [12]. Evidence exists that the Western dietary pattern association
with fasting glucose varies among different ethnic groups [13]. However, nutrients are universal,
thereby making nutrient patterns associations with disease risk applicable for multiple population
groups [14]. To the best of our knowledge, no study has reported on the association of the nutrient
patterns with fasting glucose and glycated haemoglobin levels among apparently healthy individuals.
T2D is a complex and multifactorial diseases, however glycated haemoglobin and fasting glucose
levels are proxies for the development of this disease which are affected by diet [15]. Fasting glucose
levels are indicative of the short term changes in glucose metabolism, while glycated haemoglobin
depicts the long term changes [15]. This study seeks to evaluate the association of nutrient patterns
derived by factor analysis with fasting glucose and glycated haemoglobin levels among apparently
healthy black South Africans.
2. Materials and Methods
2.1. Study Population
The study participants (n = 2010) were recruited from two urban and rural areas of the North
West Province into the South African arm of the Prospective urban and rural epidemiological (PURE)
study using a population based sampling strategy. Apparently healthy male and female volunteers
between the ages of 35 and 60 years were recruited by the fieldworkers. Individuals were considered
to be apparently healthy if they were not using any medication for chronic disease and if they were not
diagnosed with a chronic medical condition/disease. The international PURE study is a large-scale
epidemiological study, which comprises research participants recruited from 17 low, middle, and high
income countries [16]. The South African arm of the PURE study was initiated in 2005 with initial
five-year follow-up intervals up to 2015. At baseline in 2005 and at the five-year intervals during the
course of the study, medical history, lifestyle behaviour (physical activity and dietary intake), blood
collection (for both genetic and biochemical analyses), an electrocardiogram, and anthropometric
assessments were performed to determine the role of risk factors in the development of cardiovascular
diseases [16]. Our study was nested in the 2005 PURE study baseline data. Stratified nutrient pattern
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the PURE study. However, significant associations of the nutrient patterns with fasting glucose and
glycated haemoglobin were noted only among the rural women and rural men. Therefore, the detailed
nutrient pattern and association results of the rural participants are elaborated in the main text while
results of the urban men and women are illustrated in the Supplementary Materials.
2.2. Ethical Approval
The participants gave written informed consent before participating in the study and the study
was conducted according to the Declaration of Helsinki principles [17]. Ethical approval was
granted by the Ethics Committee of the North-West University, Potchefstroom Campus, with ethics
number NWU-00016-10-A1.
2.3. Dietary, Anthropometric and Physical Activity Assessments
The trained fieldworkers captured the dietary intake of the participants using a standardised
quantitative food frequency questionnaire (QFFQ) which had been validated for the same ethnic
population group of the study participants [18,19]. The reproducibility of the QFFQ was also assessed
and found to be good in this specific study population [20]. The dietary intake data were coded,
analysed and nutrient intakes were computed using the South African Food Composition Database [21].
Body weight measurements were performed in duplicate by the PURE research team members using a
portable electronic scale (Precision Health Scale, A & D Company, Tokyo, Japan), after which the mean
was recorded. The heights of the subjects were determined by the PURE study research team members
using a stadiometer (IP 1465, Invicta, and London, UK). The BMI of the participants was computed
using the formula: BMI = weight (kg/height (m2)). The Baecke physical activity questionnaire (BPAQ)
which was validated for South Africa was used to collect the physical activity information of the
participants [22]. The questionnaire was used to compute a physical activity index score as described
elsewhere [22,23]. This physical activity index scores were used in the multivariate regression analysis
to adjust for physical activity.
2.4. Biochemical Measurements
The research participants were required to fast (at least 8 h with no food or beverages, including
water before measurements) and their blood glucose levels were measured by the PURE research team.
These fasting glucose levels were measured using the SYNCHRON® System from fluoride plasma.
The Bio-Rad D-10TM, HbA1c kit (Bio-Rad Laboratories, Inc., Hercules, France), which operates via
cation exchange high performance liquid chromatography was used to assess HbA1c levels from
whole blood ethylenediaminetetraacetic acid (EDTA) treated samples. The coefficient of variation of
the glycated haemoglobin and fasting glucose tests were 1.16% and 2.1%, respectively.
2.5. Statistical Analysis
The statistical analysis was performed using the statistical package for social scientists (SPSS)
version 23. Normality tests for the continuous variables were performed using the Q-Q plots.
Twenty-five nutrients were used to determine the nutrient patterns as has been reported previously
by Pisa et al. [24]. Among these 25 nutrients, total protein was split into animal protein and plant
protein; total carbohydrates were divided into total sugar, starch, and total dietary fibre; and total fat
was categorised into saturated fat, monounsaturated fat and polyunsaturated fat. The total dietary
fibre comprised soluble and insoluble dietary fibre. Alcohol was not regarded as a nutrient and not
included in deriving the nutrient pattern analysis. However, in view of the reported association of
alcohol intake with glycated haemoglobin, it was adjusted for in the multivariate linear models for
the association of the derived nutrient patterns with glycated haemoglobin and fasting glucose [25].
The nutrient intake variables from the quantitative food frequency questionnaire (QFFQ) were log
transformed to remove bias due to variance as a result of the different measures of scale used to
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(standard) method [11]. The multivariate method was selected as it yielded more cumulative variance
and interpretable nutrient patterns compared to the standard nutrient density method of adjusting
for total energy intake [11]. Principal component analysis (PCA) was the factor reduction tool used
to determine the nutrient patterns from the 25 selected nutrients. The PCA was performed with the
variance based on the covariance matrix and Varimax rotation. The retained principal components (PC)
were used to identify the nutrient patterns. The scree plot (Figure 1) was used to determine the number
of PCs to retain. The nutrient patterns were named using the nutrients with loadings greater than
±0.47 on the PCs. The total variances explained by the retained PCs were also evaluated to determine
the relevance of the extracted PCs. The PCA was a suitable data reduction approach for the nutrient
data in this study as was indicated by a Kaiser–Meyer–Olkin measure of sampling adequacy of 0.911,
and a Bartlett’s test of sphericity which was significant at p < 0.001. The PCs were categorised into
tertiles and analysis of variance ANOVA (for continuous variables) and Chi-square (for categorical
variables) tests were used to determine the descriptive characteristics of the study participants across
the tertiles of the extracted PCs.
Figure 1. Scree plot of the nutrients and the extracted principal components among rural women.
Crude and adjusted multiple linear regression models were computed to assess the association
between the extracted PCs with glycated haemoglobin and fasting glucose as dependent variables
separately through varied models. In these models, regression coefficients for 1 standard deviation
(SD) increase in the PC scores (and their 95% confidence intervals) were computed for four models:
M1: (crude); M2: (adjusted for M1 plus Log Total Energy); M3: (adjusted for M2 plus Body Mass
Index); and M4: (adjusted for M3 plus age, smoking, physical activity, education level, seasonality,
alcohol intake and other PCs). Seasonality was adjusted based on the months in which the dietary
assessments were conducted. Thus, for the rural participants, seasonality was adjusted basing on
August and September; and the months of October and November were used to adjust for seasonality
in the urban participants. Partial R2 values were computed to express the variance explained by each
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3. Results
3.1. Nutrient Patterns
Three nutrient patterns (Table S1) were extracted from the PCA, which explained 73% of the
total variation of the selected nutrient factors among the rural women. The first nutrient pattern was
depicted as “Magnesium, phosphorus and plant protein driven nutrients”. This pattern consisted of
higher loadings for magnesium, phosphorus and plant protein. The second nutrient pattern was termed
“Fat and animal protein driven nutrients” as it had higher loadings of cholesterol, monounsaturated
fat, animal protein, polyunsaturated fat and saturated fat. The “Starch, dietary fibre and B vitamins
driven” based nutrient pattern was the third extracted nutrient pattern. This nutrient pattern had high
loadings of starch, folate, vitamin B6, dietary fibre and thiamine as illustrated in Table S1.
Three nutrient patterns were extracted among rural men and named according to the nutrients
with the highest loadings as indicated in Table S1. These were the “Thiamine, zinc and plant protein
driven nutrients”, “Fat and animal protein driven nutrients”, and “Retinol and vitamin B12 driven
nutrients”. Three similar nutrients patterns were extracted among the rural men, urban men and urban
women, which explained 76%, 77% and 76% (Tables S1 and S2) variance of the nutrients, respectively.
However, some considerable differences were noted in the plant driven nutrient patterns, which
accounted for the greater variation of the nutrients among the urban and rural participants (Table S3).
3.2. Descriptive Characteristics of the Study Population
The study participants included 659 rural women, 347 rural men, 605 urban women and 399 urban
men. The mean fasting glucose levels and glycated haemoglobin were 4.96 ± 1.57 mmol·L−1 and
5.64% ± 0.88%, respectively [26]. The women had a mean BMI of 26.73 ± 7.21, which signified that
a considerable proportion of the women were overweight. Overall, in the whole study population,
39.4% of the participants were overweight and 87.3% of these were women. The mean total energy
intake was 7707.13 ± 3692.36 KJ. The high scores of magnesium, phosphorus and plant protein driven
nutrient pattern were associated with high total energy intake and energy from alcohol in rural women,
as indicated in Table 1. The high scores for the fat and animal protein driven nutrient pattern was
significantly associated with tertiary education status, as indicated inTable 1.
High scores for the thiamine, zinc and plant protein nutrient pattern were associated with higher
energy and alcohol intake compared to other nutrient patterns among the rural men (Table 2).
3.3. Nutrient Patterns Associations with Fasting and Glycated Haemoglobin Levels
The association results of glycated haemoglobin and fasting glucose levels with 1 SD increases
in the extracted nutrient patterns are shown in Tables 3–6 for the rural women and rural men.
The magnesium, phosphorus and plant protein driven nutrient pattern was associated with a consistent
trend of increases in fasting glucose and glycated haemoglobin among rural women, as illustrated in
Table 3.
Conversely, the starch, dietary fibre and B vitamins nutrient pattern was consistently associated
with reduced glycated haemoglobin and fasting glucose levels in all evaluated linear models, for
instance the M4 model: −0.175% (−0.303; −0.047); p = 0.007) and −0.236 mmol·L−1 (−0.458; −0.014);
p = 0.037), respectively, as indicated in Tables 3 and 4 among rural women.
The thiamine, zinc and plant protein nutrient pattern was associated with reduced glycated
haemoglobin and fasting glucose levels in rural men as illustrated in Tables 5 and 6. For instance, the
M4 models, which explained the highest variances of the fasting glucose and glycated haemoglobin,
indicated reductions of these outcome variables to be −0.382 mmol·L−1 (−0.752; −0.012; p = 0.043)
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The plant driven nutrient patterns had significant results as has been shown above among the
urban and rural participants. However, some notable differences were depicted in the plant driven
nutrient patterns illustrated in Table S3. The following nutrient patterns, “thiamine, zinc and plant
protein driven nutrients”, “thiamine, starch and folate driven nutrients”, and “magnesium, phosphorus
and plant protein driven nutrients” extracted from the urban men, urban women and rural women,
respectively, had higher loadings for animal protein, saturated fat, mono-saturated fat and sugar
compared to the “thiamine, zinc and plant protein driven nutrients” and “the starch, dietary fibre
and B vitamin driven nutrients patterns”, which were associated with significant reductions in fasting
and glycated haemoglobin among the rural men and women respectively (see factor loadings in bold
in Table S3). These two nutrient patterns that had significant associations with fasting glucose and
glycated haemoglobin had very low cholesterol and saturated fat as illustrated in Table S3.
4. Discussion
We set out to determine the nutrient patterns associated with fasting glucose and glycated
haemoglobin levels among apparently healthy volunteers. The principal component analysis method
enabled the extraction of three nutrient patterns among a black South African population which
explained about 73% of the variation of the nutrient factors in the urban/rural and gender stratifications.
The magnesium, phosphorus and plant protein driven nutrient pattern was associated with a trend
of increasing fasting glucose and glycated haemoglobin levels per 1 SD increase in the pattern in
the rural women while the thiamine, zinc and plant protein nutrient pattern was associated with a
positive trend of increasing glycated haemoglobin among urban men. Notably, the starch, dietary
fibre and B vitamin nutrient pattern was associated with decreases in glycated haemoglobin and
fasting glucose levels, −0.175% ((−0.303; −0.047); p = 0.007) and −0.236 mmol·L−1 ((−0.458; −0.014);
p = 0.037), respectively, among rural women. The thiamine, zinc and plant protein driven nutrient
pattern was associated with significant reductions in fasting glucose and glycated haemoglobin of
−0.382 mmol·L−1 (−0.752; −0.012; p = 0.043) and −0.288% (−0.543; −0.033; p = 0.027) in rural men.
These associations were significantly maintained after adjusting for age, BMI, log total energy intake,
smoking, physical activity, alcohol intake, seasonality and education level attained thus indicating an
independent association of the starch, dietary fibre and B vitamin nutrient pattern and the thiamine,
zinc and plant protein driven nutrient pattern with fasting glucose and glycated haemoglobin in the
rural women and rural men strata’s, respectively.
Comparable studies evaluating the associations of nutrients patterns with fasting glucose and
glycated haemoglobin are scarce. However, evidence exists of dietary patterns which have evaluated
this phenomenon [10]. The Health/Prudent dietary pattern has been associated with decreases in
fasting glucose and glycated haemoglobin levels while the Western dietary pattern has been associated
with increases in these biomarkers of T2D [27,28]. However, the association of the Western dietary
pattern, which is characterised with high intakes of animal proteins and snacks, with fasting glucose
levels was noted to vary among ethnic groups [13]. The Western dietary pattern was reported in one
study to be only significantly associated with high fasting glucose levels and glycated haemoglobin
levels among Dutch and not among the Moroccans and Turkish groups [13]. Dietary patterns are
known to vary among different ethnic groups, therefore nutrient patterns that were considered in our
study are considered helpful in indicating a non-ethnic insight into this phenomenon.
In our study, we noted that fat and animal protein driven nutrients were also not associated
with fasting glucose and glycated levels, as had been depicted in dietary pattern analysis studies
among different ethnic groups [13]. This disparity from the Western populations where the animal
based/Western dietary patterns are associated with increasing fasting glucose levels has been explained
by the realisation that ethnic groups such as Asians may adopt the Western diets but their intake
of animal products will remain lower as they also continue to consume traditional cereals and
vegetables [29]. Similarly, in this study population, the intake of fat and animal protein nutrients were
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nutrients patterns extracted per stratum as illustrated in Table S3. In other local studies, the protein
and fat intakes as percentage of total energy intake for urban women from 1975 to 2005 did not change
drastically though evidences of the adoption of Western dietary patterns were being noted and the
greater proportion of the energy intake was still being contributed by the carbohydrate intake as had
been noted in the Asians [6]. From 1975 to 2005, the percentage of energy of protein intake changed
from 14% to 13%, while fat intake as percentage of energy changed from 21% to 30% and carbohydrate
intake changed from 67% to 57% of total energy intake [6]. Thus, the intake of fat and animal protein
driven nutrients in this population group might have been lower and thus not associated with increases
in fasting glucose and glycated haemoglobin as was expected.
The magnesium, phosphorus and plant protein driven nutrient pattern indicated a positive trend
association with increases in fasting glucose and glycated haemoglobin levels among rural women,
while the thiamine, zinc and plant protein driven nutrient pattern was associated with a trend of
increasing glycated haemoglobin levels in the urban men (Table S7). However, plant protein and
zinc, which were high in these nutrient patterns, have been reported to independently lower fasting
glucose levels [30–33]. In addition, the thiamine, zinc and plant protein driven nutrient pattern was
associated with a trend of decreasing glycated haemoglobin and fasting glucose levels in the rural
men. In view that the study population comprised people who consumed diets with both animal
and plant based nutrients and not purely vegetarians, the discrepancies in the associations of the
plant driven nutrients can be explained by the varied proportions of animal protein, saturated fat,
mono-saturated fat, cholesterol and sugar among these plant driven nutrient patterns, as illustrated
in Table S3. The magnesium, phosphorus and plant protein driven nutrient pattern in rural women
and the thiamine, zinc and plant protein driven nutrient pattern in urban men had higher loadings of
animal protein, saturated fat, mono-saturated fat, cholesterol and sugar compared to the other nutrient
patterns discussed below such as the starch, dietary fibre and B vitamins driven nutrient pattern
among rural women and the thiamine, zinc and plant protein nutrient pattern among rural men which
associated with low fasting glucose and glycated haemoglobin levels. Animal protein, saturated fat,
cholesterol and sugar are high in Western dietary patterns which have been previously associated
with increased risk of T2D and this helps clarify the positive trend of association of the magnesium,
phosphorus and plant protein driven nutrient pattern in rural women and the thiamine, zinc and plant
protein driven nutrient pattern in urban men with the study outcome variables [34]. The comparisons
of the varied constituents of the plant driven nutrients as discussed above and illustrated in Table S3
indicates the attractiveness of the PCA approach of nutrient pattern determination as it allows a whole
based approach of the effect of nutrients to particular outcomes to be evaluated.
The starch, dietary fibre and B vitamins driven nutrient pattern was consistently associated
with reduced fasting glucose and glycated haemoglobin levels in all the multivariate linear models
which were considered in this study among rural women. The thiamine, zinc and plant protein
nutrient pattern was also associated with significant reductions in glycated haemoglobin and fasting
glucose among rural men. These findings are similar to the results of other studies on plant based
dietary patterns and T2D risk [10,34]. It has been consistently reported that plant based diets are
protective against T2D risk [10,34,35]. A number of mechanisms have been proposed to explain this
phenomenon [10]. Plant based diets which are rich in dietary fibre are suggested to reduce T2D risk
by reducing postprandial insulin demand, improving insulin sensitivity and the antioxidants found
in these diets may help enhance β-cell function [36,37]. Dietary fibre from cereal foods which are
also high in starch has been consistently shown across eight European countries to be associated with
reduced T2D risk [38]. Maize meal fortified with iron, zinc and B vitamins which is largely consumed
among the black South African population group is known to contain resistant starches that are
partially digested and have been associated with improved insulin sensitivity which may then lead to
reductions in fasting glucose levels [39,40]. Thiamine was also high in this nutrient pattern. Evidence
exists that dietary fibre beneficial effects might also be due to its concomitant intake together with
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and plant protein consumed together may lead to the lowering of fasting and glycated haemoglobin
levels as has been postulated elsewhere [35].
The strengths of the current study include the use of a validated QFFQ and recruitment criteria of
selecting apparently healthy individuals who were not taking chronic medications or suffering from
chronic diseases. This might have helped to prevent the confounding of drugs and T2D to the nutrient
pattern association results with glycated haemoglobin and fasting glucose levels. The factor analysis
approach used to derive the nutrient patterns is known for depicting real-world dietary behaviours [42].
However, this approach is based on a number of subjective decisions such as naming nutrient patterns,
method of rotation and selection of food groups which can lead to an overall measurement error [10,42].
Since this approach is a posteriori analysis tool, it derives nutrient patterns based on data at hand and
this makes comparisons with other studies difficult [10,42]. However, regardless of the differences
in the constituents of the nutrient patterns due to the data driven approaches used to derive them,
consistent similarities of the dietary factors associated with T2D risk as reported in this study, has been
depicted in multiple populations [10,34,37]. It might be probable that the residual confounding effect
of total energy intake might have led to distortions in the association of the nutrient patterns with
fasting glucose and glycated haemoglobin levels. Residual confounding is a result of measurement
error in a confounder included in the model [43]. Although the nutrient and total energy intake based
on the QFFQs are not precisely measured, adjustment for total energy intake should control for total
energy intake confounding [44]. However, evidence exists that the control of total energy intake is not
complete in epidemiological studies involving QFFQs thereby leading to residual confounding [44,45].
Therefore, there is need to further explore the association of the nutrient patterns in isocaloric clinical
trials which are better designed to control for confounding for total energy intake [45].
5. Conclusions
In summary, our results indicate the beneficial associations of plant driven nutrient patterns with
reductions in fasting glucose and glycated haemoglobin levels. However, the small variances that
were explained by the models explored in this study are suggestive of the presence of other factors
that affect the variation of fasting glucose and glycated haemoglobin which were not accounted for in
this study. Thus, more studies are required to further explore the association of nutrient patterns with
fasting glucose and glycated haemoglobin.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/1/9/s1,
Table S1. Extracted nutrient patterns and factor loadings of rural women and rural men, Table S2. Nutrient
patterns and factor loadings for urban participants, Table S3. Comparison of the factors loadings in the plant
driven nutrient patterns among the urban and rural participants, Table S4. Regression coefficients for fasting
glucose for 1 SD increase in the derived nutrient pattern scores among urban black South African women, Table S5.
Regression coefficients for glycated haemoglobin for 1 SD increase in the derived nutrient pattern scores among
urban black South African women, Table S6. Regression coefficients for fasting glucose for 1 SD increase in
the derived nutrient pattern scores among urban black South African men, Table S7. Regression coefficients
for glycated haemoglobin for 1 SD increase in the derived nutrient pattern scores among urban black South
African men.
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Abstract: Emerging studies revealed that maternal protein restriction was associated with increased
risk of type 2 diabetes mellitus in adulthood. However, the mechanisms of its effects on offspring,
especially during early life of offspring, are poorly understood. Here, it is hypothesized that impaired
metabolic health in offspring from maternal low-protein diet (LPD) is associated with perturbed
miRNAs expression in offspring as early as the weaning age. We examined the metabolic effects on
the C57BL/6J mice male offspring at weaning from dams fed with LPD or normal chow diet (NCD)
throughout pregnancy and lactation. Maternal LPD feeding impaired metabolic health in offspring.
Microarray profiling indicated that mmu-miR-615, mmu-miR-124, mmu-miR-376b, and mmu-let-7e
were significantly downregulated, while, mmu-miR-708 and mmu-miR-879 were upregulated in
LPD offspring. Bioinformatic analysis showed target genes were mapped to inflammatory-related
pathways. Serum tumor necrosis factor-α (TNF-α) levels were higher and interleukin 6 (IL-6) had a
tendency to be elevated in the LPD group. Finally, both mRNA and protein levels of IL-6 and TNF-α
were significantly increased in the LPD group. Our findings provide novel evidence that maternal
LPD can regulate miRNAs expression, which may be associated with chronic inflammation status
and metabolic health in offspring as early as the weaning age.
Keywords: maternal low-protein diet; metabolic health; microRNAs; inflammation; early life; offspring
1. Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is increasing significantly throughout the
world. However, the pathogenesis of diabetes has not been clearly demonstrated. Traditionally, it is
generally believed that genes and adult lifestyle are critical factors of some metabolic diseases. Recently,
several epidemiological studies of human populations highlighted that maternal nutrition, including
over-nutrition and under-nutrition, may strongly influence the risks of developing metabolic diseases
in adult life [1–3]. The mechanism underlying the increased susceptibility of T2DM in offspring of
maternal malnutrition is poorly determined.
Recently, it seems as though epigenetic modifications may be one of the major mechanisms
explaining the association between early life malnutrition and late-onset diseases, such as obesity,
insulin resistance, impaired glucose tolerance, and T2DM [4–7]. MicroRNAs (miRNAs) have emerged
as important epigenetic modifications in recent years. They are a major class of small non-coding RNAs
with about 20–22 nucleotides, which can mediate posttranscriptional regulation of gene expressions.







Nutrients 2017, 9, 205
miRNAs can specifically bind to the 3′-untranslated regions (3′-UTR) of target genes, resulting in
translation inhibition [8]. Numerous studies show that miRNAs play critical roles in the pathogenesis
of diabetes, such as glucose uptake, transport, and insulin secretion [9].
Human studies have revealed that poor intrauterine environment elicited by maternal dietary
insufficiency or imbalance increased the risk for intrauterine growth restriction (IUGR) and led to
metabolic diseases in the offspring during adulthood, such as insulin resistance, impaired glucose
tolerance, and T2DM [3,10]. The maternal protein restriction model, with 5%–9% protein, as compared
to 20% protein in normal diet, has been one of the most extensively studied models [11]. However,
these studies were confined to long-term influences in offspring of a maternal low-protein diet (LPD)
with varying durations range from 1 to 18 months (adulthood to aging) [12–14], yet the metabolic
health in the early life of offspring, such as at weaning, has not been well documented. Furthermore,
little information is known about the role of miRNAs between maternal low-protein diet (LPD) and
glucose metabolism in the early life of offspring, such as at weaning. It is noted that computational
predictions of miRNA targets based on several databases exhibits that one single miRNA can affect a
gamut of different genes, ranging from several to hundreds, suggesting that a large proportion of the
transcriptome is subjected to miRNA modulation [15]. Thus, using a trans-generational mouse model
of maternal protein restriction and microarray platform, we address the hypothesis that impaired
metabolic health in offspring from LPD-fed dams is associated with perturbation of the programmed
expression of key miRNAs in offspring as early as at weaning age.
2. Materials and Methods
2.1. Animals and Diets
The seven-week-old C57BL/6J female and male mice were purchased from the Institute of
Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College
(Beijing, China). All of the mice were maintained under controlled conditions with room temperature
at 22 ± 2 ◦C and 12-h light/dark cycle. The mice were fed a normal chow diet (NCD) (D02041001,
Research Diets, New Brunswick, NJ, USA) for one week for acclimatization. Then, mating was
performed by housing males with females together (male:female = 1:2) until a vaginal plug was
detected, which was considered day 0.5 of pregnancy. Pregnant females were single-housed and were
randomly assigned to either isocaloric LPD (9.6% protein, 80.2% carbohydrate, and 10.2% fat as kcal%,
D02041002, Research Diets, New Brunswick, NJ, USA) or NCD (23.5% protein, 66.3% carbohydrate,
and 10.2% fat as kcal%, D02041001, Research Diets, New Brunswick, NJ, USA) during pregnancy and
lactation. Thus, offspring were divided into two groups according to maternal diets as the LPD group
and the NCD group. At day 1 after birth, all of the litters were adjusted to six pups each to ensure
no litter was nutritionally biased. Birth weight was measured by calculating the average of one litter.
All offspring were weaned at 21 days postnatal. At weaning, only one male offspring was randomly
selected from one litter and was sacrificed in each group (one mouse per litter, n = 6 to 8 per group).
The female offspring were not examined in our present study in order to prevent confounding factors
related to their hormone profile and estrus cycle. Blood samples were taken from the intraorbital
retrobulbar plexus after 12-h of fasting in anesthetized mice, and the liver samples were quickly
removed, snap frozen in liquid nitrogen, and stored at −80 ◦C for further analysis. Body weight
in offspring and food intake of dams were monitored weekly. All of the animal experiments were
conducted in accordance with the Guide of the Care and Use of Laboratory Animals (NIH Publication
No. 86-23, revised 1996) and were approved by the Animal Care and Use Committee of the Peking
Union Medical College Hospital (Beijing, China, MC-07-6004).
2.2. Glucose Tolerance Tests
The tolerance test was performed as described previously [16]. Mice were overnight-fasted
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intraperitoneally with glucose (2 g/kg body weight), and blood glucose was measured at 30 min,
60 min, and 120 min following injection using a glucometer (Bayer, Beijing, China). Blood glucose
response to glucose tolerance tests was calculated as the area under the glucose curve for each mouse
according to the trapezoidal method, as previously described [17].
2.3. Measurement of Serum Insulin and Inflammatory Factors
Serum insulin levels were measured using the mouse ultrasensitive insulin enzyme-linked
immunosorbent assay (ELISA) kit (80-INSMSU-E01, ALPCO Diagnostics, Salem, NH, USA). Serum
interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) concentrations were measured by mouse
ELISA kits (ab100712 and ab108910, Abcam, MA, USA), respectively.
2.4. Microarray Profiling of MiRNAs in Offspring
Because of financial constraints, we could not perform a whole genome array for each mouse
in the LPD and NCD groups. Thus, in order to obtain a relatively reliable estimate of the mean
gene expression, each group contained three biological replicates, which were randomly selected
from each group. We performed the microarray with pooled RNA samples, a method that has been
shown to be appropriate and statistically valid for efficient microarray experiments, according to
previous studies [18,19]. As our study previously described [20], total RNA was extracted from the
liver tissues in LPD and NCD offspring using Trizol reagent (Life Technologies Inc., Carlsbad, CA,
USA), according to the manufacturer’s instructions. MiRNAs expressions in livers were detected by
GeneChip microRNA 3.0 Array (Affymetrix, Inc., Santa, CA, USA), which provides for 100% miRBase
v17 coverage [21,22].
2.5. Differential MiRNAs Expression Analysis in Offspring
Robust Multi-array Analysis (RMA) was utilized to convert raw data into recognizable miRNA
expression data. Then it was followed by median normalization and log2 transformation using Affy
package [23]. Differentially-expressed miRNAs between the LPD and NCD groups were analyzed
by the Limma package of R language [23], which is based on the combined two criteria for true
positive differences: (1) |FC (fold change)| ≥ 2 and (2) p value < 0.05 [21], which is a relatively robust
cutoff point.
2.6. Bioinformatics Analysis of Predicted Targets for MiRNAs in Offspring
All of the microarray data were also pooled for further analysis. According to our previously
published work [24], target genes of differentially expressed miRNAs between the two groups were
identified using the miRWalk database [25], which can provide validated target genes information on
miRNAs for mouse [26]. To further reveal the potential biological functions and pathways of the target
genes, the target genes were analyzed with the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways [27] using Database for Annotation, Visualization and Integrated Discovery (DAVID) [28].
p value < 0.05 was the criterion for significant KEGG pathway terms.
2.7. Validation of Differentially Expressed MiRNAs in Offspring
In order to validate the expressions of differential miRNAs, quantitative real-time PCR (qRT-PCR)
were utilized to detect the relative expression of differentially-expressed miRNAs, with samples
enlarged in each group (n = 6 to 8 per group) using the TaqMan detection system (Life Technologies,
Foster City, CA, USA). All of the mice in each group were included for the validation. Total RNA was
reversely transcribed using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems,
Life Technologies, Foster City, CA, USA). All of the miRNA-specific reverse-transcription primers
were provided with the TaqMan MicroRNA Assay and purchased from Life Technologies Corporation
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(ID 2353), mmu-miR-124 (ID 2197), mmu-miR-376b (ID 2452), mmu-let-7e (ID 2407), mmu-miR-708
(ID 1643), and mmu-miR-879 (ID 2473). U6 small nuclear RNA (ID 1973) was used as an endogenous
control. Gene expression was quantified by qRT-PCR and performed on an ABI prism Vii7 Sequence
Detection System platform (ABI Prism® Vii7, Applied Biosystems, Life Technologies, Foster City, CA,
USA). Data were analyzed and the fold change was calculated using the comparative Ct method.
All reactions were carried out with three biological replicates, and each analysis consisted of three
technical replicates.
2.8. Target Gene Expression by Quantitative Real-Time PCR
For the validation of miRNA target genes, mRNA expressions of target genes were performed
using SYBR Green. Prior to PCR, total RNA of each sample was processed with Rnase-free Dnase
(Qiagen, New York, NY, USA). The RNA was reverse transcribed by 1 μg of total RNA from
each sample using the Power cDNA Synthesis kit (A3500, Promega BioSciences LLC, Sunnyvale,
CA, USA). We used Oligo 7.0 software (Molecular Biology Insights, Inc., Cascade, CO, USA)
to design the sequences of the primers for IL-6, TNF-α, and housekeeping gene β-actin. The
sequences of the primers are as following: IL-6, forward 5′-CCAAGAGGTGAGTGCTTCCC-3′,
reverse 5′-CTGTTGTTCAGACTCTCTCCCT-3′; TNF-α, forward 5′-CCCACGTCGTAGCAAACCA-3′,
reverse 5′-ACAAGGTACAACCCATCGGC-3′; MAPK1, forward 5′-AATTGGTCAGGACAAGGGCT-3′,
reverse 5′-GAGTGGGTAAGCTGAGACGG-3′; β-actin, forward 5′-TGTTACCAACTGGGACGACA-3′
reverse 5′-GGGGTGTTGAAGGTCTCAAA-3′. The reaction production was accurately measured
by the ABI prism Vii7 Sequence Detection System (ABI Prism® Vii7, Applied Biosystems, Life
Technologies, Foster City, CA, USA). Data were analyzed and quantified using the comparative
Ct method, as described in the preceding section.
2.9. Immunohistochemical Staining
The liver tissues from offspring mice were rapidly dissected. Then, they were fixed overnight in a
freshly-prepared 10% buffered formaldehyde solution. The tissue samples were ethanol-dehydrated
and embedded in paraffin wax. Serial 5 μm paraffin embedded tissue sections were mounted on slides.
Then, the slides were stained with the primary antibodies overnight at 4 ◦C, which were IL-6 (1:300;
ab83339, Abcam, Cambridge, MA, USA) and TNF-α (1:50, ab6671, Abcam, Cambridge, MA, USA),
while negative controls were incubated with phosphate-buffered saline (PBS). The slices were then
washed and incubated for 1 h at 37 ◦C with secondary antibodies (1:1000, Cell Signaling, Danvers, MA,
USA). Then, the slides were stained with 3, 3′-diaminobenzidine (DAB) and hematoxylin. Brownish
yellow granular or linear deposits were identified as positive. Image-Pro Plus 5.0 (Media Cybernetics,
Silver Spring, MD, USA) was used for semi-quantitative analysis.
2.10. Statistical Analysis
Results are expressed as the mean ± SEM. Statistical analyses were performed with Student’s
t-tests of unpaired samples. The comparisons of glucose tolerance tests were analyzed with a two-way
ANOVA. Fisher’s exact test was used for KEGG pathway analysis. A p value < 0.05 was considered
statistically significant. Prism version 6.0 (GraphPad Software Inc., San Diego, CA, USA) was used for
statistical analysis.
3. Results
3.1. Effects of Diets on Body Weight and Glucose Tolerance in Dams
By the end of lactation, there was no significant difference in maternal body weight between the
dams (noted as F0) fed with LPD and NCD (Figure 1a). Glucose tolerance testing showed that blood
glucose was indistinguishable between the two groups, as well as with the area under the curve (AUC)
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Figure 1. Effects of diets during pregnancy and lactation on metabolic phenotype in dams. (a) Body
weight; (b) intraperitoneal glucose tolerance tests; and (c) area under the curve (AUC) of glucose
tolerance tests. Data represented as the mean ± SEM (n = 6 to 8, per group). Dams were noted as F0;
LPD, low-protein diet; NCD, normal chow diet.
3.2. Effects of Maternal Diet on Metabolic Profile in Offspring at Weaning
At birth, newborns whose mother was fed with LPD during pregnancy and lactation showed
lower body weight compared to offspring of control diet mothers (p < 0.05, Figure 2a). No significant
difference was found in litter size between LPD and NCD groups (Figure 2b). At weaning, the male
offspring of LPD-fed dams exhibited significantly lower body weight, compared with the offspring
of dams fed a control diet (p < 0.05, Figure 2c). There was no difference of fasted blood glucose in
the LPD and NCD male offspring at weaning. However, the blood glucose of the male offspring in
LPD group was higher at 30 min (p < 0.05) after intraperitoneal glucose administration (Figure 2d).
Consistently, the area under the curve (AUC) of the glucose tolerance test was greater in LPD offspring
(p < 0.05, Figure 2e). We further examined insulin concentration of the male offspring. As consistent
with previous studies [15,29], LPD offspring showed lower fasted insulinemia at weaning, compared
to control offspring (Figure 2f), which may be caused by aberrant insulin secretion due to intrauterine
growth restriction.
Figure 2. Metabolic profile and serum insulin concentration in offspring at weaning. (a) Birth weight;
(b) litter size; (c) body weight at weaning; (d) intraperitoneal glucose tolerance test; (e) area under
curve (AUC) of glucose tolerance test; and (f) serum insulin level. Data represented as the mean ± SEM
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3.3. Differential MiRNAs Expression in Offspring
Six miRNAs were shown to be significantly differentially expressed (|fold change| ≥ 2 and
p value < 0.05) between LPD and NCD groups. In the livers of LPD offspring, mmu-miR-615,
mmu-miR-124, mmu-miR-376b, and mmu-let-7e were significantly downregulated (fold change ≤ −2
and p value < 0.05). Meanwhile, mmu-miR-708 and mmu-miR-879 were significantly upregulated
(fold change ≥ 2 and p value < 0.05) (Table 1, Figure 3).
Table 1. Differentially-expressed miRNA (|fold change| ≥ 2 and p-value < 0.05).
Probe Set ID Fold Change p Value Sequence Length Sequence
mmu-miR-615 −7.61 0.004 22 GGGGGUCCCCGGUGCUCGGAUC
mmu-miR-124 −4.37 0.014 22 CGUGUUCACAGCGGACCUUGAU
mmu-miR-376b −3.81 0.016 21 AUCAUAGAGGAACAUCCACUU
mmu-let-7e −2.60 0.000 22 CUAUACGGCCUCCUAGCUUUCC
mmu-miR-708 3.89 0.007 23 AAGGAGCUUACAAUCUAGCUGGG
mmu-miR-879 10.05 0.034 22 GCUUAUGGCUUCAAGCUUUCGG
Figure 3. The volcano plot of the miRNA array. This graph shows log2 (fold change) in the expression
miRNAs and p value from the t-test between LPD and NCD offspring. The vertical blue line indicates
that the threshold of |log2 (fold change)| is 1. The horizontal red line indicates that the p value
threshold is 0.05. It showed six miRNAs were significantly differentially expressed (|fold change| ≥ 2
and p value < 0.05) between LPD and NCD offspring. LPD, Low-protein diet; NCD, normal chow diet.
3.4. Validation of Differentially Expressed MiRNAs
To verify the results of microRNA array, all the six differentially-expressed miRNAs were validated
by increasing the quantity of samples in LPD and NCD groups using qRT-PCR (n = 6 to 8, per group).
It showed that the expression levels of all the six miRNA were consistent with the results of microRNA
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Figure 4. Differentially-expressed miRNAs were detected by miRNA array and validated by qRT-PCR.
Data represented as the mean ± SEM (n = 6 to 8, per group). The fold change was calculated using the
comparative Ct method. qRT-PCR: quantitative real time-PCR.
3.5. Functional Enrichment Analysis for Target Genes by Bioinformatics Analysis
Furthermore, target genes of these six differentially-expressed miRNAs were identified by the
miRWalk database. The six miRNAs, including mmu-miR-615, mmu-miR-124, mmu-miR-376b,
mmu-let-7e, mmu-miR-708, and mmu-miR-879 had a total of 349 validated target genes in the miRWalk
database (Table 2). By utilizing the Database for Annotation, Visualization and Integrated Discovery
(DAVID) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, the functional enrichment
analysis of these 349 validated genes were mapped in the MAPK signaling pathway, TGF-beta signaling
pathway, Jak-STAT signaling pathway, cytokine-cytokine receptor interaction, chemokine signaling
pathway, adipocytokine signaling pathway, and Toll-like receptor signaling pathway (Table 3), which
are all associated with inflammation responses.
Table 2. Validated targeted genes for differentially-expressed miRNAs.
MiRNA Count Target Genes
mmu-miR-615 6 Msx2, Hoxa7, Mbp, Lin28, Cdkn2a, Igf2
mmu-miR-124 87
Dll1, Sox9, Camk2g, Zic2, Fabp7, Hod, Pou5f1, Dicer1, Fgf8, Fgf10, H1foo, Bmp4, Lin28, Tcfap2b, Calb2,
Btg2, Dcx, Pax6, Ifitm3, Dppa3, Mapk14, Evi1, Nr4a2, Mtpn, Nefm, Eomes, Cpeb1, Ctdspl, Mstn, Gata1,
Stmn2, Rest, Trpm3, Mbp, Hprt1, Th, Oog4, Des, Uchl1, Foxp2, Rho, Eif2c3, Efnb1, Dnmt3b, Dbh ,H2afx,
Npy, Med13, Prkca, Eif2c2, Fgf21, Phox2a, Mos, Gbx2, Emx1, Myh6, Mt1, Eif2c1, L1cam, Phox2b, Ctdsp1,
Lmx1b, Tbr1, Nppa, Ccne1, Ccnb2, Eif2c4, Casp3, Tcfap2a, Sycp1, Gja1, Zp3, Rfpl4, Cdh1, Vax2, Slc6a3,
Dlk1, Ntrk2, Pou3f3, Myh7, Sycp3, H2afz, Stat3, Wnt1, Foxa2, Ntrk3, Gja5
mmu-miR-376b 28 Hprt1, Oog4, Dnmt3b, H2afx, Fgf21, Mos, Dlk1, Mt1, Mbp, Ccne1, Ccnb2, Lin28, Zp3, Rfpl4, Gpr172b,Sycp3, H2afz, Timp4, Camk2g, Dicer1, Atg4c, Pou5f1, H1foo, Frap1, Ifitm3, Dppa3, Cpeb1, Ctdspl
mmu-let-7e 217
Lin28, Casp3, Ptch1, Zfp106, Mov10, Fgf16, E2f6, Fgf21, Ptges, Akt1, Scpep1, Rad52, Mgst1, Cdc34, Git1,
Ebp, Mos, Kras, Il6, Capn10, Col1a1, Smad4, Hace1, Igfbp3, Fas, Hmga2, Fgfr1, Sox2, Irf4, Mt1, Kcnj16,
Socs1, Mmp9, Prl, Nr2e1, Sp1, Il10, Trim71, Notch1, Nrip1, Lamc1, Acvr2a, Smox, Igf2, Cdkn1a, Egr1,
Ccne1, Tagln, Akt1, Ccnb2, Vsnl1, Spp1, Egfr, Syne1, Mdk, Hnf4a, Msi1, Dnmt3a, Cd4, Sparcl1, Hspd1,
Tppp3, Vim, Smad3, Tnf, Cyp2b10, Gtf2h4, Zp3, Hyou1, E2f2, Csf1r, Rfpl4, Akap6, Stat3, Golph3, Snai1, Arc,
Scamp2, bp1, Mov10, Nanog, Clock, Acvr1, Wnt1, Bcl2l1, BC060632, Cdkn2a, Trp53, Fn1, Sycp3, Tpm1,
Scpep1, Lpar1, H2afz, Gmfb, Pten, Arc, Snai1, Dync1i1, Mapre1, Dcn, Bcl2, Scpep1, Hras1, Igf1, E2f6, Grb2,
Camk2g, Ogt, Pgc, Ctcf, Dicer1, Mapk1, Scpep1, Cxcr4, Rcan1, Clu, Dut, Piwil2, Ifng, Mtpn, Dclk1, Igfbp3, ,
Igf1r, Akt1, Kdr, Nanog, Hras1, Neurod1, Dppa3, H1foo, Bmpr2, Ebp, Hmox1, Gpd1, Cyp2b10, Socs3, Inha,
Eif2c2, Epb4.1l3, Serpina1c, Ssr3, E2f2, Dicer1, Mstn, Pten, Ifitm3, Dhcr24, Racgap1, Dppa3, Gad1, Ccr4,
Ddit3, Nr4a1, Hmga1, Ppargc1a, Bcl2, Nr6a1, Gadd45a, Scpep1, Ptp4a2, Nanog, Runx2, Zeb1, Bak1, Ghr,
Birc2, Sall4, Cpeb1, Capn8, Il23r, Ctdspl, Ptges3, Ephb2, Rpe, Syt4, Trim32, Foxp1, Scpep1, Mmp14, Bcl2,
Gnb1, Madd, Pgc, Gnrh1, Hmox1, Myc, Mycn, Socs1, Jarid1b, Hprt1, Cyp2b10, Oog4, Pdzd7, Cdkn1a, Cebpb,
Aqp4, Rdx, Mbp, Hand1, Bcl2, Lancl1, Mapk3, Casp9, Fmr1, Klf15, Dnmt3b, Adora1, Stx1a, Kitl, Cd34,
H2afx, Itgb1, Smad5, Pou5f1
mmu-miR-708 9 Foxo3, Cd34, Mbp, Lin28, Stat5a, Cd34, E2f6, Aqp1, Bmi1
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Table 3. Validated target genes enriched by the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway.
KEGG ID Term Count % p Value Genes
mmu04010
MAPK signaling
pathway 24 9.7 2.8 × 10
−8
Egfr, Prkca, Trp53, Fgfr1, Fgf8, Tnf , Grb2,
Fgf16, Fgf10, Nr4a1, Fgf21, Ddit3, Hras1,
Akt1, Mapk1, Casp3, Kras, Mapk14, Ntrk2,
Mapk3, Mos, Fas, Myc, Gadd45a
mmu04350
TGF-beta signaling
pathway 14 5.7 7.3 × 10
−8
Bmp4, Tnf , Smad5, Bmpr2, Smad4, Smad3,




pathway 14 5.7 4.4 × 10
−5 Il6, Il23r, Socs3, Grb2, Stat5a, Socs1, Bcl2l1,
Stat3, Il10, Akt1, Ifng, Myc, Prl, Ghr
mmu04060
Cytokine-cytokine
receptor interaction 17 6.9 1.4 × 10
−4
Egfr, Il6, Tnf , Il23r, Bmpr2, Kitl, Il10, Kdr,




pathway 11 4.5 9.3 × 10
−3 Akt1, Mapk1, Kras, Ccr4, Gnb1, Cxcr4,
Grb2, Mapk3, Foxo3, Stat3, Hras1
mmu04920
Adipocytokine
signaling pathway 6 2.4 1.9 × 10
−2 Akt1, Tnf , Npy, Socs3, Ppargc1a, Stat3
mmu04620
Toll-like receptor
signaling pathway 7 2.8 2.7 × 10
−2 Akt1, Mapk1, Il6, Tnf , Mapk14,
Mapk3, Spp1
MAPK: mitogen-activated protein kinase; TGF: transforming growth factor; Jak-STAT: janus kinase-signal transducer
and activator of transcription. Il-6 and Tnf were marked as bold.
3.6. Effects of Maternal Diet on Serum Pro-Inflammatory Cytokines in Offspring
Our functional enrichment analysis indicated that target genes of our six differentially-expressed
miRNAs were mapped in inflammatory pathways (Tables 2 and 3). IL-6 and Tnf were two important
target genes, which were located in several pathways (marked as bold in Table 3). Therefore, we
first measured two important pro-inflammatory cytokines (serum IL-6 and TNF-α) in male offspring
of dams fed with LPD and NCD, to determine whether maternal diets modulated the levels of
inflammatory markers in the early life of offspring. It showed there was a tendency to be higher of
serum IL-6 level in LPD male offspring (p = 0.07) (Figure 5a), and it also showed the level of serum
TNF-α was significantly elevated in LPD male offspring at weaning (p < 0.05) (Figure 5b). However,
no difference of MAPK1 expression was observed in offspring (data not shown).
Figure 5. Effect of maternal LPD on serum IL-6 and TNF-α concentrations and mRNA expression in
the offspring at weaning. (a) Serum IL-6; (b) serum TNF-α; and (c) IL-6 and TNF-α mRNA expression
in the livers of offspring. Data represented as the mean ± SEM (n = 6 to 8, per group). * p < 0.05, vs.
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3.7. Differential Expression of Pro-Inflammatory Markers in Offspring
Next, we measured Il-6 and TNF-α expression in liver samples of male offspring of LPD- and
NCD-fed dams using qRT-PCR. It indicated that IL-6 and TNF-α expression were significantly increased
in the LPD group, and the fold change of IL-6 and TNF-α expression is about 1.8 and 2.2, respectively
(p < 0.05, Figure 5c). To further determine whether the protein expressions of IL-6 and TNF-α in
offspring were modulated by maternal LPD, the protein expressions of these two genes were examined
by immunohistochemistry. As shown in Figure 6, there was a statistically significant increase in the
immunoreactivities of IL-6 and TNF-α in the early life of offspring exposed to maternal LPD during
pregnancy and lactation, compared to offspring of NCD-fed dams (p < 0.05).
Figure 6. Immunohistochemistry for IL-6 and TNF-α expression and semi-quantitative assessments.
(left) IL-6 and TNF-α staining in NCD and LPD groups. (right) Semi-quantitative scores of IL-6 and
TNF-α. Data represented as the mean ± SEM (n = 6 to 8, per group). * p < 0.05, vs. the NCD group.
LPD, low-protein diet; NCD, normal chow diet; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α.
4. Discussion
Epidemiological studies and animal experiments have indicated that adverse maternal nutriture
influence organ development and metabolism of progeny, which may increase the susceptibility of
developing diabetes in later life, and even in the following generation [30,31]. Maternal nutrition has
long-term metabolic effects on offspring, which was known as the “fetal programming hypothesis” [32].
Here, our findings demonstrate that the exposure of LPD feeding during pregnancy and lactation
resulted in low birth weight, impaired glucose tolerance, and lower insulin secretion in offspring, at as
early as weaning age. We also observed that offspring from LPD-fed dams showed perturbation of
the programmed expression of some key miRNAs in offspring at weaning. Thus, using microarray
profiling, bioinformatics approaches, and functional enrichment analysis, all of the target genes of
misexpressed miRNAs were mapped in seven inflammatory-related pathways. Finally, we showed
that that serum levels of pro-inflammatory cytokines IL-6 and TNF-α were also increased in offspring
from LPD-fed dams. Furthermore, the mRNA expression and protein levels of IL-6 and TNF-α were
significantly increased in offspring from maternal LPD feeding. Therefore, these results show that
maternal LPD consumption may regulate the expression of miRNAs, which may be associated with
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Figure 7. The possible mechanism of maternal low-protein diet during pregnancy and lactation
on offspring at weaning. Maternal nutrition has long-term metabolic effects on offspring, which is
known as the “fetal programming hypothesis”. Epigenetics (such as miRNAs) has been deemed
as an important molecular basis of maternal nutrition and metabolic health in offspring. Using
functional enrichment analysis, the target genes of differentially-expressed miRNAs were mapped
into seven pathways, which are all associated with inflammation. Thus, it may be related to chronic
low-grade inflammation, which may cause impaired insulin secretion and glucose intolerance. MAPK:
mitogen-activated protein kinase; TGF: transforming growth factor; Jak-STAT: Janus kinase-signal
transducer and activator of transcription.
Obesity, insulin resistance, and diabetes mellitus are associated with chronic low-grade
inflammation [33–35]. One recent review summarized that chronic inflammation is characterized
by increased levels of pro-inflammatory cytokines in response to physiological and environmental
stimuli that can arrest the immune system in a low-level activation state [36]. Our study demonstrates
that maternal protein restriction diet during pregnancy and lactation may induce an inflammatory
state in offspring at weaning age. Similar to our study, one recent study showed that male Wistar
rats exposed to a low-protein (8%) diet in utero that had a low birth weight, but then underwent
postnatal catch-up growth exhibited higher indexes of inflammatory, with increased hepatic expression
of interleukin-6 (IL-6) levels, tumor necrosis factor α (TNF-α), and monocyte chemotactic protein-1
(MCP-1) at 12 months of age [37]. Sílvia et al. also showed that maternal low-protein (6%) diet during
pregnancy and lactation showed increased transcription of nuclear factor kappa B (NF-κB) and IL-6,
with reduced transcription of interleukin-6 (IL-10) (an anti-inflammatory cytokine) at 90 days of age in
offspring [38]. However, the inflammatory state of offspring was examined at an adult or even older
age in the aforementioned studies. Here our findings demonstrate that maternal LPD feeding during
pregnancy and lactation can induce an inflammatory state in the offspring as early as weaning age.
In our previous study, we found that a maternal high-calorie diet is associated with altered hepatic
microRNA expression and impaired metabolic health in offspring at weaning age [20]. The composition
of the high-calorie diet is 16.4% protein, 25.6% carbohydrate, and 58% fat as the kcal%. However, we
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offspring. We cannot draw a conclusion that the same biological mechanisms are at play in these two
studies because our study is very preliminary, which needs further experimentation and validation.
However, we can speculate that maternal malnutrition (whether over-nutrition or under-nutrition)
may be associated with aberrant metabolic health and inflammation status in offspring at weaning.
Increasing evidence showed that epigenetic information could be inherited as a trans-generational
carrier between generations. It showed that nutrient-dependent regulation of miRNAs may trigger
disease susceptibility and metabolic complications in offspring [39]. One clinical study indicated that
placental expression of miR-210 increased in preeclampsia and was inversely related to birth weight and
gestational age [40]. It showed that a maternal low-protein diet exhibited impaired glucose tolerance
and suppressed pancreatic β-cell proliferation in mouse offspring via miR-15b at 12 weeks of age [41].
In addition to maternal nutrition, the advanced fetal programming hypothesis proposes that maternal
genetic variants may influence the offspring’s phenotype indirectly via epigenetic modification. Hocher
et al. showed that altered expression of hepatic microRNA was observed in offspring of female
eNOS −/+ mice, demonstrating that a maternal genetic defect can epigenetically alter the phenotype
of the offspring, without inheritance of the defect itself [42]. Recently, inflammatory signaling has
been identified as an epigenetic mediator and increasing evidence has shown the epigenetics can
regulate inflammatory gene expression, which can ultimately result in multiple adverse physiological
consequences [43]. Our study shows that validated target genes of differentially-expressed miRNAs
in offspring from LPD-fed dams are part of inflammatory signaling pathways. IL-6 and TNF are two
validated target genes of let-7e. Recent findings offer a putative role of non-coding RNAs, especially
miRNAs, in the progression and management of the inflammatory response [44]. The let-7 family of
miRNAs is highly conserved across diverse animal species, and plays critical roles in the regulation
of cell proliferation and differentiation [45]. In addition to cancer, an altered expression of let-7 has
been reported in inflammation. Let-7 miRNAs demonstrated to be repressed in inflammation, which
resulted in increased expression of pro-inflammatory cytokines and increased inflammatory status [46],
which is consistent with our results. One clinical study showed that let-7e target genes were predicted
to be associated with ulcerative colitis susceptibility [47]. In addition, several miRNAs, such as miR-126,
miR-132, miR-146, miR-155, and miR-221 have also emerged as important transcriptional regulators of
some inflammation-related mediators [44]. Therefore, we propose that maternal protein restriction diet
induce altered hepatic microRNA expression, which may be associated with enhanced inflammatory
responses in offspring as early as at weaning age.
To the best of our knowledge, our study provides the first evidence that maternal LPD feeding
may regulate the expression of miRNA, which may be associated with chronic inflammation status
and glucose intolerance in offspring as early as weaning age. However, some limitations should be
considered in our study. First, we agree with the reviewer that our data is preliminary and cannot
exclude the possibility that the association between miRNAs and markers of inflammation is due to
a state of chronic systemic inflammation causing altered hepatic miRNA, rather than the other way
around. Second, our present study focused on the mechanisms between maternal protein restriction
and its detrimental effects on offspring during early life of offspring and there was no data on long-term
effects in adulthood of our model. Our further research will be focused on the miRNAs expression
and inflammation status in older mice offspring to examine the long-term effects in adulthood of
our model. Third, the function of miRNA analysis, which showed to be related to inflammation,
is mainly based on microarray profiling, bioinformatics analysis, and some preliminary molecular
biology experiments. Therefore, using in vivo and in vitro experiments, further studies should be
investigated to demonstrate the role of perturbed miRNA expression on glucose metabolism and
inflammation status. A fourth limitation is that it is unknown when the critical time window of
maternal LPD consumption is; during the gestation period or lactation period, or both periods. Our
undergoing work aims to determine the effects of LPD in the dams on glucose metabolism in offspring
in specific time window. Furthermore, recent reviews showed that paternal nutritional challenges
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sperm micro-RNAs, histone acetylation, and targeted, as well as global, DNA methylation seem to be
particularly involved in paternal programming of offspring’s diseases in later life [48,49]. Therefore,
our future study will be interested in examining the underlying epigenetic mechanism linking paternal
nutrition and its programming effect on offspring.
In conclusion, here we demonstrated that maternal protein restriction diet with IUGR predisposes
to impaired glucose tolerance in the offspring as early as weaning age. This study contributes to
the current knowledge on the putative role of miRNAs between maternal low-protein diet and
metabolic health in offspring, which are likely to be associated with inflammatory responses. A better
understanding of the function of these miRNAs might open the way to the development of new
strategies for the early prevention of diabetes. Thus, further studies in the field of trans-generational
effects to clarify the underlying mechanisms are urgently warranted.
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Abstract: Consistent evidence from both experimental and human studies suggest that inadequate
nutrition in early life can contribute to risk of developing metabolic disorders including type 2 diabetes
(T2D) in adult life. In human populations, most findings supporting a causative relationship between
early-life malnutrition and subsequent risk of T2D were obtained from quasi-experimental studies
(‘natural experiments’). Prenatal and/or early postnatal exposures to famine were demonstrated
to be associated with higher risk of T2D in many cohorts around the world. Recent studies have
highlighted the importance of epigenetic regulation of gene expression as a possible major contributor
to the link between the early-life famine exposure and T2D in adulthood. Findings from these studies
suggest that prenatal exposure to the famine may result in induction of persistent epigenetic changes
that have adaptive significance in postnatal development but can predispose to metabolic disorders
including T2D at the late stages of life. In this review, quasi-experimental data on the developmental
programming of T2D are summarized and recent research findings on changes in DNA methylation
that mediate these effects are discussed.
Keywords: type 2 diabetes; famine; natural experiment; quasi-experimental design; epigenetics
1. Introduction
Type 2 diabetes (T2D) is one of most common chronic diseases, constituting a serious social
and economic problem in modern societies, both developed and developing. It is caused by insulin
resistance resulting from decreased activity and enhanced obesity levels that occur with increasing
age. T2D is considered to be adult-onset disease, since it typically occurred in middle-age and old
adults. Generally, T2D occurs after the age of 40, although it is now increasingly diagnosed in younger
patients [1]. Over the last decades, a rapid increase in the prevalence of obesity arising from high
caloric diet intake and sedentary lifestyle is driving a global pandemic of T2D. Currently, 415 million
people (about 9% of whole adult population) across the world have T2D. During the next decade,
the number of T2D patients is expected to rise to around 642 million persons [2]. Obviously, genetics
plays a crucial role in driving this disease; however, the dramatic increase in T2D incidence across the
globe cannot be explained by genetic factors alone but must involve environmental factors as well [3].
There is increasing experimental and epidemiological evidence that the risk of development of T2D
can be influenced not only by actual adult-life environmental conditions (primarily, lifestyle ones)
but also by conditions in early life [3]. Convincing evidence that risk of T2D cannot be completely
attributable to genetic predisposition and/or adult-life environmental factors was obtained, e.g., in a
study on Pima Indian nuclear families in which at least one sibling was born before and other after the
mother was diagnosed with T2D [4]. In this research, those siblings conceived after the mother has
been diagnosed with T2D were 3.7 times more likely to have T2D compared to siblings born before
their mother developed diabetes, even though they lived in similar conditions the rest of their life.
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In the present review, we have summarized and discussed findings on this topic from
epidemiological studies conducted with quasi-experimental design (‘natural experiments’).
2. Conceptual Framework for Developmental Nutritional Programming of Type 2 Diabetes (T2D)
According to the developmental programming of health and disease (DOHaD) hypothesis, which
has been confirmed by many research findings over the past decades, the physiology and structure
of the developing organism may be adapted in response to unfavourable environmental conditions,
thereby predisposing it to many pathological conditions in adult life [5]. In particular, poor nutritional
environments in early life can induce structural and functional changes in key organs responsible
for nutrient regulation, including brain, liver, adipose tissue, muscle and pancreas [6]. Presently, this
view is commonly referred to as the ‘predictive adaptive response (PAR)’ concept [7]. Exposure to
adverse environmental factors such as inadequate or unbalanced nutrient supply during in utero
development may ‘program’ for the long term appetite regulation, feeding behaviour, as well as
adipose tissue and pancreatic beta cell dysfunction in the developing foetus [3]. As a result of
these processes, the foetus may be adapted to adverse nutritional conditions by reducing ability
to produce insulin and by occurrence of insulin resistance. According to the ‘thrifty phenotype’
hypothesis [8], such metabolic adaptation may provide short-term survival benefit in a poor postnatal
environment via enhanced capacity to store fat in conditions of irregular availability of food resources,
but may predispose the child to T2D development in conditions of food abundance in postnatal
life. More specifically, in malnourished conditions when the foetus exhibits poor growth in utero
(commonly referred to as intrauterine growth restriction, IUGR), the foetal adaptation to undernutrition
is realized by a variety of mechanisms responsible for the energy and glucose metabolism, such as
enhanced peripheral insulin sensitivity for glucose utilization, increased hepatic glucose production,
lowered insulin sensitivity for protein synthesis in muscle, and impaired pancreatic development [9].
All these mechanisms provide obvious survival benefit for the IUGR foetuses by promoting both
energy uptake and utilization, reducing the demand for amino acids and anabolic hormone production,
and elevating glucose production to maintain glucose supply to vital organs, primarily the heart and
brain. These adaptations lead to asymmetrical growth restriction of the foetus. The muscle and
subcutaneous tissues exhibit the most pronounced growth restriction, while the least pronounced
growth restriction is peculiar to the growing brain. Collectively, such adaptations allow IUGR foetal
tissues to maintain the energy-dependent basal metabolic functions at the expense of body growth
in conditions of reduced nutrient supply. If these adaptive modifications persist, or are more readily
inducible later in life, they have the potential to promote energy absorption beyond metabolic capability
when energy supplies increase, thereby causing insulin resistance, obesity and T2D in adulthood [9].
Among the factors affecting the risk of metabolic dysfunctions, including T2D, in adulthood, the
prenatal and early postnatal malnutrition (both under- and overnutrition) is currently believed to be
most important [10,11]. It should be noted that in this review only one aspect of malnutrition i.e.,
undernutrition but not overnutrition will be discussed.
The majority of early population studies used birth weight as a proxy for foetal conditions.
From the data obtained, it has been initially concluded that low birth weight is a risk factor for
T2D and that birth weight is inversely related to the disease risk [12]. In addition to T2D, low birth
weight is a predictor of other T2D-associated conditions and complications later in life, including the
impaired body composition and fat distribution [13], fasting lipid profile, blood pressure and insulin
resistance [14], life-long activation of the hypothalamic-pituitary-adrenal axis [15], as well as coronary
heart disease in adulthood [16]. Several more recent studies, however, found that a relationship
between birth weight and risk of T2D is not linear but rather U-shaped, and high birth weight (>4000 g)
is associated with an increased risk of T2D to the same extent as low birth weight (<2500 g) [17].
An association between low birth weight and risk of T2D in later life is most thoroughly studied
to date. This association is apparently mediated by catch-up growth early in life which is an important
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gain in comparison with lean tissue gain [18]. Such preferential catch-up fat is partly driven by
mechanisms of energy conservation operating through suppression of thermogenesis and resulting
in the development of thrifty ‘catch-up fat’ phenotype generally characterized by insulin and leptin
resistance. Abnormalities in the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, known
to play a central role in promoting human growth and development, have been repeatedly reported in
children born small for gestational age (SGA) [19]. Such long-lasting abnormalities of IGF-1 in SGA
children with catch-up growth are believed to be critically implicated in the association with metabolic
disorders, including T2D, later in life.
Precise molecular mechanisms responsible for the nutritional developmental programming of
T2D are not yet thoroughly characterized. In many recent studies, compelling evidence was provided
that changes in epigenetic regulation of gene expression (heritable alterations in gene function without
changes in the nucleotide sequence) is the most plausible mechanism for the link between unfavourable
conditions in early development and adverse health outcomes in later life [20]. The main epigenetic
mechanisms are DNA methylation and post-translational modifications of histone tails, as well as
regulation by non-coding RNAs (microRNAs and long non-coding RNAs) [21]. Evidence for the key
role of DNA methylation and other epigenetic mechanisms in mediating the risk of T2D and obesity
has been repeatedly documented over the past years [22]. Initial evidence for the role of epigenetic
regulation in obesity and T2D has been mainly provided by studies in animal models. These studies
reported changes in epigenetic marks in key metabolic tissues following feeding with high-fat diet and
by human investigation that demonstrated epigenetic alterations in T2D and obesity candidate genes
in obese and/or diabetic persons. More recently, rapid technological advances and price reduction in
epigenetic methodologies led to a rapid expansion of epigenome-wide association studies (EWAS) in
human epidemiological examinations [22]. These studies clearly demonstrated epigenetic differences
between diabetic and healthy control individuals, as well as epigenetic alterations associated with
lifestyle interventions.
Within the DOHaD concept, an important point is that throughout embryonic and foetal
development, intense epigenetic remodelling takes place that is necessary for the establishment
of transcriptional programs responsible for cellular proliferation and differentiation. During
these sensitive developmental periods, the epigenome is especially plastic and most sensitive to
environmental disturbances [23]. Numerous research findings suggest that early-life adverse events
(i.e., insufficient nutrition in utero) might be epigenetically ‘imprinted’ and ‘remembered’ decades
later, thereby permanently influencing the metabolic phenotype [24]. There is convincing evidence
that epigenetic alterations, including those triggered by early-life events and persisting through
adulthood, is an important etiological factor in the development of T2D. Changes in DNA methylation
and associated changes in patterns of expression of genes implicated in various aspects of glucose
metabolism such as β-cell dysfunction, glucose intolerance and insulin resistance, have been shown to
be critically involved in the pathogenesis of T2D [25]. The specific DNA methylation markers have
been repeatedly identified in peripheral blood and pancreatic islets of the T2D patients (for review,
see [26]).
A schematic representation of hypothetical regulatory pathways responsible for developmental
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Figure 1. Schematic representation of hypothetical regulatory pathways responsible for developmental
programming of type 2 diabetes (T2D) through prenatal undernutrition followed by catch-up growth
in a nutrient-rich postnatal environment.
3. Evidence from Animal Models
The bulk of evidence linking intrauterine and/or early postnatal nutrient environment and
predisposition to beta-cell failure and T2D in adulthood comes from animal models (for review,
see [27–29]). Most of these studies have used rodent models of 50% maternal dietary restriction
(DR) during pregnancy to examine the postnatal beta-cell mass development in pups exposed to
either normal or restricted post-natal nutritional conditions. Rodents exposed to intrauterine DR and
subsequent normal or restricted post-natal nutrition exhibited diminished beta-cell mass both at birth
(30%–50% vs. control) and throughout the early postnatal development (50%–70% vs. control) [30–33].
In adulthood, these animals were unable to adaptively enhance beta-cell mass in response to rising
metabolic demand and consequent insulin resistance. As a result, they developed diabetic phenotypes
characterized by beta-cell failure due to insufficient expansion of beta-cell mass, impaired insulin
secretion, glucose intolerance and fasting hyperglycaemia [34,35]. For example, in a study using
cross-fostering methodology to isolate effects of selective pre- and postnatal 50% DR [36,37], prenatal
DR resulted in a ~50% reduction in beta-cell mass whereas postnatal DR led to decreased body
weight, but both beta-cell mass and beta-cell fractional area were increased compared with control
animals. These findings indicate that prenatal DR largely determines endocrine cell development
while postnatal DR primarily impacts development of the exocrine pancreas [37].
Currently, molecular mechanisms responsible for impaired formation of beta-cell mass in
response to early-life DR have come under intensive investigation. Among them, mechanisms of
epigenetic regulation of gene activity seem to play a dominant role [38–40]. Inadequate nutritional
environment during intrauterine development suppressed transcription of key genes regulating
beta-cell development in rats [39]. Feeding pregnant females with a low-protein diet led to
hypomethylation of genes encoding glucocorticoid receptor and peroxisome proliferator-activated
receptor gamma in the offspring livers. In a rat model, maternal DR also resulted in a significant
reduction in the levels of expression of genes encoding key transcription factors regulating embryonic
beta-cell development such as the pancreatic and duodenal homeobox 1 (PDX-1) [41,42]. Such changes
on the epigenetic level were accompanied by reduced postnatal beta-cell formation and incapability to
expand beta-cell mass in response to metabolic stress. Moreover, maternal DR diminished the postnatal
expression of Pdx-1 gene in pancreatic exocrine ducts which is suspected to harbor a putative pool of
pancreatic beta-cell progenitor population in adult rodents [39]. Other factors potentially contributing
to these effects are hormones that operate during foetal life, such as insulin, insulin-like growth factors,
glucocorticoids, as well as some specific molecules such as taurine [43].
In several studies, maternal protein restriction has been shown to program an insulin-resistant
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restriction. Such mode of malnutrition resulted in expression of early markers of insulin resistance
and metabolic disease risk, including alterations in adipocyte cell size and expression levels of
several insulin-signalling proteins through post-transcriptional mechanisms [44]. Catch-up growth
following maternal protein restriction also favoured the development of obesity in adult male rat
offspring [45]. In a mice model, a protein restriction during foetal life followed by catch-up growth
led to obesity in adult male mice [46]. These changes were associated with increased relative fat mass,
hypercholesterolemia, hyperglycaemia and hyperleptinemia, and also with altered expression profile
of several gene-encoding enzymes involved in lipid metabolism.
4. Quasi-Experimental Design in Studying the Developmental Origin of T2D
The experimental research of developmental programming in human populations is not
applicable, either for ethical reasons and because the long-term follow-up is required to observe
life-long outcomes of early-life experiences. In this regard, an important point is that observational
studies in appropriate populations may be realized. The consistent evidence linking the early-life
conditions with adult health status has been accumulated from studies conducted with a
quasi-experimental design (‘natural experiments’), defined as “naturally occurring circumstances
in which subsets of the population have different levels of exposure to a supposed causal factor,
in a situation resembling an actual experiment where human subjects would be randomly allocated
to groups” [47]. Both natural and man-made disasters such as famine obviously provide a lot of
advantages to their use in quasi-experimental studies. In the sections below, empirical findings from
such a line of research across countries are reviewed.
4.1. Dutch Famine of 1944–1945
The long-term health consequences of the Dutch famine (‘Hunger Winter’) are the most
comprehensively studied up to now. This famine, caused by the Nazi food embargo, affected the
western Netherlands from November 1944 to May 1945. Many features of the Dutch famine can be
used in a quasi-experimental design. It was a severe famine, distinctly defined in time and place and
occurred in a society with a well-developed structure of administrative control. Therefore, exposure
to this famine may be accurately defined by region and date of birth in relation to distribution of the
food rations and the level of calories consumed. Such circumstances of the Hunger Winter famine
provide the opportunity to thoroughly examine the link between inadequate maternal nutrition during
particular trimesters of pregnancy and the offspring’s adult health status. While a normal daily ration
is 2000 kcal and 2500 kcal for women and men, respectively, the average daily rations during the
famine were less than 700 kcal [48]. The population that suffered from severe food shortage throughout
the famine was generally well fed before and after this period. These features of the Dutch famine
provide the researchers with a near-ideal quasi-experimental research design to examine how maternal
malnutrition throughout the critical early-life time windows can affect the life-course offspring health
status. The prenatal exposure to the Dutch famine has been repeatedly shown to be related to the
impaired metabolic phenotypes such as elevated levels of plasma lipids and body mass index (BMI),
as well as enhanced risks of obesity and cardiovascular disease (CVD) later in life (for reviews, see
refs. [48–50]). Most of these associations have been critically dependent on the timing of exposure.
In the majority of the studies, early gestation was found to be the most vulnerable period [48–51].
Childhood and puberty are other sensitive periods with high potential to trigger programming effects.
The link between exposure to the Dutch famine between age 0 and 21 years and T2D in adulthood
was clearly evident, e.g., from the study by van Abeelen et al. [52]. This relationship was found to be
dose-dependent: in those women who self-reported moderate famine exposure during their childhood
and young adulthood, the age-adjusted hazard ratio for T2D was 1.36, and in those who reported
severe famine exposure, the hazard ratio was 1.64 compared to unexposed women. The exposure to
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with enhanced probability of developing T2D and/or peripheral arterial diseases at ages 60−76 in
women, but not in men [53].
In the Dutch famine study, compelling evidence has been obtained that exposure to famine
during prenatal development may result in persistent epigenetic changes. Although no relationship
between the prenatal exposure to the Dutch famine and overall global DNA methylation in adulthood
was observed [54], levels of methylation of particular genes were clearly associated with prenatal
famine exposure. The methylation levels of the imprinted gene encoding an insulin-like growth factor
2 (IGF2), known to play a crucial role in human growth and development, have been estimated by
Heijmans et al. [51]. This gene was selected for analysis because its methylation marks are stable up to
adult age, making IGF2 gene a good candidate for such a study. In this research, those subjects exposed
to the Dutch famine during their early gestation period had much lower IGF2 methylation levels
compared to control unexposed individuals six decades after the hunger exposure. Subsequently, this
observation has been extended by examination of a set of 15 additional candidate loci responsible for
development of metabolic and cardiovascular phenotypes [55]. Levels of methylation of six of these
loci (GNASAS, IL10, LEP, ABCA1, INSIGF and MEG3) have been found to be associated with prenatal
exposure to famine.
4.2. Famines in 20th-Century Austria
Findings from the Dutch Hunger Winter Study on the developmental origin of T2D were also
confirmed in populations of other countries such as Austria, which has been subjected to three massive
famine episodes during the 20th century. These famines occurred in 1918–19 during the collapse of the
Austro-Hungarian Empire; in 1938, following the economic crisis, harvest failure, and food embargo
from Nazi Germany; and in 1946–1947 in the period following the Second World War. Based on the
data set including 325,000 Austrian diabetic patients, Thurner et al. [56] observed an excess risk of T2D
in those persons who were born during or immediately after the periods of these famine episodes.
For instance, up to 40% higher chances of having T2D in those individuals who were born in 1919–1921
compared to those who were born in 1918 or 1922, have been revealed in different Austrian regions.
Noteworthy, the excess risk of T2D was practically absent in those Austrian provinces that were less
affected by hunger. Furthermore, T2D rates have been correlated with the economic wealth of particular
regions. The authors concluded that the revealed peaks of T2D in subjects born during and after
the periods of severe starvation obviously demonstrate importance of environmental determinants
in the period from conception to early childhood, in addition to genetic predisposition and shared
life-course factors. These determinants clearly include nutritional triggers, although contribution of
other triggering factors such as the famine-related stress and infectious factors, including rodent-borne
viral infections, cannot be excluded [57]. The data obtained from this research, however, collectively
favoured the hunger hypothesis as the leading explanation for the effects observed [56,58].
4.3. Ukrainian Famine of 1932–1933
The association between prenatal exposure to the famine and adult risk of T2D has been recently
examined in large birth cohorts (total n = 43,150) born before, during and after the Great Ukrainian
Famine of 1932–1933 (‘Holodomor’) [59]. This famine was caused by the Soviet Union government’s
forced agriculture collectivization throughout the early 1930s and led to the deaths from starvation
of several million people with a ten-fold increase of mortality rate in April−July 1933 compared to
the pre- and post-famine times. The cohorts born during the famine can be well defined with respect
to the timing of the famine exposure in relation to the stage of pregnancy and the severity of the
famine around the birth date. The odds ratios (ORs) for developing T2D were 1.47 in those individuals
born in the first half of 1934 in regions affected by extreme famine, 1.26 in those born in regions with
severe famine, and there was no increase (OR = 1.0) in those born in regions with no famine, compared
to the births in other examined time periods. The associations observed between T2D and famine
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showed a dose-response relationship between the famine severity during the prenatal development
and the risk of T2D later in life, and assumed that early gestational stage is a critical time window for
modulating the prenatal environment to affect the adult T2D risk.
4.4. Leningrad Siege of 1941–1944
The Nazi Siege of the Russian city of Leningrad (the modern-day St. Petersburg) in 1941–1944
resulted in extreme hunger and death of about a million city residents. The siege-induced starvation
caused an average fall in birth weight of 500–600 g [60]. Follow-up of 549 subjects born in Leningrad
before or during the siege, however, demonstrated no effect of intrauterine undernutrition during the
siege on dyslipidaemia, glucose intolerance, hypertension and the risk of CVD in adulthood [61,62].
Starvation-exposed individuals demonstrated only evidence for endothelial dysfunction and for a
stronger influence of obesity on blood pressure. These results seem to contradict the thrifty phenotype
concept since in utero undernutrition was not related to glucose intolerance in adult persons, although
prenatal malnutrition influenced their blood pressure and differ from those obtained in the Dutch
Hunger Winter study. One possible explanation for such a contradiction suggested by some authors in
discussing these data is that the Leningrad siege research was complicated by the fact that malnutrition
extended into the postnatal period. Thus, the conflict between prenatal and postnatal environments
did not occur [63]. Indeed, in the Netherlands, the food supplies become fully adequate after the war
ended, while those babies who were born throughout the Leningrad siege remained malnourished
during all their childhood, since this famine lasted for years rather than months and nutrition was
poor in subsequent years as well. The association between starvation during the Leningrad siege
in early life and the risk of T2D development in adulthood was, however, observed in several more
recent studies. Both the increasing incidence and decreasing age of onset of T2D without obesity
have been found in women exposed to starvation throughout the Siege of Leningrad during their
childhood [64]. This cohort was characterized by higher incidence of conditions associated with
metabolic dysregulation such as severe arterial hypertension, and also atherosclerosis of coronary,
brain and carotid arteries [65]. Similar health problems were also demonstrated in cohorts exposed to
starvation during the Leningrad Siege in their childhood and puberty. Women who were 6−8 years
old and men who were 9−15 years old throughout the peak of the famine demonstrated higher systolic
blood pressure in their adulthood as compared with unexposed individuals who were born during the
same period. Moreover, men exposed to hunger at age 6−8 and 9−15 were characterized by increased
mortality from ischaemic heart disease and cerebrovascular disease, respectively [66].
4.5. Chinese Famine of 1959–1961
The long-term health consequences of the Chinese Famine of 1959–1961 (‘Great Leap Forward
Famine’) are extensively studied now. This massive famine occurred in China in the late 1950s
following the disastrous social agricultural reform commonly referred to as ‘Great Leap Forward.’
Over the years of the famine, 25 to 30 million more deaths and 30 to 35 million fewer births were
registered in China than would have been expected under normal conditions [67]. In recent years, the
Great Leap Forward Famine is the most actively studied famine episode across the globe. It should
be noted, however, that one methodological limitation of the Chinese Famine study is that famine
exposure data are not available by month; therefore, the periods of the famine exposure cannot be as
precisely defined as in the Dutch famine study or in the Ukrainian study.
In most of the studies of long-term impacts of the Chinese Famine, the evidence was obtained that
T2D as well as associated metabolic abnormalities were more common among adult Chinese residents
born during the famine than among control individuals born after the famine (for a systematic review,
see [68]). More specifically, in areas which were severely affected by famine, those subjects who were
exposed to famine prenatally had a 3.9-fold enhanced risk of hyperglycaemia in comparison with
non-exposed individuals; this difference was not seen in less severely affected regions. Remarkably,
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affluent/Western dietary pattern and 6.2-fold higher in those who had a higher economic status in
later life compared to non-exposed controls [69]. In a more recent study by Wang et al. [70], both
prenatal and childhood exposures to famine were shown to result in higher risk of being diagnosed
with T2D in adulthood (1.5-times and 1.8-times, respectively), compared with non-exposed subjects.
Individuals residing in Chinese regions with high economic status had a greater T2D risk (OR = 1.46).
Interestingly, the timing of association between the famine exposure in early life and adult T2D
was gender-specific: an elevated risk of T2D development was evident in the foetal-exposed men
(OR = 1.64) and childhood-exposed women (OR = 2.81). These findings were further confirmed
in subsequent research by the same authors, where a significant association between the famine
severity in the areas of exposure and the risk of T2D was found [71]. Those subjects who were
exposed to severe famine during the foetal and childhood periods had substantially higher odds
estimates (1.90 and 1.44, respectively). A significant interaction between the level of famine severity
in the areas of exposure throughout the prenatal and childhood periods and the risk of T2D in
adulthood has been observed. In another Chinese population, 1.44-fold higher risk of T2D development
in the middle-childhood-exposed group, and 1.5-fold higher risks of hyperglycaemia in both the
middle- and late-childhood-exposed groups were demonstrated compared to the unexposed group [72].
Remarkably, those individuals who experienced more severe famine in childhood had a 38% higher
risk of T2D development than those exposed to less severe famine. The revealed association was,
however, sex-specific and has been found in women, but not in men. Similar associations have been
observed for the hyperglycaemia risk as well.
In a recent study conducted in Suihua, China, the evidence was obtained that programming
effects can be manifested not only in those prenatally exposed to famine population (F1 generation),
but also in the F2 progeny [73]. In this research, prenatal exposure to the Chinese Famine has
been linked to a 1.75-fold enhanced risk of T2D and 1.93-fold enhanced risk of hyperglycaemia
in F1 adult offspring in comparison with unexposed individuals. Furthermore, F2 offspring of
exposed ancestors had a 2.02-fold elevated risk of adult hyperglycaemia compared to the offspring of
non-exposed ancestors. These findings suggest that famine-induced effects can be transmitted via the
germ line across generations and translated into increased T2D susceptibility in the descendants of the
famine-exposed individuals.
4.6. Nigerian Famine of 1967–1970
The Nigerian Famine (commonly referred to as ‘Biafran Famine’) occurred during the Nigerian
Civil War from 1967–1970. Of the one to three million Nigerians that died during this civil war, only
a relatively small fraction (about 10%) had lost their lives from military action as such; the majority
died from war-associated starvation [74]. The risks of glucose intolerance, hypertension and being
overweight 40 years after prenatal exposure to the Biafran Famine have been assessed in the Hult et al.
study [75]. The studied cohorts (total n = 1339) included those adults born before (1965−1967), during
(1968−1970), or after (1971−1973) the years of famine. The exposure to famine during both foetal and
infant periods has been found to be associated with significantly increased systolic and diastolic blood
pressure, higher levels of p-glucose and waist circumference, as well as with substantially elevated
risks of systolic hypertension (OR = 2.87), impaired glucose regulation (OR = 1.65) and overweight
(OR = 1.41) in adulthood compared with persons who were born after the famine. As in the case of the
Chinese Famine study, the lack of birth weight data and the resulting impossibility to separate effects of
prenatal and infant famine exposure is the main methodological weakness of Biafran Famine research.
4.7. Holocaust (1939−1945)
The Holocaust was a genocide in which Nazi Germany and its collaborators killed about six
million Jews. It was obviously associated with severe starvation and stress in affected populations.
The long-term health outcomes of exposure to the Holocaust in the period from preconception to early
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Jews born in countries under Nazi rule during the period 1940−1945 (exposed group) and 230 age-
and sex-matched Israeli-born individuals (non-exposed group) who self-reported the presence of
chronic diseases [76]. The exposed individuals have been shown to be at a higher risk of adult
metabolic disturbances, including enhanced BMI, as well as 1.46-fold increased risk of hypertension,
1.58-fold increased risk for dyslipidaemia, and 1.89-fold increased risk of T2D compared to the
Holocaust-unexposed group. The associations observed were further confirmed on larger groups
of participants (exposed group, n = 653; non-exposed group, n = 433) [77]. The higher risks of
hypertension (OR = 1.52), T2D (OR = 1.60), metabolic syndrome (OR = 2.14) and vascular disease
(OR = 1.99) were found in exposed individuals.
In general, findings from quasi-experimental studies suggest that exposure to famine in early life
may result in serious metabolic disturbances in later life including high risk of development of T2D
and associated conditions. The main findings from these studies are summarized in Table 1.
Table 1. Summary of main findings from research on long-term metabolic health consequences of
early-life undernutrition exposure
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collectivization 1932–1933 High risk of T2D [59]
Russia Leningrad Siege 1941–1944
Endothelial dysfunction, stronger influence of
obesity on blood pressure















(‘Biafran Famine’) Civil war 1967–1970
Increased blood pressure, higher levels of
p-glucose, increased waist circumference,
overweight, high risks of impaired glucose
regulation and systolic hypertension
[75]
Europe
(‘Holocaust’) Nazi genocide 1939–1945
Enhanced BMI, hypertension, dyslipidemia,
high risk of T2D and CVD [76,77]
Spain Seasonal malnutrition 1935−1954 High systolic blood pressure [82]
United Kingdom Seasonal malnutrition 1920–1930 Obesity [83]
Canada Seasonal malnutrition 1943–1995 Obesity [84]
United Kingdom Seasonal malnutrition 1924–1943 Dyslipidaemia, insulin resistance and CVD [85]
USA Seasonal malnutrition 1968–1995 High risk of T2D [86]
Netherlands Seasonal malnutrition 1920–1948 High risk of T2D [87]
Ukraine Seasonal malnutrition 1930–1938 High risk of T2D [88]
5. Seasonality of Birth
Season of birth also can be used in quasi-experimental design to examine associations between
early-life exposures, including nutritional ones, and later-life health outcomes. In this regard, month
of birth presents a good instrument which may help to examine later-life outcomes of early-life
exposures independently of life-course factors. This is true since decades ago there were strong
seasonal variations in nutrition, especially in developing countries. Availability of cereals, vegetables,
fruits and animal proteins varied significantly according to the season. Such differences in the supply
of high-quality food might potentially affect the foetal and neonatal development depending on the








Nutrients 2017, 9, 236
including temperature [90], infections [91], sunlight/photoperiod and, correspondingly, production of
melatonin and vitamin D [92], as well as maternal lifestyle factors such as physical activity [93] and
alcohol intake [94], also tend to vary seasonally.
Seasonal conditions around the period of birth were demonstrated to significantly determine
birth weight: lower birth weights were observed in the winter-born newborns and higher birth
weights in summer-born newborns in the high- and low-latitude areas, while the summer birth was
associated with relatively lower birth weight in the mid-latitude areas [95]. Seasonality of birth has been
demonstrated for many aspects of metabolic syndrome, including high systolic blood pressure [82],
obesity [83,84] and also dyslipidaemia, insulin resistance and CVD [85]. The seasonal pattern of birth
for childhood autoimmune (type 1) diabetic patients was reported repeatedly (see, e.g., [96]), while the
seasonality of birth for T2D adult persons was observed only in a few studies. Seasonal patterns of
birth were reported, e.g., in small-sample studies conducted in 155 adolescent African-Americans [86]
and in 282 T2D patients in the Netherlands [87].
By now, the most obvious evidence for the seasonality of birth in T2D patients is provided in
research conducted in a Ukrainian population [88]. In this study, those persons who were born in
April−May had increased risk ofT2D development. In the climatic conditions characteristic of the
Ukraine, these subjects ordinarily experienced their foetal life in the nutritionally marginal period
from late autumn to early spring and passed the first neonatal months during the relatively plentiful
season. In contrast, a decreased risk of T2D was observed in those born in November–December. In
these individuals, prenatal development in a nutritionally abundant season would have been followed
by early infancy in the season of relative scarcity (winter−spring). The first scenario is apparently
more high-risk for developing T2D than the second one. These results are highly consistent with the
thrifty phenotype hypothesis [8]. Interestingly, the seasonal pattern of birth was found to be very
similar in type 1 and type 2 diabetic patients, suggesting shared early-life etiological causation for
both disorders [97]. In more recent research by Jensen et al. [98], no evidence for seasonality of birth
in Danish patients with T2D was found. The authors assumed that difference in effects obtained
in Denmark and the Ukraine may be explained by standards of living or by differences in latitude
between the countries. Indeed, as the seasonal variations in both weather and nutrition were much
more pronounced in the Ukraine than in Denmark throughout the study periods, and since the Ukraine
belonged to low-income countries for much of that time, its residents experienced more pronounced
seasonal extremes than those experienced by people in a more prosperous country like Denmark.
In discussing the mechanistic basis for seasonal programming of adult-life diseases, one possible
explanation is that seasonal factors operating around the time of birth may trigger persistent epigenetic
changes that have adaptive significance in postnatal development but can predispose to chronic
disorders, including the metabolic ones, at the late stages of life. The evidence for the link between
season of birth and long-term changes in DNA methylation has been recently obtained in the
epigenome-wide association study (EWAS) by Lockett et al. [99], where methylation at 92 CpG
dinucleotides was significantly associated with season of birth. The networks related to the cell cycle,
development and apoptosis have been found to be enriched among these differentially methylated
CpG sites. Interestingly, the season-associated methylation patterns have been mainly absent in
newborns, suggesting they arise postnatally. Although these findings were not confirmed in a more
recent study by Dugué et al. [100], they, however, suggest that changes in DNA methylation might
mechanistically underlie the season-of-birth effects on the risk of later-life disease.
6. Conclusions and Future Perspectives
A trend to a dramatic enhancing incidence of type 2 diabetes (T2D) has become a serious problem
across the globe over the past years. Metabolic syndrome and associated risk factors including
dyslipidaemia, high blood pressure, impaired glucose metabolism and T2D, are among the main
causes of death in both developed and developing countries. It is widely believed that risk of T2D
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contribute to an individual susceptibility to development of obesity and T2D, the identified genetic
variants can explain only part of the variation [22,101]. Recent research has demonstrated that exposure
to unfavourable environmental stimuli early in life is another important determinant of the risk of
T2D and associated conditions during adulthood. Findings from several of these studies suggest that
epigenetic regulation can be largely contributed to development of these pathological states. Since
epigenetic marks may persist long term, epigenetic modifications triggered by environmental cues
throughout early sensitive stages may lead to lasting effects on the metabolic functioning, thereby
affecting the risk of metabolic disorders, including T2D, later in life [102]. Prenatal and early postnatal
nutrition is likely the most important factor affecting the adult risk of T2D. For instance, in studying
the long-term health consequences of prenatal exposure to the Dutch famine, a link between poor
nutritional intake in utero and impaired glucose regulation, atherogenic lipid profiles and obesity later
in life, all known to be risk factors for development of T2D, has been demonstrated [99–102]. Therefore,
it is not surprising that cohorts exposed to starvation in early life are at higher risk of T2D development.
In a very recent meta-analysis of 11 published articles, a strong association between exposure to
famine in early life and increased risk of T2D in adulthood has been observed (the pooled relative
risk (RR) = 1.38, 95% CI 1.17−1.63) [103]. RRs for T2D development were 1.36 (95% CI 1.12−1.65) for
cohorts exposed prenatally or during the early postnatal period and 1.40 (95% CI 0.98−1.99) for those
cohorts who were exposed in their childhood compared to the unexposed cohorts.
In offspring born to mothers experiencing famine during pregnancy, differential methylation of
genes, including those associated with pathogenesis of T2D, has been observed [51,55], indicating the
importance of epigenetic processes in mediating early-life starvation exposure to the risk of later-life
disease. Data from reviewed studies suggest that a focus on very early periods of gestation, and
perhaps even on the periconceptional period, should constitute the next frontier for prevention of T2D
over the human life course [104]. Some studies have indicated that epigenetic effects contributing to
development of T2D could be transmitted across several generations. In research conducted in the
Överkalix, an isolated community in northern Sweden, the possibility of transgenerational effects
on T2D mortality was observed. The transgenerational consequences of the ancestors’ nutrition
throughout their slow growth period (SGP, aged 9 to 12 years), the period of higher susceptibility
of organism to environmental influences, were investigated in cohorts born in this region in 1890,
1905 and 1920 [105,106]. In case of limited food availability in the father’s SGP, then the descendant
cardiovascular mortality was low, while the overeating of paternal grandfathers led to a four-fold
increase in diabetes mortality in the offspring [105,106]. Such transgenerational effects were shown to
be gender-specific: the paternal grandmother’s nutrient supply affected granddaughters’ mortality risk,
while the paternal grandfather’s nutrient supply was shown to be associated with the mortality risk in
grandsons [106]. Since epigenetic alterations unlike genetic mutations are potentially reversible [107],
pharmacological modification of epigenetic marks contributing to T2D development can provide a
novel approach to prevention and treatment of T2D and associated disorders.
Acknowledgments: The author would like to thank Oksana Zabuga for the technical assistance in preparing
this manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Wilmot, E.; Idris, I. Early onset type 2 diabetes: Risk factors, clinical impact and management. Ther. Adv.
Chronic. Dis. 2014, 5, 234–244. [CrossRef] [PubMed]
2. Jaacks, L.M.; Siegel, K.R.; Gujral, U.P.; Narayan, K.M. Type 2 diabetes: A 21st century epidemic. Best Pract.
Res. Clin. Endocrinol. Metab. 2016, 30, 331–343. [CrossRef] [PubMed]
3. Nielsen, J.H.; Haase, T.N.; Jaksch, C.; Nalla, A.; Søstrup, B.; Nalla, A.A.; Larsen, L.; Rasmussen, M.;
Dalgaard, L.T.; Gaarn, L.W. Impact of fetal and neonatal environment on beta cell function and development








Nutrients 2017, 9, 236
4. Dabelea, D.; Hanson, R.L.; Lindsay, R.S.; Pettitt, D.J.; Imperatore, G.; Gabir, M.M.; Roumain, J.; Bennett, P.H.;
Knowler, W.C. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: A study of
discordant sibships. Diabetes 2000, 49, 2208–2211. [CrossRef] [PubMed]
5. Eriksson, J.G. Developmental Origins of Health and Disease—From a small body size at birth to epigenetics.
Ann. Med. 2016, 48, 456–467. [CrossRef] [PubMed]
6. Kim, J.B. Dynamic cross talk between metabolic organs in obesity and metabolic diseases. Exp. Mol. Med.
2016, 48, e214. [CrossRef] [PubMed]
7. Nettle, D.; Bateson, M. Adaptive developmental plasticity: What is it, how can we recognize it and when can
it evolve? Proc. Biol. Sci. 2015, 282, 20151005. [CrossRef] [PubMed]
8. Hales, C.N.; Barker, D.J. Type 2 (non-insulin-dependent) diabetes mellitus: The thrifty phenotype hypothesis.
1992. Int. J. Epidemiol. 2013, 42, 1215–1222. [CrossRef] [PubMed]
9. Thorn, S.R.; Rozance, P.J.; Brown, L.D.; Hay, W.W., Jr. The intrauterine growth restriction phenotype: Fetal
adaptations and potential implications for later life insulin resistance and diabetes. Semin. Reprod. Med. 2011,
29, 225–236. [CrossRef] [PubMed]
10. Carolan-Olah, M.; Duarte-Gardea, M.; Lechuga, J. A critical review: Early life nutrition and prenatal
programming for adult disease. J. Clin. Nurs. 2015, 24, 3716–3729. [CrossRef] [PubMed]
11. Tarry-Adkins, J.L.; Ozanne, S.E. Nutrition in early life and age-associated diseases. Ageing Res. Rev. 2016.
[CrossRef] [PubMed]
12. Whincup, P.H.; Kaye, S.J.; Owen, C.G.; Huxley, R.; Cook, D.G.; Anazawa, S.; Barrett-Connor, E.;
Bhargava, S.K.; Birgisdottir, B.E.; Carlsson, S.; et al. Birth weight and risk of type 2 diabetes: A systematic
review. J. Am. Med. Assoc. 2008, 300, 2886–2897. [PubMed]
13. Kensara, O.A.; Wootton, S.A.; Phillips, D.I.; Patel, M.; Jackson, A.A.; Elia, M.; Hertfordshire Study Group.
Fetal programming of body composition: Relation between birth weight and body composition measured
with dual-energy X-ray absorptiometry and anthropometric methods in older Englishmen. Am. J. Clin. Nutr.
2005, 82, 980–987. [PubMed]
14. Morrison, K.M.; Ramsingh, L.; Gunn, E.; Streiner, D.; van Lieshout, R.; Boyle, M.; Gerstein, H.; Schmidt, L.;
Saigal, S. Cardiometabolic health in adults born premature with extremely low birth weight. Pediatrics 2016,
138. [CrossRef] [PubMed]
15. Stirrat, L.I.; Reynolds, R.M. The effect of fetal growth and nutrient stresses on steroid pathways. J. Steroid.
Biochem. Mol. Biol. 2016, 160, 214–220. [CrossRef] [PubMed]
16. Frankel, S.; Elwood, P.; Sweetnam, P.; Yarnell, J.; Smith, G.D. Birthweight, body-mass index in middle age
and incident coronary heart disease. Lancet 1996, 348, 1478–1480. [CrossRef]
17. Harder, T.; Rodekamp, E.; Schellong, K.; Dudenhausen, J.W.; Plagemann, A. Birth weight and subsequent
risk of type 2 diabetes: A meta-analysis. Am. J. Epidemiol. 2007, 165, 849–857. [CrossRef] [PubMed]
18. Dulloo, A.G. Thrifty energy metabolism in catch-up growth trajectories to insulin and leptin resistance.
Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22, 155–171. [CrossRef] [PubMed]
19. Cho, W.K.; Suh, B.K. Catch-up growth and catch-up fat in children born small for gestational age.
Korean J. Pediatr. 2016, 59, 1–7. [CrossRef] [PubMed]
20. Ong, T.P.; Ozanne, S.E. Developmental programming of type 2 diabetes: Early nutrition and epigenetic
mechanisms. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 354–360. [CrossRef] [PubMed]
21. Paluch, B.E.; Naqash, A.R.; Brumberger, Z.; Nemeth, M.J.; Griffiths, E.A. Epigenetics: A primer for clinicians.
Blood Rev. 2016, 30, 285–295. [CrossRef] [PubMed]
22. Van Dijk, S.J.; Tellam, R.L.; Morrison, J.L.; Muhlhausler, B.S.; Molloy, P.L. Recent developments on the role of
epigenetics in obesity and metabolic disease. Clin. Epigenet. 2015, 7, 66. [CrossRef] [PubMed]
23. Vaiserman, A. Epidemiologic evidence for association between adverse environmental exposures in early
life and epigenetic variation: A potential link to disease susceptibility? Clin. Epigenet. 2015, 7, 9. [CrossRef]
[PubMed]
24. Geraghty, A.A.; Lindsay, K.L.; Alberdi, G.; McAuliffe, F.M.; Gibney, E.R. Nutrition during pregnancy impacts
offspring’s epigenetic status—Evidence from human and animal studies. Nutr. Metab. Insights 2016, 8, 41–47.
[CrossRef] [PubMed]
25. Alam, F.; Islam, M.A.; Gan, S.H.; Mohamed, M.; Sasongko, T.H. DNA methylation: An epigenetic insight








Nutrients 2017, 9, 236
26. Kwak, S.H.; Park, K.S. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp. Mol. Med.
2016, 48, e220. [CrossRef] [PubMed]
27. Green, A.S.; Rozance, P.J.; Limesand, S.W. Consequences of a compromised intrauterine environment on
islet function. J. Endocrinol. 2010, 205, 211–224. [CrossRef] [PubMed]
28. Portha, B.; Chavey, A.; Movassat, J. Early-life origins of type 2 diabetes: Fetal programming of the beta-cell
mass. Exp. Diabetes Res. 2011. [CrossRef] [PubMed]
29. Pinney, S.E. Intrauterine growth retardation–A developmental model of type 2 diabetes. Drug Discov Today
Dis. Models. 2013, 10, e71–e77. [CrossRef] [PubMed]
30. Dumortier, O.; Blondeau, B.; Duvillie, B.; Reusens, B.; Breant, B.; Remacle, C. Different mechanisms operating
during different critical time-windows reduce rat fetal beta cell mass due to a maternal low-protein or
low-energy diet. Diabetologia 2007, 50, 2495–2503. [CrossRef] [PubMed]
31. Garofano, A.; Czernichow, P.; Breant, B. In utero undernutrition impairs rat beta-cell development.
Diabetologia 1997, 40, 1231–1234. [CrossRef] [PubMed]
32. Garofano, A.; Czernichow, P.; Breant, B. Beta-cell mass and proliferation following late fetal and early
postnatal malnutrition in the rat. Diabetologia 1998, 41, 1114–1120. [CrossRef] [PubMed]
33. Petrik, J.; Reusens, B.; Arany, E.; Remacle, C.; Coelho, C.; Hoet, J.J.; Hill, D.J. A low protein diet alters
the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a
reduced pancreatic expression of insulin-like growth factor-II. Endocrinology 1999, 140, 4861–4873. [CrossRef]
[PubMed]
34. Garofano, A.; Czernichow, P.; Breant, B. Effect of ageing on beta-cell mass and function in rats malnourished
during the perinatal period. Diabetologia 1999, 42, 711–718. [CrossRef] [PubMed]
35. Blondeau, B.; Garofano, A.; Czernichow, P.; Breant, B. Age-dependent inability of the endocrine pancreas to
adapt to pregnancy: A long-term consequence of perinatal malnutrition in the rat. Endocrinology 1999, 140,
4208–4213. [CrossRef] [PubMed]
36. Thamotharan, M.; Shin, B.C.; Suddirikku, D.T.; Thamotharan, S.; Garg, M.; Devaskar, S.U. GLUT4 expression
and subcellular localization in the intrauterine growth-restricted adult rat female offspring. Am. J. Physiol.
Endocrinol. Metab. 2005, 288, E935–E947. [CrossRef] [PubMed]
37. Matveyenko, A.V.; Singh, I.; Shin, B.C.; Georgia, S.; Devaskar, S.U. Differential effects of prenatal and
postnatal nutritional environment on ss-cell mass development and turnover in male and female rats.
Endocrinology 2010, 151, 5647–5656. [CrossRef] [PubMed]
38. Ong, T.P.; Ozanne, S.E. Developmental programming of type 2 diabetes: Early nutrition and epigenetic
mechanisms. Curr. Opin. Clin. Nutr. Metab Care 2015, 18, 354–360. [CrossRef] [PubMed]
39. Simmons, R.A. Developmental origins of diabetes: The role of epigenetic mechanisms. Curr Opin. Endocrinol.
Diabetes Obes. 2007, 14, 13–16. [CrossRef] [PubMed]
40. Simmons, R.A. Developmental origins of adult disease. Pediatr. Clin. N. Am. 2009, 56, 449–466. [CrossRef]
[PubMed]
41. Blondeau, B.; Avril, I.; Duchene, B.; Breant, B. Endocrine pancreas development is altered in foetuses from
rats previously showing intra-uterine growth retardation in response to malnutrition. Diabetologia 2002, 45,
394–401. [CrossRef] [PubMed]
42. Park, J.H.; Stoffers, D.A.; Nicholls, R.D.; Simmons, R.A. Development of type 2 diabetes following
intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1.
J. Clin. Investig. 2008, 118, 2316–2324. [CrossRef] [PubMed]
43. Reusens, B.; Theys, N.; Dumortier, O.; Goosse, K.; Remacle, C. Maternal malnutrition programs the endocrine
pancreas in progeny. Am. J. Clin. Nutr. 2011, 94, 1824S–1829S. [CrossRef] [PubMed]
44. Berends, L.M.; Fernandez-Twinn, D.S.; Martin-Gronert, M.S.; Cripps, R.L.; Ozanne, S.E. Catch-up growth
following intra-uterine growth-restriction programmes an insulin-resistant phenotype in adipose tissue.
Int. J. Obes. (Lond.) 2013, 37, 1051–1057. [CrossRef] [PubMed]
45. Bieswal, F.; Ahn, M.T.; Reusens, B.; Holvoet, P.; Raes, M.; Rees, W.D.; Remacle, C. The importance of catch-up
growth after early malnutrition for the programming of obesity in male rat. Obesity (Silver Spring) 2006, 14,
1330–1343. [CrossRef] [PubMed]
46. Bol, V.V.; Delattre, A.I.; Reusens, B.; Raes, M.; Remacle, C. Forced catch-up growth after fetal protein
restriction alters the adipose tissue gene expression program leading to obesity in adult mice. Am. J. Physiol.








Nutrients 2017, 9, 236
47. Last, J.M. A Dictionary of Epidemiology, 3rd ed.; Oxford University Press: New York, NY, USA, 1995.
48. Heijmans, B.T.; Tobi, E.W.; Lumey, L.H.; Slagboom, P.E. The epigenome: Archive of the prenatal environment.
Epigenetics 2009, 4, 526–531. [CrossRef] [PubMed]
49. Lumey, L.H.; Stein, A.D.; Susser, E. Prenatal famine and adult health. Annu. Rev. Public Health 2011, 32,
237–262. [CrossRef] [PubMed]
50. Roseboom, T.J.; Painter, R.C.; van Abeelen, A.F.; Veenendaal, M.V.; de Rooij, S.R. Hungry in the womb: What
are the consequences? Lessons from the Dutch famine. Maturitas 2011, 70, 141–145. [CrossRef] [PubMed]
51. Heijmans, B.T.; Tobi, E.W.; Stein, A.D.; Putter, H.; Blauw, G.J.; Susser, E.S.; Slagboom, P.E.; Lumey, L.H.
Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad.
Sci. USA 2008, 105, 17046–17049. [CrossRef] [PubMed]
52. Van Abeelen, A.F.; Elias, S.G.; Bossuyt, P.M.; Grobbee, D.E.; van der Schouw, Y.T.; Roseboom, T.J.;
Uiterwaal, C.S. Famine exposure in the young and the risk of type 2 diabetes in adulthood. Diabetes
2012, 61, 2255–2260. [CrossRef] [PubMed]
53. Portrait, F.; Teeuwiszen, E.; Deeg, D. Early life undernutrition and chronic diseases at older ages: The effects
of the Dutch famine on cardiovascular diseases and diabetes. Soc. Sci. Med. 2011, 73, 711–718. [CrossRef]
[PubMed]
54. Lumey, L.H.; Terry, M.B.; Delgado-Cruzata, L.; Liao, Y.; Wang, Q.; Susser, E.; McKeague, I.; Santella, R.M.
Adult global DNA methylation in relation to pre-natal nutrition. Int. J. Epidemiol. 2012, 41, 116–123.
[CrossRef] [PubMed]
55. Tobi, E.W.; Lumey, L.H.; Talens, R.P.; Kremer, D.; Putter, H.; Stein, A.D.; Slagboom, P.E.; Heijmans, B.T.
DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific.
Hum. Mol. Genet. 2009, 18, 4046–4053. [CrossRef] [PubMed]
56. Thurner, S.; Klimek, P.; Szell, M.; Duftschmid, G.; Endel, G.; Kautzky-Willer, A.; Kasper, D.C. Quantification
of excess risk for diabetes for those born in times of hunger, in an entire population of a nation, across a
century. Proc. Natl. Acad. Sci. USA 2013, 110, 4703–4707. [CrossRef] [PubMed]
57. Klitz, W.; Niklasson, B. Viral underpinning to the Austrian record of type 2 diabetes? Proc. Natl. Acad.
Sci. USA 2013, 110, E2750. [CrossRef] [PubMed]
58. Thurner, S.; Klimek, P.; Szell, M.; Duftschmid, G.; Endel, G.; Kautzky-Willer, A.; Kasper, D.C. Reply to Klitz
and Niklasson: Can viral infections explain the cross-sectional Austrian diabetes data? Proc. Natl. Acad.
Sci. USA 2013, 110, E2751. [CrossRef]
59. Lumey, L.H.; Khalangot, M.D.; Vaiserman, A.M. Association between type 2 diabetes and prenatal exposure
to the Ukraine famine of 1932–33: A retrospective cohort study. Lancet Diabetes Endocrinol. 2015, 3, 787–794.
[CrossRef]
60. Sparén, P.; Vågerö, D.; Shestov, D.B.; Plavinskaja, S.; Parfenova, N.; Hoptiar, V.; Paturot, D.; Galanti, M.R.
Long term mortality after severe starvation during the siege of Leningrad: Prospective cohort study.
Br. Med. J. 2004, 328, 11. [CrossRef] [PubMed]
61. Stanner, S.A.; Bulmer, K.; Andrès, C.; Lantseva, O.E.; Borodina, V.; Poteen, V.V.; Yudkin, J.S. Does malnutrition
in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege
study: A cross sectional study. Br. Med. J. 1997, 315, 1342–1348. [CrossRef] [PubMed]
62. Stanner, S.A.; Yudkin, J.S. Fetal programming and the Leningrad Siege study. Twin Res. 2001, 4, 287–292.
[CrossRef] [PubMed]
63. Bateson, P. Fetal experience and good adult design. Int. J. Epidemiol. 2001, 30, 928–934. [CrossRef] [PubMed]
64. Khoroshinina, L.P.; Zhavoronkova, N.V. Starving in childhood and diabetes mellitus in elderly age.
Adv. Gerontol. 2008, 21, 684–687.
65. Khoroshinina, L.P. Peculiarities of somatic diseases in people of middle and old age survived Leningrad
siege at childhood. Adv. Gerontol. 2004, 14, 55–65. (In Russian)
66. Koupil, I.; Shestov, D.B.; Sparén, P.; Plavinskaja, S.; Parfenova, N.; Vågerö, D. Blood pressure, hypertension
and mortality from circulatory disease in men and women who survived the siege of Leningrad.
Eur. J. Epidemiol. 2007, 22, 223–234. [CrossRef] [PubMed]
67. Jowett, A.J. The demographic responses to famine: The case of China 1958-61. GeoJournal 1991, 23, 135–146.
[CrossRef] [PubMed]
68. Li, C.; Lumey, L.H. Exposure to the Chinese famine of 1959–61 in early life and current health conditions:








Nutrients 2017, 9, 236
69. Li, Y.; He, Y.; Qi, L.; Jaddoe, V.W.; Feskens, E.J.; Yang, X.; Ma, G.; Hu, F.B. Exposure to the Chinese famine
in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. Diabetes 2010, 59, 2400–2406.
[CrossRef] [PubMed]
70. Wang, N.; Wang, X.; Han, B.; Li, Q.; Chen, Y.; Zhu, C.; Chen, Y.; Xia, F.; Cang, Z.; Zhu, C.; et al.
Is exposure to famine in childhood and economic development in adulthood associated with diabetes?
J. Clin. Endocrinol. Metab. 2015, 100, 4514–4523. [CrossRef] [PubMed]
71. Wang, N.; Cheng, J.; Han, B.; Li, Q.; Chen, Y.; Xia, F.; Jiang, B.; Jensen, M.D.; Lu, Y. Exposure to severe famine
in the prenatal or postnatal period and the development of diabetes in adulthood: An observational study.
Diabetologia 2017, 60, 262–269. [CrossRef] [PubMed]
72. Wang, J.; Li, Y.; Han, X.; Liu, B.; Hu, H.; Wang, F.; Li, X.; Yang, K.; Yuan, J.; Yao, P.; et al. Exposure to
the Chinese Famine in childhood increases type 2 diabetes risk in adults. J. Nutr. 2016, 146, 2289–2295.
[CrossRef] [PubMed]
73. Li, J.; Liu, S.; Li, S.; Feng, R.; Na, L.; Chu, X.; Wu, X.; Niu, Y.; Sun, Z.; Han, T.; et al. Prenatal exposure
to famine and the development of hyperglycemia and type 2 diabetes in adulthood across consecutive
generations: A population-based cohort study of families in Suihua, China. Am. J. Clin. Nutr. 2016, 105,
221–227. [CrossRef] [PubMed]
74. Miller, J.P. Medical relief in the Nigerian civil war. Lancet 1970, 760, 1330–1334. [CrossRef]
75. Hult, M.; Tornhammar, P.; Ueda, P.; Chima, C.; Bonamy, A.K.; Ozumba, B.; Norman, M. Hypertension,
diabetes and overweight: Looming legacies of the Biafran famine. PLoS ONE 2010, 5, e13582. [CrossRef]
[PubMed]
76. Bercovich, E.; Keinan-Boker, L.; Shasha, S.M. Long-term health effects in adults born during the Holocaust.
Isr. Med. Assoc. J. 2014, 16, 203–207. [PubMed]
77. Keinan-Boker, L.; Shasha-Lavsky, H.; Eilat-Zanani, S.; Edri-Shur, A.; Shasha, S.M. Chronic health conditions
in Jewish Holocaust survivors born during World War II. Isr. Med. Assoc. J. 2015, 17, 206–212. [PubMed]
78. Watson, P.E.; McDonald, B.W. Seasonal variation of nutrient intake in pregnancy: Effects on infant measures
and possible influence on diseases related to season of birth. Eur. J. Clin. Nutr. 2007, 61, 1271–1280. [CrossRef]
[PubMed]
79. Flouris, A.D.; Spiropoulos, Y.; Sakellariou, G.J.; Koutedakis, Y. Effect of seasonal programming on fetal
development and longevity: Links with environmental temperature. Am. J. Hum. Biol. 2009, 21, 214–216.
[CrossRef] [PubMed]
80. Finch, C.E.; Crimmins, E.M. Inflammatory exposure and historical changes in human life-spans. Science
2004, 305, 1736–1739. [CrossRef] [PubMed]
81. Lowell, W.E.; Davis, G.E., Jr. The light of life: Evidence that the sun modulates human lifespan.
Med. Hypotheses. 2008, 70, 501–507. [CrossRef] [PubMed]
82. Smith, A.D.; Crippa, A.; Woodcock, J.; Brage, S. Physical activity and incident type 2 diabetes mellitus:
A systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia 2016, 59,
2527–2545. [CrossRef] [PubMed]
83. Vaiserman, A.M. Early-life exposure to substance abuse and risk of type 2 diabetes in adulthood.
Curr. Diabetes Rep. 2015, 15, 48. [CrossRef] [PubMed]
84. Chodick, G.; Flash, S.; Deoitch, Y.; Shalev, V. Seasonality in birth weight: Review of global patterns and
potential causes. Hum. Biol. 2009, 81, 463–477. [CrossRef] [PubMed]
85. Banegas, J.R.; Rodríguez-Artalejo, F.; de la Cruz, J.J.; Graciani, A.; Villar, F.; del Rey-Calero, J. Adult men
born in spring have lower blood pressure. J. Hypertens. 2000, 18, 1763–1766. [CrossRef] [PubMed]
86. Phillips, D.I.; Young, J.B. Birth weight: Climate at birth and the risk of obesity in adult life. Int. J. Obes. Relat.
Metab. Disord. 2000, 24, 281–287. [CrossRef] [PubMed]
87. Wattie, N.; Ardern, C.I.; Baker, J. Season of birth and prevalence of overweight and obesity in Canada.
Early Hum. Dev. 2008, 84, 539–547. [CrossRef] [PubMed]
88. Lawlor, D.A.; Davey-Smith, G.; Mitchell, R.; Ebrahim, S. Temperature at birth, coronary heart disease, and
insulin resistance: Cross sectional analyses of the British women’s heart and health study. Heart 2004, 90,
381–388. [CrossRef] [PubMed]
89. Laron, Z.; Lewy, H.; Wilderman, I.; Casu, A.; Willis, J.; Redondo, M.J.; Libman, I.; White, N.; Craig, M.
Seasonality of month of birth of children and adolescents with type 1 diabetes mellitus in homogenous and








Nutrients 2017, 9, 236
90. Grover, V.; Lipton, R.B.; Sclove, S.L. Seasonality of month of birth among African American children with
diabetes mellitus in the City of Chicago. J. Pediatr. Endocrinol. Metab. 2004, 17, 289–296. [CrossRef] [PubMed]
91. Jongbloet, P.H.; van Soestbergen, M.; van der Veen, E.A. Month-of-birth distribution of diabetics and
ovopathy: A new aetiological view. Diabetes Res. 1988, 9, 51–58. [PubMed]
92. Vaiserman, A.M.; Khalangot, M.D.; Carstensen, B.; Tronko, M.D.; Kravchenko, V.I.; Voitenko, V.P.;
Mechova, L.V.; Koshel, N.M.; Grigoriev, P.E. Seasonality of birth in adult type 2 diabetic patients in three
Ukrainian regions. Diabetologia 2009, 52, 2665–2667. [CrossRef] [PubMed]
93. Vaiserman, A.M.; Khalangot, M.D. Similar seasonality of birth in type 1 and type 2 diabetes patients: A sign
for common etiology? Med. Hypotheses 2008, 71, 604–605. [CrossRef] [PubMed]
94. Jensen, C.B.; Zimmermann, E.; Gamborg, M.; Heitmann, B.L.; Baker, J.L.; Vaag, A.; Sørensen, T.I. No evidence
of seasonality of birth in adult type 2 diabetes in Denmark. Diabetologia 2015, 58, 2045–2050.
95. Lockett, G.A.; Soto-Ramírez, N.; Ray, M.A.; Everson, T.M.; Xu, C.J.; Patil, V.K.; Terry, W.; Kaushal, A.;
Rezwan, F.I.; Ewart, S.L.; et al. Association of season of birth with DNA methylation and allergic disease.
Allergy 2016, 71, 1314–1324. [CrossRef] [PubMed]
96. Dugué, P.A.; Geurts, Y.M.; Milne, R.L.; Lockett, G.A.; Zhang, H.; Karmaus, W.; Holloway, J.W. Is there an
association between season of birth and blood DNA methylation in adulthood? Allergy 2016, 71, 1501–1504.
[CrossRef] [PubMed]
97. Desiderio, A.; Spinelli, R.; Ciccarelli, M.; Nigro, C.; Miele, C.; Beguinot, F.; Raciti, G.A. Epigenetics: Spotlight
on type 2 diabetes and obesity. J. Endocrinol. Investig. 2016, 39, 1095–1103. [CrossRef] [PubMed]
98. Sterns, J.D.; Smith, C.B.; Steele, J.R.; Stevenson, K.L.; Gallicano, G.I. Epigenetics and type II diabetes mellitus:
Underlying mechanisms of prenatal predisposition. Front. Cell Dev. Biol. 2014, 2, 15. [CrossRef] [PubMed]
99. Ravelli, A.C.; van der Meulen, J.H.; Michels, R.P.; Osmond, C.; Barker, D.J.; Hales, C.N.; Bleker, O.P. Glucose
tolerance in adults after prenatal exposure to famine. Lancet 1998, 351, 173–177. [CrossRef]
100. Lussana, F.; Painter, R.C.; Ocke, M.C.; Buller, H.R.; Bossuyt, P.M.; Roseboom, T.J. Prenatal exposure to the
Dutch famine is associated with a preference for fatty foods and a more atherogenic lipid profile. Am. J.
Clin. Nutr. 2008, 88, 1648–1652. [CrossRef] [PubMed]
101. Lumey, L.H.; Stein, A.D.; Kahn, H.S.; Romijn, J.A. Lipid profiles in middle-aged men and women after
famine exposure during gestation: The dutch hunger winter families study. Am. J. Clin. Nutr. 2009, 89,
1737–1743. [CrossRef] [PubMed]
102. Roseboom, T.; de Rooij, S.; Painter, R. The Dutch famine and its long-term consequences for adult health.
Early Hum. Dev. 2006, 82, 485–491. [CrossRef] [PubMed]
103. Liu, L.; Wang, W.; Sun, J.; Pang, Z. Association of famine exposure during early life with the risk of type 2
diabetes in adulthood: A meta-analysis. Eur. J. Nutr. 2016. [CrossRef] [PubMed]
104. Gillman, M.W. Prenatal famine and developmental origins of type 2 diabetes. Lancet Diabetes Endocrinol.
2015, 3, 751–752. [CrossRef]
105. Kaati, G.; Bygren, L.O.; Edvinsson, S. Cardiovascular and diabetes mortality determined by nutrition during
parents’ and grandparents’ slow growth period. Eur. J. Hum. Genet. 2002, 10, 682–688. [CrossRef] [PubMed]
106. Pembrey, M.E. Male-line transgenerational responses in humans. Hum. Fertil. (Camb.) 2010, 13, 268–271.
[CrossRef] [PubMed]
107. Vaiserman, A.M.; Pasyukova, E.G. Epigenetic drugs: A novel anti-aging strategy? Front. Genet. 2012, 3, 224.
[CrossRef] [PubMed]
© 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution










Serum Magnesium Concentrations in the Canadian
Population and Associations with Diabetes,
Glycemic Regulation, and Insulin Resistance
Jesse Bertinato 1,2,*, Kuan Chiao Wang 3 and Stephen Hayward 3
1 Nutrition Research Division, Food Directorate, Health Products and Food Branch, Health Canada,
Sir Frederick G. Banting Research Centre, 251 Sir Frederick Banting Driveway, Ottawa,
ON K1A 0K9, Canada
2 Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa,
ON K1H 8M5, Canada
3 Bureau of Food Surveillance and Science Integration, Food Directorate, Health Products and Food Branch,
Health Canada, Ottawa, ON K1A 0K9, Canada;
kuan.chiao.wang@hc-sc.gc.ca (K.C.W.); stephen.hayward@hc-sc.gc.ca (S.H.)
* Correspondence: jesse.bertinato@hc-sc.gc.ca; Tel.: +1-613-957-0924; Fax: +1-613-946-6212
Received: 26 January 2017; Accepted: 14 March 2017; Published: 17 March 2017
Abstract: Total serum magnesium (Mg) concentration (SMC) is commonly used to assess Mg status.
This study reports current SMCs of Canadians and their associations with demographic factors,
diabetes, and measures of glycemic control and insulin resistance using results from the Canadian
Health Measures Survey cycle 3 (2012–2013). Associations were examined in adults aged 20–79 years
using linear mixed models. Mean SMCs and percentile distributions for 11 sex-age groups between
3 and 79 years (n = 5561) are reported. SMCs were normally distributed and differences (p < 0.05)
among sex and age groups were small. Between 9.5% and 16.6% of adult sex-age groups had a SMC
below the lower cut-off of a population-based reference interval (0.75–0.955 mmol·L−1) established
in the United States population as part of the NHANES I conducted in 1971–1974. Having diabetes
was associated with 0.04 to 0.07 mmol·L−1 lower SMC compared to not having diabetes in the
various models. Body mass index, glycated hemoglobin, serum glucose and insulin concentrations,
and homeostatic model assessment of insulin resistance were negatively associated with SMC. This is
the first study to report SMCs in a nationally representative sample of the Canadian population.
A substantial proportion of Canadians are hypomagnesaemic in relation to a population-based
reference interval, and SMC was negatively associated with diabetes and indices of glycemic control
and insulin resistance.
Keywords: Canada; diabetes; glycemic regulation; homeostatic model assessment of insulin
resistance; serum magnesium concentration
1. Introduction
Magnesium (Mg) is a mineral nutrient that functions as a catalytic co-factor and structural
component of enzymes and plays an important role as a calcium antagonist [1]. Mg is essential
for many biological processes including the synthesis of organic molecules, cell proliferation,
energy production, muscle contraction and relaxation, bone development, mineral metabolism,
and glucose homeostasis [1–4]. In North America, Mg intakes fall short of dietary recommendations
for a large segment of the population [5–7]. However, the extent of Mg deficiency in the general
population and related health risks are unclear because of the uncertainty regarding Mg intakes
needed for optimal health. This is underscored by the large differences in recommended intakes for
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Mg established by different scientific bodies [8–10]. In addition, current information on Mg status of
the North American population is lacking.
Total serum Mg concentration is the most widely used nutritional biomarker for assessing
Mg status [1,11,12]. A recent meta-analysis of randomized controlled trials showed that serum
(or plasma) Mg concentrations were significantly increased by oral Mg supplementation in a dose-
and time-dependent manner [13]. Notably, little or no change in serum Mg was observed with higher
baseline circulating Mg concentrations. Together, these results suggest that serum Mg concentrations
can provide meaningful information on Mg status.
Information on serum Mg concentrations in the Canadian or United States populations from
nationally-representative health surveys is limited. The last national estimates were based on data
collected over 40 years ago in the first National Health and Nutrition Examination Survey (NHANES I)
conducted in the United States between 1971 and 1974 [14]. These estimates were used to establish
a population-based reference interval for adults of 0.75–0.955 mmol·L−1. Based on this reference
interval, a serum Mg concentration below 0.75 mmol·L−1 is usually defined as hypomagnesaemia
(low serum Mg concentration).
Low Mg intakes and/or serum Mg concentrations have been associated with a number of diseases
and health conditions including hypertension [15,16], sudden cardiac death [17,18], reduced bone
mineral density [19], cardiovascular disease events [20,21], and colorectal cancer [22,23]. Poor Mg
status may also impair growth of lean body mass [24] and decrease physical performance [25].
Diabetes (both type 1 and type 2) is the most common metabolic disorder associated with Mg
deficiency [26–30], with reported incidence rates of hypomagnesaemia in diabetics as high as
13.5%–47.7% [27]. Multiple factors likely contribute to the hypomagnesaemia, including increased Mg
loss through excretion by the kidneys. The higher renal Mg excretion is caused by reduced tubular Mg
reabsorption resulting from glucose-induced osmotic diuresis and possibly insulin resistance [27,31].
Serum Mg has been negatively associated with fasting glucose and insulin concentrations and glycated
hemoglobin (HbA1c), a measure of long-term glycemic control [32–34]. Negative associations have also
been reported with indirect indices of insulin resistance including quantitative insulin sensitivity check
index (QUICKI), homeostatic model assessment of insulin resistance (HOMA-IR), and McAuley’s
index [32,35].
Nationally-representative data are preferred over non-national data for the development of
nutrition policies and regulations. National estimates of serum Mg concentrations have never been
reported for Canadians. The primary objective of this study was to report current national estimates
of serum Mg concentrations for the Canadian population for ages 3–79 years using results from the
Canadian Health Measures Survey (CHMS) cycle 3 conducted between 2012 and 2013. In Canada,
the high prevalence of obesity [36] and co-morbidities such as insulin resistance and diabetes [37] may
have a negative effect on the Mg status of the population. Thus, secondary analyses were performed
to examine population-level associations between serum Mg concentrations and demographic factors,
diabetes, and measures of glycemic regulation and insulin resistance in adults in order to add to our
understanding of subpopulations at increased risk for Mg deficiency.
2. Materials and Methods
2.1. Survey Design
The CHMS is a cross-sectional, population-based survey that collects health information through
a household interview and direct physical measures. The CHMS used a multi-stage sampling design.
For cycle 3 of the survey, anthropometric measurements and biological samples were collected in
a mobile examination centre (MEC) over 2 years from January 2012 to December 2013. Samples were
collected from ~5700 volunteers aged 3 to 79 years from 16 collection sites stratified in five regions
across Canada: Atlantic, Quebec, Ontario, Prairies, and British Columbia. The survey was designed to
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for both sexes. Cycle 3 included members of the populations of the 10 provinces. Persons living in the
territories, living on reserves and other aboriginal settlements in the provinces, full-time members of
the Canadian Forces, the institutionalized, and persons living in certain remote areas were excluded
from the survey. Altogether, these exclusions represent ~4% of the target population. The CHMS
cycle 3 was approved by the Health Canada and Public Health Agency of Canada Research Ethics
Board. Informed written consent was obtained from all participants older than 14 years of age.
Parents or legal guardians provided written consent for younger children and the child gave assent.
More detailed information on the aims of the CHMS, target population, and methodologies can be
found elsewhere [38].
2.2. Biochemical Measurements
Fasted (≥12 h) and nonfasted blood samples were collected and processed in a MEC. Whole
blood was collected in 10 mL K2EDTA tubes (CABD366643L, VWR International, Mississauga,
ON, Canada). Serum was isolated from blood collected in 4 mL serum tubes (CABD367812L,
VWR International). Whole blood and serum samples were shipped to the Nutrition Laboratory,
Health Canada for measurement of HbA1c (whole blood) and serum Mg, albumin, triglyceride,
and glucose concentrations using the Vitros 5.1 FS clinical chemistry analyzer (Ortho Clinical
Diagnostics, Mississauga, ON, Canada). Serum insulin concentration was measured using the Advia
Centaur XP immunoassay analyzer (Siemens Healthcare Diagnostics, Mississauga, ON, Canada).
The inter-assay (within lab precision) coefficients of variability (low–high concentration range) for
HbA1c, Mg, albumin, triglycerides, glucose and insulin were 1.9%–3.1%, 1.7%–0.9%, 1.7%–0.9%,
1.4%–0.9%, 1.5%–1.2%, and 5.9%–4.8%, respectively. Triglycerides and insulin were only measured in
fasted participants. Results from samples with degree of hemolysis exceeding the threshold value for
the assay were excluded from the analyses.
2.3. Collection of Demographic Information
Information on age, sex, race (i.e., white, South Asian, Chinese, black, Filipino, Latin American,
Arab, Southeast Asian, West Asian, Korean, Japanese, other), diabetes, and yearly household income
was collected at a household interview with the participants. The interview was conducted by trained
interviewers using a computer-assisted interviewing method [38].
2.4. Calculations
QUICKI, HOMA-IR, and McAuley’s index were calculated using the following equations:
QUICKI, (log insulin (μIU·mL−1) + log glucose (mg·dL−1))−1; HOMA-IR, (glucose (mmol·L−1)
× insulin (μIU·mL−1)) 22.5−1; and McAuley’s index, exp(2.63 − 0.28 ln insulin (μIU mL−1) − 0.31 ln
triglycerides (mmol·L−1)). BMI was calculated from weight and height measurements.
2.5. Statistical Analyses
The CHMS cycle 3 sampling design yields national estimates when survey weights are applied.
Bootstrap weights were used for all variance estimations to account for the complex sampling
design [39]. The 16 collection sites from five regional strata restricted the statistical analyses to
11 degrees of freedom. Descriptive statistics are presented as arithmetic means and percentiles with 95%
confidence intervals. A t-test or ANOVA followed by Tukey’s test was used for pairwise comparison
of means. Association of serum Mg concentration with demographic and biochemical characteristics
were assessed via linear mixed models. Age, sex, race (white or non-white), diabetes (type 1 and
type 2 combined), BMI, and yearly household income were designated as fixed effects. HbA1c,
QUICKI, HOMA-IR, McAuley’s index, and serum albumin, glucose, insulin, and triglyceride
concentrations were modeled as random effects to account for the inherent variability associated
with these measurements during sampling. Model 1 included the full adult sample set (fasted and
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household income, albumin, and HbA1c were examined. Two additional models were developed
using the fasted subsample. In model 2, associations with glucose, insulin, and triglycerides were
investigated in addition to the variables examined in Model 1. In Model 3, associations with the
indirect indices of insulin resistance QUICKI, HOMA-IR, and McAuley’s index were examined instead
of the direct measures glucose, insulin, and triglycerides. The SURVEYREG procedure with backwards
elimination was used to develop the final models. For the purpose of interpretation, estimates for the
continuous variables were also determined after a transformation using the 5th and 95th percentiles:
Y = (X − 5th percentile of X) ÷ (95th percentile of X − 5th percentile of X) (1)
Pregnant women (n = 19) and participants with a missing or invalid value were excluded from
the analyses. The coefficients of variation for all estimates were <16.6% and considered acceptable for
unrestricted release based on the CHMS sampling variability guidelines [40]. Statistical significance
was set a p < 0.05. Statistical analyses were performed using SAS/STAT® 9.3 software (SAS Institute
Inc., Cary, NC, USA).
3. Results
Means and percentile distributions for total serum Mg concentration for 11 sex-age groups
between 3 and 79 years are presented in Table 1. Distributions were symmetrical and thus arithmetic
means were reported. In general, differences (p < 0.05) among sex and age groups were small. For ages
6–11 years, 20–39 years and 40–59 years females had lower means compared to males. Estimations for
adolescents and adults at the 10th percentile were below a population-based reference interval for
adults of 0.75–0.955 mmol·L−1 [14]. Between 9.5% and 16.6% of the adult sex-age groups had a serum
Mg concentration below 0.75 mmol·L−1 (Figure 1). Estimates for the 25th and 95th percentiles for all
sex-age groups were within the reference interval (Table 1). Boxplots show a greater number of older
adults of both sexes with serum Mg concentration below the lower fence (i.e., 1.5 × interquartile range)
(Figure S1).
Mean serum Mg concentration between fasted and nonfasted participants were similar (p ≥ 0.05)
for most sex-age groups (Table S1). However, fasted males and females 6–11 years had lower means
than corresponding nonfasted participants. Conversely, fasted females aged 60–79 years had a higher
mean compared to non-fasting females of the same age range.
Association of serum Mg concentration with demographic factors, diabetes and measures of
glycemic control and insulin resistance were examined in adults aged 20–79 years using mixed models
(data for children and adolescents aged 3–19 years were excluded from these analyses). Serum albumin
concentration was included in the models because of a linear relationship with serum Mg at high and
low concentrations [41]. For continuous variables associations were estimated for a defined unit change
and after transformation using the 5th and 95th percentiles. After transformation the estimated change
in serum Mg corresponds to the change in the continuous variable from the 5th to the 95th percentile in
the population. This is a better indication of the relative strengths of the associations among variables
since the magnitudes of associations are compared without confounding by their scales. Estimates of
the 5th and 95th percentiles for each continuous variable are presented for each model.
In Model 1, associations were estimated in fasted and nonfasted adults (Table 2). Being male was
associated with higher serum Mg, whereas white race (compared to non-white) or having diabetes
(type 1 or type 2) was associated with lower Mg concentrations. Age, household income, and serum
albumin concentration were positively associated with serum Mg, while BMI and HbA1c showed
a negative association.
In Models 2 and 3, associations were examined in fasted adults. In Model 2, serum Mg was
positively associated with age and household income and negatively associated with diabetes and
serum glucose and insulin concentrations (Table 3). In Model 3, age and household income showed
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Figure 1. Percentage of each sex and age group with a serum Mg concentration below 0.75 mmol·L−1.
The total number of participants (n) examined for each sex-age group is shown in Table 1. F, females;
M, males; y, years.
4. Discussion
This study describes current (2012–2013) estimates of serum Mg concentrations in a nationally
representative sample of the Canadian population for ages 3–79 years. These results are the first
national estimates in Canada or the United States since the NHANES I conducted between 1971 and
1973 [14]. Results from that study showed a normal distribution for serum Mg concentration, with 95%
of adults aged 18–74 years having a value between 0.75 and 0.955 mmol·L−1. Those estimates were
considered as normative for the United States population and were used to establish a population-based
reference interval. Serum Mg concentrations in the present study were also normally distributed.
Substantial proportions of the adult sex-age groups (9.5%–16.6%) and adolescents aged 12–19 years
(15.8%–21.8%) had a serum Mg concentration below 0.75 mmol·L−1, the lower cut-off of the reference
interval. All estimates at the 10th percentile for adolescents and adults were also below 0.75 mmol·L−1.
In addition, means in this study were lower than means reported in the NHANES I for comparable
sex-age groups [14]. Collectively, these results suggest that present-day serum Mg concentrations
in Canada are lower compared to concentrations in the United States population in the early 1970s.
Since it has been suggested that a serum Mg concentration below 0.75 mmol·L−1 represents relatively
severe Mg deficiency [11], these results raise suspicions of Mg deficiency in the Canadian population.
Estimates at the 95th percentile for all sex-age groups were within the reference interval indicating the
rarity of hypermagnesaemia in the population.
Similar to results from the NHANES I, only small differences in serum Mg concentrations
were found among sex and age groups. Serum Mg concentrations were highest for children
and showed a small increase with age from adolescents 12–19 years to older adults 60–79 years.
Among demographic factors, age was the strongest predictor of serum Mg concentration in adults.
The magnitudes of associations with sex, race, and household income were considerably smaller.
A major finding from the NHANES I was the lower serum Mg in black Americans compared to white
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than being non-white. It should be mentioned that because of the small sample sizes for all racial
groups other than whites (including blacks), comparison among races in this study was restricted to
the general groups of whites and non-whites.
Boxplot analyses revealed a greater number of older adults with serum Mg values below the
lower fence (outliers) indicating that older adults are more prone to marked hypomagnesaemia.
Possible explanations include lower dietary Mg intakes, reduced gastrointestinal Mg absorption,
and increased renal Mg excretion in the elderly [42]. The higher occurrence of health conditions
(e.g., diabetes) and other factors (e.g., use of hypermagnesuric diuretics) that alter Mg metabolism may
also contribute [43].
Serum Mg concentrations were compared between fasted and nonfasted participants. Mean serum
Mg concentrations were found to be lower for fasted children aged 6–11 years, but higher for fasted
females aged 60–79 years. It is presently unclear what accounts for these differences. While the
differences could be considered modest, these data offer a caution when interpreting results from
a routine serum Mg test for these sex-age groups.
Inverse associations between serum Mg and diabetes and comorbidities such as poor glycemic
control and insulin resistance have been well established. However, it is likely that these relationships
are affected by factors that can differ among countries or change in populations over time
(e.g., dietary Mg intakes, supplement and medication use). Thus, in this study associations of
serum Mg concentration with diabetes and measures of glycemic regulation and insulin resistance
were investigated in adults to determine the magnitude of these associations in a relatively current
nationally-representative dataset. Diabetes was a strong predictor of serum Mg concentration.
The estimated lower serum Mg in diabetics (ranging from −0.04 to −0.07 mmol·L−1 in the various
models) accounts for ~20% to 34% of the spread between the lower and upper limits of the normal
reference interval. These estimates are substantial and likely have clinical relevance. Serum Mg was
also negatively associated with HbA1c and fasting serum glucose concentration. A negative effect of
diabetes on Mg status is noteworthy given the high prevalence of diabetes in Canada which is expected
to rise to over 10% by the year 2020 [37].
The hyperinsulinemic euglycemic clamp is considered the “gold standard” for assessment
of insulin sensitivity, but the complexity of the method limits its use in large studies [44].
In this study, associations between serum Mg and more practical surrogate indices of insulin
resistance [45] were examined. Fasting insulin concentration correlates strongly with insulin
resistance [46] and HOMA-IR is considered a robust tool for the evaluation of insulin resistance
in large epidemiological studies [47,48]. Serum Mg showed a negative association with both fasting
insulin and HOMA-IR, indicating a positive relationship between serum Mg and insulin sensitivity.
Notably, these relationships were observed in models controlling for diabetes. It should be mentioned
that HOMA-IR was determined to be a better predictor of serum Mg concentration compared to other
proxy measures of insulin resistance such as QUICKI or McAuley’s index that were insignificant
(p ≥ 0.05) in our selection process.
There is evidence indicating that the relationship between Mg deficiency and type 2 diabetes is
bidirectional. Mg deficiency is a common manifestation in type 1 and type 2 diabetics [26,27] and may
also increase the risk of diabetes and its complications [29–31]. The negative associations between
serum Mg and measures of glycemic regulation observed in this study are in agreement with studies
indicating that poor glycemic control lowers serum Mg concentrations [33,34]. However, lower serum
Mg may also contribute to poorer glycemic regulation and insulin sensitivity. Studies indicate that
Mg supplementation improves glucose and insulin sensitivity parameters [49,50]. A meta-analysis
of randomized controlled trials showed that Mg supplementation for over four months improved
fasting glucose and HOMA-IR in diabetic and non-diabetic subjects [49]. In another meta-analysis,
Mg supplementation was shown to reduce fasting plasma glucose in diabetics and improve HOMA-IR
and plasma glucose (in a 2 h oral glucose tolerance test) in persons at high risk of diabetes [50].
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involve increased oxidative stress and inflammation [35,51,52]. It is important to mention that this
study does not provide any information on the temporality of the reported associations with serum
Mg given the cross-sectional design.
The main strength of this study is the CHMS cycle 3 study design, including the large sample
size that is representative of the Canadian population that is ideal for estimating national serum Mg
concentrations and population distributions. The use of mixed models and continuous variables
(rather than dichotomizing continuous variables) is also a strength. Limitations include the absence
of Mg intake data (including supplement use) for comparison with serum Mg concentrations.
The different methodologies used to measure serum Mg in this study and the NHANES I (colorimetric
vs. atomic absorption spectroscopy) limits, to some extent, the comparison of results between studies;
however, serum Mg measurements by the colorimetric method (the most commonly used method)
or atomic absorption show excellent agreement (R > 0.99) [53]. Also, based on the responses to the
household questionnaire, many diabetics in this study could not be categorized as having type 1 or
type 2 diabetes. Thus, in our analyses, diabetics included participants with type 1 or type 2 diabetes
or both.
The limitations of total serum Mg concentration as a biomarker of Mg status also merit discussion.
Only a small fraction (~0.3%) of total body Mg is present in the serum and fluctuations in serum proteins
such as albumin can alter Mg concentrations [41]. Furthermore, serum Mg may not always accurately
reflect intracellular Mg deficiency. Serum Mg concentration is tightly regulated primarily at the level
of renal excretion. Bone also maintains circulating concentrations by acting as a store for Mg and
supplementing the serum under conditions of deficiency. This homeostatic regulation is likely a major
factor accounting for the poor association observed between serum Mg concentrations and dietary
Mg intakes, particularly when intakes meet nutrient requirements [54,55]. Despite these limitations,
low serum Mg is usually indicative of Mg deficiency. Serum Mg is decreased in a dose-dependent
manner in animal models of dietary Mg deficiency, demonstrating that low Mg intakes (Mg deficiency)
reduce serum Mg concentration [56,57]. Human studies have shown that serum Mg is responsive
to long-term changes in dietary Mg intakes [58] and increases with Mg supplementation [13,59,60].
A meta-analysis of randomized controlled trials showed that serum Mg concentrations increase in
a dose- and time-dependent manner with oral Mg supplementation, and the response is greater
when baseline circulating Mg concentrations are lower, suggesting that serum Mg provides useful
information about underlying Mg status [13]. It has been suggested that a serum Mg value below
0.75 mmol·L−1 is a useful measure of relatively severe Mg deficiency, but Mg deficiency cannot be
excluded for persons with a value between 0.75 and 0.85 mmol·L−1 [11,12].
5. Conclusions
This study reports serum Mg concentrations for 11 sex-age groups between 3 and 79 years in the
Canadian population. Between 9.5% and 16.6% of the adult sex-age groups were hypomagnesaemic
(serum Mg < 0.75 mmol·L−1) in relation to a population-based reference interval [14]. There is a need
to establish an evidence-based reference interval (or at minimum a lower cut-off value) for health that
will allow more accurate assessment of the prevalence of Mg deficiency in Canada and related health
risk based on results from this study [61]. Among demographic factors, age was the strongest predictor
of serum Mg concentration. Serum Mg concentration was negatively associated with diabetes, BMI,
serum glucose, serum insulin, HbA1c, and HOMA-IR. These results are consistent with a growing
body of evidence indicating a negative effect of diabetes, poor glycemic control, and insulin resistance
on Mg status.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/3/296/s1,
Figure S1: Boxplots of serum Mg concentrations by sex-age group, Table S1: Means and distributions of serum
magnesium concentrations by sex and age in fasted and nonfasted Canadians.
Acknowledgments: This research was funded by the Bureau of Nutritional Sciences and the Bureau of Food








Nutrients 2017, 9, 296
Author Contributions: J.B. conceived the study; J.B., K.C.W. and S.H. analyzed the data; J.B. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Swaminathan, R. Magnesium metabolism and its disorders. Clin. Biochem. Rev. 2003, 24, 47–66. [PubMed]
2. Volpe, S.L. Magnesium in disease prevention and overall health. Adv. Nutr. 2013, 4, 378S–383S. [CrossRef]
[PubMed]
3. Elin, R.J. Magnesium: The fifth but forgotten electrolyte. Am. J. Clin. Pathol. 1994, 102, 616–622. [CrossRef]
[PubMed]
4. Wolf, F.I.; Cittadini, A. Magnesium in cell proliferation and differentiation. Front. Biosci. 1999, 4, D607–D617.
[CrossRef] [PubMed]
5. Moshfegh, A.; Goldman, J.D.; Ahuja, J.; Rhodes, D.; LaComb, R. What We Eat in America, NHANES 2005–2006:
Usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium,
Phosphorus, and Magnesium; U.S. Department of Agriculture, Agriculture Research Service: Washington, DC,
USA, 2009.
6. Health Canada. Do Canadian Adults Meet Their Nutrient Requirements through Food Intake Alone?
Available online: http://www.hc-sc.gc.ca/fn-an/surveill/nutrition/commun/art-nutr-adult-eng.php
(accessed on 23 February 2017).
7. Ford, E.S.; Mokdad, A.H. Dietary magnesium intake in a national sample of US adults. J. Nutr. 2003, 133,
2879–2882. [PubMed]
8. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium,
Vitamin D, and Fluoride; National Academy Press: Washington, DC, USA, 1997; pp. 190–249.
9. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on dietary reference
values for magnesium. EFSA J. 2015, 13, 4186.
10. Joint FAO/WHO Expert Consultation. Vitamin and Mineral Requirements in Human Nutrition: Report of a Joint
FAO/WHO Expert Consultation, 2nd ed.; World Health Organization: Geneva, Switzerland, 2004.
11. Arnaud, M.J. Update on the assessment of magnesium status. Br. J. Nutr. 2008, 99, S24–S36. [CrossRef]
[PubMed]
12. Elin, R.J. Assessment of magnesium status for diagnosis and therapy. Magnes. Res. 2010, 23, S194–S198.
[PubMed]
13. Zhang, X.; Del Gobbo, L.C.; Hruby, A.; Rosanoff, A.; He, K.; Dai, Q.; Costello, R.B.; Zhang, W.; Song, Y.
The circulating concentration and 24-h urine excretion of magnesium dose- and time-dependently respond
to oral magnesium supplementation in a meta-analysis of randomized controlled trials. J. Nutr. 2016, 146,
595–602. [CrossRef] [PubMed]
14. Lowenstein, F.W.; Stanton, M.F. Serum magnesium levels in the United States, 1971–1974. J. Am. Coll. Nutr.
1986, 5, 399–414. [CrossRef] [PubMed]
15. Ma, J.; Folsom, A.R.; Melnick, S.L.; Eckfeldt, J.H.; Sharrett, A.R.; Nabulsi, A.A.; Hutchinson, R.G.;
Metcalf, P.A. Associations of serum and dietary magnesium with cardiovascular disease, hypertension,
diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis Risk in Communities
Study. J. Clin. Epidemiol. 1995, 48, 927–940. [CrossRef]
16. Zhang, X.; Li, Y.; Del Gobbo, L.C.; Rosanoff, A.; Wang, J.; Zhang, W.; Song, Y. Effects of magnesium
supplementation on blood pressure: A meta-analysis of randomized double-blind placebo-controlled trials.
Hypertension 2016, 68, 324–333. [CrossRef] [PubMed]
17. Kieboom, B.C.; Niemeijer, M.N.; Leening, M.J.; van den Berg, M.E.; Franco, O.H.; Deckers, J.W.; Hofman, A.;
Zietse, R.; Stricker, B.H.; Hoorn, E.J. Serum magnesium and the risk of death from coronary heart disease
and sudden cardiac death. J. Am. Heart Assoc. 2016, 5, e002707. [CrossRef] [PubMed]
18. Peacock, J.M.; Ohira, T.; Post, W.; Sotoodehnia, N.; Rosamond, W.; Folsom, A.R. Serum magnesium and risk
of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 2010, 160,
464–470. [CrossRef] [PubMed]
19. Orchard, T.S.; Larson, J.C.; Alghothani, N.; Bout-Tabaku, S.; Cauley, J.A.; Chen, Z.; LaCroix, A.Z.;
Wactawski-Wende, J.; Jackson, R.D. Magnesium intake, bone mineral density, and fractures: Results from the








Nutrients 2017, 9, 296
20. Del Gobbo, L.C.; Imamura, F.; Wu, J.H.; de Oliveira Otto, M.C.; Chiuve, S.E.; Mozaffarian, D. Circulating and
dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective
studies. Am. J. Clin. Nutr. 2013, 98, 160–173. [CrossRef] [PubMed]
21. Qu, X.; Jin, F.; Hao, Y.; Li, H.; Tang, T.; Wang, H.; Yan, W.; Dai, K. Magnesium and the risk of cardiovascular
events: A meta-analysis of prospective cohort studies. PLoS ONE 2013, 8, e57720. [CrossRef] [PubMed]
22. Chen, G.C.; Pang, Z.; Liu, Q.F. Magnesium intake and risk of colorectal cancer: A meta-analysis of prospective
studies. Eur. J. Clin. Nutr. 2012, 66, 1182–1186. [CrossRef] [PubMed]
23. Qu, X.; Jin, F.; Hao, Y.; Zhu, Z.; Li, H.; Tang, T.; Dai, K. Nonlinear association between magnesium intake and
the risk of colorectal cancer. Eur. J. Gastroenterol. Hepatol. 2013, 25, 309–318. [CrossRef] [PubMed]
24. Bertinato, J.; Lavergne, C.; Rahimi, S.; Rachid, H.; Vu, N.A.; Plouffe, L.J.; Swist, E. Moderately low magnesium
intake impairs growth of lean body mass in obese-prone and obese-resistant rats fed a high-energy diet.
Nutrients 2016, 8, 253. [CrossRef] [PubMed]
25. Veronese, N.; Berton, L.; Carraro, S.; Bolzetta, F.; De Rui, M.; Perissinotto, E.; Toffanello, E.D.; Bano, G.;
Pizzato, S.; Miotto, F.; et al. Effect of oral magnesium supplementation on physical performance in healthy
elderly women involved in a weekly exercise program: A randomized controlled trial. Am. J. Clin. Nutr.
2014, 100, 974–981. [CrossRef] [PubMed]
26. De Valk, H.W. Magnesium in diabetes mellitus. Neth. J. Med. 1999, 54, 139–146. [CrossRef]
27. Pham, P.C.; Pham, P.M.; Pham, S.V.; Miller, J.M.; Pham, P.T. Hypomagnesemia in patients with type 2
diabetes. Clin. J. Am. Soc. Nephrol. 2007, 2, 366–373. [CrossRef] [PubMed]
28. Kao, W.H.; Folsom, A.R.; Nieto, F.J.; Mo, J.P.; Watson, R.L.; Brancati, F.L. Serum and dietary magnesium and
the risk for type 2 diabetes mellitus: The Atherosclerosis Risk in Communities Study. Arch. Intern. Med. 1999,
159, 2151–2159. [CrossRef] [PubMed]
29. Larsson, S.C.; Wolk, A. Magnesium intake and risk of type 2 diabetes: A meta-analysis. J. Intern. Med. 2007,
262, 208–214. [CrossRef] [PubMed]
30. Weng, L.C.; Lee, N.J.; Yeh, W.T.; Ho, L.T.; Pan, W.H. Lower intake of magnesium and dietary fiber increases
the incidence of type 2 diabetes in Taiwanese. J. Formos. Med. Assoc. 2012, 111, 651–659. [CrossRef] [PubMed]
31. Gommers, L.M.; Hoenderop, J.G.; Bindels, R.J.; de Baaij, J.H. Hypomagnesemia in type 2 diabetes: A vicious
circle? Diabetes 2016, 65, 3–13. [CrossRef] [PubMed]
32. Bertinato, J.; Xiao, C.W.; Ratnayake, W.M.; Fernandez, L.; Lavergne, C.; Wood, C.; Swist, E. Lower serum
magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and
white Canadian women but not men. Food Nutr. Res. 2015, 59, 25974. [CrossRef] [PubMed]
33. Arpaci, D.; Tocoglu, A.G.; Ergenc, H.; Korkmaz, S.; Ucar, A.; Tamer, A. Associations of serum magnesium
levels with diabetes mellitus and diabetic complications. Hippokratia 2015, 19, 153–157. [PubMed]
34. Sinha, S.; Sen, S. Status of zinc and magnesium levels in type 2 diabetes mellitus and its relationship with
glycemic status. Int. J. Diabetes Dev. Ctries. 2014, 34, 220–223. [CrossRef]
35. Kim, D.J.; Xun, P.; Liu, K.; Loria, C.; Yokota, K.; Jacobs, D.R., Jr.; He, K. Magnesium intake in relation to
systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010, 33, 2604–2610.
[CrossRef] [PubMed]
36. Shields, M.; Carroll, M.D.; Ogden, C.L. Adult obesity prevalence in Canada and the United States.
NCHS Data Brief 2011, 56, 1–8.
37. Public Health Agency of Canada. Diabetes in Canada: Facts and Figures from a Public Health Perspective.
Available online: http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-
chiffres-2011/index-eng.php (accessed on 23 February 2017).
38. Statistics Canada. Canadian Health Measures Survey (CHMS). Available online: http://www23.statcan.gc.
ca/imdb/p2SV.pl?Function=getSurvey&Id=136652 (accessed on 23 February 2017).
39. Giroux, S. Canadian Health Measures Survey: Sampling strategy overview. Health Rep. 2007, 18, S31–S36.
40. Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 1. Available online:
http://www23.statcan.gc.ca/imdb-bmdi/document/5071_D2_T1_V1-eng.htm (accessed on 23 February 2017).
41. Kroll, M.H.; Elin, R.J. Relationships between magnesium and protein concentrations in serum. Clin. Chem.
1985, 31, 244–246. [PubMed]
42. Seelig, M.S.; Preuss, H.G. Magnesium metabolism and perturbations in the elderly. Geriatr. Nephrol. Urol.








Nutrients 2017, 9, 296
43. Barbagallo, M.; Belvedere, M.; Dominguez, L.J. Magnesium homeostasis and aging. Magnes. Res. 2009, 22,
235–246. [PubMed]
44. DeFronzo, R.A.; Tobin, J.D.; Andres, R. Glucose clamp technique: A method for quantifying insulin secretion
and resistance. Am. J. Physiol. 1979, 237, E214–E223. [PubMed]
45. Singh, B.; Saxena, A. Surrogate markers of insulin resistance: A review. World J. Diabetes 2010, 1, 36–47.
[CrossRef] [PubMed]
46. Olefsky, J.; Farquhar, J.W.; Reaven, G. Relationship between fasting plasma insulin level and resistance to
insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 1973, 22, 507–513. [CrossRef]
[PubMed]
47. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model
assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations
in man. Diabetologia 1985, 28, 412–419. [CrossRef] [PubMed]
48. Gutch, M.; Kumar, S.; Razi, S.M.; Gupta, K.K.; Gupta, A. Assessment of insulin sensitivity/resistance. Indian J.
Endocrinol. Metab. 2015, 19, 160–164. [CrossRef] [PubMed]
49. Simental-Mendia, L.E.; Sahebkar, A.; Rodriguez-Moran, M.; Guerrero-Romero, F. A systematic review and
meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin
sensitivity and glucose control. Pharmacol. Res. 2016, 111, 272–282. [CrossRef] [PubMed]
50. Veronese, N.; Watutantrige-Fernando, S.; Luchini, C.; Solmi, M.; Sartore, G.; Sergi, G.; Manzato, E.;
Barbagallo, M.; Maggi, S.; Stubbs, B. Effect of magnesium supplementation on glucose metabolism in
people with or at risk of diabetes: A systematic review and meta-analysis of double-blind randomized
controlled trials. Eur. J. Clin. Nutr. 2016, 70, 1354–1359. [CrossRef] [PubMed]
51. Zheltova, A.A.; Kharitonova, M.V.; Iezhitsa, I.N.; Spasov, A.A. Magnesium deficiency and oxidative stress:
an update. BioMedicine 2016, 6, 8–14. [CrossRef] [PubMed]
52. Barbagallo, M.; Dominguez, L.J. Magnesium and type 2 diabetes. World J. Diabetes 2015, 6, 1152–1157.
[CrossRef] [PubMed]
53. Instructions for Use. VITROS Chemistry Products Mg Slides. Available online: https://www.cmmc.org/
cmmclab/IFU/Mg_MP2-47_EN_I.pdf (accessed on 23 February 2017).
54. Lakshmanan, F.L.; Rao, R.B.; Kim, W.W.; Kelsay, J.L. Magnesium intakes, balances, and blood levels of adults
consuming self-selected diets. Am. J. Clin. Nutr. 1984, 40, 1380–1389. [PubMed]
55. Misialek, J.R.; Lopez, F.L.; Lutsey, P.L.; Huxley, R.R.; Peacock, J.M.; Chen, L.Y.; Soliman, E.Z.; Agarwal, S.K.;
Alonso, A. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African
Americans: Atherosclerosis Risk in Communities (ARIC) Study. Circ. J. 2013, 77, 323–329. [CrossRef]
[PubMed]
56. Bertinato, J.; Lavergne, C.; Plouffe, L.J.; El Niaj, H.A. Small increases in dietary calcium above normal
requirements exacerbate magnesium deficiency in rats fed a low magnesium diet. Magnes. Res. 2014, 27,
35–47. [PubMed]
57. Bertinato, J.; Plouffe, L.J.; Lavergne, C.; Ly, C. Bioavailability of magnesium from inorganic and organic
compounds is similar in rats fed a high phytic acid diet. Magnes. Res. 2014, 27, 175–185. [PubMed]
58. Klevay, L.M.; Milne, D.B. Low dietary magnesium increases supraventricular ectopy. Am. J. Clin. Nutr. 2002,
75, 550–554. [PubMed]
59. Witkowski, M.; Hubert, J.; Mazur, A. Methods of assessment of magnesium status in humans: A systematic
review. Magnes. Res. 2011, 24, 163–180. [PubMed]
60. Song, Y.; He, K.; Levitan, E.B.; Manson, J.E.; Liu, S. Effects of oral magnesium supplementation on glycaemic
control in type 2 diabetes: A meta-analysis of randomized double-blind controlled trials. Diabet. Med. 2006,
23, 1050–1056. [CrossRef] [PubMed]
61. Costello, R.B.; Elin, R.J.; Rosanoff, A.; Wallace, T.C.; Guerrero-Romero, F.; Hruby, A.; Lutsey, P.L.; Nielsen, F.H.;
Rodriguez-Moran, M.; Song, Y.; et al. Perspective: The case for an evidence-based reference interval for
serum magnesium: the time has come. Adv. Nutr. 2016, 7, 977–993. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution










A Multifunctional Bread Rich in Beta Glucans and
Low in Starch Improves Metabolic Control in Type 2
Diabetes: A Controlled Trial
Paolo Tessari 1,* and Anna Lante 2
1 Department of Medicine (DIMED), University of Padova, 35128 Padova PD, Italy
2 Department of Agronomy, Food, Natural Resources, Animals & Environment (DAFNAE),
University of Padova, 35123 Padova PD, Italy; anna.lante@unipd.it
* Correspondence: paolo.tessari@unipd.it; Tel.: +39-049-821-1748; Fax: +39-049-821-7878
Received: 28 December 2016; Accepted: 9 March 2017; Published: 17 March 2017
Abstract: Design: Functional foods may be useful for people with diabetes. The soluble fibers beta
glucans can modify starch digestion and improve postprandial glucose response. We analyzed
the metabolic effects of a specifically designed ‘functional’ bread, low in starch, rich in fibers
(7 g/100 g), with a beta glucan/starch ratio of (7.6:100, g/g), in people with type 2 diabetes
mellitus. Methods: Clinical and metabolic data from two groups of age-, sex- and glycated
hemoglobin-matched diabetic subjects, taking either the functional bread or regular white bread,
over a roughly six-month observation period, were retrieved. Results: Bread intake did not change
during the trial. The functional bread reduced glycated hemoglobin by ~0.5% (absolute units) vs.
pre-treatment values (p = 0.028), and by ~0.6% vs. the control group (p = 0.027). Post-prandial and
mean plasma glucose was decreased in the treatment group too. Body weight, blood pressure and
plasma lipids did not change. The acceptance of the functional bread was good in the majority
of subjects, except for taste. Conclusions: A starch-restricted, fiber-rich functional bread, with an
increased beta glucan/starch ratio, improved long term metabolic control, and may be indicated in
the dietary treatment of type 2 diabetes.
Keywords: plasma glucose; beta glucan; starch; metabolic control; fibers
1. Introduction
Background and Aims
Type 2 diabetes mellitus (T2DM) is a disease with high prevalence and increasing incidence.
The world population currently affected by T2DM is about 400 million, and it is expected to grow
to more than 600 million by 2040 [1]. The increase of T2DM is largely due to changes of lifestyle [2],
i.e., excess dietary intake combined to low physical activity. Therefore, diet represents a cornerstone for
both prevention and therapy of T2DM, and a tool to maintain plasma glucose values close to normal.
Carbohydrates (CHO) are the key nutritional factors conditioning circulating glucose levels,
particularly in the post-prandial state. In order to prevent excessive post-prandial glycemicexcursions,
dietary CHO should be predominantly represented by starch (>90% of total CHO), with less than 10%
by either mono- or di-saccharides [3]. Furthermore, since T2DM is associated with a constellation
of conditions (obesity, dyslipidemia, hypertension) and risk factors (e.g., for cardiovascular disease)
recognized in the concept of the ‘metabolic syndrome’ [4–6], food capable of addressing most, if not all
these abnormalities, can be recommended. Thus, current understanding is that foods and diets for
T2DM patients are considered, for the present, to be energy controlled, with a low glycemic index (GI),
and with favorable effects on blood pressure and dyslipidemia. A reduction of cardiovascular (CV)
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risk and the prevention of long term diabetic complications are also expected to result from long-term
use of such ‘ideal’ foods.
Post-prandial glucose increments in diabetes may be blunted by foods containing starch and/or
simple CHO with a slow absorption rate, thus resulting in a low GI. Besides by the CHO type itself,
CHO absorption may be modulated by a variety of additional factors, such as starch characteristics
(i.e., resistance to digestion), fiber type and content, and by the presence of other compounds that
can decrease carbohydrate intestinal digestion and absorption. Conversely, the guidelines for dietary
treatment of hypertension, obesity and dyslipidemia include a reduction of sodium and energy intakes,
and a control of intestinal lipid absorption. Thus, targeting some, if not all, these risk factors, by means
of functional foods seems to be both recommended and promising in the dietary management of
both diabetes and the metabolic syndrome, through health-beneficial properties conveyed by natural
components and/or by added ingredients [7].
Functional foods rich in natural fibers, such as beta glucans, are among those most-widely studied
and employed. Beta glucans are naturally-occurring soluble fibers of some cereals (oats and barley),
composed of mixed-linkage (1,3)(1,4)-β-D-glucose units, mainly consisting of the linear polysaccharide
(1→3), (1→4)-β-D-glucan. Beta glucans increase viscosity in the upper digestive tract, thus reducing
postprandial glucose and insulin responses [8]. An optimal beta glucan/starch ratio has been proposed
as a method to decrease starch digestion in functional breads [9].
Bread is a staple food and a fundamental source of CHO worldwide in everyday diet. Therefore,
the design of a bread with targeted functional properties could retain a major impact on nutrition and
on metabolic parameters.
In this study, we examined the metabolic effects of long-term (roughly six months) substitution of
regular white bread with a functional bread, starch-restricted and rich in fiber (mostly beta glucans),
in the everyday diet of persons with type 2 diabetes.
2. Methods
2.1. Study Design and Participants
In the context of a comprehensive analysis of clinical and biochemical parameters of people with
type 2 diabetes mellitus, data from T2DM subjects of both sexes, collected at their regularly-scheduled
outpatient visits at the Diabetes Center of the Padova University Hospital, Italy, were retrieved.
This was an observational, controlled study with parallel groups, performed following recently
published guidelines and format (http://www.consort-statement.org/). The subjects’ inclusion criteria
were: a diabetes duration longer than 2 years; an unsatisfactory diabetes control (HbA1c values greater
than 7%); age between 50 and 80 years; treatment with diet only, or diet plus oral hypoglycemic agents
(OHA) and/or basal insulin; and a reported daily intake of at least 50 g CHO as either white bread,
breadsticks or other bread substitutes. The patients were visited at 3–6 months intervals.
2.2. Interventions
The patients had routinely been recommended to consume foods considered to be beneficial to
peoples with diabetes, such as low calorie items, with CHO predominantly represented by starch,
with a high fiber content and/or a low glycemic index, and low amounts of fats of animal origin.
Furthermore, the patients had been informed about the availability in supermarkets, of flour products
enriched with fibers and/or other compounds that could be beneficial to control glucose levels.
They were encouraged to prepare homemade bread using any of these flour products, as a substitute
of their usually consumed white bread made of refined flour.
At subsequent examinations, the type of bread used by every subjects was recorded. Therefore,
two groups of subjects could be selected over time: those who had shifted to the use of one of the
functional bread types (‘functional bread’ group), and those who had been still using their regular
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functional flour and/or bread, and its type, were retrieved and recorded. For the sake of homogeneity,
we report here data of those subjects consuming only one type of these fiber-enriched products, i.e.,
a flour labelled Salus® (produced by Ruggeri srl, Padova, Italy), that was the most largely used.
These subjects were included into the ‘functional bread’ group. The data of the case-control group,
i.e., that of patients who were consuming their regular bread, were collected in a similar fashion.
The matching criteria with the ‘functional bread’ group were age, sex, absolute HbA1c values as well
as absence of HbA1c changes between the two selected time intervals (i.e., approximately ~6–7 months.
apart), greater than ±1% (absolute value). For both groups, other inclusion criteria were: no variation
in both hypoglycemic and other drug therapy, and no major intercurrent diseases over the chosen
observation periods. A total of eleven subjects in each group were selected.
The target observations interval after the ‘start’ time point was set between 3 and 12 months.
Each patient had been advised to maintain his/her usual dietary habits and nutrient intake, except
for the type of bread used. The 24-h recall method was used to assess dietary intake of the day before
each visit. The data of each patients were handled rigorously in anonymous fashion. Of the 20 subjects
originally enrolled into the ‘functional bread group’, only eleven completed the intended observational
time period. The causes for drop-out were: insufficient bread intake (less than 40 g of starch equivalents
per day, possibly preventing the detection of a significant effect by substitution with the functional
bread); intercurrent diseases and/or changes of therapy; major dietary changes and/or failure to
observe the standard recommendations for people with T2DM.
As controls, two sets of data were used. First, each patient’s own HbA1c value(s) in the 3–12 month
period antecedent either the start of consumption of the functional bread/flour, or a comparable period
of use of the regular bread in the ‘control’ group, were recorded. These data are referred to as the
‘previous’ time points. Each patient was thus the control of him/herself. Second, data collected after
use of either the ‘functional bread’ and of the ‘control bread’, as described above, recorded over the
subsequent 3–12 months from the ‘start’ time point, were retrieved.
The subjects were either in the fasting state or had consumed their breakfast at home before
coming to the Diabetes Centre. Breakfast composition was pretty reproducible in the same subject
on the two/three visits, but different from patient to patient. In general, the patients consumed a
medium-to-low-calorie Italian breakfast, consisting of milk, coffee (or tea), cereals (or bread slices),
dressed with a thin layer of jam with a low sugar content, and/or one fruit, and/or one portion
of yoghurt.
On the occasion of each visit, the patients’ glucose value (either in the fasting state or 2-h
post-breakfast, the latter labeled as ‘post-prandial’ value), were determined by a reflectometer.
These directly determined values were averaged with those retrieved from the home glucose
monitoring of each patients, in the two–three days preceding the visit. Thus, both the fasting and
post-breakfast data were the mean of these values.
The local Ethics Committee of Padova University Hospital had approved, as part of broader
clinical data investigations in diabetes, the retrieval in anonymous form, of clinical and biochemical
data from medical records of the diabetic patients (Approval N. 14809, released on 11 March 2016).
2.3. Bread Preparation
The functional bread was prepared at home by every subject using the instructions of the
producer(s). Typically, a Moulinex bread machine (model. OW 3101, Moulinex, Groupe Seb Italia Spa,
Milan, Italy) was employed. The composition of the functional bread (Salus®) flour and that of the
refined flour used for the preparation of the control white bread, are reported on Table 1. The botanical
source of the Beta-glucans was oat, as reported by the producers on the label of flour Salus (see Reg.
(CE) n. 1924/2006 and Reg. (CE) n. 1160/2011). The mix of ingredients to prepare the functional bread
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Table 1. Flour composition of the ‘functional’ and the ‘control’ (made with refined wheat white
flour) breads.
Expressed per 100 g Functional Bread Control Bread
Edible part (%) 100 100
Water (g) 43 29
Protein (g) 12 8.6
Lipid (g) 1.2 0.4
Cholesterol (mg) n.d. 0
Available carbohydrates (g) 31 66.9
Starch (g) 30.2 59.1
Soluble sugars (g) 0.8 1.9
Solubile fiber (g) 2.3 1.46
as beta-glucan 2.3 0
Insolubile fiber (g) 4.7 1.72
Total fiber (g) 7 3.2
Beta-glucan/starch 7.62 0
Energy (kJ) 827 1209
Energy (kcal) 197 289
Salt (mg) 885 1465
Sodium (mg) 354 586
The carbohydrates unit is expressed as g/100 g of the sum of glucose and starch. In this value, fiber is not included.
Bread baking was carried out using standard conditions for a white bread, as indicated by the
manufacturer, as follows. Five hundred grams of the ingredient’s mixture and 430 mL of water were
added into the bread machine’s pan. The bread maker took three hours to bake a loaf of bread.
From about 450 g dough, 320–360 g cooked bread are obtained with a moisture percent ranging
between 42%–43%. A bread loaf of 100 g contained about 2.3 g of β-glucans.
In order to determine consumer acceptability, a simple 5-point hedonic scale (questionnaire) for
each sensorial attribute, was used, where 5 was the highest (i.e., extremely positive) score (‘like very
much’) and 1 the lowest (i.e., extremely negative) (‘dislike very much’). Participants were asked to rate
odor, taste (salty and sweet), texture (soft and crisp) and general acceptance on the five-point Likert
scale [10].
2.4. Outcome
The data of plasma glucose, HbA1c, lipids, blood pressure, and weight were retrieved from
each subject’s medical records on the regularly scheduled visits. The methods of analyses were
those standardized in the central analysis laboratory of the Padova University Hospital [11].
The post-prandial glucose values refer to measurements taken ~2 h after the meal (breakfast). The mean
glucose concentrations resulting from the fasting and the post-prandial values was also calculated.
2.5. Sample Size and Statistical Analysis
By considering the primary end-point, i.e., a relative change of HbA1c of 0.6% (as absolute units)
between the treated vs. the control group, and assuming a population mean of HbA1c of 8%, and an
SD of 10% of the mean, a significant effect (α = 0.05, 1 − β = 0.80), would be attained by the sample
size here studied.
All data were expressed as means ± standard error (SE). The two-way analysis of variance
(ANOVA) for repeated measurements, followed by post-hoc test, was employed, to compare the data
of the test group with those of the case-control group. The two tailed Student’s t test for either paired
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3. Results
The basal, pre-treatment clinical data of the patients are reported on Table 2. There was no
statistical difference between the treatment and the control groups in any clinical or biochemical
parameter. Although there were some differences between the two groups in drug consumption, no
subject modified his/her current therapy (including both hypoglycemic agents and other drugs) during
the test period, both in the test and in the control group. The subjects allocated to the ‘functional bread’
group had reported a daily intake of CHO (as bread, breadsticks, cereals or other bread substitutes)
of approximately 70 ± 10 g. In the control group, the estimated intake of CHO (starch)-equivalents
was similar. From medical records there were no evidence of changes in everyday diet in any of the
selected subjects.
Table 2. Clinical characteristics of the type 2 diabetic subjects, included in either the functional bread
or the control group. Data are expressed as means ± SE.
Parameter Functional Bread Group Control Bread Group
Number 11 11
Sex (M/F) 4/7 4/7
Age (years) 68.6 ± 1.9 68.0 ± 2.3
Body weight (kg) 72.9 ± 3.6 76.2 ± 4.0
BMI (kg/m2) 27.8 ± 1.2 27.9 ± 1.3













Abbreviations: BMI: Body Mass Index; ACE-I: angiotensin-conversion-enzyme inhibitors; ARB: angiotensin-
receptor-blockers.
Following the time point defined as ‘start’, clinical and biochemical data were retrieved, after
6.0 ± 0.5 months in the ‘treatment’ group, and after 6.9 ± 0.8 months in the control group (p = NS
between the two groups).
In the treatment group, the use of the functional bread resulted in (insignificantly) lower
fasting glucose concentrations (by −20.4 ± 16.7 mg/dL, i.e., −1.15 ± 0.92 mmol/L, p > 0.05 by
paired t test), but in significantly lower postprandial glucose concentrations (by −16.4 ± 6.3 mg/dL,
i.e., −0.91 ± 0.35 mmol/L, p = 0.045 by paired t test). The resulting average glucose concentrations
were reduced by −17.4 ± 8.0 mg/dL (i.e., by −0.97 ± 0.44 mmol/L, p = 0.08 by paired t test) (Table 3).
In contrast, in the control group, modest though insignificantly greater fasting
(by +2.8 ± 9.9 mg/dL, i.e., +0.15 ± 0.55 mmol/L), post-prandial (by +29.0 ± 10.6 mg/dL, i.e.,
+1.6 ± 0.6 mmol/L) and mean (by +12.7 ± 6.6 mg/dL, i.e., +0.71 ± 0.34 mmol/L) plasma glucose
concentrations were observed. As a result, a significant difference between the two groups was
observed (by ANOVA, as interaction effect), as regards both the post-prandial (p = 0.011) and the mean
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Table 3. Hemoglobin A1c (HbA1c) (as percent, %), fasting plasma glucose (FPG), post-prandial plasma
glucose (PPG) and mean plasma glucose (MPG), in the ‘functional bread’ and in the ‘control’ treatment
groups, before (‘start’) and after (‘end’) the observation periods. Data are expressed as means ± SE.
Functional Bread Group Control Group
Start End Start End p Value
HbA1c (%) 7.97 ± 0.36 7.45 ± 0.31 * 8.03 ± 0.34 8.10 ± 0.31 0.0265
FPG (mmol/L) 9.1 ± 0.8 8.0 ± 0.5 8.7 ± 0.7 8.8 ± 0.5 0.29
PPG (mmol/L) 9.2 ± 0.5 8.4 ± 0.6 * 8.7 ± 0.4 9.9 ± 0.6 0.0113
MPG (mmol/L) 9.2 ± 0.6 8.2 ± 0.4 * 8.5 ± 0.6 9.0 ± 0.5 0.02
* Significant difference between the ‘functional bread’ and the ‘control’ groups. The reported p values are those
resulting from the two-way analysis of variance for repeated measurements, interaction effect.
The HbA1c values are shown in Figure 1. Between the ‘previous’ and the ‘start’ observation
time points, no difference between the functional and the control bread groups were observed, both
groups showing a slight trend (albeit insignificant) towards worsening of HbA1c. The observation
periods between these two time points were not different between the two groups (treatment group:





























Figure 1. The effect of the functional bread on roughly six-month metabolic control as reflected by
HbA1c. Hemoglobin A1C values (expressed as percent, mean ± SE) in the seven to eight months
before (‘previous’), at the beginning (‘start’) and after six to seven months (‘end’) of intake of either the
functional bread (open symbols) or the control white bread (filled symbols). The data are expressed as
mean ± SE. The p value in the figure indicates the significant difference in the changes of HbA1c %
values, before and following the intake of between either the functional bread or the control bread
(by ANOVA).
Following the ‘start’ time point, in the group treated with the functional bread, a −0.52% decrease
(as absolute value) of HbA1c levels (p < 0.028 by the pair t test, Figure 1) was observed. In contrast, in the
control group HbA1c did not change (+0.21% ± 0.13%). As a result, there was a significant difference
between the two groups in the post-treatment HbA1c values (p = 0.027 by ANOVA, interaction effect).
Again, there was no difference in the duration of the observation periods between the ‘start’ and the
‘end’ time points, between the treatments and the control group (Table 2). No significant differences
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such a systolic and diastolic blood pressure, total, low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) cholesterol.
Table 4. Body weight, systolic and diastolic blood pressure, and fasting lipid concentrations, in the
groups treated with either the ‘functional’ or the ‘control’ bread, before (‘start’) and after (‘end’) the
observation periods. Data are expressed as means ± SE.
Functional Bread Control Bread
Parameter Start End Start End
Weight (kg) 72.9 ± 3.4 73.9 ± 3.5 77.6 ± 3.3 76.9 ± 3.2
Systolic pressure (mm·Hg) 139.7 ± 5.4 138.6 ± 4.2 137.3 ± 4.9 136.4 ± 6.1
Diastolic pressure (mm·Hg) 75.0 ± 3.4 77.3 ± 3.1 78.6 ± 1.7 79.6 ± 1.9
Total cholesterol (mmol/L) 4.60 ± 0.33 4.55 ± 0.48 4.26 ± 0.16 4.32 ± 0.26
HDL cholesterol (mmol/L) 1.50 ± 0.10 1.46 ± 0.12 1.67 ± 0.08 1.57 ± 0.12
LDL cholesterol (mmol/L) 2.23 ± 0.25 2.36 ± 0.48 2.08 ± 0.15 2.26 ± 0.18
Triglycerides (mmol/L) 1.90 ± 0.29 * 1.60 ± 0.16 * 1.11 ± 0.06 1.08 ± 0.12
* p < 0.05 between the ‘functional’ and the ‘control’ bread groups (by ANOVA, group effect). Abbreviations: HDL:
high-density lipoprotein; LDL: low-density lipoprotein.
Although plasma triglyceride concentrations were greater (p < 0.015) in the functional than in
the control group at the ‘start’ time point, they did not significantly change in either group between
the start and the end periods. Body weight increased by roughly one kilogram in the treatment group
(p = 0.05 by paired t test vs. baseline), but it did not significantly change in the controls (though without
significance differences between the groups by ANOVA).
The data on consumer acceptability are reported in Supplementary material. The overall response
was satisfactory, and positive judgments on texture, odor and general acceptance, were delivered,
with ranges between 60% and 80%. In contrast, the responses regarding taste were on the whole
‘neutral’, as they did not elicit any prevalence between sweet and salty taste. As a matter of fact, the
functional bread was well accepted by the subjects who completed the study. The relatively large
drop-out rate (9 out of originally enrolled 20 subjects) was due to reasons other than bread acceptability
(see Methods). Most subjects really appreciated the functional bread and are still continuing to use
it regularly.
4. Discussion
Bread is a staple food, and one of the main sources of carbohydrates and energy worldwide.
The diet recommended for a person with diabetes should contain 40%–50% energy as carbohydrates,
15% to 20% as proteins and ~30% as fat. A fiber daily intake of 20–40 g is also suggested [3,12].
Foods with a low glycemic index and/or a low glycemic load would be preferred in diabetes, since
they blunt post-prandial hyperglycemia [13,14]. Absolute fiber content [15], type (soluble/insoluble),
as well as the presence of active compounds interacting with starch, are important modifiers of
carbohydrate digestion and absorption particularly in diabetes. Therefore, the design of a flour
containing active ingredients, to be employed for bread preparations, is a ‘hot’ issue today.
In this study, we report the results of roughly six months’ administration of a home-prepared
‘functional’ bread, made up with a flour enriched with fiber (mainly beta glucan), low in starch and
salt, as a substitute for common bread, in subjects with type 2 diabetes in everyday life conditions.
We report that this ‘functional bread’ significantly improved the metabolic control in the T2DM
subjects, as shown by significant reductions of glycated hemoglobin, of post-prandial and mean
glucose concentrations. In contrast, both HbA1c and glucose concentrations did not change in the
‘control’ bread group (Figure 1 and Table 3). Furthermore, in the six to seven months preceding the
observation periods, HbA1c was nearly stable in both groups (Figure 1). Therefore, these data indicate
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This study was conducted on everyday life conditions, and based on data retrieval of a limited
number of patients regularly visited at the diabetes Centre. Although larger prospective, controlled
studies would be required to confirm these findings, our data nevertheless suggest that daily intake
of a functional bread could be useful in subjects with T2DM. Notably, in this group the percent
reduction of HbA1c (−0.52%, as absolute values) was consistent with the concurrent reduction of mean
plasma glucose (−17 mg/dL). Indeed, it is well established that a ‘one-point’ reduction of % HbA1c is
associated with a reduction of 30–40 mg/dL of mean plasma glucose [16]. In addition, the decrease of
HbA1c values here observed is within the range of changes previously observed after high fiber diets
in type 2 diabetes [15].
The efficacy of the functional bread here tested could be due to several, concurring factors. First,
as reported in Table 1, the starch content was about half that of the reference, regular bread prepared
with refined white wheat flour, on a bread-weight basis. However, no patient reported a decrease
in bread intake (as grams) with the use of the functional bread. Rather, some of them informed the
investigators about a (small) increase in the intake of the functional bread, once they realized that
the post-prandial glucose values were improved. Thus, a decrease in the intake (as grams) of the
functional bread is very unlikely. Second, the functional bread contained beta glucans, that were
absent in the reference bread. Third, the beta glucan/starch ratio in the functional bread was 7.6/100.
Such a ratio, although lower than that previously reported to be the optimal value to reduce starch
digestion/absorption, could have nevertheless produced a favorable effect [9]. On the other hand,
greater ratios than those here tested could further improve post-prandial glucose excursions and the
metabolic control in T2DM, should bread palatability be preserved. Fourth, the beta-glucans contained
in the functional bread, due to their hydrophilic effect, were probably responsible for its greater water
content that, on turn, contributed to bread weight despite the lower starch content. Finally, the total
fiber content of the functional bread was nearly double that of the reference bread (Table 1). Therefore,
several concurrent variables in the composition of the functional bread could have contributed to its
beneficial effects. However, the aim of this study was not to analyze separately the impact of each
variable on glucose control in type 2 diabetes. We rather tested the effects of the chosen flour product,
available in the supermarket, on glucose control and on sensorial aspects in everyday life conditions.
A high (>40 g/day) dietary fiber intake is usually recommended to subjects with type 2
diabetes [3–12]. However, the fiber effect on medium- as well as on long-term metabolic control
in T2DM remains controversial [17,18]. A fiber effect had usually been demonstrated when associated
to intake of foods with low glycemic index. On the other hand, a high fiber diet may be difficult
to be maintained in the long term, because of its poor palatability [19]. In addition, the large gel
volume associated to the intake of fibers such as guar gum, despite their efficacy, is often a hurdle in
food consumption. In contrast, using beta glucans, the amount of fiber per serving may be increased
without either expanding the volume to be ingested or reducing palatability [20]. In this respect, the
peculiar composition of the ‘functional flour’ here reported may represent an optimal balance between
fiber intake, starch reduction, bread ‘mass’ (i.e., weight), and, last but not least, palatability.
Beta glucans have been reported to improve satiety and to decrease caloric intake and appetite [21].
These effects are likely driven by an increased viscosity [22], a delay in CHO absorption [23],
and a ‘bulking action’ [24]. Beta glucans have also been reported to improve glucose and insulin
responses [20]. In addition, the consumption of three grams per day of oat or barley beta-glucans daily
was sufficient to decrease blood cholesterol levels [25]. Since beta-glucans reduce the rapidly-digestible
starch (RDS) fraction, while increasing that of slowly digestibly starch (SDS) [8], these combined
effects would result in a relative increase of resistant starch (RS). However, the beta-glucan-associated
reduction of starch digestion rate may also be product- and process-dependent [26]. As a matter of
fact, the relationships among beta glucan to starch ratio, starch gelatinization and solubility, and RS
formation, are quite complex. At beta glucan to starch ratios below 2 [9], starch solubility was lower
at the 1.6/10 than at the 1.1/10 ratio, leading to higher RS and lower SDS values. Our beta-glucan
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Conversely, others reported that a beta glucan to starch ratio of 0.5/10 ratio nevertheless resulted in a
significant reduction in starch gelatinization and in its breakdown rate evaluated in vitro [27]. Further
research need to be carried out to elucidate these difficult issues.
An association between beta glucan-induced decrease of post-prandial insulin levels, increase
satiety and decrease caloric intake, with increase of cholecystokinin, has also been suggested [28].
In our study, neither cholecystokinin nor insulin were measured. Therefore, no conclusions on possible
relationships between changes in these two hormones and the observed effects, can be drawn.
Body weight was not significantly different between the two groups (an analyzed by ANOVA).
However, a one kilogram positive change in the treatment group was observed (p = 0.05 vs. basal
value), whereas weight did not change at all in the control groups. As an explanation of such an
unexpected finding, as reported above, some subjects of the treatment group admittedly reported
that they had increased the bread intake because they realized that their plasma glucose values were
improving, as well as because an increased sense of hunger. Nevertheless, the functional bread was
capable to improve the metabolic control, thus independently from any major body weight change.
It should also be considered that the raw amount and the energy intake of the diet was generally
reported to be unchanged in either group.
At variance with the improvement of the glycemic control, other clinical and biochemical
parameters, such systolic and diastolic blood pressure, total, LDL, and HDL cholesterol, were
unchanged by the functional bread intake, being rather stable in both groups. Lack of any effect of
blood pressure might be due to the hypotensive treatment of most of our subjects (Table 2). Conversely,
despite the reported hypocholesterolemic effects of beta glucan [25,29], in our study lack of any change
in cholesterol could be due to the already near-normal values of our subjects, of total as well as LDL
cholesterol, (also in respect to target values) (Table 2). Nevertheless, the hypolipidemic effects of beta
glucans t in medium-term studies (four weeks) are controversial [29].
Since high-fiber products may decrease palatability [19], our subjects were accurately tested for
sensorial responses. The overall response to the functional bread was however satisfactory, with
positive judgments on texture, odor and general acceptance recorded in >50% of the subjects, and a
virtually neutral response regarding taste (see Table S1 in the Supplementary material). In this regard,
other authors [30,31] reported that beta-glucan inclusion improves both the rheological and the sensory
properties of bread.
Although there were some differences in the pharmacological therapy (other than the
hypoglycemic agents) between the two groups, with a lower use of statins and ACE-I/ARB, and
increased consumption of beta-blockers, in the functional bread group, these differences likely did
not affect the results, since no subject modified drug therapy throughout the study. Although statins
have been reported to exhibit deleterious effects on plasma glucose [32], plasma glucose was actually
unchanged in the control group. Furthermore, the control subjects as well as those of the functional
group were on long term therapy with statins. Therefore, statins use per se should not represent a bias
in this study.
5. Conclusions
In conclusion, regular intake of a low-starch functional bread, enriched with beta glucan fibers,
could improve the medium- to long-term glycemic control in type 2 diabetes mellitus in addition to
the drugs used to control of blood glucose.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/3/297/s1.
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Abstract: Emerging evidence from in vivo and in vitro studies have shown that vitamin D may play
an important role in the development of diabetic retinopathy (DR), but individually published studies
showed inconclusive results. The aim of this study was to quantitatively summarize the association
between vitamin D and the risk of diabetic retinopathy. We conducted a systematic literature
search of Pubmed, Medline, and EMBASE updated in September 2016 with the following keywords:
“vitamin D” or “cholecalciferol” or “25-hydroxyvitamin D” or “25(OH)D” in combination with
“diabetic retinopathy” or “DR”. Fifteen observational studies involving 17,664 subjects were included.
In this meta-analysis, type 2 diabetes patients with vitamin D deficiency (serum 25(OH)D levels
<20 ng/mL) experienced a significantly increased risk of DR (odds ratio (OR) = 2.03, 95% confidence
intervals (CI): 1.07, 3.86), and an obvious decrease of 1.7 ng/mL (95% CI: −2.72, −0.66) in serum
vitamin D was demonstrated in the patients with diabetic retinopathy. Sensitivity analysis showed
that exclusion of any single study did not materially alter the overall combined effect. In conclusion,
the evidence from this meta-analysis indicates an association between vitamin D deficiency and
an increased risk of diabetic retinopathy in type 2 diabetes patients.
Keywords: vitamin D; diabetic retinopathy; type 2 diabetes; meta-analysis
1. Introduction
Diabetes mellitus (DM) is a large public health problem which affects more than 300 million
individuals in the world, with significant morbidity and mortality worldwide [1]. In addition to the
deleterious effects of the disease itself, its long-term complications can conspicuously decrease the
quality of life of diabetes patients. Diabetes patients with uncontrolled or poorly-controlled blood
glucose are at high risk of microvascular complications. Diabetic retinopathy (DR) is among the most
common diabetic complications, and is the leading cause of blindness among working-aged individuals
worldwide [2]. The prevalence of DR varies from 20% to 80% in different studies. Recent estimates
suggest that the number of people with diabetic retinopathy will increase to 191 million by 2030 [3].
Diabetic retinopathy has a complex process. Many risk factors for DR have been established, such as
poor glycemic control, long duration of diabetes, smoking, inflammation, obesity, and hypertension.
Stratton et al. have given evidence that poor glycemic control and long duration of diabetes are
independent risk factors of DR [4]. Praidou et al. found that increased physical activity is associated
with less severe levels of DR, independent of the effects of HbA1c and body mass index (BMI) [5].
However, detailed pathophysiological mechanisms and other DR risk factors are not fully clarified.
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Vitamin D is a multi-functional fat-solute metabolite required for humans’ growth and
development. Vitamin D deficiency (VDD) is seen across all ages, races, and geographic regions.
Due to the wide functionality of vitamin D and because vitamin D deficiency is epidemic,
vitamin D’s non-classical functions are gaining more attention for the close association between
vitamin D deficiency and cancers, infectious diseases, autoimmune diseases, diabetes, and diabetic
complications [6–8]. The prevalence of vitamin D deficiency is high in type 2 diabetes mellitus (T2DM)
patients [9–11]. Vitamin D receptors are expressed extensively in the retina [12], and an animal study
showed that calcitriol was a potent inhibitor of retinal neovascularization in an oxygen-induced
ischemic retinopathy mouse model [13]. This evidence indicated that vitamin D may play a role in the
pathogensis of diabetic retinopathy.
While there are accumulating studies on the effect of vitamin D on diabetic retinopathy,
the association between vitamin D and diabetic retinopathy are conflicting. According to some
studies, vitamin D deficiency is associated with an increasing risk of diabetic retinopathy. Patrick et al.
found an association between serum 25-hydroxyvitamin D concentration and diabetic retinopathy in
a cohort of 1790 type 2 diabetes patients [14]. Inukai et al. reported that serum 25-hydroxyvitamin D
(25(OH)D) levels were decreased in type 2 patients with retinopathy when compared with type 2
patients who had no microangiopathy [15]. However, others suggested that no significant differences in
vitamin D status were found between type 2 diabetes with or without diabetic retinopathy. Alam et al.
found no association between serum 25(OH)D levels and the presence and the severity of diabetic
retinopathy [16].
Currently, there is insufficient evidence showing whether serum vitamin D deficiency is related to
diabetic retinopathy, and the determination of this relationship has rarely been conducted. To address
these issues, we carried out this meta-analysis by pooling the results from observation studies to
examine the potential association between vitamin D and diabetic retinopathy.
2. Methods
2.1. Data Sources
Relevant articles were identified by a systematic literature search of Pubmed, Medline,
and EMBASE through September 2016, using the following keywords: “vitamin D” or “cholecalciferol”
or “25-hydroxyvitamin D” or “25(OH)D” in combination with “diabetic retinopathy” or “retinopathy”
or “DR”. Additionally, we manually searched all eligible original articles, reviews, and other relevant
articles. This meta-analysis was performed following the guidelines for observation study protocols
(Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines) [17].
2.2. Study Selection
Original articles evaluating the relationship between serum vitamin D status and diabetic
retinopathy were reviewed and selected if they met the following inclusion criteria: (a) the study
population was type 2 diabetes patients; (b) DR was the outcome, and the control group consisted of
type 2 diabetes patients without DR; (c) the study presented sample sizes and odds ratios (OR) with
95% confidence intervals (CI) or information that could be used to infer these results; (d) vitamin D
deficiency was defined as a 25(OH)D level below 20 ng/mL, and vitamin D insufficiency was defined
as 25(OH)D levels of 21–29 ng/mL; (e) the study was published in English; and (f) the study met
the predefined methodological quality assessment criteria for observational studies (Supplementary
Data Box 1). Animal experiments, chemistry, or cell-line studies and editorials, commentaries, review
articles, and case reports were excluded. Other exclusion criteria consisted of studies with a score of 0
for any item or a total score <7 out of 10 maximal points [18].
Two independent reviewers (Bang-An Luo and Fan Gao) reviewed all the literature searches and
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exclusion decisions were made after reading the full text. We resolved any disagreements through
consensus or arbitration by a third reviewer (Lu-Lu Qin).
The following information was extracted from each article: the last name of first author,
publication year, location of study, study design, sample size, 25(OH)D assay methods, 25(OH)D
concentration, and the prevalence of vitamin D deficiency. In the case of relevant missing data, contacts
were made to the main authors for more information.
2.3. Statistical Analysis
We performed this meta-analysis with RevMan Software (Version 5.2, Cochrane Collaboration,
London, UK). The odds ratio (OR) and weight mean difference (WMD) were used as measures of
associations between vitamin D status and risk for DR. If the OR and 95% CI were not available for the
meta-analysis, these data were extracted from the selected articles to construct 2 × 2 tables of serum
low vitamin D status versus the presence or absence of diabetic retinopathy.
We used forest plots to visually assess pooled estimates and corresponding 95% CIs for each
study. The heterogeneity among the results of the included studies was evaluated with I2 statistical
tests. The percentage of I2 < 25, near 50, and >75 indicated low, moderate, and high heterogeneity,
respectively. A fixed-effects model or a random-effects model was used to combine the study results
according to the heterogeneity. Once the effects were found to be heterogeneous (I2 > 50%), a random
effects model was used. Otherwise, a fixed effect model was used.
Potential publication bias was assessed using the funnel plots. A sensitivity analysis was
conducted to test the robustness of results, as well as to investigate the effect of a single article
on the overall risk estimated by removing one article in each turn. Additionally, a subgroup analysis
was performed to explore the possible explanations for heterogeneity. All the p-values were for
a two-tailed and p < 0.05 was considered as statistically significant.
3. Results
3.1. Search Results
Of the 238 articles identified from our initial search, a total of 15 studies were finally identified as
eligible for inclusion in this meta-analysis through a strict screening process (Figure 1). The quality
assessment showed that the quality scores of these studies ranged from 8.5 to 10 according to the
MOOSE guidelines, which indicates that all of the selected studies were of high quality (Supplementary
Table S1).
3.2. Characteristics of the Included Studies
The characteristics of these articles in this meta-analysis are summarized in Table 1. These studies
were published from 2000 to 2016. Among these studies, nine were conducted in Asia, two each in
North America and Europe, one in Africa, and one each in three countries (Australia, New Zealand,
and Finland). Seven studies had cross-sectional design, five were case–control, two were prospective
cohort, and one had a retrospective cohort design. Four different assay techniques were used to
measure the serum 25(OH)D levels, and four different ways were used to diagnose DR. Eight of the
included studies explored the association between vitamin D deficiency and diabetic retinopathy, four
explored the association between vitamin D insufficiency and diabetic retinopathy, and ten explored
the mean difference in vitamin D status among diabetic retinopathy and non-diabetic retinopathy.
The diversity of participant characteristics was considerable in these studies. Out of 17,664
participants, 3455 (19.6%) were diagnosed with diabetic retinopathy, consisting of different ages and
races. In addition, the age of type 2 diabetes participants were older than 18 years and the mean
BMI—if provided by articles—varied from 13.9 to 42.0 kg/m2. The vitamin D status of diabetic
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Figure 1. Flow chart of literature search and study selection.
3.3. Main Analysis
The relationship between serum vitamin D deficiency (VDD) and the risk of diabetic retinopathy
is shown in Figure 2 and Supplementary Table S2. Eight studies involving 13,435 participants were
included. As the results of this meta-analysis show, type 2 diabetes with vitamin D deficiency (serum
25(OH)D levels <20 ng/mL) had an increased risk of developing diabetic retinopathy (OR = 2.03,
95% CI: 1.07, 3.86) in the random-effects model.
Figure 2. The meta-analysis of the association between vitamin D deficiency (VDD) and diabetic
retinopathy (DR).
Based on four studies, the pooled OR for vitamin D insufficiency (VDI, serum 25(OH)D
levels <30 ng/mL) was calculated as (OR = 0.89, 95% CI: 0.20, 4.02) (Supplementary Table S2 and
Supplementary Figure S1). Only the result of vitamin D deficiency showed that low serum vitamin D
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The comparison of the mean difference between the DR group and the control group (non-DR
group) is shown in Figure 3. From the results of the random-effects model, the pooled effect was
−1.7 ng/mL (95% CI: −2.75, −0.66) and significant heterogeneity was observed (I2 = 80%, p < 0.001).
It showed that serum 25(OH)D levels were significantly lower in diabetic retinopathy patients than the
control in type 2 diabetes. This result demonstrated that vitamin D deficiency is significantly related
with an increased risk of DR.
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3.4. Sensitivity and Subgroup Analysis
To explore the impact of various exclusion criteria on the overall risk estimate, we conducted
sensitivity and subgroup analyses to examine the potential sources of heterogeneity in this
meta-analysis. In the result of the pooled ORs, the study conducted in China [24] was responsible
for most of the heterogeneity in this meta-analysis. After excluding this study, the heterogeneity
was down to 67% and the pooled OR was 1.50 (95% CI: 1.41, 1.98). Besides, there were no obvious
changes in the pooled ORs as a result of the exclusion of any other single study. In the comparison of
the mean difference between the DR group and the control group, moderate heterogeneity (I2 = 70%,
p < 0.001) was observed among the remaining studies after the exclusion Jee’s study [25]. Jee’s study
was responsible for most of the heterogeneity. Further exclusion of any single study did not alter
the overall combined relative risk, with a range from −2.2 ng/mL (−3.28, −1.17) to −1.6 ng/mL
(−2.43, −0.69), and each outcome had statistical significance.
In the subgroup with study design, there were moderate heterogeneities in cross-sectional
and prospective cohort studies for the pooled OR (I2 = 52%, p = 0.15 for cross-sectional studies;
I2 = 61%, p = 0.11 for prospective cohort studies) (Supplementary Materials Figure S2). We found that
there were obvious heterogeneities in the cross-sectional and the case–control studies for the pooled
WMD (I2 = 79%, p = 0.0007 for cross-sectional studies; I2 = 76%, p = 0.006 for case–control studies)
(Supplementary Materials Figure S3). In the subgroup with VD assay methods, there were high
heterogeneities in the chemiluminescence (CL) vitamin D assay method for the pooled OR (I2 = 99%,
p < 0.0001), and the study conducted in China [24] was responsible for the heterogeneities. After
excluding this study, the heterogeneity in the CL subgroup was down to 8% and the pooled OR was
1.25 (95% CI: 1.06, 1.48) (Supplementary Materials Figure S4). In the subgroup with DR diagnosis, there
were modern heterogeneities in the ophthalmologists group (OR = 1.71, 95% CI: 1.11, 2.62, I2 = 74%,
p = 0.0004) (Supplementary Materials Figure S5). Subgroup analyses of BMI, season, duration of
diabetes, race, and age were not conducted due to insufficient data in some studies.
3.5. Publication Bias
No obvious publication bias was observed in the funnel plots of this meta-analysis (Supplementary
Materials Figure S6).
4. Discussion
Vitamin D’s non-classical functions have attracted much public health attention for its closer
association with some diseases. This is the first meta-analysis of the relationship between serum
vitamin D status and DR in type 2 diabetes. In this meta-analysis, the results of 15 observational studies
provided strong evidence that serum 25(OH)D levels were associated with an increased risk of DR in
type 2 diabetes patients. Both the results of the pooled OR for vitamin D deficiency (serum 25(OH)D
levels <20 ng/mL) and the pooled effect of WMD showed that the serum 25(OH)D levels in type 2
diabetes had a relationship with DR, while the pooled OR for vitamin D insufficiency (serum 25(OH)D
levels <30 ng/mL) did not. Considering the results of vitamin D deficiency and that serum 25(OH)D
levels were more reliable and accurate than the result of vitamin D insufficiency (only four studies),
we concluded that low 25(OH)D levels were associated with an increased risk of DR.
The quality of the studies included in this meta-analysis was high. From the funnel plots,
we concluded that there was no obvious publication bias in this meta-analysis. We further conducted
sensitivity and subgroup analyses to explore potential sources of heterogeneity. From the forest plots,
we observed high heterogeneity among the pooled OR and WMD as the association of DR (Figures 2
and 3), which was not surprising given the different characteristics of participants and adjustments for
confounding factors. Regarding the results of sensitivity analyses, two studies probably contributed to
the heterogeneity [24,25]. After excluding the two studies, there was moderate heterogeneity, and there
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on the levels of vitamin D denoting deficiency and insufficiency, and the diagnosis standards of
DR might not be uniform among different ophthalmologists in these studies. Secondly, there were
four methods for measuring vitamin D, such as HPLC (high performance liquid chromatography)
and RIA (radioimmunoassay). Thirdly, the time of collecting blood sample were different. Fourthly,
the heterogeneity might be a result of differences in the study populations—there were several
races included in this meta-analysis. Fifthly, the duration of diabetes, the age of patients, the diet,
the treatment of diabetes, and the sunlight exposure are confounding factors in this meta-analysis.
Hence, more studies are needed to give full proof.
There is an epidemic of vitamin D deficiency around the world [6]. From this meta-analysis, the
prevalence of vitamin D deficiency was high among type 2 diabetes patients, although it may vary
from different latitude, ethnicity, body mass index, season, and supplementation of vitamin D. VDD
was consistent with previous studies [9–11]. For patients with diabetes, the association with vitamin D
deficiency and risk of developing diabetes has been acknowledged. Vitamin D deficiency is associated
with an increased risk for diabetes [9,22,29].
In patients with diabetic retinopathy, the level of serum 25(OH)D was lower than patients without
diabetic retinopathy. The characteristic feature of diabetic retinopathy is the appearance of vascular
lesions of increasing severity, ending up in the growth of new vessels (neovascularization). Vitamin D
has anti-inflammation properties and inhibits vascular smooth muscle cell growth and effects on
the expression of transforming growth factor β1 [13,33–35]. Vitamin D is an important regulator of
hundreds of genes regulating key biological processes from cell division to apoptosis [36]. It is well
known that poor glycemic control is a risk factor for the development and progression of DR, and
vitamin D deficiency has been shown to impair insulin synthesis and secretion in animal models
of diabetes [37]. On the other hand, an optimal concentration of vitamin D is strongly proven to
be necessary for efficient insulin secretion and function [38–40], and vitamin D receptors (VDR)
are ubiquitously expressed in every human tissue, including retina. Active vitamin D mediates its
biological function by binding to vitamin D receptors. Vitamin D receptors have been found to be
associated with insulin secretion and sensitivity, and have been identified in pancreatic beta cells [41].
Additionally, some genes associated with the development of diabetic retinopathy have been found,
such as Bsm1, rs2228570, and TT. So, vitamin D status is related with the development and progression
of diabetic retinopathy among type 2 diabetes patients.
Increasing studies have given more evidence of this. Annwelier et al. found that the serum
25(OH)D levels were associated with optic chiasm volume [42], and in a vitro experiment, vitamin D
was found to inhibit neovascularization in retinal tissue in a model of ischemic retinopathy [13]. What
is more, proof of the VDR polymorphisms related with diabetic retinopathy was found. Hong et al.
showed that patients with the B allele (BB or Bb) of Bsm1 polymorphism in VDR were associated with
lower risk of diabetic retinopathy compared to patients without the B allele (bb) in Korean type 2
diabetic patients [41]. Bucan et al. showed that the bb genotype in VDR has a higher risk of developing
diabetic retinopathy [43]. Zhong et al. found that rs2228570 was associated with increased risk of
diabetic retinopathy in Han Chinese type 2 diabetes patients [44]. Benjamin et al. reported that the
anticipation of retinopathy onset is significantly associated with the exaggeration of oxidative stress
biomarkers or decrease of antioxidants in African type 2 diabetics, and supplementation with vitamin
D should be recommended as complement therapies of T2DM [26]. Therefore, low serum 25(OH)D
levels are association with an increased risk of diabetic retinopathy, but more studies are required to
identify the mechanism of the relationship between vitamin D and diabetic retinopathy fully.
It is well known that one of the two major sources of vitamin D is cutaneous synthesis by solar
ultraviolet B radiation and the other is dietary intake. The cutaneous synthesis of vitamin D is affected
by many factors, such as season, latitude, time of day, skin pigmentation, the amount of skin exposed,
and whether makeup with sunscreen is used, so serum 25-hydroxyvitamin D levels vary between
areas and persons. Hence, dietary vitamin D supplementation and physical activity might be a feasible
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may increase blood 25-hydroxyvitamin D concentrations as a consequence of an associated increase in
sunlight exposure. Praidou et al. reported that increased physical activity is associated with less severe
levels of diabetic retinopathy, independent of the effects of HbA1c and BMI [5]. Lee et al. showed
that 3 months of vitamin D supplementation improved neuropathic symptoms by 50% in diabetic
patients whose 25-hydroxyvitamin D status was deficient at baseline [45]. However, there has yet to be
a dietary vitamin D supplementation trial on diabetic retinopathy. Thus, large randomized controlled
trials researching on reducing diabetic retinopathy in type 2 diabetes are needed to accurately evaluate
the potential benefits of these low-cost interventions in the future.
Diabetic retinopathy may develop and progress to advanced stages without producing any
immediate symptoms to the patient. Screening for DR is essential in order to establish early treatment
of sight-threatening retinopathy and has been demonstrated to be successful at achieving vision
loss [46]. Considering the heavy burden of DR and the association between serum 25(OH)D level and
diabetic retinopathy, low 25(OH)D levels may help us to find more early stage diabetic retinopathy
patients. Therefore, screening low 25(OH)D levels may be a potential simple way for screening diabetic
retinopathy among type 2 diabetes in primary hospitals—especially where there is a shortage of
ophthalmic equipment or ophthalmologists.
The main strength of this study is giving strong evidence of the association of serum vitamin D
and diabetic retinopathy. However, there were several limitations in this study. Firstly, different
diagnostic criteria of diabetic retinopathy and different measured assays could have influenced the
pooled effect. Secondly, there were some confounding factors in this meta-analysis, such as age,
race, diet, the treatment of diabetes, sun exposure, physical activity, and so on. Some, but not all,
of the studies generated adjusted OR, so we could not pool the findings by adjusting for confounding
factors. Thirdly, there was a lack of access to complete data of all related published papers, despite
correspondence with the authors. Fourthly, the association between vitamin D and the severity of
diabetic retinopathy was not analyzed in this meta-analysis because of a lack of enough data and
information. Finally, only published articles in English were included.
5. Conclusions
In conclusion, this meta-analysis indicates an association between vitamin D deficient type 2
diabetes mellitus patients and an increased risk of diabetic retinopathy. Type 2 diabetes patients with
vitamin D deficiency experienced an increased risk of diabetic retinopathy. However, further studies
are required to better understand the relationship between vitamin D deficient type 2 diabetes patients
and diabetic retinopathy, and well-designed randomized controlled trials are needed to determine the
explicit effect of vitamin D supplementation on the prevention of diabetic retinopathy. Considering
the high prevalence of vitamin D deficiency and the burden of the diabetic retinopathy, screening type
2 diabetes patients who are at risk of vitamin D deficiency should be considered.
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mean difference (WMD) according to study design. Figure S4. Subgroup analysis of pooled ORs according
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Abstract: Individuals living with metabolic syndrome (MetS) such as diabetes and obesity are at high
risk for developing chronic kidney disease (CKD). This study investigated the beneficial effect of
whole grape powder (WGP) diet on MetS-associated CKD. Obese diabetic ZSF1 rats, a kidney
disease model with MetS, were fed WGP (5%, w/w) diet for six months. Kidney disease was
determined using blood and urine chemical analyses, and histology. When compared to Vehicle
controls, WGP intake did not change the rat bodyweight, but lowered their kidney, liver and
spleen weight, which were in parallel with the lower serum glucose and the higher albumin or
albumin/globin ratio. More importantly, WGP intake improved the renal function as urination
and proteinuria decreased, or it prevented kidney tissue damage in these diabetic rats. The renal
protection of WGP diet was associated with up-regulation of antioxidants (Dhcr24, Gstk1, Prdx2, Sod2,
Gpx1 and Gpx4) and downregulation of Txnip (for ROS production) in the kidneys. Furthermore,
addition of grape extract reduced H2O2-induced cell death of cultured podocytes. In conclusion,
daily intake of WGP reduces the progression of kidney disease in obese diabetic rats, suggesting
a protective function of antioxidant-rich grape diet against CKD in the setting of MetS.
Keywords: metabolic syndrome; chronic kidney disease; grape powder; antioxidants; natural products;
dietary supplements
1. Introduction
Chronic kidney disease (CKD) is multifactorial, and is defined as abnormalities of kidney structure
or function that is present for more than three months. While not progressive in all, it can lead to
end-stage renal disease (ESRD)—total and permanent kidney failure [1,2]. CKD places a major public
health burden on our community as it affects more than 10% of adults aged 20 years or older, or more
than 40% in those aged 65 years or older in the United States (source: Centers for Disease Control and
Prevention), and 12.5% of adults, representing approximately three million, in Canada [3,4]. Like other
chronic diseases, many cases of CKD are not curable, but there are substantial numbers of people
who can benefit from prevention or delay of progression [5], suggesting that an effective and feasible
preventive strategy is expected to reduce the burden of CKD in our community. However, there are
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a limited number of these that are proven or used in our daily practice. Recently, there is an increasing
interest in diet, the interaction of gut microbiome and CKD progression. Dietary supplements or
natural health products is definitely an attractive and feasible strategy for CKD prevention.
Metabolic syndrome (MetS) is a collective term for several clinical measures, which include
insulin resistance, high serum glucose, overweight or obesity, high triglyceride or low high-density
lipoprotein cholesterol and hypertension [6]. Literature suggests that MetS may increase the risk
of the development of CKD [7–9], mainly seen as hypertensive and diabetic nephropathy (DN).
While the etiology for MetS-induced CKD remains unknown [9], oxidative stress is theorized to a play
a role [8,10,11]. The oxidative stress is induced by the imbalance between the level of reactive oxygen
species (ROS, free radicals) and the capacity of antioxidant defenses, which leads to the generation of
excessive ROS and consequently tissue damage [11,12]. One of major antioxidant defense mechanisms
in our body is exogenous antioxidants, such as flavonoids, vitamins, resveratrol, anthocyanine,
curcumin and phenolic acid that come from our food and other dietary sources [11,13–15]. There are
some data that antioxidant rich berry diet has benefit in preventing or mitigating MetS [15,16],
suggesting that a dietary strategy of using antioxidant-rich food may be a novel strategy to employ to
reduce the incidence of CKD among individuals who are living with MetS.
Grapes are one of the most widely cultivated and popularly consumed fruits in the world, and contain
over 1600 phytonutrients including some major antioxidant flavonoids, such as catechins (catechin and
epicatechin), anthocyanins (peonidin, cyaniding, and malvidin), flavonols (quercetin, kaempferol,
and isorhamnetin) and resveratrol (source: the California Table Grape Commission report, Fresno,
CA, USA). The renoprotective activities of these compounds have been demonstrated in various
experimental models. For example, epicatechin, quercetin or resveratrol has been shown to lower the
oxidative stress in the kidneys and reduce renal damage in animals with cisplatin nephropathy [17–19],
and feeding with anthocyanin-rich food reduces diabetes-associated kidney failure in db/db mice [20].
A recent study shows that daily drinking of whole grape powder (WGP) prevents age-related decline
of kidney function in rats [21], but its beneficial effect on MetS-associated CKD, a common public
health problem in our community [22], has not been investigated. Obese ZSF1 male rats are generated
by a cross between a Zucker diabetic fatty (ZDF) female and a spontaneously hypertensive heart
failure (SHHF) male rat, which have MetS similar to humans, including hypertension, type 2 diabetes,
hyperlipidemia and nephropathy [23–27]. Hence, these rats have been widely used as a disease model
for renal failure in the condition of MetS [27–30]. The objective of this study was to examine the effect
of daily feeding with the WGP on the progression of kidney disease in obese ZSF1 rats, as compared to
control animals.
2. Materials and Methods
2.1. Animals and Cells
Obese ZSF1 male rats (~300 g bodyweight, 8 weeks old) were purchased from Charles River
Laboratories International, Inc. (Wilmington, MA, USA). These rats were F1 hybrids from a cross
between a female ZDF rat and a male SHHF rat [27], and were maintained in the animal facility of
the Jack Bell Research Centre (Vancouver, BC, Canada). All animal experiments were performed in
accordance with the Canadian Council on Animal Care guidelines under protocols approved by the
Animal Use Subcommittee at the University of British Columbia (Vancouver, BC, Canada).
Heat-sensitive mouse podocyte (HSMP) cell line was a gift from Dr. Stuart Shankland
(University of Washington School of Medicine, Seattle, WA, USA). HSMP cells were maintained
and grown in RPMI 1640 culture medium supplemented with 10% fetal bovine serum and 0.2 ng·mL−1
of IFN-γ in a CO2 incubator at 33 ◦C as described previously [31]. To induce quiescence and the
differentiated phenotype for experiments, HSMP cells were grown at 37 ◦C in the same medium but in
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2.2. Whole Grape Powder (WGP)
WGP was provided by the California Table Grape Commission (CTGC), and was a freeze-dried
grape product developed for the usage of research purposes only. WGP was composed of seeded and
seedless varieties of fresh green, red and black California grapes that were initially frozen, and then
ground with food-quality dry ice. The processing and storage of the WGP were done properly for
preserving the bioactivities of the compounds found in the grapes. Approximately 90% of the WGP
by weight was sugars (glucose and fructose found in a 1:1 ratio), and the remainder consisted of
organic acids, phenolic compounds, nitrogenous compounds, aroma compounds, and minerals
and pectic substances. Antioxidants, such as resveratrol, flavans (including catechin), flavonols
(including quercetin), anthocyanins and many simple phenolics (as per the CTGC report) were
also found. This product was stored at −80 ◦C in moisture-proof containers until it was mixed
with regular rat chow for the animal experiments.
2.3. Food Supplements
According to the CTGC guideline of the usage of WGP as food supplements for animal studies,
WGP supplement food (denoted as WGP here) was prepared for this study by mixing regular
chow (95%, w/w) with WGP (5%, w/w), and its Vehicle control the regular chow (95.5%, w/w)
with 2.25% (w/w) glucose and 2.25% (w/w) fructose. Rats were randomly assigned to two groups
(WGP and Vehicle), in which they were fed with either WGP or sugar control. The animal experiment
was repeated twice with total 15 rats in each group. One rat in WGP group suffered a urinary tract
infection diagnosed early during the second month of the feeding experiment, and was consequently
excluded from the experiment and data analysis.
2.4. Preparation of WGP Extract
The WGP extract was prepared for both cell culture experiments to determine its antioxidative
activity. In brief, WGP (4 g) was dissolved in 200 mL of methanol (anhydrous, 99.8%) and was stirred for
72 h at room temperature, followed by centrifugation at 3000 rpm for 15 min. The resultant supernatant
fraction was subsequently dried by lyophilization using a centrifugal evaporator. Around 3.3 g of
WGP-methanol extract was produced from 4 g of WGP by this procedure. The stock solution of WGP
extract was prepared by dissolving the dried extract pellet in culture medium at the concentration
of 5 mg·mL−1.
2.5. Primary Outcomes from This Study
Our primary outcomes were to measure renal function through assessment of urine volume,
proteinuria, urine protein to creatinine ratio (uPCR), and estimated glomerular filtration rate (GFR).
Renal injury was also measured via the kidney organ index and histological analysis.
2.6. Urine Collection and Determination of Kidney Function
A 24-h urine sample was collected using metabolic caging, in which the rat had unrestricted
access to food and drinking water. The collected urine was immediately centrifuged at 3000 rpm for
15 min to remove any food scraps and fecal matters. After its volume was measured, the sample was
stored in aliquots at −20 ◦C until all the samples were collected for the determination of both protein
and creatinine levels at the same time.
The levels of urine creatinine (UCr) were measured in the Chemistry Laboratory at the Vancouver
Coastal Health Regional Laboratory Medicine (Vancouver, BC, Canada) by using the Dimension
Vista® System with CRE2 reagent cartridges (Siemens Healthcare Diagnostics Inc., Newark, DE, USA).
The levels of urine protein were determined using Bio-Rad protein assay following manufacturer’s
instruction (Bio-Rad Laboratories-Canada, Mississauga, ON, Canada). In brief, the protein in the urine








Nutrients 2017, 9, 345
The protein pellet was suspended in 3% sodium hydroxide (NaOH) solution, and 1 μL of this protein
solution was added to 200 μL of Bio-Rad dye (10 × dilution). The optical density (OD) of urine protein
samples, background control and bovine serum albumin (BSA) standards at 595 nm was measured
using an ELx808 Ultra Microplate Reader (BioTek, Winooski, VT, USA), and protein concentration
(mg·mL−1) in the urine sample was calculated based on the BSA standard curve.
2.7. Blood Collection and Chemical Analysis
Blood samples were collected from the tail vein using a lithium heparin tube after 1, 3 and
6 months of WGP feeding. A comprehensive metabolic panel of 14 blood substances, including alanine
aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), amylase (AMY), total calcium
(Ca2+), creatinine (CRE), globulin (GLOB), glucose (GLU), phosphorus (PHOS), potassium (K+),
sodium (Na+), total bilirubin (TBIL), total protein (TP), and urea nitrogen (BUN), were determined
using the VetScan® Comprehensive Diagnostic Profile reagent rotor with the VetScan Chemistry
Analyzer VS2 (Abaxis, Inc., Union City, CA, USA) in the Animal Unit Hematology Diagnostic
Laboratory at Jack Bell Research Centre (Vancouver, BC, Canada).
2.8. Glomerular Filtration Rate (GFR)
The renal function was estimated using GFR that was calculated based on the creatinine clearance
using the following: GFR = (UCr × V)/SCr, where UCr was creatinine level in urine sample,
V the volume of the 24-h urine sample, and SCr the creatinine in serum.
2.9. Renal Histopathology
The kidney tissues (6 rats/group) were randomly selected. The tissues were fixed in 10% neutral
buffered formalin, followed by embedding in paraffin wax. Sections were cut at 4-μm thickness,
and were stained with hematoxylin and eosin (HE) or periodic acid-Schiff (PAS). The stained tissue
sections were scanned with Leica SCN400 Slide scanner (Leica Microsystens Inc., Concord, ON,
Canada), and the pathological parameters of renal disease were determined in two separate sections of
each kidney using the Digital Image Hub—A slidepath Software Solution (Leica Microsystems Inc.)
in a blinded fashion.
The number of intratubular protein cast formation or glomerular atrophy in each microscopic
view was counted in HE-stained section, and the average number of at least 20 randomly selected
views under 40× magnification represented these two parameters in each kidney.
A semi-quantitative scoring system using a 0 to 4 scale was established to determine the severity
of the tubular atrophy (including tubular dilution and/or cellular flatting) in the renal cortex of
HE-stained kidney sections. The scale/score was measured based on the percentage of damaged
tubules occupying a microscopic view: 1 (0%–24% of the area affected with damaged tubules),
2 (25%–49%), 3 (50%–74%), and 4 (>75%). The average of at least 30 randomly selected views under
200× magnification represented the tubular atrophy in each kidney.
The mesangial expansion was also determined using a 0 to 4 scale based on the percentage of
the area stained strongly with PAS, indicating the mesangial expansion in an affected glomerulus:
1 (0%–24% of the area affected with densely stain, minimal ), 2 (25%–49%, mild), 3 (50%–74%, moderate),
and 4 (>75%, severe). A range of 180 to 250 glomeruli were counted and averaged for each kidney.
2.10. PCR Array Analysis of Oxidative Stress
The expression of 84 oxidative stress-associated genes in kidney tissues was quantitatively
examined using PCR Arrays kits (Cat. No.: PARN-065Z, SABiosciences—QIAGEN Inc., Valencia,
CA, USA) following manufacturer’s instruction. Four samples/rats (one from each rat) were
randomly selected from each group. In brief, one piece of kidney cortex was snap-frozen in liquid
nitrogen and stored at −80 ◦C until all the samples were ready for the experiment. The total
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(QIAGEN), and converted to cDNA using RT2 First Strand Kit (QIAGEN). The expression of
selected genes was amplified by real-time PCR using RT2 Profile PCR arrays (QIAGEN). Data were
analyzed using Web-based PCR Array Data Analysis Software at the website of the manufacturer
(http://www.SABiosciences.com/pcrarraydataanalysis.php).
2.11. Flow Cytometric Analysis
Cell death or viability was quantitatively determined by using fluorescence-activated cell sorter (FACS)
analysis following the manufacturer’s protocol (BD Biosciences, Mississauga, ON, Canada). Annexin-V
conjugated with phycoerythrin (Annexin-V-PE) stained apoptotic cells, and 7-amino-actinomycin D
(7-AAD) positivity indicated late apoptotic and necrotic cells. Briefly, cells were stained with both
Annexin-V-PE and 7-AAD for 15 min in the dark, and cell apoptosis and necrosis were detected
by using a flow cytometry and further quantified using FlowJo software (Tree Star Inc., Ashland,
OR, USA). In a FACS graph, the lower right quadrant—only Annexin V positive indicated early
apoptosis; the upper right quadrant—Annexin V/7-AAD double positive showed late apoptosis;
and the upper left quadrant—7-AAD positive cells were necrosis. Finally, negative staining (the lower
left quadrant—Annexin V/7-AAD double negative) showed the population of viable cells.
2.12. Statistical Analysis
Data were presented as mean ± standard derivation (SD) of each group. Statistical analysis of
difference between groups was performed using GraphPad Prism software (GraphPad, San Diego,
CA, USA) by t-test or analysis of variance (ANOVA) as indicated in the text. A p value of ≤0.05 was
considered statistically significant.
3. Results
3.1. Daily Intake of WGP Is Associated with Lower Organ Index of the Kidney, Liver and Spleen but Does Not
Affect Bodyweight in Obese Diabetic Rats
Both bodyweight and diet consumption were monitored once a week. As shown in Figure 1,
the weight gain of rats during six months of WGP feeding was the same as sugar-fed Vehicle control
group, indicated by a complete overlap of growth curves between these two groups (WGP vs. Vehicle:
p = 0.7701, two-way ANOVA). This observation was correlated with their diet consumption,
which remained the same at 25 ± 2 g·day−1·animal−1 between these two groups throughout the
experiment. Interestingly, at the end of feeding experiment, significantly lower organ weight index was
seen in the kidney (WGP vs. Vehicle: p = 0.0127, two-tailed t-test), liver (WGP vs. Vehicle: p < 0.0001,
two-tailed t-test) and spleen (WGP vs. Vehicle: p = 0.0341, two-tailed t-test) of WGP-fed rats compared
to Vehicle controls, whereas both the heart and the lung remained the same (Table 1). The data
suggested that daily intake of WGP reduced the weight/size of these three organs—the liver, kidney
and spleen—as compared to those in control group in these obese diabetic rats.
The bodyweight of rats in both Vehicle (n = 15) and WGP (n = 14) groups was recorded during
a period of six months of dietary supplements. Data were presented as mean ± SD of each group.
Vehicle vs. WGP: p = 0.7701 (two-way ANOVA).
Table 1. Organ index (organ weight/bodyweight) after six months of feeding sugar (Vehicle) or whole
grape powder (WGP).
Kidneys Liver Spleen Heart Lung
Vehicle (n = 15) 0.0070 ± 0.00072 0.0627 ± 0.00418 0.00135± 0.00010 0.00289 ± 0.00115 0.00356 ± 0.00096
WGP (n = 14) 0.0063 ± 0.00069 0.0544 ± 0.00546 0.00129 ± 0.00001 0.00251 ± 0.00022 0.00371 ± 0.00103
p value * 0.0127 <0.0001 0.0341 0.2351 0.6880
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Figure 1. No effect of daily intake of whole grape powder (WGP) on bodyweight gain or obesity in
obese diabetic ZSF1 rats.
3.2. Daily Intake of WGP Is Associated with Higher Serum Albumin and Lower Blood Glucose in Obese
Diabetic Rats
The overall metabolism status of these rats was determined by using the changes in
a comprehensive metabolic panel of 14 blood substances that represent the basic metabolism (GLU),
electrolytes (Na+, K+, Ca2+, and PHOS) and both kidney and liver functions (BUN, CRE, ALB, GLOB.
ALB/GLOB ratio, ALP, ALT, AMY, TP and TBIL). Over six months of feeding experiment, the rats
in both groups experienced a significant decline in ALB (including ALB/GLOB ratio), ALP, BUN,
K+ and PHOS, and at the same time an increase in GLU, AMY, TBIL, GLOB, TP, Ca2+ and Na+
(Table S1). Only CRE and ALT remained unchanged (Table S1). The importance for this examination
was that as compared to the Vehicle group, WGP-fed rats had significantly higher levels of serum ALB
(p = 0.0013, two-way ANOVA) or ALB/GLOB ratio (p = 0.0092, two-way ANOVA), and lower levels of






























Figure 2. Daily intake of WGP has beneficial effect on the maintenance of blood albumin and the
reduction of blood glucose in obese diabetic ZSF1 rats. The blood levels of albumin (ALB), globulin
(GLOB) and glucose (GLU) were measured in randomly selected rats in Vehicle (n = 8–12) or WGP
(n = 8–11) group after one, three or six months of dietary supplements. Data were presented as
mean ± SD of each group. (A) Blood ALB levels. Vehicle vs. WGP: p = 0.0013 (two-way ANOVA);
(B) ALB/GLOB ratio. Vehicle vs. WGP: p = 0.0092 (two-way ANOVA); (C) Blood GLU levels. Vehicle vs.
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3.3. Daily Intake of WGP Significantly Is Associated with Lower Urine Volume and Urine Protein Excretion
but Does Not Impact GFR after Six Months in Obese Diabetic Rats
The baseline ranges for renal function in obese ZSF1 rats at the age of eight weeks were
164.8 ± 14.5 mL·kg−1·day−1 of urine volume, 307 ± 23 mg·kg−1·day−1 of proteinuria or 5.98 ± 0.41 of
urine protein to creatinine ratio (uPCR) [28], and the average of bodyweight of the rats at this age was
approximately 300 g (Figure 1). After six months of feeding, a 24-h urine sample was collected from
each rat. As shown in Figure 3A, WGP-fed rats had lower urine output than Vehicle controls (p = 0.0092,
one-tailed t-test). Similarly, the WGP group had significantly lower proteinuria (p = 0.0412, one-tailed
t-test) (Figure 3B), and uPCR (p = 0.0084, one-tailed t-test) (Figure 3C), when compared to the Vehicle
controls. When GFR (mL·24 h−1) between these two groups was compared, no significant difference







































Figure 3. Daily intake of WGP reduces urine production and proteinuria but no effect on GFR in obese
diabetic ZSF1 rats. A 24-h urine sample was collected from each rat in both Vehicle (n = 15) and WGP
(n = 14) at the end of six months of dietary supplements. (A) Total volume of urine production from
each rat during 24 h. Vehicle vs. WGP: p = 0.0092 (one-tailed t-test); (B) Total amount of protein in
24-h urine sample of each rat. Vehicle vs. WGP: p = 0.0412 (one-tailed t-test); (C) Protein to creatinine
ratio (uPCR) in the urine sample of each rat. Vehicle vs. WGP: p = 0.0084 (one-tailed t-test); (D) GFR of
each rat calculated based on creatinine clearance. Vehicle vs. WGP: p = 0.3474 (one-tailed t-test).
Line: mean with the standard error of the mean (SEM).
3.4. Daily Intake of WGP Partially Prevents Renal Pathological Changes in Obese Diabetic Rats
To further explore the beneficial effect of daily intake of WGP on the prevention of kidney damage
in obese diabetic rats, histological analysis of kidney sections was performed and compared between
these two groups. The histological score of all four renal pathological parameters in WGP group
were significantly lower than that in Vehicle group (Figure 4A–E). The WGP group had lower scores
of glomerular atrophy per view (p = 0.0225, two-tailed t-test, n = 9) (Figure 4B), reduced mesangial
expansion (p < 0.0001, two-tailed t-test, n = 9) (Figure 4C), fewer tubular protein cast formation per view
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two-tailed t-test, n = 12) (Figure 4E), when compared to the Vehicle controls. Together, the histological
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Figure 4. Daily intake of WGP reduces kidney injury in obese diabetic ZSF1 rats. At the end of
six months of dietary supplements, six kidneys/rats were randomly selected from each group
(Vehicle vs. WGP), and kidney sections were stained with either hematoxylin and eosin (HE)
or Periodic acid-Schiff (PAS). (A) Typical microscopic images of renal cortex, outer medulla and
a glomerulus in each group (Vehicle: top panel; WGP: bottom panel); data showed the same
area of renal cortex and outer medulla stained with either HE or PAS. PC: protein cast formation;
black stars (*): damaged glomerulus (glomerular atrophy); arrows: PAS-stained mesangial expansion;
(B) The glomerular atrophy was scored in at least 20 randomly selected views in two separate sections
of each kidney, and was presented in average per view; data are presented as mean ± SD of each group
(n = 9); vehicle vs. WGP: p = 0.0225 (two-tailed t-test); (C) The mesangial expansion was determined
using a 0 to 4 scale based on the percentage of the area stained strongly with PAS; a range of 180 to
250 glomeruli were counted and averaged for each kidney. Data are presented as mean ± SD of
each group (n = 9); vehicle vs. WGP: p < 0.0001 (two-tailed t-test); (D) The number of intratubular
protein cast formation in each microscopic view was counted in HE-stained section, and the average
number of at least 20 randomly selected views under 40× magnification represented in each kidney;
data are presented as mean ± SD of each group (n = 12); vehicle vs. WGP: p = 0.0006 (two-tailed
t-test); (E) Tubular dilation and atrophy were determined using a 0–4 scale based on the percentage
of damaged tubules occupying an area in each microscopic view; the average of at least 30 randomly
selected views under 200× magnification represented the tubular atrophy in each kidney; data are
presented as mean ± SD of each group (n = 12). Vehicle vs. WGP: p = 0.0036 (two-tailed t-test).
3.5. Daily Intake of WGP Is Associated with Increasing Local Antioxidant Defense in the Kidney of Obese
Diabetic Rats
To understand the mechanisms by which the daily intake of WGP reduced the progression of
kidney disease in these rats, the transcriptional profile of 84 genes that are involved in oxidative stress
and antioxidant defense in the kidney was examined using PCR array. In the kidneys of WGP-fed rats
compared to Vehicle controls, the expression levels of antioxidants (Gpx1, Gpx4, Gstk1 and Prdx2) and
reactive oxygen species (ROS) metabolism (Sod2, Cyba, Dhcr24 and Park7) were significantly up-regulated
while oxidative stress response genes (Hmox1, Ercc6, Gstp1 and Txnip) downregulated (Table S2 and
Table 2). These results suggest an increase in antioxidant defense in the kidneys by WGP diet.
Table 2. Significant changes of oxidative stress-related gene expression in renal cortex of WGP-fed rats
as compared to Vehicle controls, analyzed using PCR array.
Gene Symbol Gene Names Functions Fold Change * p Value (n = 4)
Dhcr24 24-dehydrocholesterol reductase H2O2 scavenger, preventingH2O2-induced cell death
4.265 0.00222
Cyba Cytochrome b-245, alpha polypeptide NADPH oxidase subunit,optimizing immunity 4.215 0.00875
Gstk1 Glutathione S-transferase kappa 1 Cellular detoxification(lipid peroxide detoxification) 1.1475 0.01279
Prdx2 Peroxiredoxin 2 H2O2 and Alkylhydroperoxide antioxidant 1.7625 0.02746
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Table 2. Cont.
Gene Symbol Gene Names Functions Fold Change * p Value (n = 4)
Park7 Parkinson disease (autosomalrecessive, early onset) 7 Redox-sensitive chaperone 1.24 0.03723
Gpx4 Glutathione peroxidase 4 H2O2, lipid peroxide andhydroperoxide reduction 1.96 0.03756
Gpx1 Glutathione peroxidase 1 H2O2 antioxidant 3.235 0.04614





Damaged DNA repair −3.9575 0.02908
Gstp1 Glutathione S-transferase pi 1 Cellular detoxification −22.4875 0.0405
Txnip Thioredoxin interacting protein Increasing ROS production −37.8825 0.04436
* Minus: decreased.
3.6. Addition of WGP Extract Reduced H2O2-Induced Cell Death in Cultured Podocytes
Podocyte injury plays a key role in the initiation and early progression of DN [32]. To investigate if
the antioxidant compounds from WGP prevented podocyte injury under oxidative stress, the protective
activity of WGP extract was tested in cultured podocytes in the presence of H2O2. Methanol extraction
of WGP exhibited a high antioxidative activity, indicated by the equivalence of approximately 1.7 mg
of the extract to 5 μg of ascorbic acid in all three different assays (Figure S1). H2O2 induced significant
podocyte cell death through apoptosis (positive stain with Annexin-V) (Figure 5A). However, cells that
were co-treated with WGP extract (200 mg·mL−1) and H2O2 had significantly more cell viability than
cells that were treated with H2O2 only (p = 0.037, two-tailed t-test, n = 8). The viability of cells treated
with both H2O2 and WGP extract was not different from that in cultures treated with the extract only
(p = 0.2732, two-tailed t-test. n = 8), suggesting that the extract significantly inhibited H2O2-induced
cell death under this condition.
Figure 5. Grape extract protects cultured podocytes from H2O2-induced cell death. Grape extract
was prepared by using methanol extraction. HSMP cells (0.25 × 106 cells/well) were grown in
RPMI 1640 culture medium in 24-well plates at 37 ◦C overnight, followed by grape extract treatment
(200 mg·mL–1) in the presence or absence of H2O2 (1 μM). (A) Cell viability or apoptosis was
determined by FACS analysis with Annexin-V-PE and 7-AAD staining after 24-h treatment with
the grape extract. Data were represented as a typical FACS graph in each group; (B) Cell viability
represented the percentage of viable cells (double-Annexin-V-PE/7-AAD negative cells in lower
left quadrant). Data were presented as mean ± SD of eight separate experiments in each group.
Untreated vs. H2O2, p = 0.0033 (two-tailed t-test); H2O2 vs. H2O2 + Extract, p = 0.037 (two-tailed t-test);
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4. Discussion
CKD is a major health problem in our society. In addition to pharmacological therapy, such as
through angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) for
proteinuria and/or hypertension control, nutritional interventions have been widely recommended in
the management of CKD [33]. A low-protein diet is a popular and practical nutritional management
of CKD [34–36]. Interestingly, a recent pilot clinical study shows that dietary supplementation with
two gram of grape seed extract a day for six months can improve some kidney function parameters of
2–4 stage CKD in patients, in which the grape seed extract likely acts through the strong antioxidative
activity and anti-inflammation of phytochemicals [37]. This study may suggest that a diet containing
the antioxidative grape extract can potentially become a nutritional management strategy for the
prevention of CKD.
In the present study, when the rats started diet supplement at 8 weeks old, compared to the
reference range [38] (Table S3), they had significant higher levels of blood GLU, BUN, TBIL, ALT, ALP
and AMY, which may represent a sign of mild diabetes (higher GLU), pancreatic (higher AMY) and
nonalcoholic fatty liver disease (higher ALT, ALP, TBIL and BUN). During six months of feeding
experiments, the serum levels of AMY, Ca2+, GLOB, GLU, Na+, TBIL and TB were increased and of
ALB (including ALB/GLOB ratio), ALP, BUN, K+ and PHOS decreased in both groups (Table S1).
These data may suggest progressively worsening diabetic (high GLU) and pancreatic (high AMY),
fatty liver (high GLOB, TB and TBIL, low ALB and BUN), and kidney disease (low ALB or ALB/GLOB
ratio for albumin loss, and the imbalance of Na+, Ca2+, K+ and PHOS). When compared to the vehicle
control group, with no difference in their bodyweight (Figure 1) the lower organ index of WGP-fed
rats may indicate the reduced fatty liver, kidney hypertrophy and perhaps low-degree systemic
immune response activity (indicated by the smaller size of the spleens) (Table 1). Further chemical tests
showed that daily intake of WGP improved blood ALB and ALB/GLOB ratio and decreased GLU levels
(Figure 2), and lower proteinuria, uPCR and urination (probably due to higher renal water reabsorption)
(Figure 3). Histologically, we found that glomerular atrophy, mesangial expansion, tubular injury
and protein cast formation, all of which are elevated in early stages of diabetic related CKD [39,40],
were reduced in the WGP-fed rats (Figure 4). In vitro, the grape extract inhibited H2O2-induced cell
death in cultured podocytes and exhibited a high antioxidative activity (Figure 5). In consistent with
our study, a recently study demonstrates similar benefits of the grape powder to age-related kidney
functions in Fischer 344 rats [21].
We described higher urine volumes in the vehicle fed rats versus WGP fed rats (Figure 3A),
which may be due to either a manifestation of higher glycemic levels (Figure 2C) or worsened MetS,
resulting in increasing hyperfiltration and renal injury. Hyperglycemia-induced hyperfiltration is an
early manifestation of diabetes that causes polyuria and is an early predictor of glomerular damage
in late stages of kidney disease [41–43]. While there was no evidence of better renal function (eGFR
levels) in the WGP group (Figure 3D), this may have been due to the short duration of the study, since
decline in GFR is a late marker of nephropathy when around 50% of nephrons are already lost [39,44].
The obese ZSF1 rats in this study indeed show the signs of early stages of CKD where an evidence of
kidney damage such as proteinuria is present with normal or slightly decreased eGFR.
The renal protective pathway of WGP diet in obese diabetic ZSF1 rats is not fully understood.
A previous study has demonstrated that the kidney disease of these rats is mostly independent
on hypertension and/or hypertensive nephropathy [45], suggesting the attribution of renal
pathophysiology strictly to other components of MetS, such as obesity and/or hyperglycemia. Indeed,
many studies in literature use these rats as an appropriate model for the purposes of investigating
MetS-related kidney disease or DN [28,46]. Our data show that the daily intake of WGP had no
impact on the bodyweight or obesity of these rats (Figure 1). Therefore, the beneficial effect of WGP
diet on the diseased kidney may act through direct and/or indirect pathways, which include the
improvement of glucose metabolism and/or fatty liver disease (Figure 2), and the probability of
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(Table 1), but not relate to hypertension and obesity. The mechanism by which a WGP diet protects
the kidney under the influence of both diabetic mellitus and fatty liver disease remains unknown and
requires further investigation.
Oxidative stress is induced by the excess levels of ROS that are generated in many different
situations, including the mitochondrial injury [47], the increased activity of oxidases (e.g., cytochrome
p450s, xanthine oxidase, 5-lipoxygenase, and NADPH oxidase) in the response to inflammatory
stimuli (e.g., hypoxia and immunologic stimuli) [48–50] and the loss of antioxidant defense system
that includes enzymes (e.g., SOD, CAT and GSH-Px) and small molecular antioxidant scavengers
(e.g., vitamin E, N-acetylcysteine and α-lipoic acid) [51,52]. The oxidative stress or ROS causes
cellular damage by reacting with and/or denaturing cellular macromolecules including lipid, protein
and nucleic acids, and/or even mediating or activating intracellular death signaling pathways [53],
which plays an important role in the pathogenesis and progression of diabetes, fatty liver disease and
their associated CKD including DN [52,54–56]. Grape products are rich in antioxidant chemicals,
such as phenolic, flavonoid, and anthocyanidin [57–59], and exhibit anti-oxidative activities in
both humans and animals [37,60,61]. Our study showed that each gram of WGP extract from
methanol extraction contained approximately 21.5 mg of phenolics (reference: tannic acid), 0.25 mg
of total flavonoids (reference: quercetin) and 5.2 mg of proanthocyandins (reference: catechine).
The antioxidative activity of approximately 1.7 mg of this extract was equivalent to that of 5 μg of
ascorbic acid in all three different assays (ABTS, DPPH, and FRAP) (Figure S1), and addition of this
extract prevented H2O2-induced podocyte injury in cultures (Figure 5). Consist with these data, the
anti-oxidative stress system in the kidneys of the rats receiving WGP diet was improved (Table 2).
Taken together, these findings from both the literature and our study imply that WGP diet may improve
antioxidant capability not only systemically (e.g., in the liver and the immune system/spleen and
glucose metabolism) but also locally specific in the kidneys, resulting in less cellular damage in the
setting of MetS and CKD.
The US Department of Agriculture considers 1.5 to 2 cups (250 g to 340 g, or 3.125 g·kg−1 to
4.25 g·kg−1 based on 80 kg, an average bodyweight of an adult) of fresh grapes per day as a standard
serving size. In this experimental study, each ZSF1 rat (300 g to 600 g) consumed an average of
approximately 25 g of food or 1.25 g of WGP a day that was equal to 2.8 g·kg−1·day−1. There are
two simple ways to converse this dose between rats and humans [62]; one is based on the
equivalent surface area (1 for rats = 1/7 for humans), so that the equivalent dose for humans
will be 2.8 × 1/7 = 0.4 g·kg−1; the other is based on the representative surface area to weight ratio
(Km), whereas rat Km = 5.9 and human (adult) Km = 37, then the dose for adult humans will
be 2.8 × (5.9/37) = 0.45 g·kg−1. The result from both calculations is similar. Given that grapes are
approximately 80% water by weight, 0.45 g·kg−1 of WGP dose equals to 2.25 g·kg−1 of fresh grapes,
indicating that the dose we used in this experimental study was less than the standard serving size
recommended by the US Department of Agriculture.
There are several limitations of this study. First, this is an experimental study using a relatively
small number of animals from one strain, so the results may just limit to this strain and disease
type. It is not certain if the same results would be seen in different species, or in different models
of kidney disease. Second, a relatively short duration of this study may not represent the most of
metabolic conditions and strategies that require life-long exposure and long duration of intervention.
Finally, if the findings of the renoprotective effects of WGP diet are possibly attributable to better
glycemic control, so there is a need to test the WGP diet in non-diabetic animal models.
5. Conclusions
CKD has been known as an initially silent condition where clinical manifestations are usually
underreported at its early stages. By the time SCr reaches abnormally high levels, there already is
50% nephron loss in the kidneys [44]. This highlights the importance of early stage management, such
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experimental study, we demonstrate that a daily intake of WGP for six months shows renoprotection
in a MetS animal model (obese diabetic ZSF1 rats), as evidenced by decreased proteinuria, lower uPCR,
improved diabetic uremia and reduced renal injury in DN (early stages of CKD). Our findings suggest
that a daily intake of grape product rich in antioxidants may delay the progression of early CKD to
late or ESRD in humans, and warrants further investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/4/345/s1,
Figure S1: Antioxidant activity of WGP extract, Table S1: The blood chemistry of obese male ZSF1 rats over
six months of daily intake of whole grape powder (WGP) compared to sugar (Vehicle) group, Table S2: Oxidative
stress-related gene expression in kidney cortex of WGP-fed rats compared to Vehicle controls at the end of
six months of feeding experiment, Table S3: Blood chemistry of metabolism of obese male ZSF1 rats (approximately
eight weeks old) compared with a reference in the literature [36].
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Abstract: The treatment of obesity and cardiovascular diseases is one of the most difficult and
important challenges nowadays. Weight loss is frequently offered as a therapy and is aimed at
improving some of the components of the metabolic syndrome. Among various diets, ketogenic
diets, which are very low in carbohydrates and usually high in fats and/or proteins, have gained in
popularity. Results regarding the impact of such diets on cardiovascular risk factors are controversial,
both in animals and humans, but some improvements notably in obesity and type 2 diabetes have
been described. Unfortunately, these effects seem to be limited in time. Moreover, these diets are not
totally safe and can be associated with some adverse events. Notably, in rodents, development of
nonalcoholic fatty liver disease (NAFLD) and insulin resistance have been described. The aim of this
review is to discuss the role of ketogenic diets on different cardiovascular risk factors in both animals
and humans based on available evidence.
Keywords: ketogenic diets; obesity; NAFLD; fibroblast growth factor (FGF21); insulin resistance;
type 2 diabetes; cardiovascular risk factors
1. Introduction
As a consequence of the rising obesity prevalence in industrialized countries, the incidence of
cardiovascular diseases also increases [1]. Obesity is also a major risk factor for insulin resistance
and type 2 diabetes [2]. This state of insulin resistance is frequently associated with ectopic lipid
accumulation, notably in the liver and skeletal muscle. This can lead to the development of nonalcoholic
fatty liver disease (NAFLD), which is an independent predictor of cardiovascular disease [3,4]. NAFLD
is defined as steatosis which is not due to excess consumption of alcohol, viral or autoimmune causes,
and iron overload [5,6]. No evidence-based pharmacological treatment for NAFLD exists so far.
NAFLD is an important risk factor for the development of insulin resistance and type 2 diabetes, which
may be associated with other cardiovascular risk factors such as dyslipidemia and high blood pressure.
As NAFLD is present in almost 90% of obese patients [7], weight loss represents one of the pillars of
the treatments among others, such as physical activity.
In the literature, diets rich in carbohydrates, and notably rich in refined sugars and fructose,
are associated with the metabolic syndrome [8,9]. Therefore, to lose weight, different diets have
been suggested. Among them, carbohydrate restriction has been proposed to be the single most
effective intervention for reducing all features of the metabolic syndrome [10–12]. Since the publication
of Atkins’s book in the early 1970s [13], low-carbohydrate diets have become increasingly popular,
particularly ketogenic diets (KD). These diets are known for being very low in carbohydrates, but
usually high in fats and/or proteins. In practice, KD are characterized by a reduction in carbohydrates
(usually less than 50 g/day) and a relative increase in the proportions of proteins and fats [14]. Some
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variations exist, like very-low-carbohydrate KD, which are even more restrictive, with less than
30 g/day (Table 1).
Table 1. Standard composition of ketogenic diets in adults * (calculated for a 2000 kcal diet/day).
Classical KD
Defined as <130 g carbohydrate per day or <26% of caloric
intake by the American Diabetes Association
Modified Atkins Diet 65% caloric intake from fat, 30% protein, 6% carbohydrates
Very low-carbohydrate KD Carbohydrates < 30 g/day
KD, Ketogenic Diet. * Adapted from Kossoff et al. [15], Feinman et al. [16], Accurso et al. [17].
After a few days of such diets, glucose reserves (i.e., glycogen stored in liver and skeletal muscle)
become insufficient to provide body energy needs. This leads to the production of ketone bodies by the
liver, which will be used as an alternative energy source notably by the central nervous system [18].
KD are known to be efficient in the treatment of seizures and can be used as an alternative
treatment [19], but this aspect will not be discussed in this review. Nevertheless, for about forty years,
the potential use of KD has also been investigated in the prevention and treatment of cardiovascular
risk factors. The aim of this review is to discuss the available evidence in animal and human studies,
and the role of KD on different cardiovascular risk factors, namely obesity, NAFLD, insulin resistance
and type 2 diabetes, dyslipidemia and high blood pressure. To our knowledge, this is the first review
comparing the effects of KD on cardiovascular risk factors in animals and humans.
2. Method
This article is neither a systematic review nor a meta-analysis. We searched Medline (PubMed) for
trials in animals and humans, reviews or meta-analyses, using the query “ketogenic diet” + “weight
loss”, “obesity”, “fibroblast growth factor (FGF21)”, “NAFLD”, “diabetes”, “insulin resistance”,
“dyslipidemia” or “blood pressure”. Then, we selected the most recent papers (less than 15 years) and
publications with potential practical usefulness. Finally, we only kept studies of adults, not children.
3. Results
3.1. KD and Obesity
Studies in rodents (obese or non obese) show that KD are efficient for weight loss [20,21].
Nevertheless, it is important to assess body composition changes, as it is always better to lose fat mass
than lean mass. Indeed, in a study by Garbow et al., after 12 weeks KD led to a significantly lower
weight gain compared to chow-fed and high-simple-carbohydrate high-fat Western diet fed mice,
but lean mass was significantly reduced in KD-fed mice compared to chow-fed mice [22]. In another
study, accumulation of visceral fat mass was significantly higher (at least 30%) in rats fed a KD
(two compositions of KD were tested: a high-protein “Atkins-style” or a low-protein diet, both with a
low-carbohydrate and high-fat content), compared with chow-fed controls, after 4 weeks of diet [23].
Finally, Jornayvaz et al. showed that KD-fed mice during 5 weeks gained significantly less weight
than regular-chow fed mice. Nevertheless, KD-fed mice had an increased fat mass percentage than
regular-chow fed mice, without differences in the percentage of lean body mass between diets [24].
It is also important to assess whether weight loss can be maintained. Long-term studies reveal
an absence of weight loss after 22 weeks of KD in mice, despite an initial weight loss during the
first week of diet [25]. Moreover, another study showed that mice fed a KD for 80 weeks initially
lost weight, but after 18 weeks, their weight returned to baseline and then increased gradually [26].
Nevertheless, they gained less weight than chow-fed mice, and, with body composition analysis,
the authors showed that this difference resulted from both a lower lean mass and a lower fat mass.
Moreover, the survival curves were the same between the two diets. Finally, KD-fed mice also had an
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indicated continuous use of fatty acids as an energy substrate [26]. This rise in energy expenditure was
analyzed in another study which showed that KD promotes weight loss (20% of total body weight)
through an increased energy expenditure and this correlated with a rise in plasma fibroblast growth
factor 21 (FGF21) levels [27]. The role of FGF21 in KD will be further discussed later. In another
study, compared to non-KD, rats fed a low protein (10% of total content) KD had a waste of energy in
urine. [28]. Indeed, KD-fed rats had a lower urine nitrogen excretion due to a lower protein intake and
a urine energy-to-nitrogen ratio almost twice as high as the other diets.
Overall, an increase in energy expenditure in mice fed a KD compared to mice fed a chow diet
could be the mechanism responsible for decreased weight gain or weight loss seen in rodents, despite a
similar caloric intake [24]. As a potential component of the increased energy expenditure, other authors
performed microarrays in the liver of KD-fed mice and described an increased expression of genes
involved in fatty acid oxidation and a reduced expression in genes involved in lipid synthesis [20].
A recent study analyzed the effects of KD on exercising rats and sedentary rats [29]. Compared to
other diets (Western diet, standard chow), after 6 weeks, sedentary KD-fed rats had an approximately
25% lower body mass, a lower size of adipocytes from omental adipose tissue, 80% lower levels of
serum insulin, 50% lower levels of glucose, 55% lower levels of triglycerides and 20% lower levels of
total cholesterol. Activity did not confer a benefit, as KD-fed exercising rats did not show better results
than the sedentary rats. Nevertheless, exercising rats had 40% lower serum β-hydroxybutyrate levels
than sedentary rats, independent of diet, while they had more favorable adipose tissue characteristics.
These results suggest that body fat regulation (e.g., reduced adipose tissue mass and cell size) under a
KD (with or without exercise) could rather be due to lower insulin levels. Therefore, increased serum
ketones may have a smaller role.
In humans, KD are known to be an effective weight-loss therapy [30–33] (in average up to 5%
of body weight at 6 months), but the mechanisms are not clearly established. Some authors suggest
that it results simply from reduced caloric intake and an increased satiety effect of proteins [34].
Other studies suggest a metabolic effect of KD: possibly, the use of energy from proteins in KD
is an expensive process and therefore increases weight loss [35–37]. Also, there is the suggestion
that gluconeogenesis, which is increased with carbohydrate restriction, is energy demanding [35,38].
Another hypothesis of KD-induced weight loss is decreased appetite induced by ketosis [39]. Some
authors also suggest digestive metabolic changes: with ketogenic very-low energy diets, ghrelin levels
and subjective appetite (usually increased in a hypocaloric diet) were reduced when patients were
in a ketotic state [39]. Surprisingly, leptin levels were lower under ketosis. A study in 132 severely
obese patients (mean body mass index (BMI) 43 kg/m2) with a high prevalence of type 2 diabetes or
metabolic syndrome showed that participants using a low-carbohydrate diet lost more weight than
those using other diets, suggesting a greater reduction in overall caloric intake, rather than a direct
effect of macronutrient composition [32].
As discussed in rodents, the problem is that a lot of studies are of short duration. For example,
a small study [40] of 17 obese men, randomized to two different high-protein diets (one low-carbohydrate,
“ketogenic”; one medium-carbohydrate, “non-ketogenic”) with a cross-over design, eating ad libitum
during 4 weeks each, revealed that KD reduced hunger and was associated with a lower food intake.
Weight loss was also significantly greater with the ketogenic diet than with the non-ketogenic diet, and
weight loss was equally comprised of fat mass and fat-free mass. Only 35% of the difference in total
weight loss between the two diets was due to water depletion; the remainder was attributed to fat mass
and lean mass loss [40]. In a bigger study of 311 participants [41], a very low-carbohydrate KD followed
by a period of slow re-insertion of a Mediterranean diet and alimentary education was associated
with an overall improvement (mean total body weight loss of 14 ± 10 kg, BMI 5 ± 3 kg/m2, waist
circumference 13 ± 7 cm) at 1–4 months, which remained stable after 1 year [41]. The limitations were
the composition of the diet (low-carbohydrate, but also low-fat) and the fact that it was an observational
study. Other authors [42] compared different diets in the same group of patients eating alternatively a
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and a normal Mediterranean diet (4 months during the rotation of the two other diets, then 6 months)
during 1 year. Significant weight loss and reduction of body fat percentages were observed only during
ketogenic periods compared to the two other diets. Moreover, if the patients were compliant to the
prescribed Mediterranean diet (which was relatively strict: 1800 kcal/day) during the maintenance
period, no weight regain was observed at 12 months [42]. In an older study in obese non-diabetic
participants, a low-carbohydrate diet led to a greater weight loss after 6 months, but no significant
difference at 1 year [33]. The authors suggested that weight loss was probably due to a greater energy
deficit, but the mechanisms remain unknown, and no relation between weight loss and ketosis was
found at any time during the study. Finally, in a study with obese type 2 diabetes patients [43], the
authors compared a low-carbohydrate high unsaturated fat diet to a high-carbohydrate low-fat diet,
in adjunction with structured exercise: weight loss was similar in both groups (−9.1%), but a trend
toward regaining more weight was observed in the low-carbohydrate diet group at 52 weeks. Weight
loss is usually related to a high intensity of lifestyle interventions. Thus, it would be interesting to
know the evolution on the next months/years of follow-up, and if the weight loss would be maintained
without structured exercise. Exercise has an impact on body weight, but also on body composition as
described in a study that analyzed the association of KD or regular diet in combination with exercise
(resistance training) in overweight women [44]. The KD group lost fat mass without experiencing a
significant alteration in lean mass, while the other group gained lean mass without a significant change
in fat mass [44].
To summarize, in rodents and humans, KD seem to have a benefit on weight loss, notably by
increased energy expenditure in animals and decreasing food intake in humans. In humans, weight
loss affects both fat mass and lean mass. Greater weight loss is also associated with structured
professional support, which may be difficult and expensive to maintain over time. Long-term studies
are nevertheless needed to assess the evolution of weight loss.
3.2. KD and NAFLD
In mice, KD induce hepatic inflammation and lipid accumulation [22], while inflammation is
reduced in white adipose tissue [27]. KD also lead to hepatic steatosis in both short-term [24,25] and
long-term feeding in mice [26]. Biological markers such as aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) are increased at least twofold in parallel with increased intrahepatic
triglyceride content [24,25]. On the contrary, a study described that compared to other diets (Western
diet, standard chow), KD-fed mice display reduced ALT levels, hepatic triglyceride accumulation and
markers of liver inflammation [29]. The authors explained that these results, different from previous
studies, could be due to the protein content of the diet (they used a KD with 20% protein, versus <10%
in other studies) and differences in animal models (rat in this study, versus mice in others). Thus,
this shows the importance of the diet’s composition. Another study reported an increase in hepatic
triglyceride content in KD-fed mice after 12 weeks, and this correlated with an elevation in ALT levels,
suggesting that chronic KD feeding causes an injury pattern similar to a NAFLD phenotype [22].
Another interesting marker of NAFLD is FGF21. In humans, FGF21 levels are increased in NAFLD and
correlate with hepatic triglyceride content [45–47]. Nevertheless, the role of FGF21 in NAFLD induced
by a KD has mostly been studied in rodents [26,27,48,49]. Notably, a study in mice showed that FGF21
plasma levels and liver expression are increased by 5 weeks of KD feeding, and this was accompanied
by an increased hepatic fat content as revealed by increased hepatic triglycerides, diacylglycerols and
ceramides levels [24]. Moreover, KD-fed mice developed hepatic insulin resistance and this was due
to increased hepatic diacylglycerol content, as diacylglycerols are known to activate protein kinase
Cε [50]. In this study [24], the authors suggested that increased plasma FGF21 levels and hepatic
expression in KD-fed mice was probably secondary to hepatic fat accumulation and may represent
a compensatory mechanism to counteract hepatic insulin resistance, suggesting that FGF21 may be
beneficial in reversing hepatic insulin resistance. This has been further verified in high-fat diet fed
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notably hepatic diacylglycerol content, and improved hepatic insulin sensitivity [51]. The beneficial
role of FGF21 on hepatic insulin sensitivity was also shown by other authors [52]. Moreover, mice
lacking FGF21 gain weight, have an increased fat mass and develop glucose intolerance. Moreover,
when the chow diet was changed for a KD, these mice not only gained weight and developed glucose
intolerance, but also developed NAFLD [53]. Finally, another study revealed that FGF21 knock-out
mice fed a KD develop NAFLD and severe hepatic insulin resistance as assessed by the gold-standard
technique, the hyperinsulinemic-euglycemic clamp [54]. Finally, FGF21 has been shown to act as an
endocrine signal of protein restriction [55]. In summary, these studies suggest an important role of
FGF21 in the pathophysiology of NAFLD.
In humans, liver fat content was shown to be increased during an isocaloric high-fat
low-carbohydrate diet [56]. This result should be analyzed with caution, as with 31% of carbohydrates
the diet is not a “real” KD. Caloric restriction also had an impact: compared to the high-carbohydrate
(“standard”) hypocaloric diet, reduction of liver fat content was significantly higher with the
hypocaloric low-carbohydrate diet [57,58]. This effect was limited in time, with no significant difference
at 11 weeks [57]. KD have also been associated with a higher decrease in liver volume compared with
a standard hypocaloric diet, probably due to the depletion of liver glycogen [59]. Finally, the response
to KD may be influenced by genetic predisposition to NAFLD, as shown by two studies with a better
response to KD for patients with variants of the PNPLA3 gene [60,61]. When fed a KD, subjects with
PNPLA3 variants had a lower liver fat content than controls.
To summarize, the effect of KD on the liver was mostly investigated in rodents. The results are
rather negative, with induction of hepatic inflammation and NAFLD, but these findings have not been
reported in humans. An alteration of FGF21 expression could be a potential cause or consequence.
More studies are warranted in humans to assess whether KD could induce or improve NAFLD.
3.3. KD and Insulin Resistance / Type 2 Diabetes
Obesity is often associated with the development of NAFLD, insulin resistance and type 2 diabetes.
Notably, as already discussed, KD can lead to decreased weight gain in mice but with concomitant
development of NAFLD and associated hepatic insulin resistance [24]. In the latter study, mice fed a
KD for 5 weeks developed whole body insulin resistance despite reduced basal plasma glucose and
insulin levels. In this case, the use of indices of insulin sensitivity, such as the homeostatic model
assessment for insulin resistance (HOMA-IR) and quantitative insulin-sensitivity check index (QUICKI)
indices, would lead to the conclusion that insulin sensitivity is improved in KD fed mice [62]. However,
using the hyperinsulinemic-euglycemic clamp, glucose infusion rates were 47% lower in KD-fed mice
than in chow-fed mice, demonstrating whole body insulin resistance in KD-fed mice [24]. KD-fed
mice also had an impaired insulin ability to suppress endogenous glucose production confirming
insulin resistance at the level of the liver. In this case, KD induced severe hepatic insulin resistance in
mice despite lower body weight gain, and this was attributed to an increased hepatic diacylglycerol
content. Finally, insulin resistance was also attributed to a decreased insulin-stimulated whole body
glucose disposal, which was notably due to decreased glucose uptake in brown adipose tissue and the
heart [24].
In another study, mice fed a KD during 12 weeks remained euglycemic, but had reduced
mean serum insulin levels and HOMA-IR indices, and exhibited glucose intolerance as assessed
by intra-peritoneal glucose tolerance tests [22]. However, despite mild hepatic steatosis, systemic
response to insulin was preserved, unlike in other studies. The authors explained this discrepancy by a
relatively reduced lean body mass in KD-fed mice, resulting in higher insulin dose in insulin-tolerance
tests. Also, hepatic insulin resistance may confer a smaller contribution to overall glucose homeostasis
than peripheral glucose disposal [22]. In studies using rats, KD also induced glucose intolerance and
insulin resistance [23,63], despite reduced glucose and insulin levels [23]. In the latter study, the authors
showed that these effects were not due to energy overconsumption. Moreover, as KD-fed rats had a
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visceral fat mass. In the same study, short term KD feeding in rats was also associated with decreased
β-cell mass, but this effect could be due to a lower lean body mass of KD fed rats [23]. Nevertheless,
these findings were corroborated by another study where long term KD feeding in mice led to glucose
intolerance that was associated with insufficient insulin secretion from β-cells, potentially due to a
decrease in β-cell mass [25]. Interestingly, after only 6 days of KD feeding, mice showed impairments
in glucose tolerance and insulin sensitivity, and this was attributed to a possible adaptation to maintain
blood glucose levels against insufficient amounts of carbohydrates [48]. In this case, insulin signaling
was impaired only in white adipose tissue, but not in liver and muscle. The authors suggested that this
impairment in white adipose tissue could not be the only culprit for whole body glucose intolerance
in KD fed mice. Indeed, a low-carbohydrate diet might account for an impaired nutritional state
compared to a chow diet. These results were explained by a lower lean mass and a proportionally
higher insulin dose in insulin tolerance tests. The possible role of KD in inducing insulin resistance is
nevertheless controversial. Indeed, several authors reported that long term KD fed mice had normal
glucose tolerance, lower baseline insulin levels and improved insulin sensitivity [26,29].
In humans, the effect of KD on glucose homeostasis is more controversial, and notably depends
on the presence of type 2 diabetes or not at baseline. A study showed that a high-fat, low-carbohydrate
intake reduces the ability of insulin to suppress endogenous glucose production in healthy men,
by using the gold standard method, the hyperinsulinemic-euglycemic clamp [64]. The limitation is
the small number of participants (only 6). Other studies described the opposite: with a KD, obese
non-diabetic participants had a significant lower HOMA-IR and fasting glucose after a KD than at
baseline [40], and an improvement in insulin sensitivity using the QUICKI [32]. Finally, another trial
also described a better insulin sensitivity by consuming a KD [33], but this improvement does not
seem to be permanent. Indeed, Forster et al. found a significant improvement in insulin sensitivity at
6 months, but not at 1 year [33]. This reduction in insulin levels could be explained by the satietogenic
effect of this diet [65].
In type 2 diabetic patients, KD could be an interesting approach, as most patients have glycemic
variability due to food carbohydrate content. A lot of studies have been designed around this purpose.
KD are frequently associated with a diminution of blood glucose levels (up to 0.5 mmol/L) [41,66–68],
glycosylated hemoglobin (HbA1c (up to 0.3%) [41,66,68,69], glycemic variability [70] and improvement
in insulin sensitivity [32,68], sometimes without weight loss [67]. Low-carbohydrate diets can lead
to a reduction in medications in type 2 diabetic patients [69–74]. An important aspect is to assess
the long-term effect of a KD on these outcomes. In studies in obese type 2 diabetic patients fed
a KD, a significant improvement in fasting glucose levels was seen after 12 weeks and continued
after 56 weeks [75]. Nevertheless, in another study, a short-term decrease in HbA1c was observed
at 6 months, but was not sustained at 24 months [76]. The latter study is probably more relevant
to daily clinical practice because it was a low-intensity intervention. A recent study in obese type 2
diabetic patients compared a hypocaloric high-unsaturated/low-saturated fat very-low-carbohydrate
diet to a high-carbohydrate low-fat diet [43]. After 52 weeks, the low-carbohydrate diet group showed
a decrease in glycemic variability two times greater that the low-fat diet group, which indicates a
greater diurnal blood glucose stability. However, improvement in HbA1c was similar in both diets
(−1%). Nevertheless, the low-carbohydrate diet led to a greater reduction in antidiabetic medications,
which could overall be helpful to optimize glycemic control [43]. Still, long-term effects of such dietary
changes need to be evaluated.
In a prospective cohort of non-diabetic men, health professionals younger than 65 years old
followed during 20 years, a low-carbohydrate diet high in animal proteins and fats was associated
with a twofold increased risk of type 2 diabetes [77]. On the other hand, a low-carbohydrate diet
high in vegetal proteins and fats was associated with a decreased risk of type 2 diabetes [77]. These
findings suggest that a low-carbohydrate diet should contain proteins and fats from foods other than
red and processed meat. However, these results were found from non-ketogenic diets. Therefore,
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assumptions are validated. In another trial [32], a greater decrease of mean fasting glucose levels (−9%)
was observed in all subjects of the low-carbohydrate group, but was significant only in diabetic patients
(−15%), with more reduction of oral hypoglycemic agents or insulin in the low-carbohydrate group.
Interestingly, in a study in obese non diabetic patients, after 8 weeks, a very-low-energy KD led to a
rise in postprandial glucose levels, but not in fasting glucose levels [39]. The authors postulated that
KD reduces insulin ability to suppress endogenous glucose production and impairs insulin-stimulated
glucose oxidation, suggesting that there may be a different effect of ketosis on glucose homeostasis
between diabetic and non-diabetic patients. For example, in obese type 2 diabetic patients, a strong
inverse correlation between circulating ketones and hepatic glucose output has been described [78],
suggesting that higher levels of ketones are associated with more favorable effects on glycemic control
in these subjects.
An interesting study using biology systems approaches found a strong relationship between the
insulin resistance pathway and the ketosis main pathway, providing a possible explanation for the
improvement in glucose homeostasis found in clinical trials using low-carbohydrate diets. Notably,
maps analyses suggest a direct implication of glucose transporters and inflammatory processes [79].
In summary, in rodents, KD mostly induces insulin resistance and glucose intolerance, while in
type 2 diabetic humans KD is associated with a better control in glucose homeostasis and a reduction
in antidiabetic medications. Nevertheless, these improvements seem to be limited in time. Further
studies should evaluate if a higher weight loss correlates with a better glucose control or with higher
ketones levels.
3.4. KD and Dyslipidemia
Dyslipidemia is a well-known risk factor for cardiovascular diseases. As KD are usually high in
fats, it is necessary to assess their potential effect on the lipid profile.
In rodents, short term (14 days) studies showed no change in fatty acids and triglycerides levels
in mice fed a KD [48]. The duration and the composition of KD feeding are very important. In a
study of 4 weeks, Bielohuby et al. compared the effects on rats of chow diet and two different KD:
one with 78.7% fat, 19.1% protein, 2.2% carbohydrates, and the other with 92.8% fat, 5.5% protein,
1.7% carbohydrates. The very high-fat KD-fed group had a reduction in high-density lipoproteins
(HDL) cholesterol levels and higher triglycerides levels. No significant difference in total cholesterol
levels was found between the three groups [23]. It should be noticed that the authors did not mention
the effect on low-density lipoproteins (LDL) cholesterol levels. In another study, Jornayvaz et al.
showed that mice fed a KD during 5 weeks had similar levels of LDL cholesterol than mice fed a
chow diet [24]. In longer term (28–80 weeks) studies, KD fed mice displayed a twofold increase in
plasma total cholesterol and triglyceride levels [25,26]. On the opposite, a recent study reported that
mice fed a KD during 6 weeks had lower total cholesterol and triglycerides levels than with other
diets [29]. The authors suggested that there was a KD-induced reduction in insulin levels, which
further decreased liver fatty acids and cholesterol biosynthesis pathways [20,29]. Overall, most studies
in animals used KD rich in saturated fats, which may have detrimental effects on the lipid profile
compared to KD rich in unsaturated fats, and therefore limits definitive conclusions on the role of KD
on dyslipidemia.
In humans, KD have been associated with significant reductions in total cholesterol [75], increases
in HDL cholesterol levels [33,70,75,80–83], decreases in triglycerides levels [32,33,70,75,82,83] and
reductions in LDL cholesterol levels [75]. These results were obtained in non epileptic obese
participants with [32,70,75,83] or without [33,82] at least one risk factor of the metabolic syndrome,
but also in healthy normal weight participants [80]. This is of importance as the effects of KD on the
lipid profile may differ in epileptic subjects [84]. KD have also been associated with an increase in
size and volume of LDL cholesterol particles, which is considered to reduce cardiovascular risk by
decreasing atherogenicity [81]. Nevertheless, several studies showed an increase in LDL cholesterol
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mostly composed of saturated fats. In other studies, total and LDL cholesterol were significantly
more reduced with a high-protein medium-carbohydrate diet than with a KD [40]. Another study [33]
reported no significant difference in total and LDL cholesterol levels after 12 months of a KD compared
to a conventional diet, except at 3 months, where LDL cholesterol levels were lower in the conventional
diet group. The absence of improvement suggests that weight loss with a low-carbohydrate diet is
not associated with a decrease in LDL cholesterol usually observed with moderate weight loss [33].
Interestingly, the effect of a KD on lipid profile may be associated with ethnicity: in a study, white
subjects lost more weight and had a bigger decrease in triglycerides levels than black subjects [32].
However, in this study, there was no significant change in total cholesterol, HDL cholesterol and LDL
cholesterol levels.
As discussed for other cardiovascular risk factors, the composition of the diet used is very
important. For example, in a study that reported a benefit of a KD on triglycerides and HDL cholesterol
levels [70], the authors decided to use a low-carbohydrate diet rich in unsaturated but low in saturated
fatty acids, which may greatly influence the lipid profile, but also the development of other metabolic
complications such as NAFLD, insulin resistance and type 2 diabetes, as discussed earlier.
The impact of KD on the lipid profile differs between rodents and humans. In rodents, KD seem
to be associated with worsened levels of total, HDL and LDL cholesterol, and triglycerides. In humans,
the opposite is reported. These differences are mostly explained by differences in the composition
of the diets, which are usually higher in total fat, but also in saturated fat in animal studies. Both in
rodents and humans, comparison between saturated fat and unsaturated fat KD in long-term studies
would be necessary. Later in this review, we will discuss whether saturated fat diets are as harmful as
once thought.
3.5. KD and Blood Pressure
Studies reporting a potential effect of KD on blood pressure are scarce. We could not find studies
in animals. In humans, KD are usually associated with a slight but not significant reduction in
systolic and/or diastolic blood pressure [32]. Moreover, no change in antihypertensive therapy was
observed [32,33]. Nevertheless, a study described an improvement in both systolic and diastolic
blood pressure in obese participants when fed a KD during 48 weeks compared to a low-fat diet plus
orlistat [69]. Weight loss was not a confounding factor as weight loss was similar in both arms. Finally,
a reduction in systolic blood pressure was found in a study using a KD, but only after 3 months,
without change after 1 year of observation [41].
Overall, there is a clear lack of conclusive data on the potential beneficial effect of KD on arterial
blood pressure and further studies are therefore needed.
4. Discussion
Both in rodents and humans, controversies remain regarding the effect of KD on metabolic risk
factors such as NAFLD, insulin resistance, type 2 diabetes and dyslipidemia. The potential beneficial
and adverse effects of KD are summarized in Figure 1, and the effects of KD on different biomolecular
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Figure 1. Effects of ketogenic diets in rodents and humans.
Figure 2. Effects of ketogenic diets on biomolecular markers. FGF21: fibroblast growth factor-21; ALT:
alanine aminotransferase; AST: aspartate aminotransferase; QUICKI: quantitative insulin-sensitivity
check index; HOMA-IR: homeostasis model assessment of insulin resistance.
Overall, KD composition greatly differs between studies. KD used in rodents are usually not
similar to KD used in humans (almost no carbohydrates and low protein content in rodent KD).
Moreover, low-carbohydrate diets can be different in macronutrient composition, i.e., high-fat versus
high-protein content, which may account for some of the differences between the studies. Moreover, as
previously mentioned, fat composition can substantially differ between studies, some using KD
rich in unsaturated fatty acids and others rich in saturated fatty acids. Nevertheless, a recent
systematic review and meta-analysis revealed that saturated fat intake was not associated with
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but with heterogenous evidence [87]. The authors conclude that trans fats were associated with
all-cause and cardiovascular mortality and also with coronary heart disease. Moreover, it is well
known that different ratios of some unsaturated and saturated fatty acids in diet compositions can
alter metabolic parameters such as insulin sensitivity [9]. Therefore, it is a real challenge for physicians
to advise patients with different metabolic diseases about the best diet composition to use. If a KD
has to be prescribed, maybe it could be better to favor a vegetable-based KD, as vegetable-based
low-carbohydrate diets have been correlated with a decrease in all-cause and cardiovascular-related
mortality [88]. In the latter study, two US cohorts (121,700 females, 51,529 males) were followed during
26 and 20 years, respectively. Both in men and women, animal-based low-carbohydrate diets were
found to be associated with higher all-cause (especially cardiovascular mortality) and cancer mortality,
compared to vegetable-based low-carbohydrate diets. Nevertheless, similar studies with “real” KD
need to be performed to confirm this assumption, as a low-carbohdyrate diet is not necessarily inducing
ketosis and is therefore not a ketogenic diet per se. Another problem when using a KD is the long-term
effect and sustainability of effects, notably due to a lack of long-term studies in metabolic diseases
such as type 2 diabetes. Restrictive diets are often associated with poor long-term adherence [89].
Nevertheless, some evidence suggests that adherence to low-carbohydrate diets is better than to low-fat
diets, because of the allowance to unlimited access to food as long as carbohydrates are reduced, given
that proteins and fats are known to induce satiety [16].
Three meta-analyses about the effect of KD on cardiovascular risk factors were published
recently [90–92]. Their conclusions are unanimous about general positive effects, but not unanimous
about each single variable. Santos et al. concluded in 2012 that low-carbohydrate diets lead to a
significant decrease in body weight, BMI, abdominal circumference, both systolic and diastolic blood
pressure, triglycerides levels, fasting plasma glucose and HbA1c, an increase in HDL cholesterol
levels, and no change in LDL cholesterol levels. As we mentioned before, the authors suggested
a possible duration effect, specifically for body weight and blood pressure, where benefits seem to
decrease over time [90]. Bezerra Bueno et al. compared very-low carbohydrate diets to low-fat diets
and their effects after a follow-up of at least 12 months. Very-low carbohydrate diets confer a greater
weight loss, reduction in triglycerides and diastolic blood pressure, and increase in HDL and LDL
cholesterol levels. There was however no difference in systolic blood pressure. There was no significant
difference between diets for fasting blood glucose and insulin levels, and HbA1c. It is interesting to
note that in the studies (only 4) with 24 months of follow-up, only the change in HDL cholesterol levels
remained significant [91]. The latest meta-analysis on KD by Naude et al. included 19 randomized
controlled trials (RCT) and revealed that there is probably little or no difference in changes in weight or
cardiovascular risk factors when comparing low-carbohydrate diets to isoenergetic diets (both showed
weight loss) after two years of follow-up. These results were found in overweight and obese patients,
with or without type 2 diabetes. This meta-analysis showed that strict adherence failed and declined
with follow-up in most trials [92].
It is also important to keep in mind that KD could have some adverse side effects when chronically
used. Indeed, studies in children using KD to treat epilepsy and other neurological disorders show an
increase in kidney stones, osteoporosis, hyperlipidemia and impaired growth [93,94]. While several
authors found that a low-carbohydrate high-protein diet was not associated with higher mortality
after 12 years of follow-up [95], others described a weak statistically significant higher mortality rate
after 10 years [96]. However, they did not evaluate sources of proteins and fats.
Finally, it should be mentioned that it is difficult to really know in studies if low-carbohydrate
diets were “real” KD. Indeed, most of the time there is no report about a potential induction of ketosis,
by for example reporting measurements of plasma ketone bodies.
5. Conclusions
Based on the available literature, KD may be associated with some improvements in some








Nutrients 2017, 9, 517
are usually limited in time. As KD are often rich in fats, some negative effects could happen. Mainly in
rodents, developments of NAFLD and insulin resistance were described. In humans, insulin resistance
is also a potential negative effect, but some studies have shown improvements in insulin sensitivity.
Nevertheless, many subjects contemplating such diets are overweight or obese at baseline, and even a
moderate weight loss could be metabolically beneficial for them. However, it is mandatory to maintain
body weight after weight loss, which is usually a major problem. More studies are therefore warranted
to better assess the effects of long term use of KD on metabolic diseases and cardiovascular risk factors,
but also to better define which dietary macronutrient composition is optimal.
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Abstract: The available findings concerning the association between branched-chain amino acids
(BCAAs)—particularly leucine—and insulin resistance are conflicting. BCAAs have been proposed
to elicit different or even opposite effects, depending on the prevalence of catabolic and anabolic
states. We tested the hypothesis that leucine supplementation may exert different effects at different
stages of insulin resistance, to provide mechanistic insights into the role of leucine in the progression
of insulin resistance. Male Sprague-Dawley rats were fed a normal chow diet, high-fat diet (HFD),
HFD supplemented with 1.5% leucine, or HFD with a 20% calorie restriction for 24 or 32 weeks.
Leucine supplementation led to abnormal catabolism of BCAA and the incompletely oxidized
lipid species that contributed to mitochondrial dysfunction in skeletal muscle in HFD-fed rats in
the early stage of insulin resistance (24 weeks). However, leucine supplementation induced no
remarkable alternations in BCAA catabolism, but did enhance mitochondrial biogenesis with a
concomitant improvement in lipid oxidation and mitochondrial function during the hyperglycaemia
stage (32 weeks). These findings suggest that leucine trigger different effects on metabolic signatures
at different stages of insulin resistance, and the overall metabolic status of the organisms should be
carefully considered to potentiate the benefits of leucine.
Keywords: leucine; BCAAs; BCAA catabolism; insulin resistance; metabolomic; mitochondria
1. Introduction
Branched-chain amino acids (BCAAs), comprising leucine, isoleucine and valine, are essential
amino acids and important nutrient signals that have direct and indirect effects on metabolism.
Substantial evidence indicates that increased dietary intake of BCAAs, particularly leucine, has
positive effects on the regulation of body weight, muscle protein synthesis, glucose homeostasis, lipid
metabolism, and the ageing process [1–4]. Nevertheless, the idea that BCAAs or their supplementation
might have a positive role in glucose metabolism and insulin resistance remains controversial. In other
studies, leucine supplementation has no effect, or leads to deterioration in insulin sensitivity [5,6].
Along with these effects on metabolic health, it has long been recognized that elevated levels of
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circulating BCAAs and related metabolites are strongly associated with obesity and insulin resistance
and are predictive of future type 2 diabetes mellitus (T2DM) in humans and in some rodent
models [7–10]. The mechanisms underlying these paradoxical findings are not completely understood.
BCAAs modulate insulin resistance via multiple mechanisms. Generally, BCAAs have been shown
to induce insulin resistance by phosphorylation of serine IRS-1 via activating mammalian targets of the
rapamycin complex 1 (mTORC1) signaling pathway, and lead to a negative feedback loop of insulin
signaling [11]. However, several previous studies, including a study conducted in our laboratory,
have indicated that BCAA–associated mTORC1 activation is not required or sufficient to elicit insulin
resistance [12,13]. Alternatively, the Lynch group have observed that abnormal tissue-specific BCAA
metabolism in obesity results in the accumulation of BCAAs and related toxic metabolites, thereby
triggering “anaplerotic stress” and mitochondrial dysfunction associated with insulin resistance and
type 2 diabetes mellitus (T2DM) [14,15]. In contrast, BCAAs supplementation has been shown to
promote mitochondrial biogenesis and extend the lifespan of yeast and middle-aged mice [16]. Recently,
BCAAs and leucine have been hypothesised to elicit different or even opposing effects, depending
on the catabolic and anabolic states of the organism [17]. Development of T2DM is a time-dependent
process accompanied with different metabolic characteristics [18]. Notably, during the progression
of insulin resistance to T2DM, the predominantly anabolic processes transition to predominantly
catabolic processes, with the loss of insulin activity. This complexity introduces interpretive limitations,
when using data derived from a static time point, on understanding how BCAAs affect the progression
of insulin resistance [19].
In the present study, we performed comprehensive metabolic and physiological profiling to
investigate dynamic alterations in BCAA catabolism, mitochondrial function, and metabolic responses
to long-term leucine supplementation in rats with hyperinsulinaemia or hyperglycaemia induced by
a high-fat diet (HFD). We aimed to provide mechanistic insights into the role of leucine in insulin
resistance progression. Furthermore, we compared the effects of leucine with those of calorie restriction
(CR), a well-known approach for improving insulin sensitivity.
2. Materials and Methods
2.1. Animals, Diets and Treatments
Male Sprague-Dawley rats at six weeks of age (160–180 g) were obtained from Sino-British Sipper/BK
Lab Animal Co., Ltd. (Shanghai, China) and housed in a temperature- and humidity-controlled
environment on a 12 h light/dark cycle with free access to food and water. After acclimation, the
rats were randomly divided into four groups (n = 20 per group) based on body weight and fed
a normal chow diet (ND; D12450B, Research Diet Inc., New Brunswick, NJ, USA), HFD (D12451,
Research Diet Inc., New Brunswick, NJ, USA), HFD supplemented with 1.5% leucine (HFD + Leu) or
HFD with 20% CR (HFD + CR). The administered leucine dose was determined in our preliminary
experiments [12] and nearly doubled the total daily leucine intake from food. The diet of the HFD + Leu
group was also supplemented with small amounts of valine and isoleucine to prevent valine and
isoleucine deficiencies. The HFD was rendered isonitrogenous and isocalorie to the HFD + Leu diet
by the addition of a mixture of non-essential amino acids (alanine, glycine, proline, aspartate and
serine in isomolar amounts) (Table 1). Food intake was monitored daily, and that of HFD controls
was used as a reference to calculate the amount of food provided to the rats subjected to CR (80% of
food consumption of controls). Half of the rats in each group were killed at week 24, and the other
half were killed at week 32 after overnight fasting. Blood samples were obtained and centrifuged
at 4000× g for 20 min. The serum was then collected and stored in a freezer at −80 ◦C until further
analysis. Tissues were rapidly excised, weighed, flash-frozen in liquid nitrogen and then stored at
−80 ◦C until use. All animal studies were conducted in accordance with the National Institutes of
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Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology
(IACUC No. 417, Date: 2015.3.28).
Table 1. Composition of the experimental diets (/100g).
ND HFD HFD + Leu
Macronutrients (g)
Protein 20.3 20.3 20.3
Carbohydrate 64.5 44.6 44.6
Fat 4.5 24.4 24.4
Fiber 5.0 5.0 5.0
Minerals 3.0 3.0 3.0
Calories (kcal) 379.7 479.2 479.2
Fat (energy %) 10.7 45.8 45.8
Protein (energy %) 21.3 17.0 17.0
Carbohydrate (energy %) 68.0 37.2 37.2
Amino acids (g)
Leucine 1.3 1.5 2.9
Isoleucine 0.6 0.7 1.0
Valine 0.7 0.9 1.1
Alanine 0.8 0.8 0.5
Aspartic acid 1.5 1.6 1.2
Glycine 0.7 0.5 0.3
Threonine 0.7 0.7 0.7
Serine 0.8 1.0 0.8
Glutamic acid 3.4 3.2 3.2
Tyrosine 0.5 0.7 0.6
Phenylalanine 0.7 0.8 0.8
Lysine 1.1 1.2 1.2
Histidine 0.5 0.5 0.4
Proline 1.2 1.7 1.6
Arginine 1.0 0.5 0.6
Methionine 0.4 0.3 0.4
Serine 0.8 1.0 0.8
ND: Normal chow diet; HFD: High fat diet.
2.2. Insulin Sensitivity Analysis
After 24 or 32 weeks on the respective diets, the fasting serum glucose levels were determined
by colorimetric assay (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), and insulin
levels were assessed using a commercial ELISA kit (Mercodia AB, Uppsala, Sweden), according to
the manufacturer’s instructions. The HOMA-IR index was calculated using the following formula:
HOMA-IR = [fasting glucose levels (mmol/L)] × [fasting serum insulin (mU/L)]/22.5. The glucose
tolerance test (GTT) and insulin tolerance test (ITT) were performed following intragastric glucose
administration and intraperitoneal insulin injection, respectively, after overnight starvation of the rats.
Blood samples were collected from the tail vein at 0, 15, 30, 60 and 120 min, and the glucose levels
were measured with a Glucose Meter (Roche Diagnostics, Shanghai, China).
2.3. Western Blot Analysis
Frozen gastrocnemius muscle, liver and adipose tissues were lysed in RIPA buffer (Beyotime
Biotechnology, Shanghai, China) supplemented with phosphatase inhibitors and PMSF (Roche, Ltd.,
Basel, Switzerland) before use. For the total MitoProfile Oxidative phosphorylation complexes
(OXPHOS) analysis, mitochondrial proteins were extracted from the gastrocnemius muscle according
to the manufacturer’s instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Protein concentrations were assayed using a bicinchoninic acid (BCA) kit (Beyotime Biotechnology,
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to polyvinylidene difluoride (PVDF) membranes. Information regarding the primary antibodies used
in this study is provided in Table S1. Protein bands were visualized with Molecular Imager VersaDoc
MP 4000 System (Bio-Rad, Berkeley, CA, USA).
2.4. Transmission Electron Microscopy
The mitochondrial morphology was investigated using electron microscopy. Briefly, gastrocnemius
muscles were isolated and fixed with 2.5% glutaraldehyde for 1 day. The muscles were washed and cut
longitudinally into 0.5 mm thick strips. Following osmification with 2% osmium tetroxide and 1% uranyl
acetate en bloc, the stained tissue was routinely dehydrated in a methanol gradient and embedded
in Eponate-12. After polymerization, the ultrastructural features of the mitochondria were observed
and photographed using a Tecnai G2 12 transmission electron microscope (FEI Company, Holland,
The Netherlands).
2.5. Quantitative Real-Time PCR Analysis
Total RNA was extracted from gastrocnemius muscles with Trizol reagent (Invitrogen, New York,
NY, USA) and reverse transcribed into cDNA using a high-capacity cDNA archive kit (Takara,
Dalian, China). Real-time PCR was performed using the StepOnePlusTM Real-Time PCR System
(Applied Biosystems, Grand Island, NY, USA) with the cDNA templates, gene-specific primers and
the SYBR Green qPCR Master mix (Takara, Dalian, China). Calculations were performed using
a comparative method (2−ΔΔCt), with GAPDH as the internal control. Total DNA was extracted
from the gastrocnemius muscles using acommercial kit (Tiangen Biotech Co., Ltd., Beijing, China),
according to the manufacturer’s instructions. The mitochondrial DNA (mtDNA) content was assessed
using RT-PCR by measuring the threshold cycle ratio of a mitochondria-encoded gene (COXII) to a
nucleus-encoded gene (β-globin). All RT-PCR experiments were performed in triplicate using the
same sample. The primer pairs for each gene are shown in Table S2.
2.6. Statistical Analysis
Unless otherwise stated, data are presented as means ± SD. Statistical analyses were performed
using the SPSS 15.0 software package (SPSS, Inc., Chicago, IL, USA). Significant differences were
assessed by student t test or one-way ANOVA followed by the Student-Newman-Keuls test. p < 0.05
were considered statistically significant.
2.7. Serum Preparation and Metabolite Profiling
A targetedLC-MS/MSbased analysis was performed in the State Key Laboratory of Quality
Research in Chinese Medicine at Macau University of Science and Technology and Beijing Mass
Spectrometry Medical Research Co., Ltd. Broad metabolite profiling of serum was performed using
LC-MS/MS (ACQUITYTM ultra-Performance LC (Waters, Milford, MA, USA) equipped with an AB
4000 Q-TRAP mass spectrometer (Applied Biosystems, Grand Island, NY, USA). Serum (200 μL) was
mixed with 200 μL of n-Ethylmaleimide (10 mol/L) in PBS buffer and 1000 μL of methanol containing
the internal standard L-phenylalanine-d5 (Phe-d5) at a concentration of 10 ng/mL. The mixture was
incubated at −20 ◦C for 20 min and centrifuged at 12,000 rpm for 10 min at 4 ◦C. The supernatant was
evaporated under a vacuum, and the dry residue was reconstituted with distilled water in preparation
for analysis.
In addition to the internal standards used for quality control, a quality control (QC) sample was
prepared and analyzed after every 10 serum samples. The blank serum used for QC was prepared
from serum that had been stripped of endogenous materials by adding 6 g of charcoal activated
powder (Sigma-Aldrich, St. Louis, MO, USA) to 100 mL of serum. This suspension was stirred at room
temperature for 2 h and centrifuged at 13,500 rpm for 20 min at 4 ◦C. Then, the supernatant was filtered
using a Millipore Express PES Membrane (Merck Millipore, Ltd., Hesse, Germany). The obtained
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For quantitative amino acid profiling, the LC-MS/MS analysis was performed on an UltiMate3000
(Dionex, Sunnyvale, CA, USA) equipped with an API 3200 Q TRAP MS System (Applied Biosystems,
Grand Island, NY, USA). The samples were thawed, extracted and derivatized before analysis. In detail,
after dilution with 80 μL of water, the sample was extracted with 500 μL of a mixture of methanol and
acetonitrile (1:9, v/v). The extraction procedure was performed at −20 ◦C for 10 min after 2 min of
vortexing and 1 min of ultrasonication. Then, the residue was re-dissolved in 100 μL of a mixture of
methanol and water (1:1, v/v) with 1 μg/mL of L-2-chlorophenylalanine, and the same steps were
repeated (vortexing, ultrasonication and centrifugation). The supernatant (80 μL) was transferred into
the sample vial for the analysis.
2.8. Metabolomics Data Processing and Multivariate Analysis
The pre-processed LC-MS/MS data were log-transformed, and the resulting data were analyzed
by orthogonal partial least squares projection to latent structure-discriminant analysis (OPLS-DA)
using SIMCA-P version 14.0 (Umetrics, Umea, Sweden). OPLS-DA was also used to identify and rank
signature metabolites that discriminated the different groups. Qualities of the OPLS-DA models were
assessed by R2 indicative of variation described by all components in the model and by Q2, measuring
the model ability to predict class membership.
Variables with a variable importance in the projection (VIP) score >1 were considered relevant
for group discrimination. Serum metabolite concentrations in HFD + Leu and HFD + CR rats at
different time points were compared with their age-matched HFD controls and significantly changed
metabolites were analyzed by One-way ANOVA. p value < 0.05 was considered statistically significant.
In addition, metabolic pathway interpretation of differential metabolites were performed using the
MetaboAnalyst 3.0 and KEGG database.
3. Results
3.1. Body Weight and Calorie Intake
As expected, HFD-fed rats exhibited a higher body weight than controls. However, HFD-induced
weight gain was significantly attenuated by CR or leucine supplementation from 3 or 13 weeks,
respectively. The rats supplemented with leucine had significantly higher body weight when compared
to CR rat from 7 weeks (Figure S1A). Consistent with our experimental design, the total calorie intake
of CR rats was reduced by 20% over the 32-week feeding period compared with that of HFD-fed rats.
Leucine addition to the high fat diet did not significantly alter calorie intake across all time points,
with the exception of a slight decrease during week 3 (Figure S1B). The average daily leucine intake in
ND, HFD, HFD + CR and HFD + Leu-fed rats were 0.68 g, 0.69 g, 0.54 g and 1.28 g, respectively.
3.2. Insulin Sensitivity
As shown in Figure 1A,B, the 24-week HFD did not alter fasting blood glucose but significantly
increased fasting serum insulin. Leucine addition to the HFD for 24 weeks had no obvious effects
on fasting serum glucose or insulin, but CR prevented the HFD-induced increase in fasting insulin.
Accordingly, the HOMA-IR index was unchanged in leucine-supplemented rats, but was decreased in
CR rats (Figure 1C). CR rats had lower insulin level and HOMA-IR than HFD + Leu rats at 24 weeks
(Figure 1B,C). After 32 weeks, both fasting blood glucose and insulin were elevated in HFD-fed rats
compared with ND-fed rats. HFD + Leu diet induced no significant effect on fast serum glucose
and insulin levels. CR largely prevented HFD-induced hyperglycaemia and hyperinsulinaemia
(Figure 1A,B). The HOMA-IR index was lower in rats treated with either leucine or CR than that in the
corresponding HFD-fed controls (Figure 1C), while the CR rats had lower glucose than HFD + Leu rats
at 32 weeks (Figure 1A). The results of the OGTT and ITT confirmed that CR or leucine-supplemented
rats were significantly more glucose-tolerant and insulin-sensitive than HFD-fed rats (Figure 1D–I) at
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in the skeletal muscle was increased in CR rats compared with the HFD-fed controls at both time
points (Figure 1J). However, leucine-induced AKT phosphorylation was only observed at 32 weeks.
The insulin-stimulated AKT phosphorylation protein expression in CR rats was higher than HFD + Leu
rats at week 24 (Figure 1J).
Figure 1. Leucine supplementation improved insulin sensitivity in HFD-fed rats. (A) Serum glucose
and (B) insulin levels were measured after overnight fasting. (C) HOMA-IR indices were calculated
from fasting glucose and insulin levels. (D,E) The intraperitoneal ITT (0.8 IU/kg.bw) and (G,H) OGTT
(2 g/kg.bw) were performed after overnight fasting at the end of 24 and 32 weeks, respectively. (F,I) The
area under the curve was calculated (n = 8). The results are presented as the mean ± SD. (J) AKT and
phospho-AKT (Ser473) protein levels in skeletal muscle before (insulin−) and after (insulin+) 2 IU/kg
insulin stimulation for 15 min were determined by immunoblotting (n = 3–6). * p < 0.05 versus ND-fed
rats, # p< 0.05 versus HFD-fed rats, & p < 0.05 versus HFD + CR rats. HFD: High fat diet; ND: Normal
chow diet; CR: Calorie restriction; ITT: Insulin tolerance test; OGTT: Oral glucose tolerance test; AKT:
Protein kinase B.
3.3. Serum Amino Acid Profiles
Over 24 weeks of feeding, serum concentrations of BCAAs (valine and leucine), glucogenogenic
amino acids (alanine, asparagine and glutamate), and gluconeogenic and ketogenic amino acids
(phenylalanine and tryptophan) were significantly lower in HFD-fed rats relative to ND control, While
the ketogenic amino acids (lysine) was significantly increased (Table 2). However, BCAA (except
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compared with those in HFD-fed rats. The concentrations of other amino acids, such as aromatic amino
acids (phenylalanine and tryptophan) and several gluconeogenic amino acids (asparagine, proline and
alanine), were also significantly elevated (Table 3).
Table 2. Amino acids profile in HFD rats.
Parameter 24 weeks 32 weeks
BCAAs
isoleucine 1.01 (0.93, 1.09) 0.97 (0.89, 1.06)
valine 0.62 (0.55, 0.70) * 1.04 (0.96, 1,11)
leucine 0.70 (0.56, 0.84) * 0.92 (0.84, 1.01)
Glucogenogenic amino acids
alanine 0.48 (0.37, 0.59) * 1.02 (0.89, 1.16)
asparagine 0.72 (0.65, 0.80) * 1.36 (1.14, 1.59) *
aspartic acid 1.01 (0.60, 1.43) 1.01 (0.83, 1.20)
cysteine 1.06 (0.92, 1.20) 1.33 (1.24, 1.42) *
glutamate 0.79 (0.69, 0.90) * 1.65 (1.38, 1.92) *
glutamine 1.04 (0.98, 1.10) 1.08 (1.02, 1.14)
glycine 1.46 (1.24, 1.68) 0.94 (0.83, 1.05)
histidine 1.02 (0.95, 1.09) 0.83 (0.77, 0.88) *
methionine 1.01 (0.93, 1.08) 1.09 (0.94, 1.24)
proline 0.91 (0.84, 0.99) 1.23 (1.06, 1.41) *
serine 1.23 (1.04, 1.42) 1.08 (1.02, 1.15)
arginine 1.19 (1.06, 1.32) 0.95 (0.83, 1.08)
Gluconeogenic and ketogenic amino acids
phenylalanine 0.54 (0.48, 0.59) * 1.10 (0.94, 1.25)
threonine 1.05 (0.95, 1.15) 1.34 (1.25, 1.42) *
tryptophan 0.76 (0.68, 0.85) * 0.90 (0.83, 0.98)
tyrosine 1.12 (0.95, 1.29) 0.89 (0.82, 0.96)
Ketogenic amino acids
lysine 1.37 (1.20, 1.54) * 1.46 (1.21, 1.71) *
Data were expressed as mean fold difference (95% CI) of HFD-fed rats relative to their corresponding ND-fed
controls at week 24 and 32, respectively (n = 8). * p < 0.05 versus age-matched ND controls. HFD: High-fat diet; ND:
Normal chow diet; CR: Calorie restriction; BCAAs, branched-chain amino acids.
At week 32, serum BCAA levels were not significantly changed in HFD rats compared to
corresponding controls, but glucogenogenic amino acids (asparagine, cysteine, glutamate and
proline), gluconeogenic and ketogenic amino acids (threonine) and ketogenic amino acid lysine
were significantly increased (Table 2). However, after 32 weeks of leucine treatment, serum BCAA
and aromatic amino acid levels did not significantly differ, whereas asparagine and glycine were
significantly reduced and proline was increased. The concentrations of most amino acids in CR rats
were reduced at week 24 compared with those in HFD controls, but the observed differences were not
statistically significant (except for leucine, isoleucine, alanine, phenylalanine and lysine). However,
CR-induced alterations in serum amino acid concentrations were not remarkable at 32 weeks, but
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Table 3. Amino acids profile.
24 weeks 32 weeks
Parameter CR HFD + Leu CR HFD + Leu
BCAAs
isoleucine 0.82 (0.76, 0.88) * 0.91 (0.84, 0.98) 0.88 (0.79, 0.96) 0.94 (0.77, 1.11)
valine 0.91 (0.86, 0.96) 1.38 (1.18, 1.58) * 0.94 (0.85, 1.03) 0.95 (0.74, 1.15)
leucine 0.85 (0.79, 0.91) * 1.43 (1.02, 1.84) * 0.91 (0.84, 0.98) 0.98 (0.69, 1.27)
Glucogenogenic amino acids
alanine 0.79 (0.71, 0.87) * 1.49 (1.34, 1.65) * 1.29 (1.02, 1.56) * 0.92 (0.71, 1.12)
asparagine 0.91 (0.76, 1.06) 1.49 (1.25, 1.72) * 0.90 (0.73, 1.06) 0.79 (0.60, 0.98) *
aspartic acid 0.93 (0.82, 1.03) 0.91 (0.74, 1.08) 1.08 (0.96, 1.20) 1.14 (0.97, 1.31)
cysteine 1.19 (1.08, 1.30) * 0.96 (0.85, 1.08) 1.09 (0.93, 1.25) 0.93 (0.77, 1.08)
glutamate 0.93 (0.80, 1.07) 1.07 (0.92, 1.23) 1.08 (0.86, 1.31) 1.00 (0.83, 1.17)
glutamine 0.93 (0.85, 1.01) 0.92 (0.84, 1.00) 1.03 (0.88, 1.18) 1.06 (0.91, 1.21)
glycine 0.96 (0.90, 1.03) 0.95 (0.91, 0.99) 0.89 (0.81, 0.98) 0.82 (0.71, 0.93) *
histidine 0.98 (0.90, 1.05) 0.97 (0.83, 1.11) 1.09 (0.98, 1.20) 1.05 (0.92, 1.18)
methionine 0.94 (0.86, 1.03) 1.01 (0.94, 1.08) 0.94 (0.86, 1.02) 0.97 (0.89, 1.04)
proline 1.04 (0.80, 1.29) 1.28 (1.00, 1.57) * 1.24 (1.00, 1.49) * 1.27 (1.02, 1.52) *
serine 0.98 (0.91, 1.04) 0.92 (0.85, 0.98) 1.08 (0.98, 1.18) 0.95 (0.84, 1.05)
arginine 0.86 (0.82, 0.91) 0.98 (0.84, 1.12) 1.08 (1.00, 1.15) 1.16 (0.96, 1.36)
Gluconeogenic and ketogenic amino acids
phenylalanine 0.89 (0.83, 0.95) * 1.35 (1.20, 1.50) * 0.94 (0.90, 0.97) 1.07 (0.91, 1.21)
threonine 1.17 (1.05, 1.29) 0.92 (0.81, 1.02) 1.08 (0.92, 1.25) 1.09 (0.97, 1.21)
tryptophan 1.00 (0.69, 1.31) 1.43 (1.17, 1.69) * 1.22 (0.94, 1.50) 0.97 (0.77, 1.16)
tyrosine 0.87 (0.71, 1.04) 1.00 (0.87, 1.14) 1.08 (0.92, 1.25) 1.09 (0.97, 1.21)
Ketogenic amino acids
lysine 0.82 (0.74, 0.90) * 0.65 (0.55, 0.74) * 0.90 (0.75, 1.06) 0.99(0.79, 1.19)
Data were expressed as mean fold difference (95% CI) of HFD + Leu and HFD + CR rats relative to their
corresponding HFD control at week 24 and 32, respectively (n = 8). * p < 0.05 versus age-matched HFD controls.
HFD: High-fat diet; CR: Calorie restriction.
3.4. Serum Metabolic Profiles
An LC-MS/MS-based metabolic approach was used to obtain more insights into the mechanisms
underlying the different effects of leucine supplementation on insulin resistance. OPLS-DA model
was carried out for ND, HFD, HFD + Leu and HFD + CR groups at week 24 and 32, respectively, and
the R2 and Q2 values confirmed good qualities for all models (Figure 2A,B). The score plots for each
model showed clear separation among the different groups suggesting they had different metabolic
features at different pathological stages of HFD induced insulin resistance.
The metabolites detected in the serum were almost decreased in HFD-fed rats compared to
the ND controls at week 24. Prominent decreases were observed for metabolites from amino
acids including aromatic amino acid catabolites (5-hydroxytryptophan, 4,6-dihydroxyquinoline, and
L-kynurenine), methionine catabolites (spermidine and S-adenosylhomocysteine) and nitrogenous
compounds derived from amino acid catabolism (creatinine, Creatine, and uridine), fatty acid
metabolites (3-hydroxybutyric, Acetylcarnitine and Carnitine), tricarboxylic acid (TCA) cycle
intermediates (Fumaric acid and a-Ketoglutaric acid), bile acid metabolites (Ursodeoxycholic acid,
Glycochenodeoxycholic acid) and some lysophosphatidylcholines (LPCs). However, fatty acid
metabolism (palmitic acid) and TCA intermediate (malic acid) were marked elevated (Table 4).
The serum metabolites that discriminated between leucine-supplemented and HFD-fed rats were
primarily involved in the TCA cycle, fatty acid, bile acid and amino acid metabolism (Table 5).
Specifically, the serum levels ofTCA intermediates (fumaric acid, malic acid and α-ketoglutarate) and
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and 3-hydroxybutyrate) were markedly higher in leucine-treated rats than in HFD-fed controls at
week 24.
Figure 2. Orthogonal partial least squares projection to latent structure-discriminant analysis
(OPLS-DA) score plots displaying the separation of the ND-fed, HFD-fed, Calorie-restricted and
HFD + leurats after (A) 24 and (B) 32 weeks of treatment. Model parameters: (A) R2X = 0.944,
Q2 = 0.424; (B) R2X = 0.938, Q2 = 0.652.HFD: High-fat diet; ND: Normal chow diet.
Table 4. Fold difference of serum metabolites significantly changed in HFD rats relative to the
corresponding ND controls.
Metabolites 24 weeks 32 weeks
Amino acids derivatives
L-Kynurenine 0.72 (0.64, 0.79) * 1.09 (0.87, 1.31)
5-hydroxytryptophan 0.55 (0.44, 0.66) * 1.11 (0.93, 1.29) *
Spermidine 0.52 (0.48, 0.57) * 1.26 (1.10, 1.42)
2-hydroxyisobutyrate 0.86 (0.77, 0.95) 2.23 (1.87, 2.59) *
2-hydroxyglutarate 0.55 (0.47, 0.62) * 1.37 (1.20, 1.54) *
S-(adenosyl)-L-homocysteine 0.49 (0.41, 0.58) * 1.28 (0.96, 1.60)
4,6-dihydroxyquinoline 0.55 (0.49, 0.62) * 1.20 (0.93, 1.46)
Creatinine 0.43 (0.33, 0.54) * 1.19 (0.98, 1.40)
Creatine 0.41 (0.31, 0.52) * 1.34 (1.04, 1.64) *
Uridine 0.39 (0.25, 0.52) * 1.36 (1.17, 1.54) *
Fatty acid metabolism
3-hydroxybutyric 0.77 (0.70, 0.85) * 1.92 (1.56, 2.27) *
Palmitic acid 3.92 (3.25, 4.59) * 1.53 (0.93, 2.12)
Acetylcarnitine 0.70 (0.64, 0.77) * 1.02 (0.84, 1.19)
Palmitoyl-L-carnitine 0.91 (0.75, 1.08) 1.48 (1.11, 1.86)
Carnitine 0.46 (0.38, 0.54) * 1.04 (0.68, 1.41)
Phospholipids
Lysophosphatidylcholine (C18:1) 0.50 (0.43, 0.57) * 1.18 (0.99, 1.37)
Lysophosphatidylcholine (C16:1) 0.38 (0.34, 0.41) * 0.99 (0.82, 1.16)
Lysophosphatidylcholine (C16:0) 0.65 (0.58, 0.72) * 0.97 (0.83, 1.12)
Lysophosphatidylcholine (C20:4) 0.16 (0.12, 0.20) * 1.21 (0.94, 1.48)
TCA cycle intermediates
Fumaric acid 0.82 (0.74, 0.89) * 1.12 (0.93, 1.31)
Malic acid 3.54 (2.81, 4.27) * 1.23 (1.07, 1.39) *
Citric acid 0.91 (0.80, 1.03) 1.22 (1.10, 1.34) *
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Table 4. Cont.
Metabolites 24 weeks 32 weeks
Bile acid metabolism
Ursodeoxycholic acid 0.28 (0.19, 0.38) * 1.15 (0.73, 1.56)
Glycochenodeoxycholic acid 0.32 (0.28, 0.35) * 0.73 (0.60, 0.86)
Glycocholic acid 0.71 (0.13, 1.28) 0.65 (0.22, 1.08)
Purine metabolism
Xanthosine 0.71 (0.46, 0.96) 0.93 (0.71, 1.16)
Allantoin 0.42 (0.33, 0.50) * 1.00 (0.85, 1.14)
Uric acid 0.88 (0.77, 0.98) 1.10 (0.95, 1.25)
Xanthine 0.83 (0.56, 1.09) 1.00 (0.71, 1.29)
Data were expressed as mean fold difference (95% Confidence Interval) of HFD-fed rats relative to their
corresponding ND controls at week 24 and 32, respectively (n = 8). * p < 0.05 versus age-matched ND controls. HFD:
High fat diet; ND: Normal chow diet; TCA, tricarboxylic acid.
Table 5. Fold difference of serum metabolites significantly changed in HFD + CR or HFD + Leu rats
relative to the corresponding HFD-fed controls.
24 weeks 32 weeks
Metabolites HFD + CR HFD + Leu HFD + CR HFD + Leu
Amino acids derivatives
L-Kynurenine 1.30 (0.66, 1.95) 1.70 (1.23, 2.19) * 1.10 (0.43, 1.78) 1.10 (0.81, 1.39)
5-hydroxytryptophan 1.10 (0.96, 1.25) 1.58 (1.16, 1.92) * 1.29 (0.82, 1.76) 1.43 (1.07, 1.79) *
Spermidine 1.17 (1.02, 1.33) * 1.43 (1.26, 1.60) * 1.18 (1.04, 1.32) * 1.05 (0.89, 1.21)
2-hydroxyisobutyrate 0.90 (0.70, 1.10) 1.54 (1.26, 1.81) * 0.82 (0.56, 1.09) 0.67 (0.38, 0.95) *
2-hydroxyglutarate 0.88 (0.73, 1.03) 1.71 (1.50, 1.92) * 1.07 (0.86, 1.28) 1.01 (0.86, 1.16)
S-(adenosyl)-L-homocysteine 1.24 (0.87, 1.60) 1.57 (1.28, 1.86) * 1.51 (1.20, 1.83) * 1.34 (1.03, 1.66) *
4,6-dihydroxyquinoline 1.54 (1.21, 1.87) * 1.81 (1.56, 2.06) * 1.50 (1.17, 1.82) * 0.90(0.75, 1.05)
Creatinine 1.31 (1.19, 1.43) * 1.50 (1.36, 1.64) * 1.14 (0.91, 1.37) 1.16 (0.91, 1.40)
Creatine 0.91 (0.76, 1.06) 1.33 (0.99, 1.68) 1.04 (0.70, 1.37) 1.71 (1.34, 2.08) *
Uridine 1.32 (0.93, 1.72) 1.61 (1.37, 1.85* 1.02 (0.88, 1.17) 0.92 (0.68, 1.17)
Fatty acid metabolism
3-hydroxybutyric 0.92 (0.71, 1.13) 1.36 (1.13, 1.59) * 0.92 (0.60, 1.24) 0.91 (0.48, 1.33)
Palmitic acid 1.28 (1.03, 1.53) * 1.81 (1.47, 2.15) * 1.55 (1.17, 1.94) * 0.54 (0.38, 0.70) *
Acetylcarnitine 1.12 (0.96, 1.30) 1.34 (1.21, 1.48) * 1.15 (0.92, 1.39) 0.87 (0.67, 1.07)
Palmitoyl-L-carnitine 1.17 (0.97, 1.37) 1.90 (1.54, 2.26) * 0.99 (0.59, 1.40) 0.49 (0.39, 0.58) *
Carnitine 1.29 (1.09, 1.48) * 1.86 (1.46, 2.26) * 1.28 (1.09, 1.47) 1.04 (0.93, 1.15)
Phospholipids
Lysophosphatidylcholine (C18:1) 1.35 (1.13, 1.56) * 1.42 (1.19, 1.65) * 1.55 (1.19, 1.90) * 1.49 (1.14, 1.83) *
Lysophosphatidylcholine (C16:1) 1.40 (1.15, 1.64) * 1.42 (1.23, 1.60) * 1.41 (1.00, 1.83) * 0.91 (0.71, 1.10)
Lysophosphatidylcholine(C16:0) 1.20 (1.05, 1.36) * 1.34 (1.18, 1.49) * 1.31 (1.13, 1.48) * 1.21 (1.03, 1.40) *
Lysophosphatidylcholine (C20:4) 1.06 (0.87, 1.25) 1.04 (0.77, 1.30) 0.87 (0.50, 1.24) 3.82 (3.23, 4.41) *
TCA cycle intermediates
Fumaric acid 1.09 (0.93, 1.24) 1.23 (1.08, 1.38) * 1.09 (0.96, 1.22) 0.82 (0.72, 0.93) *
Malic acid 0.87 (0.74, 1.00) 1.33 (1.11, 1.55) * 0.97 (0.48, 1.47) 0.15 (0.09, 0.22) *
Citric acid 1.02 (0.90, 1.15) 1.18 (0.97, 1.39) 0.94 (0.77, 1.11) 0.86 (0.74, 0.97) *
a-Ketoglutaric acid 0.95 (0.80, 1.09) 1.32 (1.13, 1.50) * 1.23 (1.00, 1.47) 1.05 (0.85, 1.25)
Bile acid metabolism
Ursodeoxycholic acid 1.57 (0.96, 2.19) 2.58 (1.91, 3.24) * 1.37 (1.06, 1.68) * 1.35 (1.08, 1.61) *
Glycochenodeoxycholic acid 1.45 (1.19, 1.71) * 1.26 (0.92, 1.60) 1.63 (1.13, 2.13) * 1.43 (1.19, 1.66) *
Glycocholic acid 2.20 (1.04, 3.36) * 4.17 (0.60, 7.74) 3.17 (1.08, 5.27) * 3.76 (1.45, 6.07) *
Purine metabolism
Xanthosine 0.90 (0.63, 1.18) 1.20 (0.77, 1.62) 1.49 (1.13, 1.85) * 1.05 (0.90, 1.19)
Allantoin 1.05 (0.86, 1.24) 1.33 (1.00, 1.66) * 1.27 (1.04, 1.50) * 1.41 (1.23, 1.59) *
Uric acid 0.91 (0.77, 1.05) 1.24 (1.07, 1.41) * 1.08 (0.93, 1.23) 0.90 (0.83, 0.96)
Xanthine 1.05 (0.55, 1.55) 1.26 (0.76, 1.76) 1.71(1.38, 2.02) * 1.12 (0.96, 1.27)
Data were expressed as mean fold difference (95% Confidence Interval) of HFD + Leu and HFD + CR rats relative
to their corresponding HFD controls at week 24 and 32, respectively (n = 8). * p < 0.05 versus age-matched HFD
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The amino acid derivatives (5-hydroxytryptophan, 2-hydroxyisobutyrate, 2-hydroxyglutarate,
Creatine and Uridine), fatty acid metabolites (3-hydroxybutyric), TCA cycle intermediates (Malic acid,
Citric acid) were significantly elevated after 32 weeks of HFD feeding relative to the age-matched ND
control (Table 4). Notably, we observed sharp decreases in the levels of TCA intermediates (fumaric
acid, malic acid and citric acid) and lipid-related metabolites (palmitoyl-L-carnitine and palmitic acid)
at week 32 relative to HFD-fed controls (Table 5).
In addition, leucine supplementation for 24 weeks contributed to the accumulation of
metabolites associated with amino acid catabolism, including aromatic amino acid catabolites
(5-hydroxytryptophan, 4,6-dihydroxyquinoline, and L-kynurenine), methionine catabolites
(spermidine and S-adenosylhomocysteine) and nitrogenous compounds derived from amino acid
catabolism (creatinine, uric acid, and uridine).In contrast, at week 32, the levels of amino acid
catabolites that discriminated the leucine group from the HFD-fed controls were reduced. Moreover,
prominentincreases in bile acid metabolites and some lysophosphatidylcholines (LPCs) were detected
at both 24 and 32 weeks (Table 5).
Metabolites related to lipid metabolism (palmitic acid and LPCs), bile acid metabolism
(glycochenodeoxycholic acid and glycocholic acid) and some amino acid catabolites were significantly
elevated at week 24 and 32 in CR rats compared with the corresponding HFD-fed controls (Table 5).
3.5. BCAA Catabolizing Enzymes and Metabolites
HFD feeding for 24 weeks, the levels of transamination products of BCAAs— branched-chain
α-keto acids (BCKAs)—did not change significantly compared with ND-fed control at 24 weeks
(Figure 3B). Mitochondrial branched-chain aminotransferase (BCATm) protein expression in
skeletal muscle and adipose tissue were both significantly increased. Branched-chain α-keto acid
dehydrogenase kinase (BCKDK) protein expression in HFD rats was lower in skeletal muscle, while
higher in adipose tissue than ND controls (Figure 4A–C). BCATm protein expression was significantly
increased in skeletal muscle and adipose tissue, concurrent with a significant increase in BCKDKandno
change in branched-chain α-keto acid dehydrogenase E1 α (BCKDHE1α) in skeletal muscles, livers
and adipose tissues of leucine-supplemented rats, compared with those of HFD-fed controls at week
24 (Figure 4A–C). Furthermore, the levels of transamination products of leucine (α-Ketoisocaproate,
KIC) were also increased (Figure 3B).
Figure 3. Leucine supplementation-induced alterations in the levels of BCAA derivatives. (A) Serum
levels of short-chain acylcarnitines (C3 and C5) and (B,C) Branched-chain α-keto acids (BCKAs) (n = 8).
The results are presented as means ± SD. * p < 0.05 versus ND-fed rats, # p < 0.05 versus HFD-fed rats,
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Figure 4. Leucine supplementation-induced alterations in BCAA catabolic enzyme protein expression.
Representative immunoblots of total mBCAT, BCKDHE1α and BCKDK protein levels in skeletal
muscle (A,D), adipose tissue (B,E) and liver (C,F); n = 6. The results are presented as the mean ± SD.
* p < 0.05 versus ND-fed rats, # p < 0.05 versus HFD-fed rats, & p < 0.05 versus HFD + CR rats.
mBCAT: Mitochondrial branched-chain aminotransferase; BCKDHE1α: Branched-chain α-keto acid
dehydrogenase E1 α; BCKDK: Branched-chain α-keto acid dehydrogenase kinase, HFD: High fat diet;
ND: Normal chow diet; CR: Calorie restriction.
However, HFD feeding for 32 weeks led to significantly increase in the levels of transamination
products of leucine (α-Ketoisocaproate, KIC) and transamination products of valine (α-Ketoisovalerate,
KIV) compared to corresponding ND control (Figure 3C). BCATm and BCKDK protein expression
were significantly elevated, but BCKDHE1αprotein expression was significantly decreased in skeletal
muscle. In addition, BCATm protein expression in adipose tissue was significantly decreased compared
with ND-fed control at 32 weeks (Figure 4D–F). In contrast, the only changes observed in the
levels of BCAA catabolizing enzymes and metabolites were an increased expression of BCATm
in adipose tissue (Figure 4D–F) and increased isoleucine-derived KMV (α-Keto-β-methylvalerate,
KMV) levels compared to the HFD-fed controls after 32 weeks of leucine supplementation (Figure 3C).
BCAA-catabolizing enzyme protein expression did not significantly differ between CR rats and
HFD-fed controls at week 24 (Figure 4A–C). However, BCATm and BCKDK protein expression was
significantly decreased, whereas BCKDHE1α expression was significantly increased in skeletal muscle
in CR rats at week 32 compared to the HFD-fed controls (Figure 4D–F). Notably, neither leucine
supplementation nor CR had a significant impact on serum BCAA-derived short-chain acylcarnitine
(C3 and C5) levels throughout the experiment (Figure 3A).
3.6. Mitochondrial Properties
Long-term HFD feeding-induced mitochondrial structural damage was exacerbated by leucine
supplementation at 24 weeks (Figure 5A). Mitochondrial function was also impaired, as indicated by
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The expression of genes controlling mitochondrial biogenesis, including mitochondrial transcription
factor A (TFAM), peroxisome proliferator-activated receptor γ coactivator-1-α (PGC-1α) and sirtuin 1
(SIRT1), were greatly decreased (Figure 5F) in HFD + Leurats at this time point. In contrast, HFD-induced
mitochondrial damage was partially restored by leucine supplementation at 32 weeks (Figure 5A),
accompanied by increases in the mtDNA content (Figure 5E), the expression of genes involved in
mitochondrial biogenesis (TFAM) (Figure 5G) and ATP production (Figure 5D). As expected, CR
ameliorated HFD-induced mitochondrial damage at both time points. At week 24, CR enhanced
expression of enzymes involved in OXPHOS, and the gene expression related to mitochondrial biogenesis
(TFAM, NRF-1, PGC-1α and SIRT1) (Figure 5B,F). At week 32, CR-induced mitochondrial biogenesis
was not greatly changed, but ATP production was significantly increasedcompared to HFD controls
(Figure 5D,E,G). CR exhibited better effects on improving HFD-induced mitochondrial damage at week
24 as demonstrated by increases in OXPHOS protein levels (Figure 5B), ATP production (Figure 5D), and
mitochondrial biogenesis compared to leucine supplementation (Figure 5F).
Figure 5. Leucine supplementation-induced alterations in mitochondrial properties. (A) Transmission
electronic microscopy (×20,000) of the mitochondrial ultrastructure in skeletal muscle (n = 4).
(B,C) Protein expression of Oxidative phosphorylation complexes (OXPHOS) complexes I to V in
the electron transport chain in skeletal muscle were analyzed by western blotting (n = 6). (D) Serum
ATP levels (n = 8). (E) Mitochondrial DNA (mtDNA) copy number (n = 6). (F,G) Expression of
mitochondrial biogenesis-related genes (n = 6). The results are presented as the mean ± SD. * p < 0.05
versus ND-fed rats, # p < 0.05 versus HFD-fed rats, & p < 0.05 versus HFD + CR rats. ND: Normal
chow diet; HFD: High fat diet; CR: Calorie restriction.
4. Discussion and Conclusions
The effects of BCAA (especially leucine) supplementation on insulin resistance remains
elusive. Numerous studies have shown that leucine supplementation may prevent HFD-induced
obesity [1,2,20], modulate glucose metabolism [21,22] and improve insulin sensitivity in rodent models.
However, Newgard et al. suggested that excess BCAAs could contribute to development of insulin
resistance, at least under conditions of high fat feeding or elevated tissue fatty acid availability [7].
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Exactly how leucine exerts effects on insulin resistance is complex, and may depend on the study
design, dietary composition, the animal models typically used and the BCAA concentrations, duration
and form of administration. Recently, it has been supposed that BCAAs can trigger different and
even opposite effects, depending on the catabolic and anabolic state of the organisms [17]. Given the
different metabolic signature in the progression of T2DM, and leucine’s ability to stimulate both
anabolic and catabolic processes [23], we applied an integrative, time-resolved approach to gain a
deeper understanding the effects of leucine supplementation in the complexity of the disease on BCAA
metabolism, mitochondrial properties and metabolic profiling. Several interesting and important
findings were obtained.
In the present study, HFD feeding induced hyperinsulinaemia at 24 weeks. During this period,
the rats became increasingly obese, and exhibited lower concentrations of amino acids and related
metabolites, fatty acid metabolites and TCA intermediates compared to corresponding ND controls.
Studies have shown that insulin signaling functions at an increased basal level in the presence of
insulin resistance and hyperinsulinaemia [24,25]. Compensatory increased insulin secretion response
to overnutrition may slow fat oxidation and promote anabolism (syntheses of glycogen, proteins,
and fats), leading to body weight gain and glucose homeostasis. In contrast, after HFD feeding for
32 weeks, the rats progressively developed hyperglycaemia. The increased insulin level could not
maintain glucose at normal levels, and was accompanied by elevated levels of amino acids and related
metabolites, fatty acid metabolites and TCA intermediates relative to corresponding ND-fed rats.
These data suggested that at this stage the anabolic response to hyperinsulinaemia was blunted, HFD
rats were transition from predominantly anabolic condition to predominantly catabolic condition.
The effect of supplementation of HFD with leucine was examined in these two different metabolic
conditions, respectively. Our results indicated that doubling dietary leucine globally improved
HFD-induced insulin resistance but caused different changes in BCAA catabolism in rats with
hyperinsulinaemia or hyperglycaemia. These results seem inconsistent with the finding that elevated
circulation of BCAAs and related metabolites promotes insulin resistance, particularly in response to
HFD feeding [5,7]. Leucine supplementation ameliorated HFD-induced insulin resistance to different
extents at the two time points, as indicated by the improved HOMA-IR values, insulin tolerance
and glucose tolerance. Interestingly, this leucine-induced elevation in insulin sensitivity may not be
correlated with changes in serum BCAAs, which were increased in HFD + Leu rats at 24 weeks and
unaltered at 32 weeks compared with those in HFD-fed rats.
Recent metabolomic, proteomic and genomic studies have suggested that altered BCAA
catabolism contributes to elevated BCAAs [14,26,27]. The enzymes involved in the first two steps
of the BCAA catabolic pathway, BCATm and Branched-chain α-keto acid dehydrogenase (BCKDH),
were examined in the present study. Leucine supplementation increased BCATm protein expression
in adipose tissue and skeletal muscle at 24 weeks, suggesting a substrate-induced effect of increased
dietary BCAAs (~70% increase for three BCAAs) compared with that in HFD-fed rats. No differences
were observed in protein expression of BCKDHE1α, whereas that of BCKDK, a kinase that inactivates
BCKDH by phosphorylating the subunit E1α, was increased in observed tissues, including skeletal
muscle, liver and adipose tissues. BCKDK participates in a key mechanism for the nutritional and
hormonal regulation of BCAA oxidative flux [28,29], and its expression is increased by insulin [30].
This potentially impaired BCKD activity may contribute to the accumulation of BCKAs, such as KIC, in
leucine-supplemented rats during the early stage of insulin resistance, which was characterized
by hyperinsulinaemia in the present study. Following the progression of insulin resistance to
hyperglycaemia, no significant leucine-induced alterations were observed in serum BCAAs or
BCAA-catabolizing enzyme levels, with the exception of increased BCATm in adipose tissue. This tight
regulation of BCAA catabolism suggests that an elegant method exists for increasing the degradation
of BCAAs when they are present in excess and sparing them [31] when they are needed for anabolic or
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In addition to alterations in BCAA catabolism, we identified several leucine-associated changes
in TCA cycle intermediates, lipids and other amino acid metabolites in rats with hyperinsulinaemia
or hyperglycaemia. Leucine-induced alterations in serum amino acid concentrations at 24 weeks
included increased aromatic amino acid (phenylalanine and tryptophan), alanine and asparagine
levels, which may have occurred because BCAAs share a competitive transport system with aromatic
amino acids [32]. In addition, BCAA transamination provides a nitrogen source for the synthesis
of other dispensable amino acids. The levels of almost all amino acid catabolites investigated in
the present study were increased in leucine-supplemented rats at 24 weeks, but were unaltered or
decreased at 32 weeks, compared with those in HFD-fed controls. It is noteworthy that various
factors affect serum amino acid concentrations, including protein turnover (protein synthesis and
degradation), and the metabolism of individual amino acids. The exact mechanisms by which leucine
supplementation affect the levels of amino acids and their metabolites at different stage of insulin
resistance are still unknown, and warrant further study.
Acylcarnitines are intermediates of fatty acid oxidation, and accumulate as a consequence of
the metabolic dysfunction resulting from the insufficient integration between β-oxidation and the
TCA cycle [33–35]. Elevated BCAAs in a lipotoxic environment have been proposed to induce
the accumulation of BCAA-derived acylcarnitines and incompletely oxidized lipid species [5,7].
In HFD-induced hyperinsulinaemic rats in the present study, leucine supplementation caused increases
in acylcarnitine species (carnitine, acylcarnitine and palmitoyl-L-carnitine), but no remarkable changes
in BCAA-derived short-chain acylcarnitines (C3 and C5). However, TCA cycle intermediates were
significantly elevated, reflecting an early compensatory response to substrate overload. Accumulated
by-products of BCAA transamination are catabolized to BCAA-related acetyl-CoAs, ketones and
other intermediates, leading to competitive inhibition of lipid-derived acetyl-CoA entry into the
TCA cycle [36–38]; in turn, this process may reduce fatty acid oxidation and induce acylcarnitine
accumulation and ketogenesis, as indicated by the results (Table 3). Interestingly, as insulin resistance
progressed, leucine promoted reductions in the accumulation of serum acylcarnitine species and
levels of multiple TCA cycle intermediates at 32 weeks compared with those in age-matched HFD-fed
controls.Skeletal muscle serves as a major reservoir of free carnitine and is thought to be a principal
contributor to the serum acylcarnitine pool. The accumulation of acylcarnitine species is mitotoxic and
promotes mitochondrial dysfunction. The above-mentioned alterations in the metabolic phenotype
might be correlated with changes in skeletal muscle mitochondrial properties. Consistent with
this hypothesis, the HFD + Leu treatment caused increased mitochondrial damage, accompanied
by decreases in mitochondrial biogenesis, ATP production and mitochondrial oxidative enzyme
levels in skeletal muscle compared with those in HFD-fed controls.These data were seemingly
in conflict with the favorable effects of leucine on overall insulin sensitivity at this stage. It is
well-known that insulin resistance is associated with mitochondrial dysfunction, but the causality
of this association is controversial. More recent findings suggest that mitochondrial dysfunction is
not an early event in the development of insulin resistance [39], but rather an adaptation to excess
nutrients [40,41]. Skeletal muscle is the initial site for most BCAA catabolism and major insulin-target
tissue. Thus, at this stage, improved insulin sensitivity by leucine supplementation may facilitate
both the anabolic effects of insulin and the adaptive catabolic effects of “nutrient overload” in skeletal
muscle under the background of a HFD, leading to an impaired mitochondrial function. Notably, the
HFD-induced mitochondrial damage was relieved and mitochondrial biogenesis was increased by
leucine supplementation after 32 weeks. These results are consistent with previous studies reporting
that leucine supplementation increases mitochondrial biogenesis while simultaneously enhancing
lipid oxidation [42–44], leading to the reduced accumulation of acylcarnitine species. Therefore, we
speculate that BCAAs are primarily used for anabolism at this stage; thus, BCAAs and their derivatives
that flow into the mitochondria are decreased. This hypothesis is consistent with our observations of
decreased levels of TCA cycle intermediates and no obvious changes in BCAAs and amino acids related
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improved mitochondrial function, leading to increased ATP production. Thus, altered mitochondrial
function may partly account for the improvement in skeletal muscle insulin sensitivity. Moreover, Li et
al. observed that in HFD-induced obese mice, leucine supplementation prevented obesity and insulin
resistance in association with attenuation of mitochondrial dysfunction [45].
Taken together, these results indicated that abnormal BCAA metabolism induced by dietary
supplementation coupled with HFD intake might lead to the accumulation of BCKAs and incompletely
oxidized lipid species, which contributed to mitochondrial dysfunction in skeletal muscle during the
early stage of insulin resistance (24 weeks). In contrast, during the hyperglycaemic stage (32 weeks),
when catabolic processes predominate, leucine supplementation enhanced mitochondrial biogenesis,
with concomitantly improved lipid oxidation and mitochondrial function in skeletal muscle (Figure 6).
Figure 6. Summary of the possible metabolic alterations induced by leucine supplementation at the
different stage of insulin resistance in high-fat diet-fed rats. The red arrows indicate the changes
observed at 24 weeks, whereas the blue arrows represent the changes observed at 32 weeks compared
with the age-matched high-fat diet-fed controls. The up-arrows indicate an increase in concentration;
the down-arrows indicate a decrease in concentration; the dotted lines indicate no significant change
in concentration.
CR without malnutrition has long been considered an effective strategy for protecting
againstage-associated disorders by modulating mitochondrial biogenesis and activating the reactive
oxygen species defense system [46–48]. However, long-term CR is hard for compliance and its
possible disadvantages remain to be determined, particularly in the elderly [49]. There has been
a growing interest in developing dietary strategies that mimic the beneficial effects of CR. Dietary
supplementation with BCAAs has been shown to improve mitochondrial biogenensis and prevent
oxidative damage in middle-aged mice [4,16]. In this study, both CR and leucine supplementation
improved HFD-induced insulin resistance, but they differently modulated mitochondrial properties
at the different stage of insulin resistance. At the hyperinsulinaemia stage, CR improved skeletal
muscle mitochondrial biogenesis and function in HFD rats. However, leucine supplementation
increased metabolic overload in mitochondria of skeletal muscle accompanied by impaired
mitochondrial biogenesis and function. Interestingly, at the hyperglycaemic stage, both CR and
leucine supplementationalleviate the HFD-induced mitochondrial damage, whereas HFD + Leu
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Our study has several limitations. First, T2DM progression and development are long-term
processes, with different metabolic characteristics at different stages. Our animal studies only revealed
alterations at two time points; thus, they may not reflect the total metabolic changes associated with
leucine supplementation. Second, the metabolites detected in our study were limited and we only
observed the skeletal muscle’s response to leucine supplementation, further investigation should use
untargeted metabolomic analysis to capture a large number of differences in metabolite levels and
metabolic responses in multiple organs to improve our understanding of the relevant mechanisms.
Third, our data demonstrated that the effects of leucine supplementation on insulin resistance were
associated with the metabolic condition of the organisms, but the metabolic conditions of HFD rats in
the progression of insulin resistance were mainly estimated by the serum metabolites in the present
study;this should be further verified by other experiments.
To our knowledge, this study is the first to report that leucine exerts different effects during
different stages of insulin resistance in a diet-induced animal model, depending on the prevalence
of catabolic and anabolic signals in the organism [17]. During the early stage of insulin resistance,
increased insulin levels to maintain normal blood glucose by promoting anabolism (glycogen, protein
and fat synthesis) and suppressing fat oxidation [50–52]. Thus, strategies that improve insulin
sensitivity may facilitate both the anabolic effects of insulin and the adaptive catabolic effects
of “nutrient overload” in the context of a HFD, leading to an adverse metabolic phenotype and
mitochondrial dysfunction. Leucine supplementation may not be beneficial if calorie intake is not
restricted at this stage. However, as insulin resistance progresses and insulin loses its effectiveness, the
condition is characterized by a catabolic state. BCAA or leucine supplementation improves insulin
sensitivity, mitochondrial function and other metabolic outcomes, as demonstrated in many conditions,
including muscle sarcopaenia, burns, trauma and T2DM in elderly patients [53–55]. The findings
of this study help explain the conflicting results reported by different studies and indicate that the
patients’ overall metabolic status should be carefully considered to potentiate the health benefits of
leucine or BCAAs in each clinical setting.
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Abstract: Background: Type 2 diabetes mellitus (T2DM) is accompanied by chronic low-grade
inflammation, with an imbalance in the secretion of adipokines and, worsening insulin resistance.
Supplementation with n-3 PUFA in T2DM decreases inflammatory markers, the purpose of the study
was to investigate the effect of n-3 PUFA supplementation on adipokines, metabolic control, and
lipid profile in T2DM Mexican adults. Methods: In a randomized, single-blind, placebo-controlled
pilot study, 54 patients with T2DM received 520 mg of DHA + EPA-enriched fish-oil (FOG) or a
placebo (PG) daily. Baseline and 24-week anthropometric and biochemical measurements included
glucose, insulin, glycosylated hemoglobin (Hb1Ac), leptin, adiponectin, resistin, and lipid profile;
n-3 PUFA intake was calculated in g/day. Results: Waist circumference and blood glucose showed
significant reductions in the FOG group (p = 0.001 and p = 0.011, respectively). Hb1Ac (p = 0.009
and p = 0.004), leptin (p < 0.000 and p < 0.000), and leptin/adiponectin ratio (p < 0.000 and p < 0.000)
decreased significantly in both groups after 24 weeks (FOG and PG respectively). Serum resistin
(FOG p < 0.000 and PG p = 0.001), insulin (FOG p < 0.000 and PG p < 0.000), and HOMA-IR (FOG
p = 0.000 and PG p < 0.000) increased significantly in both groups. FOG had an overall improvement
in the lipid profile with a significant decrease in triacylgycerols (p = 0.002) and atherogenic index
(p = 0.031); in contrast, the PG group had increased total cholesterol (p < 0.000), non-HDL cholesterol
(p < 0.000), and atherogenic index (p = 0.017). Conclusions: We found a beneficial effect of n-3 PUFA
supplementation on waist circumference, glucose, Hb1Ac, leptin, leptin/adiponectin ratio, and lipid
profile, without significant changes in adiponectin, and increases in resistin, insulin, and HOMA-IR
in both groups.
Keywords: type 2 diabetes mellitus; adipokines; lipid profile; n-3 PUFAs
1. Introduction
Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases around the world,
with an increase in its prevalence due to the increase in its risk factors such as obesity and physical
inactivity [1]. According to the National Health and Nutrition Survey, in 2012, in Mexico there were 6.4
million people with T2DM, which means an increase in prevalence from 7% in 2006 to 9.2% in 2012 [2].
T2DM is characterized by impaired pancreatic β-cell function that causes impaired insulin secretion
and insulin resistance (IR) mainly in liver, muscle, and adipose tissue [3].
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It is well recognized that the actively secreted products of adipose tissue known as adipokines
can modulate different functions [4]; adipokines play a pivotal role in the regulation of whole-body
metabolism, as well as in inflammatory and immune responses, and are considered a link between
obesity and the development of T2DM [5].
Adiponectin is a collagen-like protein exclusively expressed in adipose tissue [6], which possesses
potent antidiabetic and anti-inflammatory properties [7]. In humans, plasma adiponectin levels are
closely related to whole-body insulin sensitivity [8] and are correlated negatively with IR and T2DM.
Prospective and longitudinal studies have indicated that lower adiponectin levels are associated with
a higher incidence of T2DM [4]. Adiponectin regulates glucose and lipid metabolism through the
reduction of fat storage (lipogenesis) and the promotion of fat utilization (fatty acid oxidation) [9].
Leptin is a cytokine-like molecule secreted by adipose tissue which regulates adipose tissue mass
and body weight by inhibiting food intake and stimulating energy expenditure [6], thus maintaining
energy homeostasis. Leptin correlates directly with adipose tissue mass. Obesity and T2DM are
associated with increased plasma leptin levels, which fail to correct hyperglycemia in these patients
because of the presence of leptin resistance [5], and these elevated plasma leptin levels are associated
with IR, independent of obesity and insulin sensitivity [10].
In humans, resistin is mainly secreted by macrophages and monocytes and by organs such as
spleen and bone marrow [11]. Since its discovery, resistin has been related to obesity and IR in many
animal experiments, but the application of these findings to human studies has been difficult to
determine. However, studies in humans have shown that serum resistin levels are higher in obese
patients with T2DM compared with non-diabetic obese and that mRNA levels of resistin are higher in
female patients with T2DM compared to healthy women [12].
Dyslipidemias are very common in type 2 diabetes mellitus and are the cause of cardiovascular
disease in uncontrolled patients. Hypertriacylglyceridemia as well as low HDL-cholesterol
concentrations, together with high LDL- and non-HDL-cholesterol is a common lipid profile pattern
observed in subjects with diabetes [13–16].
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are polyunsaturated fatty acids
found at high levels in fish oils [17]. Accumulating evidence suggests that n-3 PUFAs from fish oil may
counteract the adipokine dysregulation that occurs in obesity and its related diseases like T2DM [9],
but it is not well established if the consumption of n-3 PUFAs affects circulating adiponectin, resistin,
and leptin in humans; the results are inconclusive [18]. Furthermore, research in humans and animal
models show a lipid normalizing effect of PUFA supplementation [19,20].
For these reasons, we undertook a pilot study with the aim of investigating the effect of a
six-month supplementation trial with n-3 PUFAs on adiponectin, resistin, leptin, and the lipid profile
in adults with T2DM from Toluca, Mexico.
2. Materials and Methods
2.1. Study Design
This study was a randomized, single-blind and placebo-controlled pilot study conducted in
eight Urban Public Health Centers (UPHC) in Toluca, Mexico, from February to September 2015. The
inclusion criteria were the following: men and women with T2DM, between 25 and 60 years, without
other chronic diseases such as hypertension, arthritis, kidney disease, cancer, and HIV, with a BMI ≤
29.9, without fish allergies or insulin treatment, and not lactating or pregnant.
2.2. Methods
Sixty-five Mexican subjects with T2DM were enrolled from the eight UPHC in Toluca as follows:
Capultitlán (n = 1), Emiliano Zapata (n = 6), Nueva Oxtototitlán (n = 2), Reforma (21), Seminario (3),
Tlacotepec (1), San Diego de los Padres (n = 16), and Ejido de la Y (n = 15). The 65 subjects were
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(10 males, 24 females) and a control group (placebo group: PG) of 31 patients (5 males, 26 females).
The majority of patients were medicated with Glibenclamide plus Metformin or Metformin alone and
were controlled by their family practitioner, we did not give them additional dietary or lifestyle advice;
we only asked them to continue with their regular medication and diet.
Written informed consent was given to all participants. The study was approved by the Research
and Ethics Committee of the Universidad Autónoma del Estado de Mexico and the Institute for Health
of the State of Mexico’s Research and Education Coordination. The protocol was conducted following
the regulations of the Helsinki Declaration of 1975 and its amendment of 2013, as well as the principles
for experiments with human beings from the Nüremberg Code for medical ethics. Individual data is
being maintained confidential.
Once obtained the sample, the baseline evaluation was performed as follows:
Anthropometric evaluation:
All measurements were recorded with light clothes and height without shoes by a trained
nutritionist who was previously standardized. Weight was measured in a TANITA® scale (Mod. 1631)
and was registered in kg; height was measured in cm using a portable SECA 206 stadiometer; the
percentage of body fat was obtained by electrical bioimpedance with the same TANITA scale; body
mass index (BMI) was calculated as body weight in kilograms divided by the square of height in
meters. Waist and hip circumferences were measured with a Gülick™ fiberglass tape and the waist/hip
ratio was calculated.
Biochemical evaluation:
After an overnight fast (≥12 h), collection of a venous blood sample into an 8.5 mL tiger-top
tube containing gel and clotting activator for the subsequent biochemical analysis of glucose, insulin,
adipokines, and lipid profile was undertaken. Another venous blood sample in a 3 mL tube with
EDTA for the analysis of glycosylated hemoglobin was also obtained.
Serum was obtained after centrifugation at 900 g or 3400 rpm for 10 min at 4 ◦C, within 30 min
after blood sample collection; serum samples for glucose and lipid profile were processed within one
hour, and the rest of the samples were aliquoted and stored at −80 ◦C until assayed.
Serum glucose, triacylglycerols, total cholesterol, HDL-cholesterol, LDL-cholesterol, and
glycosylated hemoglobin levels (in total blood) were measured by enzymatic colorimetric assays
in the auto-analyzer Selectra II (ROCHE™), using reagents from RANDOX™ (Cat. GL1611, Cat. Tr213,
Cat. CHO215, Cat. CH3811A, Cat. CH3811B and Cat. HA3830A). Non-HDL-cholesterol was calculated
by difference (total cholesterol − HDL-cholesterol).
Serum levels of insulin were measured with a Human Insulin ELISA kit from EMD Millipore
Corporation® (Cat. # EZHI-14K) according to the manufacturer´s instructions. We evaluated IR with
glucose and insulin concentrations using the Homeostatic model assessment as follows:
HOMA-IR = (fasting insulin (μU/mL)) × (fasting glucose (mg/dL))/405 [21].
Commercially available kits from Merck Millipore® (Cat. # HADK1MAG-61K and
HADK2MAG-61K) were used to measure the serum levels of adiponectin, resistin, and leptin in the
Luminex® 100™ analyzer by luminometry according to the manufacturer’s recommended protocols.
2.3. Supplementation
The supplementation period started after basal evaluation. Patients took two softgels per day of
the assigned supplement for 24 weeks. Each 1.4 g n-3 PUFAs softgel contained a combination of 160 mg
of eicosapentaenoic acid (EPA) with 100 mg of docosahexaenoic acid (DHA) from fish oil, so the total
daily oral dose was 520 mg of n-3 PUFAs (320 mg of EPA and 200 mg of DHA, 2 g of total fat, 1.2 mg








Nutrients 2017, 9, 573
purchased from General Nutrition Centers™. The placebo softgels were identical to the n-3 PUFAs
softgels in appearance and contained cornstarch (1 g carbohydrates and 1.7 mg of sodium per softgel).
2.4. Follow-up
After basal evaluation, patients were monitored by 6 monthly visits, in which they received their
corresponding supplement and were followed-up every two weeks by telephone to make sure that
they were taking their capsules, as well as to remind them not to change their habitual diet, medication,
or physical activity regimes.
2.5. Diet Analysis
A trained nutritionist performed 24-h recalls, one at the beginning and one at the end of the study
to analyze the diet. The dietary nutrient intake and the consumption of polyunsaturated fatty acids
were calculated in grams and percentages using DIAL® (ver 3.3.2., Universidad Complutense, Madrid,
Spain) software. In the final 24 h recalls of the FOG, we added the nutritional composition of n-3
PUFA softgels.
2.6. Statistical Analysis
Data were expressed as mean ± SD. To compare differences in the same group after intervention,
paired t-test was used for parametric variables and Wilcoxon signed rank test for non-parametric
variables. In the diet analysis, unpaired two-sample t-test was used to compare differences between
groups in a parametric way and a Mann–Whitney U-test for non-parametric data. Normality
of data was assessed by the Kolmogorov–Smirnoff test. All analyses were performed using the
statistical software SPSS (version 19.0; SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered
statistically significant.
3. Results
During the study, 10 subjects, 4 in the omega-3 group and 6 in the placebo group, were eliminated
for not completing the six-month supplementation for personal reasons, and the drop-out rate in both
groups was less than 20%. When analyzing the causes for drop-out, it is important to note that all
patients had low-education and socioeconomic levels, and even though we tried to reach them by
phone or house-visits, they were not located either to follow-up or to obtain data at the end of the trial.
We analyzed basal data for differences between those who dropped out and those who stayed, and
there were no significant differences between groups that indicated that they stopped attending due to
the variables we were evaluating.
Age, gender distribution, and diabetes duration were similar between groups without significant
differences; in the FOG, 7 subjects were males, and 22 were females; in the PG, 5 subjects were males
and 20 were females. The mean age of the FOG was of 50.4 ± 6.3 years, while in the PG it was
48.1 ± 6.8 years (p = 0.208), and the average time of diabetes duration was of 6.6 ± 5.0 years in the
FOG and of 6.5 ± 5.8 years in the PG (p = 0.954).
In anthropometric measurements, only the FOG showed a significant decrease in waist
circumference after supplementation (p = 0.001) (Table 1). No significant changes in body weight
(p = 0.250 and 0.578), BMI (p = 0.278 and 0.485), body fat (p = 0.889 and 0.614), and waist/hip ratio
(p = 0.288 and 0.076) were observed in FOG and PG, respectively, after intervention.
At baseline, there was only a significant difference between groups in serum resistin levels
(p = 0.006). The results of biochemical analysis are summarized in Table 2. Glucose serum levels only
showed a significant decrease in FOG (p = 0.001), and there were significant reductions in glycosylated
hemoglobin (p = 0.009 and p = 0.004), leptin (p = 0.000 and p = 0.000), and leptin/adiponectin ratio
in both groups (FOG and PG, respectively). Adiponectin did not show significant changes (p = 0.177
for FOG and p = 0.563 for PG). Contrary to expected, resistin showed a significant increase in both
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insulin serum levels (p = 0.000 for FOG and p = 0.000 for PG) and in HOMA-IR (p = 0.000 for FOG and
p = 0.000 for PG).
Table 1. Anthropometric measurements.
Fish Oil Group (n = 29) Placebo Group (n = 25)
Variables Basal Final p Basal Final p
Body weight (kg) 63.0 ± 9.3 62.7 ± 9.4 0.250 60.2 ± 6.4 60.0 ± 7.3 0.578
BMI (kg/m2) 25.6 ± 2.4 25.4 ± 2.7 0.278 26.0 ± 1.6 25.9 ± 2.0 0.485
Body fat (%) 30.9 ± 9.1 31.1 ± 7.2 0.889 29.9 ± 5.3 30.4 ± 6.1 0.614
Waist circumference (cm) 86.4 ± 7.6 83.1 ± 6.2 0.001 83.2 ± 5.3 83.1 ± 6.1 0.893
Waist/hip ratio 0.89 ± 0.05 0.90 ± 0.05 0.288 0.90 ± 0.05 0.92 ± 0.04 0.076
BMI: body mass index. Paired t-test was performed to compare differences in time (before and after
supplementation). A p-value < 0.05 was considered statistically significant, marked in bold numbers.
Table 2. Biochemical measurements.
Omega-3 (n = 29) Placebo (n = 25)
Variables Basal Final p Basal Final p
Glucose (mg/dL) ‡ 177.2 ± 68.4 156.1 ± 69.4 0.011 184.6 ± 71.1 183.3 ± 53.3 0.326
Glycosylated hemoglobin (%) † 9.6 ± 3.1 8.2 ± 1.9 0.009 10.0 ± 2.1 9.0 ± 1.8 0.004
Adiponectin (μg) ‡ 23.6 ± 20.3 24.5 ± 13.0 0.177 22.8 ± 10.5 24.3 ± 13.3 0.563
Leptin (ng) † 21.7 ± 15.5 3.9 ± 2.5 0.000 18.4 ± 13.2 3.5 ± 2.3 0.000
Resistin (ng) ‡ 30.2 ± 14.0 65.9 ± 23.4 0.000 39.2 ± 12.5 61.3 ± 20.6 0.000
Leptin/adiponectin ratio † 1.3 ± 1.2 0.24 ± 0.26 0.000 0.88 ± 0.68 0.17 ± 0.12 0.000
Insulin μU/mL ‡ 7.6 ± 3.0 14.2 ± 8.2 0.000 6.5 ± 1.6 10.2 ± 3.3 0.000
HOMA-IR ‡ 3.1 ± 1.3 5.3 ± 3.8 0.000 2.9 ± 1.2 4.4 ± 1.6 0.000
Total Cholesterol (mg/dL) † 203.38 ± 33.72 199.10 ± 47.63 0.542 180.32 ± 30.56 209.75 ± 36.80 0.000
Triacylglycerides (mg/dL) † 186.24 ± 85.58 137.28 ± 65.39 0.002 269.40 ± 169.30 251.20 ± 149.76 0.503
HDL-Cholesterol (mg/dL) † 43.52 ± 7.95 48.13 ± 14.59 0.076 38.35 ± 9.51 40.01 ± 9.28 0.384
LDL-Cholesterol (mg/dL) † 131.00 ± 34.66 129.82 ± 44.74 0.869 109.40 ± 34.22 127.26 ± 38.80 0.076
Non-HDL-Cholesterol (mg/dL) † 159.52 ± 31.28 150.97 ± 44.26 0.152 141.97 ± 24.98 169.74 ± 38.15 0.000
Atherogenic Index † 5.04 ± 1.77 4.37 ± 1.04 0.031 4.86 ± 1.06 5.52 ± 1.63 0.017
† Paired t-test was used for parametric variables and ‡ Wilcoxon signed rank test for non-parametric variables.
A p-value ≤ 0.05 was considered statistically significant, marked in bold numbers.
Table 2 shows changes in lipid profile indicators, FOG significantly decreased triacylglycerides
(p < 0.01) and the atherogenic index (p < 0.05), whereas the placebo group showed a statistically
significant increase in total cholesterol (p < 0.000), non-HDL-cholesterol (p < 0.000), and the atherogenic
index (p < 0.05).
The results of diet analysis are shown in Table 3. The FOG showed a significant increase in total
omega-3 fatty acids (p < 0.001), particularly in EPA and DHA (p < 0.000); n-6 to n-3 ratio decreased
from 16:1 to 10:1 (p < 0.05). The placebo group showed a statistically significant increase in protein and
monounsaturated fatty acid intake (p < 0.05). No differences were found in any other nutrient analyzed.
Table 3. Diet analysis.
Variable Omega-3 (n = 29) Placebo (n = 25)
Basal Final p Basal Final p
Energy (kcal/day) 1562.2 ± 387.4 1672.8 ± 665.2 0.476 1751.4 ± 479.9 1875.9 ± 698.5 0.276
Protein (g/day) 57.3 ± 17.2 59.4 ± 24.3 0.737 50.8 ± 19.4 60.5 ± 27.8 * 0.030
Carbohydrates (g/day) 192.1 ± 60.4 187.8 ± 68.8 0.729 258.2 ± 73.1 255.0 ± 104.7 0.905
Lipids (g/day) 59.5 ± 21.2 72.2 ± 38.4 0.097 54.2 ± 27.7 65.2 ± 31.1 0.092
Saturated fatty acids (g/day) 16.4 ± 7.2 19.3 ± 11.9 0.271 11.4 ± 9.0 14.7 ± 9.7 0.065
Monounsaturated fatty acids (g/day) 20.2 ± 8.2 24.6 ± 15.5 0.160 15.4 ± 10.6 22.6 ± 14.3 * 0.013
Polyunsaturated fatty acids (g/day) 13.2 ± 8.1 16.5 ± 12.7 0.197 13.2 ± 11.9 13.0 ± 6.4 0.367
Omega-3 fatty acids (g/day) 0.89 ± 0.76 1.32 ± 0.34 * 0.001 0.79 ± 1.12 0.75 ± 0.53 0.178
Omega-6 fatty acids (g/day) 10.5 ± 7.7 13.6 ± 12.0 0.221 9.4 ± 11.0 8.8 ± 5.2 0.382
n6:n3 Ratio 14:1 10:1 * 0.025 16:1 14:1 0.882
EPA (g/day) 0.077 ± 0.317 0.330 ± 0.018 * 0.000 0.016 ± 0.037 0.047 ± 0.177 0.837
DHA (g/day) 0.103 ± 0.236 0.287 ± 0.089 * 0.000 0.086 ± 0.109 0.155 ± 0.187 0.074
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4. Discussion
In this study, we investigated the effect of supplementation with n-3 PUFAs on serum levels of
adiponectin, resistin, and leptin in an adult Mexican population with T2DM.
The results of the anthropometric analysis (Table 1) are similar to the results observed in previous
similar studies such as a study of supplementation with n-3 PUFAs in diabetic patients [22]; patients
with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [23]; and two more in women
with polycystic ovarian syndrome [24,25], which regularly present insulin resistance. All of these
studies showed no significant change in body weight, BMI, body fat, waist circumference, or waist/hip
ratio after the supplementation period, even at higher doses of n-3 PUFAs and longer periods of
supplementation. However, in a crossover model in which 16 T2DM patients were assigned to one of
two consecutive 3.5-week periods of diabetic diets (foods rich in n-6 or n-3 PUFAs), the authors found a
slight but significant reduction in body weight and BMI in both dietary periods [26]. This suggests that
n-3 PUFAs from food are more effective in controlling body weight than n-3 PUFAs from supplements.
In our study, supplementation with n-3 PUFAs for 24 weeks only helped to significantly reduce waist
circumference and did not help control body weight or reduce BMI, body fat percentage, or waist/hip
ratio. Furthermore, one of the studies in women with polycystic ovarian syndrome reported that
effects of n-3 PUFAs on anthropometric measurements might be dependent on gender, age, and BMI
of subjects at baseline [25].
The effect of n-3 PUFAs on glucose and glycosylated hemoglobin is not clear. A study of
supplementation with DHA-rich fish oil in an Iranian diabetic population [27] and reviews of clinical
trials of supplementation with n-3 PUFAs in different diabetic populations, have not found significant
positive effects on glycemic control [17,28]. However, a recent study [23] showed that n-3 PUFA
supplementation with high doses for 18 months was effective in reducing glycemia and IR in patients
affected by IFG or IGT and that the regression of the condition of impaired glycemia to normoglycemia
seems to be helpful in delaying the development of T2DM. Flanchs et al. showed in a review that
the beneficial effects of n-3 PUFAs on insulin sensitivity and glucose metabolism in people with
IR are dependent on factors such as disease progression and age [29]. In this study, we found a
significant positive effect of n-3 PUFA supplementation on glycemic control (glucose and glycosylated
hemoglobin), but more studies are needed to test this hypothesis because most of the beneficial effects
have been shown in epidemiologic studies based on a habitual fish diet consumed for years [28].
As expected, there were significant reductions in leptin serum levels and hence in
leptin/adiponectin ratio, which has been demonstrated to be related to obesity and T2DM [29].
Contrary to expectation, adiponectin did not increase significantly, while resistin increased significantly.
Our results are not in line with the results observed in similar studies of supplementation with n-3
PUFAs in diabetes [8] and in healthy subjects with a high consumption of fish, which has shown
significant increases in adiponectin serum levels after various supplementation periods [30]. As the
changes in adipokine profile were similar in both groups, we cannot affirm that higher doses of n-3
PUFAs would have led to a decrease in leptin and leptin/adiponectin ratio because there was no
lead tendency toward lower leptin concentrations in subjects with the n-3 PUFA supplement than in
subjects with the placebo.
Our study population showed higher basal adiponectin and leptin serum levels than have been
reported in other similar studies, for example, in German [31], Finnish [32], Japanese [8], Asian
Indian [33], and Arabic diabetic populations [34], which is likely to be due to ethnicity. Resistin
showed similar results compared with serum resistin levels of Egyptians and Japanese although
slightly lower [35,36].
It has been demonstrated that weight reduction increases plasma adiponectin concentrations
and improves IR [10], but in this study, possibly because there were no significant changes in body
weight, there were no significant increases in serum adiponectin levels. In a study with ob/ob mice,
the administration of recombinant adiponectin, even after the development of diabetes, significantly
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inversely with IR [5]. Plasma adiponectin levels have also been demonstrated to be negatively
correlated to IR [4], but in this study, we did not find a negative correlation because adiponectin
(non-significant) and HOMA-IR increased.
Leptin correlates directly with adipose tissue mass; [5] however, we did not observe a significant
reduction in body weight, BMI, and body fat, despite the reduction in serum leptin levels. When we
used a bivariate correlation analysis, we found that serum leptin levels showed a positive correlation
with BMI (R = 0.353 and p = 0.009) and body fat percentage (R = 0.518 and p = 0.000), which is in line
with the results of a similar study [5].
Leptin/adiponectin ratio showed a significant reduction in both groups related to the significant
decrease in leptin levels. Leptin/adiponectin ratio was a useful measure of IR in non-diabetic white
adults [38], but we did not observe a positive correlation between HOMA-IR and leptin serum levels;
despite the reduction in this ratio, there was no reduction in HOMA-IR. However, these findings
suggest the use of the leptin/adiponectin ratio as a useful tool to detect IR. On the other hand, resistin
has been linked to obesity and IR since its discovery [12], but our results are not consistent with
these findings because we found a weak negative correlation between resistin levels and HOMA-IR
(R = −0.274 and p = 0.045).
Obesity is the most significant factor contributing to IR and T2DM [39], and although our patients
were not obese, we found a weak but significant positive correlation between body fat percentage and
HOMA-IR (R = 0.275 and p = 0.046). This factor might explain the significant increase in HOMA-IR in
both groups because there was a non-significant increase in body fat percentage.
Our results are not in accordance with those of Yamamoto et al., who showed in a supplementation
study with EPA in hyperlipidemic patients that IR determined by the HOMA-IR was significantly
improved in the supplemented group, compared with the placebo [21]. In our study, both groups
showed an increase in HOMA-IR, more studies are therefore necessary to evaluate only the EPA effect
in the IR of individuals with T2DM.
Our data show an overall improvement in the lipid profile through the atherogenic index in the
n-3 PUFA supplemented group, with an overall deterioration in the placebo group. Derosa et al. found
an increase in HDL-cholesterol and a decrease in triacylglycerides after 18 months of supplementation
with n-3 PUFA, in patients with impaired glucose metabolism [23]. While in subjects with type 2
diabetes supplemented with DHA-rich fish oil, Mansoori et al. found a decrease in triacylglycerides
independently of their initial values [27]. However, several trials of supplementation with n-3 PUFA
have not found an effect on lipid profile in adults with T2DM [40,41].
Non-HDL-cholesterol has been recommended as a sensitive proxy of the atherogenic metabolic
lipid status; importantly, its values in our study population showed a non-significant decrease in the
supplemented group but a highly significant increase in the placebo group. This may be considered
a protective effect of n-3 PUFA supplementation on the lipid metabolic deterioration caused by
T2DM [15,16].
With respect to diet analysis, our results are in line with those of a previous study of this group
that showed that a Mexican population with T2DM had a very low intake of n-3 PUFAs and a high
consumption of lipids, particularly saturated fatty acids [42]. According to the recommendations of
the Mexican Official Standard NOM-015-SSA2-2010, for prevention, treatment, and control of diabetes
mellitus [43], the mean daily energy intake of all groups was adequate, though protein and n-3 PUFA
intake in both groups and carbohydrate intake in FOG were lower than recommendations, while the
total lipid intake and saturated fatty acid intake were higher than recommendations in FOG.
It is well known that the quality of dietary fat is a key determinant of IR and that saturated and
trans fatty acids decrease insulin secretion and worsen insulin sensitivity [10]; a factor which could
explain the higher increase in HOMA-IR in FOG because of their higher intake of saturated fatty acids.
The quality of fat may have a significant influence on adiponectin concentrations. The data from
13 studies in a systematic review showed a modest and significant effect of n-3 PUFA supplementation
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may not have been able to observe significant changes in adiponectin levels. In vitro human adipocyte
studies found that EPA and DHA (100 μM) treatment for 48 h, increases adiponectin secretion, and
that only EPA led to higher cellular adiponectin being introduced into the adipocytes, suggesting that
the regulation of adiponectin by n-3 PUFAs is dose- and time-dependent and that it can be affected by
the maturation stage of adipocytes [9]. However, another study of supplementation with n-3 PUFAs
in Mexican children and adolescents with obesity and insulin resistance, showed that for n-3 PUFAs,
the duration of treatment is not associated with the effects observed and that the dosage could be
more important, which in this case would suggest that in our study the n-3 PUFA dose we used can be
considered low [45].
It has been demonstrated that diets high in fish and flaxseed oil lower the serum phospholipid ratio
of omega-6/omega-3 fatty acids and that n-3 PUFAs are beneficial in patients affected by inflammatory
diseases. The omega 6/omega 3 ratio is of importance in health and disease; during the Paleolithic
period of human evolution, there was a different balance between n-6 and n-3, but the last 150 years
have seen a significant increase, as in Western diets this ratio is now in the range of 15–20:1 [46].
Because of the low intake of n-3 PUFAs and the increased amounts of the n-6 PUFA linoleic acid (and
high levels found in plasma phospholipids to be published elsewhere) in our study population, the
omega 6/omega 3 ratios were of 11:1 and of 13:1 in FOG and PG, respectively, very similar to Western
diets [47].
Although we found a beneficial effect of EPA + DHA supplementation on waist circumference,
glucose, glycosylated hemoglobin, leptin, and leptin/adiponectin ratio in this population, these
beneficial effects may not have been due to the supplement alone because we observed similar results
in some of these parameters between patients who took the n-3 PUFA supplement and those that took
the placebo. Similarly, there were significant increases in resistin, serum insulin, and HOMA-IR in both
groups. It is possible that some of the beneficial effects observed in both groups were due to metformin
and that the combined use of n-3 PUFA and metformin gave rise to better outcome measures. However,
the significant increase in monounsaturated fatty acids and protein in the placebo group may also
have contributed to the decrease in glycosylated hemoglobin, leptin, and leptin/adiponectin ratio
and the increase in resistin, insulin, and HOMA-IR in this group. Interestingly, Schwingshack et
al., 2001, and McAllan et al., 2014, have reported that macronutrient quality and composition, i.e.
monounsaturated fat and protein can affect some of the parameters we have measured (leptin and
glycosylated hemoglobin) and in the same direction we observed for the placebo group [48,49].
5. Conclusions
Additional research is required to fully understand the associated mechanisms between n-3
PUFA-rich fish oil consumption and adipokine secretion/expression. The small sample size and
use of metformin may have limited our findings as well as the use of a relatively low dose of n-3
PUFAs, so larger studies with higher doses of n-3 PUFAs are required to confirm and extend our
findings. It would be important to measure serum levels of other adipokines related to IR and T2DM,
such as visfatin and apelin, to determine if the beneficial effects of PUFA n-3 are sustained after the
cessation of therapy and to determine if negative effects on insulin sensitivity are actually caused by
the supplement. The different effects of EPA and DHA observed in some studies highlight the need to
study their actions separately.
In summary and despite the limitations, our study is the first to report serum concentrations
of adiponectin, resistin, and leptin and show a beneficial effect of n-3 PUFA supplementation on
waist circumference, glucose, glycosylated hemoglobin, leptin, and leptin/adiponectin ratio and lipid
profile in a group of Mexican individuals with T2DM. Supplementation with n-3 PUFA and n-3 PUFA
combined with metformin both warrant further investigation in Mexican T2DM.
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Abstract: Background: This study investigated whether glycemic index (GI) or glycemic load (GL)
of morning or evening intake and morning or evening carbohydrate intake from low- or higher-GI
food sources (low-GI-CHO, higher-GI-CHO) during adolescence are relevant for risk markers of
type 2 diabetes in young adulthood. Methods: Analyses included DOrtmund Nutritional and
Anthropometric Longitudinally Designed (DONALD) study participants who had provided at least
two 3-day weighed dietary records (median: 7 records) during adolescence and one blood sample in
young adulthood. Using multivariable linear regression analyses, estimated morning and evening GI,
GL, low-GI-CHO (GI < 55) and higher-GI-CHO (GI ≥ 55) were related to insulin sensitivity (N = 252),
hepatic steatosis index (HSI), fatty liver index (FLI) (both N = 253), and a pro-inflammatory-score
(N = 249). Results: Morning intakes during adolescence were not associated with any of the adult
risk markers. A higher evening GI during adolescence was related to an increased HSI in young
adulthood (p = 0.003). A higher consumption of higher-GI-CHO in the evening was associated with
lower insulin sensitivity (p = 0.046) and an increased HSI (p = 0.006), while a higher evening intake of
low-GI-CHO was related to a lower HSI (p = 0.009). Evening intakes were not related to FLI or the
pro-inflammatory-score (all p > 0.1). Conclusion: Avoidance of large amounts of carbohydrates from
higher-GI sources in the evening should be considered in preventive strategies to reduce the risk of
type 2 diabetes in adulthood.
Keywords: glycaemic index; glycaemic load; daytime; adolescence; type 2 diabetes mellitus
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1. Introduction
Diets low in glycemic index (GI) or glycemic load (GL) are related to a lower risk of developing
type 2 diabetes mellitus [1,2]. Their preferred use has hence been advocated particularly during periods
of physiological insulin resistance, such as puberty [3]. This is supported by our recent observations
linking a higher dietary GI/GL during puberty to a lower insulin sensitivity and increased liver enzyme
activities [4] as well as increased levels of interleukin-(IL)-6 [5] in young adulthood, i.e., metabolic
markers indicating an increased risk of developing type 2 diabetes in later life [6].
Recent discussions on preventive procedures also account for chronobiological aspects of
metabolism [7]. This originates from the observation that extreme circadian (circa dies (lat.) = about 24 h)
misalignment—as experienced during shiftwork—enhances the risk of type 2 diabetes among adults [8].
In a subsample from a Finnish population-based study, behavioral traits towards eveningness (based
on a questionnaire assessing morningness-eveningness) were linked to notably higher odds for type 2
diabetes [9]. Persons with a late chronotype (i.e., those with a preference for a delayed timing of sleep
on free days, i.e., without social obligations) are at particular risk of experiencing mild, but chronic
misalignment resulting from the discrepancy between their circadian clock and socially determined,
fixed schedules [10]. Misalignment may extend to their dietary behavior if it does not match metabolic
processes, most of which follow a circadian rhythm [7]. Hence, dietary misalignment can emerge due
to a discrepancy between the biological and the social timing or result from a general mismatch of
dietary intake to metabolic circadian rhythmicity, e.g., to the decrease in insulin sensitivity over the
day [11,12]. It is conceivable that adolescents are vulnerable to dietary misalignment since adolescence
is characterized by a pronounced “lateness” in chronotype, i.e., a preference for a delayed timing of
sleep on free days [13], which may be exacerbated by the physiological insulin resistance occurring
during adolescence [14]. We hence hypothesize that recurring postprandial glycemic excursions elicited
by carbohydrate-containing foods with a higher GI are particularly detrimental in evening hours and
will have longer-term downstream adverse effects on adult metabolic health. It is possible that these
are specific to either the relative glycemic response to the carbohydrate-containing foods consumed
in evening hours, i.e., their GI [15], to their estimated postprandial glucose and insulin responses
(i.e., their GL) and/or the intake of carbohydrates from low-GI (GI < 55) or higher-GI (GI ≥ 55, thus
including sources with moderate- as well as high-GI) sources (low-GI-CHO, higher-GI-CHO).
Therefore, the aim of our current analysis was to separately examine the habitual dietary GI and
GL of morning and evening intake during adolescence as well as morning and evening low-GI-CHO
and higher-GI-CHO intake for prospective associations with risk markers of type 2 diabetes in young
adulthood. Primary outcome measures comprised established risk parameters (insulin sensitivity,
hepatic steatosis index (HSI), fatty liver index (FLI) and a pro-inflammatory score). Newly emerging
risk markers of type 2 diabetes (fetuin A, fibroblast growth factor 21 (FGF-21) [16], interleukin-1
receptor antagonist (IL-1ra) and omentin [17]) were considered as secondary outcomes.
2. Methods
2.1. DONALD Study
The DONALD (DOrtmund Nutritional and Anthropometric Longitudinally Designed) study is
an ongoing, open cohort study conducted in Dortmund, Germany, that was previously described [18].
In brief, since 1985, detailed data on diet, growth, development, and metabolism between infancy and
early adulthood have been collected from approximately 1550 healthy children. Each year, 30–35 infants
are newly recruited and first examined at the ages of three or six months. Participants regularly return
to the study center thereafter; assessment during adolescence is scheduled annually. Since 2005,
participants aged 18+ years are requested to provide a fasting blood sample in addition to the regular
examination. The study was approved by the Ethics Committee of the University of Bonn (project
identification code: 098/06, date of approval 21 June 2006); all examinations are performed with
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2.2. Dietary Assessment
Nutritional data are assessed by 3-day weighed dietary records on three consecutive days.
Participants are free to choose the days of recording. Dietary records include information on the timing
of meal consumption. Parents and/or participants are instructed by dietitians to weigh all consumed
foods and beverages, including leftovers, to the nearest 1 g. To this end, they receive regularly calibrated
electronic food scales (initially Soehnle Digita 8000 (Leifheit AG, Nassau, Germany), now WEDO digi
2000 (Werner Dorsch GmbH, Muenster/Dieburg, Germany)). When exact weighing is not possible,
semi-quantitative measures (e.g., number of spoons) are allowed. Moreover, information on recipes
and on the types and brands of food items consumed is requested. The dietary records are collected as
well as reviewed by the dietitians and analyzed using the continuously updated in-house nutrient
database LEBTAB [19]. It includes information from standard nutrient tables, product labels, or recipe
simulations based on the listed ingredients and nutrients.
2.3. Blood Analysis
Venous blood samples are drawn after an overnight fast, centrifuged at 4 ◦C and frozen at −80 ◦C
in the DONALD Study Center. Fasting plasma glucose was determined on a Roche/Hitachi Cobas
c 311 analyzer (Basel, Switzerland). Plasma insulin concentration was measured at the Laboratory
for Translational Hormone Analytics of the University of Giessen using an immunoradiometric
assay (IRMA, DRG Diagnostics, Marburg, Germany). All other measurements were performed at
the German Diabetes Center with assay characteristics as described [5,20–22]: plasma activities
of alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), gamma-glutamyltransferase
(GGT), plasma triglycerides (TG) and plasma high-sensitivity C-reactive protein (hsCRP) with the
Roche/Hitachi Cobas c311 analyzer (Roche diagnostics, Mannheim, Germany), plasma high-sensitivity
interleukin-(IL)-6 using the Human IL-6 Quantikine HS, plasma adiponectin with the Human Total
Adiponectin/Acrp30 Quantikine ELISA, serum leptin with the Leptin Quantikine ELISA, serum
interleukin-1 receptor antagonist (IL-1ra) with the Human IL-1ra/IL-1F3 ELISA, plasma fibroblast
growth factor (FGF-21) with the Human FGF-21 kits all from R & D Systems (Wiesbaden, Germany),
serum IL-18 using the Human IL-18 ELISA kit from MBL (Nagoya, Japan), and plasma chemerin with
the Human Chemerin ELISA, plasma omentin-1 with the Human Omentin-1 ELISA, plasma chemerin
with the Human Chemerin ELISA and plasma fetuin-A with the Human Fetuin-A ELISA kits from
BioVendor (Brno, Czech Republic).
Insulin sensitivity was assessed using the updated HOMA2 sensitivity (in %) based on fasting
insulin and blood glucose [23]. Indices of hepatic steatosis were calculated as follows:
Hepatic steatosis index (HSI):
• HSI = 8 × ALT/AST + BMI
(+2, if female; +2, if diabetes mellitus, but not applied, as the DONALD study excludes participants
with chronic disease) [24],
• Fatty liver index (FLI):
FLI = ex/(1 + ex) × 100
with x = 0.953 × ln(TG) + 0.139 × BMI + 0.718 × ln(GGT) + 0.053 × waist circumference − 15.745 [25].
To estimate associations with chronic low-grade inflammation a pro-inflammatory score of
established inflammation markers—assumed to be more predictive of inflammation than single
markers [26]—was obtained by averaging inflammation markers, that were standardized (z) by sex
(mean = 0, SD = 1) beforehand. To align anti-inflammatory adiponectin in the pro-inflammatory score
it was multiplied by −1:
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2.4. Anthropometric Data
Anthropometric measurements are performed by trained nurses according to standard procedures,
with the participants dressed only in underwear and barefoot. Standing height is measured to the
nearest 0.1 cm (digital stadiometer: Harpenden Ltd., Crymych, UK) and body weight to the nearest
0.1 kg (electronic scale: model 753 E; Seca, Hamburg, Germany). Waist circumference is measured at
the midpoint between the lower rib and the iliac crest to the nearest 0.1 cm. Measurements of skinfold
thicknesses are taken on the right side of the body at the biceps, triceps, subscapular and suprailiac
sites to the nearest 0.1 mm (Holtain caliper: Holtain Ltd., Crymych, UK).
From these measures, adolescent body mass index (BMI, kg/m2) and its sex- and age-specific
SD-scores (SDS) were calculated using current German BMI standards [27]. The prevalence of overweight in
adolescence was calculated using standards of the International Obesity TaskForce (IOTF) [28]. Percent
body fat (%BF) in adolescence and adulthood was estimated using the Slaughter [29] and the
Durnin-Womersley equations [30], respectively. From these, body fat mass (kg) was calculated
[(%BF× body mass)/100] and related to the square of height to obtain fat mass index (FMI, kg/m2).
2.5. Family Characteristics
On a child’s admission to the study, information on gestational characteristics and birth
anthropometrics are abstracted from a standardized document (Mutterpass), given to all pregnant
women in Germany. Moreover, parents are interviewed concerning the child’s early life data as well
as family and socio-economic characteristics at regular intervals. Additionally, parents are regularly
weighed and measured using the same equipment used for participants.
2.6. Definition of Morning and Evening Intake
The definition of morning and evening was described in earlier analyses [31,32]. Briefly, for each
age (year), the time between the end of the night and 11 a.m. and the time between 6 p.m. and the
start of the night, respectively, was used to define morning and evening.
For estimation of morning and evening GI and GL as well as morning and evening carbohydrate
intake from low- or higher-GI food sources, each carbohydrate containing food recorded in the
corresponding day-time window was assigned a published GI value [33,34], based on glucose as
reference food and according to a standardized procedure [35]. Carbohydrate content of each food
consumed in the morning or in the evening was then multiplied by the food’s GI to obtain the GL of the
corresponding day-time window. Subsequently, overall morning/evening GI was obtained by dividing
morning/evening GL by morning/evening carbohydrate intake. To distinguish carbohydrates from
low- and higher-GI food sources, a value of 55 (cutoff proposed for low-GI foods [34]) was chosen
for categorization. Accordingly, morning and evening carbohydrate intake from low-GI sources
(low-GI-CHO (GI < 55) in g) and from moderate- or high-GI sources (higher-GI-CHO (GI ≥ 55) in g)
was calculated.
2.7. Study Sample
Due to the open-cohort design of the study, many subjects have not yet reached young adulthood,
when blood samples are taken. At the time of this analysis N = 414 young adults had provided at
least one fasting blood sample, in which risk markers of type 2 diabetes were quantified. As only
term (gestational age 37–42 weeks) singletons with a minimum birth weight of 2500 g were included
in the analyses, sample size was reduced to N = 397. To allow estimation of morning and evening
GI, GL, low-GI-CHO and higher-GI-CHO during adolescence (girls: 9–15 years, boys: 10–16 years),
at least two 3-day weighed dietary records from three consecutive days were required (N = 298).
Participants, who were identified to consistently underreport their energy intake were excluded from
the study (N = 12, resulting in N = 286). In line with earlier publications [4,5] ‘consistent underreporting’








Nutrients 2017, 9, 591
implausible. A 3-day weighed dietary record was considered implausible, when the total energy
intake documented was inadequate in relation to the basal metabolic rate (estimated from Schofield
equations [36]) using cut-offs from Goldberg et al. [37] modified for children and adolescents [38].
Finally, anthropometric measurements from adolescence and young adulthood as well as data on
relevant covariates were required, resulting in analyses samples of N = 253 for liver steatosis outcomes,
N = 252 for insulin sensitivity and N = 249 for inflammation-related outcomes. Sample sizes for insulin
sensitivity and inflammation outcomes were lower because of fasting glucose concentrations below
the threshold for calculation of HOMA2 sensitivity (reflecting hypoglycemia) or insufficient amounts
of blood were available for determination of analytes.
2.8. Statistical Analysis
SAS procedures (SAS version 9.2, SAS Institute, Cary, NC, USA) were used for data analysis.
p-values < 0.05 were considered significant. Tests for interaction indicated no sex differences for the
primary outcomes, except for the relevance of evening GL for the pro-inflammatory score. Since
stratified analyses for this association yielded similar non-significant results for males and females,
all associations are from pooled analyses.
Characteristics of the study population are presented as medians (25th, 75th percentiles) for
continuous variables and as absolute (relative) frequencies for categorical variables.
The prospective associations of morning and evening GI, GL, low-GI-CHO and higher-GI-CHO
with the risk markers of type 2 diabetes were analyzed using multivariable linear regression models.
To achieve normal distribution in the outcome variables, they were transformed prior to analysis using
log, double-log, square root or reciprocal transformations, depending on the outcome. In addition,
individual outliers which substantially interfered with normal distribution or regression modeling
were winsorized, i.e., outliers were replaced by the sex-specifically closest value fitting a normal
distribution. The procedure concerned IL-6 (N = 4), adiponectin (N = 1) and IL-1ra (N = 2). Exposures
were energy-adjusted for morning and evening energy intake, respectively—except for dietary
GI-using the residual method [39]. To account for sex- and age-dependent differences in nutritional
intake, all variables were standardized (mean = 0, SD = 1) by sex and age (year) and averaged over
the time period of adolescence. Crude models (model A) included the exposure variable as well
as sex and age at blood withdrawal in adulthood. In a further step, adjusted models (model B)
were constructed by individual examination of potentially influencing covariates and hierarchical
inclusion [40] of those which substantially modified the exposure’s regression coefficient by ≥10% [41]
or independently predicted the outcome variable [42]. Potential confounding covariates considered
for inclusion in the different hierarchical levels were (1) early life characteristics (gestational weight
gain (kg), mother’s age at birth (years), duration of pregnancy (weeks) and birth weight (g), first-born
child (yes/no), full breastfeeding (≥4 months yes/no)), (2) family and socio-economic characteristics
(parental diabetes (yes/no), maternal overweight (≥25 kg/m2 yes/no), maternal educational status
(≥12 year of schooling yes/no), smoking in the household (yes/no)), (3) baseline characteristics
(adolescent BMI-SDS, intake of saturated fatty acids (SFA, E%) and intake of animal protein (E%)).
To ensure comparability, models were adjusted identically according to the strongest exposure-outcome
associations for closely related outcomes (i.e., for (i) insulin sensitivity, (ii) hepatic steatosis markers
(HSI, FLI, fetuin A, FGF-21) and (iii) inflammatory markers (pro-inflammatory score, IL-1ra, omentin)).
For significant associations (model B), we additionally ran conditional models including waist
circumferences to examine whether the observed associations are partly attributable to effects of
carbohydrate nutrition on body composition. As HSI and FLI do by definition already include adult
BMI and/or waist circumference, no conditional models were run for these outcomes.
3. Results
Characteristics of the study population at baseline and in young adulthood are shown in Tables 1
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as well as the relative contribution of carbohydrates from low- or higher-GI sources were broadly
comparable between morning and evening intake. Note that the carbohydrate content of morning
intake was higher than the carbohydrate content of evening intake. In young adulthood, median age
at blood withdrawal was 21 years (range 18–39 years).
Overall, morning GI and GL as well as morning carbohydrate intake from low- or higher-GI
sources were not related to insulin sensitivity (Table S1), the primary hepatic steatosis outcomes
HSI and FLI (Tables S2 and S3) or the pro-inflammatory score (Table 3, top) in young adulthood
(all p > 0.1). Of note, low-GI-CHO intake during the morning was related to HSI in model A (p = 0.041),
however, upon further adjustment this association was no longer statistically significant (Table S2,
model B, p = 0.24). Morning exposures were neither related to the secondary outcomes fetuin A
(Table S4), FGF-21 (Table S5), and IL-1ra (Table S6) (all p > 0.08). However, a higher morning GI
during adolescence was associated with an increased level of the secondary outcome omentin in young
adulthood (p = 0.011, Table S7); an association that persisted in the conditional model adjusting for
adult waist circumference (p = 0.003).
In contrast, a higher evening carbohydrate intake from higher-GI sources during adolescence
was associated with lower insulin sensitivity in young adulthood (p = 0.046, Figure 1). Additional
adjustment for waist circumference rendered this association non-significant (p =0.11). A higher
evening GI (p = 0.003) and a higher evening higher-GI-CHO intake (p = 0.006) were related to
an increased HSI, whereas higher evening low-GI-CHO intake (p = 0.009) was associated with a
lower HSI (Figure 2). Similarly, a higher evening GL (p = 0.005) and higher evening higher-GI-CHO
intake (p = 0.029) were associated with increased concentrations of the secondary outcome fetuin
A (Table S4); neither of these relations was explained by adult waist circumference (p = 0.006 and
p = 0.040 respectively). No prospective associations of evening intakes were observed with the primary
outcomes FLI (Table S3) and the pro-inflammatory score (Table 3, bottom), or with the secondary
outcomes FGF-21 (Table S5), IL-1ra (Table S6) and omentin (Table S7) (all p > 0.01).
Table 1. Baseline sample characteristics 1 (N = 252).
General Characteristics
Sex ♀ (n (%)) 130 (51.6)
Mean age (years) 12.4 (12.0; 13.0)
Early Life Factors
Gestational weight gain (kg) 12 (10; 15)
Mothers age at gestation (years) 30.6 (28.2; 33.3)
Birth weight (g) 3450 (3130; 3810)
Duration of gestation (weeks) 40 (39; 41)
First born child (n (%)) 152 (60.3)
Fully breastfed, ≥4 months (n (%)) 124 (49.2)
Family Characteristics
Parental diabetes (n (%)) 9 (3.6)
Maternal overweight, ≥25 kg/m2 (n (%)) 101 (40.1)
Maternal educational status, ≥12 years of schooling (n (%)) 136 (54.0)
Smoking in the household (n (%)) 72 (28.6)
Body Composition during Adolescence 2
BMI (kg/m2) 18.6 (16.8; 20.2)
BMI Standard Deviation Score −0.13 (−0.87; 0.37)
FMI (kg/m2) 3.2 (2.4; 4.5)
Overweight (n (%)) 3 31 (12.3)
Nutrition Parameters during Adolescence 2
Number of 3-day dietary records per participant 7 (6; 7)
Daily energy intake (kcal) 1922 (1658; 2158)
Total carbohydrates (E% 4) 51.0 (48.4; 54.3)
Total protein (E% 4) 13.0 (12.0; 14.1)
Animal protein (E% 4) 8.1 (7.2; 9.1)
Total fat (E% 4) 35.9 (32.9; 38.1)








Nutrients 2017, 9, 591
Table 1. Cont.
Nutrition Parameters during Adolescence 2
Energy intake before 11 a.m. (kcal) 506 (418; 603)
Energy intake before 11 a.m. (E% 4) 26.7 (22.7; 30.7)
GI 56.2 (53.6; 58.8)
GL (g) 38.0 (32.5; 47.1)
Carbohydrates with low-GI 5 (E% 6) 21.2 (16.8; 26.6)
Carbohydrates with higher-GI 5 (E% 6) 32.6 (26.8; 37.3)
Total carbohydrates (E% 6) 54.5 (49.9; 59.6)
Total protein (E% 6) 12.0 (10.6; 13.6)
Animal protein (E% 6) 6.8 (5.3; 8.4)
Total fat (E% 6) 32.7 (28.3; 36.3)
SFA (E% 6) 15.0 (12.7; 17.6)
Energy intake after 6 p.m. (kcal) 580 (471; 691)
Energy intake after 6 p.m. (E% 4) 30.3 (26.7; 34.1)
GI 56.6 (54.3; 59.2)
GL (g) 40.2 (31.5; 49.1)
Carbohydrates with low-GI 5 (E% 6) 18.6 (14.7; 23.1)
Carbohydrates with higher-GI 5 (E% 6) 30.2 (24.8; 34.0)
Total carbohydrates (E% 6) 48.7 (44.8; 52.9)
Total protein (E% 6) 14.0 (12.3; 15.3)
Animal protein (E% 6) 9.0 (7.3; 10.5)
Total fat (E% 6) 37.1 (33.5; 40.5)
SFA (E% 6) 15.6 (14.3; 17.5)
Values are n (%) for categorical variables or medians (25th, 75th percentiles) for continuous variables. 1 General
characteristics are shown for the sample used for diabetic risk markers only (N = 252), since samples used for
risk marker of hepatic steatosis (N = 253) and inflammation (N = 249) are very similar; 2 mean over six years
(♀: 9–15 years, ♂: 10–16 years); 3 includes overweight and obesity as defined by IOTF in Cole 2000 [28]; 4 % of
daily energy intake; 5 distinction between carbohydrate intake from low- and higher-GI food sources with a GI
of 55 as cut-off; 6 % of energy intake before 11 a.m./after 6 p.m. BMI—body mass index, FMI—fat mass index,
GL—glycemic load, GI—glycemic index, SFA—saturated fatty acids.
Table 2. Sample characteristics for young adulthood 1.
N Value
General Characteristic
Mean age at blood withdrawal
(years) 252 21.0 (18.1; 24.0)
Lifestyle
Alcohol consumption (g) 2 197 0.3 (0.0; 6.0)
Smokers (n (%)) 237 65 (27.4)
Body composition
BMI (kg/m2) 252 22.1 (20.6; 24.6)
FMI (kg/m2) 252 5.7 (3.8; 7.2)
Overweight (n (%)) 3 252 55 (21.8)
Waist circumference (cm) 252 75.9 (70.8; 80.9)
Risk markers of type 2 diabetes
HOMA2 sensitivity (%) 252 77.1 (61.2; 99.0)
Hepatic steatosis index (HSI) 253 29.8 (27.8; 32.8)
Fatty liver index (FLI) 253 7.3 (4.6; 15.4)
Fetuin A (mg/L) 253 273 (241; 306)
FGF-21 (pg/mL) 253 83.4 (39.7; 156.6)
Pro-inflammatory score 249 −0.11 (−0.38; 0.32)
IL-1ra (pg/mL) 249 218 (169; 295)
Omentin (ng/mL) 249 379 (317; 458)
Values are n (%) for categorical variables and median (25th, 75th percentiles) for continuous variables. 1 General
characteristics are shown for the sample used for diabetic risk markers only (N = 252), since samples used for risk
marker of hepatic steatosis (N = 253) and inflammation (N = 249) are very similar; 2 estimation is based on N = 197
participants who had provided a 3-day weighed dietary record in young adulthood; 3 including all BMI ≥ 25.0;
BMI—body mass index, FGF-21—Fibroblast growth factor 21, FMI—fat mass index, HOMA2—updated homeostasis
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Figure 1. Predicted least square means (95% confidence interval) of HOMA2 sensitivity by tertiles of
(A) glycemic index (GI) after 6 p.m., (B) glycemic load (GL) after 6 p.m., (C) intake of low-GI-CHO
1 after 6 p.m. and (D) intake of higher-GI-CHO 1 after 6 p.m. Values are least-square means for
tertiles obtained from linear regression models. p-values are based on models using the continuous
exposure variables. Models were adjusted for first born child (yes/no), baseline BMI-SDS, baseline
evening intake of saturated fatty acids and animal protein (N = 252). Values below the figure refer to
median intakes (25th; 75th percentiles) in each tertile of the respective exposure. 1 Distinction between
carbohydrate intake from low- and higher-GI food sources with a GI of 55 as cut-off; 2 % of energy
intake after 6 p.m.
Table 3. Prospective relation of GI and GL of morning (before 11 a.m.) and evening (after 6 p.m.) intake
as well as morning and evening intake from low- and higher-GI food sources during adolescence to
pro-inflammatory score in young adulthood (N = 249).
Predicted Means 1 of Pro-Inflammatory Score
by Exposure Tertiles
(Exposures: Morning and Evening GI, GL, Low-GI-CHO, Higher-GI-CHO) p for Trend 2
Low Exposure (T1) Average Exposure (T2) High Exposure (T3)
MORNING
Glycemic Index (GI)
Median GI 52.2 (50.2; 53.8) 56.2 (55.2; 57.0) 59.5 (58.5; 60.6)
Model A 3 −0.10 (−0.22; 0.03) −0.03 (−0.15; 0.10) −0.04 (−0.16; 0.08) 0.15
Model B 4 −0.10 (−0.21; 0.02) −0.04 (−0.16; 0.08) −0.02 (−0.13; 0.10) 0.18
Glycemic Load (GL)
Median GL 35.7 (30.4; 41.6) 35.9 (30.4; 42.9) 45.4 (37.1; 53.9)
Model A 3 −0.08 (−0.20; 0.04) −0.02 (−0.14; 0.10) −0.06 (−0.18; 0.06) 0.40
Model B 4 −0.11 (−0.23; 0.02) 0.00 (−0.12; 0.12) −0.05 (−0.17; 0.08) 0.27
CHO with low-GI 5
Median low-GI-CHO (E%) 15.4 (12.4; 17.3) 21.4 (19.5; 23.3) 28.8 (26.5; 32.7)
Model A 3 0.01 (−0.12; 0.14) −0.05 (−0.17; 0.08) −0.13 (−0.25; 0.00) 0.16
Model B 4 −0.01 (−0.13; 0.11) −0.03 (−0.14; 0.09) −0.11 (−0.23; 0.00) 0.39
CHO with higher-GI 5
Median higher-GI-CHO (E%) 25.0 (22.5; 27.2) 32.9 (31.0; 34.3) 38.6 (36.5; 42.8)
Model A 3 −0.15 (−0.26; −0.03) −0.06 (−0.18; 0.07) 0.04 (−0.08; 0.17) 0.06
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Table 3. Cont.
Predicted Means 1 of Pro-Inflammatory Score
by Exposure Tertiles
(Exposures: Morning and Evening GI, GL, Low-GI-CHO, Higher-GI-CHO) p for Trend 2
Low Exposure (T1) Average Exposure (T2) High Exposure (T3)
EVENING
Glycemic Index (GI)
Median GI 53.3 (52.4; 54.3) 56.6 (55.9; 57.4) 60.2 (59.1; 61.5)
Model A 3 0.04 (−0.09; 0.17) −0.05 (−0.17; 0.08) −0.15 (−0.27; −0.03) 0.30
Model B 4 0.01 (−0.11; 0.13) −0.04 (−0.16; 0.08) −0.12 (−0.23; 0.00) 0.75
Glycemic Load (GL)
Median GL 34.4 (26.9; 44.8) 37.1 (31.3; 44.6) 48.5 (40.0; 55.1)
Model A 3 −0.01 (−0.14; 0.12) −0.17 (−0.29; −0.05) 0.02 (−0.10; 0.15) 0.66
Model B 4 −0.05 (−0.18; 0.09) −0.13 (−0.24; −0.01) 0.03 (−0.10; 0.16) 0.46
CHO with low-GI 5
Median low-GI-CHO (E%) 13.1 (10.3; 14.7) 18.5 (17.2; 20.0) 24.6 (22.8; 28.2)
Model A 3 −0.07 (−0.19; 0.06) −0.06 (−0.18; 0.06) −0.04 (−0.16; 0.09) 0.56
Model B 4 −0.05 (−0.17; 0.08) −0.06 (−0.18; 0.06) −0.05 (−0.17; 0.07) 0.84
CHO with higher-GI 5
Median higher-GI-CHO (E%) 22.5 (20.8; 24.9) 30.2 (28.8; 32.0) 35.4 (33.7; 38.1)
Model A 3 −0.09 (−0.21; 0.03) −0.07 (−0.19; 0.05) 0.00 (−0.12; 0.13) 0.69
Model B 4 −0.11 (−0.23; 0.01) −0.06 (−0.17; 0.06) 0.02 (−0.10; 0.14) 0.44
Values in italic refer to median intakes (25th, 75th percentiles) in each tertile of the respective exposure. 1 Model-values are
least square means (95% confidence intervals) of pro-inflammatory score; 2 p-values for models are based on linear
regression analyses using continuous exposure variables; 3 Model A (crude model) adjusted for sex and age at blood
withdrawal; 4 Model B additionally adjusted for gestational weight gain, maternal educational status (≥12 years of
schooling yes/no), baseline BMI-SDS, baseline morning or evening intake of animal protein; 5 Distinction between
carbohydrate intake from low- and higher-GI food sources with a GI of 55 as cut-off.
Figure 2. Predicted least square means (95% confidence interval) of hepatic steatosis index (HSI)
by tertiles of (A) glycemic index (GI) after 6 p.m., (B) glycemic load (GL) after 6 p.m., (C) intake of
low-GI-CHO 1 after 6 p.m. and (D) intake of higher-GI-CHO 1 after 6 p.m. Values are least-square means
for tertiles obtained from linear regression models. p-values are based on models using the continuous
exposure variables. Models were adjusted for sex, age at blood withdrawal, gestational weight gain,
duration of pregnancy and birth weight, maternal educational status (≥12 years of schooling yes/no),
maternal overweight (≥25 kg/m2 yes/no), baseline BMI-SDS, and baseline evening intake of saturated
fatty acids (N = 253). Values below the figure refer to median intakes (25th; 75th percentiles) in each
tertile of the respective exposure. 1 Distinction between carbohydrate intake from low- and higher-GI
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4. Discussion
The present study provides novel evidence that adverse longer-term metabolic effects of recurring
postprandial glycemic excursions may be specific to evening carbohydrate consumption. Specifically,
adolescents who habitually consumed more carbohydrates from higher-GI food sources in the evening
had a lower insulin sensitivity and a higher HSI in young adulthood. By contrast, such adverse
prospective associations were not observed for morning intakes. The absence of associations with the
pro-inflammatory score suggests that day-time specific intake pattern in adolescence may not be of
longer-term relevance for low-grade inflammation among young, healthy adults.
Our observation linking evening higher-GI-CHO to insulin sensitivity is in line with our
hypothesis that evening rather than morning intake of higher-GI foods is potentially detrimental
for risk factors of type 2 diabetes. A diurnal pattern of insulin sensitivity has been confirmed for
both healthy persons [11] and participants with prediabetes [12]. The observed decrease in insulin
sensitivity over the course of the day offers a plausible mechanism for our results. In line with our
findings, a recent study measuring 20-h day-time profiles from 6 healthy volunteers (4 females, 2 males)
reported that estimated postprandial insulin sensitivity was lowest when participants consumed 60%
of their daily energy intake in the form of high-GI foods at supper [43]. In an earlier study from the
same group, 8-h daytime profiles were collected from 17 middle-aged men with overweight or obesity
and at least one cardiac risk factor [44]. Results revealed higher postprandial glucose and insulin
responses following high-GI lunch and afternoon tea, but not high-GI breakfast compared to the
corresponding low-GI meals. Upon adherence to the assigned diet over 24 days, postprandial insulin
resistance had increased in the high-GI diet group compared to the low-GI diet group; thus, there was
no metabolic adaptation to the high-GI diet. Our results expand on these findings in that they suggest
that higher-GI-CHO habitually consumed in the evening by adolescents may have longer-term adverse
consequences for adult insulin sensitivity. Our conditional model suggests that this association may be
partly mediated by adult body composition. This is supported by the fact that lower glycogen synthesis
over night was observed in subjects with diabetes mellitus type 2 compared to insulin-sensitive
subjects [45], so that high evening higher-GI-CHO intake may shift glucose metabolites to de-novo
lipogenesis and subsequent fat storage among adolescents experiencing physiological insulin resistance.
Hence, future studies should also address the relevance of higher-GI-CHO consumed in the evening
for body composition.
Glucose metabolism is closely linked to fatty acid metabolism; therefore insulin resistance and
accumulation of fat in the liver are tightly interrelated [46]. Two studies, although heterogeneous
in their methods (intervention vs observational study, extreme (dietary GI 32 vs. 84) vs. habitual
low/high-GI diets and determination of liver steatosis severity by 1H magnetic resonance spectroscopy
and liver ultrasonography scanning, respectively), suggest that the dietary GI may be related to liver
function [47,48]. However, it should be noted that imaging methods as used in these studies are time-
and cost-intensive and therefore often infeasible in observational studies.
Our study used validated indices, which are preferable over the use of single liver enzyme
activities in that they include more than one metabolic parameter predictive of hepatic steatosis.
Our results extend existing evidence [47,48] suggesting that a higher-GI diet and an increased intake
of higher-GI-CHO are both of longer-term relevance for hepatic steatosis and that these associations
are specific to evening intakes.
It is important to note that HSI was shown to reflect the presence as well as the degree of hepatic
steatosis [24]. The cut-off value to rule-out hepatic steatosis is 30, while the cut-off value to postulate
the presence of hepatic steatosis is 36. In our healthy sample, only those in the lowest tertile of
higher-GI-CHO intake had HSI levels clearly below 30, whereas those in the middle and highest
tertiles had mean HSI values between 30 and 31 (Figure 2).
Similarly, albeit non-significant associations were observed with the FLI. Both HSI and FLI have
similar efficacy to detect steatosis compared to an imaging method and were described as appropriate
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are that the latter considers the activity of GGT instead of ALT and AST activities as well as TG and
waist circumference in addition to BMI. In an earlier analysis of ours, dietary GI during adolescence
had been related to both GGT and ALT in young adulthood [4], but a recent meta-analysis does not
support an independent effect of the GI-level of diets on TG concentrations [50]. Therefore, the FLI
could by definition be less responsive to the exposures under consideration in the present analysis.
Yet, chance must be considered as a possible explanation as well. However, it was noted that results
for fetuin A—one of our secondary outcomes, which is closely related to hepatic steatosis [16]—are in
line with the findings for HSI and were independent of waist circumference.
We did not observe a relation of morning or evening GI, GL, or intake of low-GI-CHO or
higher-GI-CHO to the pro-inflammatory score. In an earlier study of ours, a higher dietary GL as
well as higher daily intakes of higher-GI-CHO during adolescence were associated with increased
levels of IL-6, but not with hs-CRP, IL-18 or adiponectin in young adulthood [5]. Individual analyses
of parameters which are included in the score confirmed these results for the current sample, albeit
without an indication of a day-time specificity: Both a higher morning and a higher evening GL as
well as higher intakes of morning and evening higher-GI-CHO were associated with increased adult
levels of IL-6 (data not shown).
Conversely, a day-time specificity emerged for omentin. Here, higher morning GI during
adolescence was associated with increased young adult omentin levels. The association was unaffected
by additional adjustment for adult waist circumference. Consistent with our results, data from healthy
normal weight children showed higher insulin levels and lower insulin sensitivity in children in
the highest as compared to the lowest tertile of omentin [51]. As omentin is discussed to exert
anti-inflammatory actions [17], we speculate that our findings may reflect an upregulation due to a
habitual counter-regulatory omentin increase in response to regular pro-inflammatory signals. Indeed,
a high-GI diet—regularly provoking postprandial glycemic spikes—induces increased oxidative
stress [52]. In terms of the day-time specificity, it is worth noting that postprandial glycemic spikes
following high GI meals are highest after breakfast compared to lunch and tea times [44].
If confirmed by other studies, our findings have several potential implications: First, the time
of day when higher-GI foods are consumed is of relevance, so that a shift in focus is needed from
‘what we eat’ also to ‘when do we eat what’. Second, our observations are based on habitual dietary
intake data and reveal that the analyzed population consumed on average more than half of their
morning and evening carbohydrates from higher-GI food sources, which translates into a third of their
morning and evening energy intake from higher-GI food sources. Of note, those who consumed less
than a quarter of their evening energy intake from higher-GI-CHO (i.e., those in the lowest tertile)
had a mean HSI below 30. Hence, our data suggest that reducing higher-GI-CHO intake from a
third to a quarter of energy intake in the evening offers preventive potential for adult type 2 diabetes
risk. Third, the absence of a relation with morning GI, GL, low-GI-CHO or higher-GI-CHO does not
justify a recommendation to shift high evening intake of high-GI foods to morning hours, as there is a
possibility of adverse longer-term effects for chronic subclinical inflammation in response to habitual
postprandial spikes induced in the morning. Moreover, due to the fact that the delay in chronotype
(i.e., the preference for a delayed timing of sleep on free days) peaks approximately at the age of
20 years [13], encouraging morning food intake may augment circadian misalignment and would
therefore be counterproductive for metabolic health in adolescents and young adults.
Our study is limited by the availability of one blood sample in young adulthood only; the use of
surrogate markers of diabetes risk instead of hard end points can be considered as further limitation.
However, our population was too young to have established type 2 diabetes. Moreover, it needs to be
assumed that the analyzed outcomes themselves follow individual circadian rhythms [53,54] so that
measurement of risk markers takes place in blood samples potentially withdrawn during the acrophase
(i.e., the maximum value of one rhythm cycle) of one parameter and the bathyphase (i.e., the minimum
value of one rhythm cycle) of another parameter. However, withdrawing all blood samples at the
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of all outcome parameters to day-time. Consequently, differences in the circadian rhythm between
the analytes do not affect the calculated indices (HOMA2 sensitivity, HSI, FLI, pro-inflammatory
score). Concerning our dietary predictors, the GI concept is still contentious. Recent criticism relates
to methodological aspects [55] and GI extrapolation to mixed meals [56]. However, the validity of
dietary GI has been demonstrated repeatedly using different methodological approaches [15,57] and
ISO-standardization will further reduce methodological errors in measuring the GI of foods [58].
It could be criticized that we excluded only participants who regularly under-reported their energy
intake from our analyses. However, exclusion of under-reporters is controversial [59] and it should
be noted that in our study only a further N = 77 participants had ever underreported their energy
intake in any of their protocols (median: 7 protocols). Additional exclusion of these participants
did not affect our results. Only the association of higher-GI-CHO with HOMA2 sensitivity was
attenuated towards a trend (p = 0.08), which is likely attributable to the lower number of participants
included in this sensitivity analysis (data not shown). Overall, our results could be subject to concerns
about multiple testing. However, three separate sets of primary outcomes were considered (insulin
sensitivity, hepatic steatosis, subclinical chronic inflammation) and different mechanisms are discussed
for the relevance of GI, GL or CHO from low- or higher-GI sources for these outcomes. Moreover, we
abstained from stressing and/or discussing findings that tended to be associated (p-values between
0.05 and <0.1). Generally, the DONALD population is characterized by a socio-economic status that is
above average [18], so that extremes in nutritional behavior might not be represented. Consequently,
a selection bias is likely introduced. However, the relatively homogeneous sample decreases the
vulnerability of the results to residual confounding.
The overall strengths of the study are its prospective design and the detailed repeated dietary
data including day-time specific nutritional information during adolescence. Due to the recruitment of
study participants during infancy and the annually repeated data collection, 3-day weighed dietary
records are documented by participants accustomed to the procedure. Moreover, availability of data
on several important potential confounders, i.e., early-life characteristics, anthropometrics, familial
and socio-economic factors strengthen our analyses.
5. Conclusions
In conclusion, our data suggest that young adult insulin sensitivity and hepatic steatosis markers
are responsive to higher evening, but not morning intakes of higher-GI-CHO during adolescence,
whereas there was no association with adult subclinical inflammation. Avoidance of large amounts of
higher-GI-CHO in the evening and/or their replacement by low-GI-CHO during adolescence may
present a promising preventive strategy to reduce risk of type 2 diabetes in adulthood.
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Abstract: Type-2 diabetes (T2D) is one of the fastest growing chronic diseases worldwide. The PREVIEW
project has been initiated to find the most effective lifestyle (diet and physical activity) for
the prevention of T2D, in overweight and obese participants with increased risk for T2D. The
study is a three-year multi-centre, 2 × 2 factorial, randomised controlled trial. The impact of a
high-protein, low-glycaemic index (GI) vs. moderate protein, moderate-GI diet in combination
with moderate or high-intensity physical activity on the incidence of T2D and the related clinical
end-points are investigated. The intervention started with a two-month weight reduction using a
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low-calorie diet, followed by a randomised 34-month weight maintenance phase comprising four
treatment arms. Eight intervention centres are participating (Denmark, Finland, United Kingdom,
The Netherlands, Spain, Bulgaria, Australia, and New Zealand). Data from blood specimens, urine,
faeces, questionnaires, diaries, body composition assessments, and accelerometers are collected at
months 0, 2, 6, 12, 18, 24, and 36. In total, 2326 adults were recruited. The mean age was 51.6 (SD 11.6)
years, 67% were women. PREVIEW is, to date, the largest multinational trial to address the prevention
of T2D in pre-diabetic adults through diet and exercise intervention. Participants will complete the
final intervention in March, 2018.
Keywords: diet; protein; carbohydrate; glycaemic index; physical activity; obesity
1. Introduction
Type-2 diabetes (T2D) is a disease associated with serious comorbidities, including microvascular
(retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular) events [1]. The estimated
global prevalence is approximately 8% and a prediction suggests that this will increase by 55% up to
the year 2035 [2,3]. An important risk factor for T2D is obesity (BMI > 30 kg/m2) predicting a more
than 10-fold increase in incidence compared to normal weight [4]. Weight gain during adulthood is
also an independent risk factor for T2D [5], as are genetic inheritance, unhealthy dietary habits, and
insufficient physical activity [6–8].
Long-term studies have shown benefits of a lifestyle intervention (diet and exercise), on T2D
incidence in China [9], USA [10], and Finland [11]. Lifestyle change (diet, physical activity, weight
loss) may reduce the incidence of T2D by 28–59% [12]. The American Diabetes Prevention Program
(DPP) [13], the Finnish Diabetes Prevention Study (DPS) [14], and the Chinese Da Qing Diabetes
Prevention Study [15] were all designed to produce weight loss by prescribing a higher carbohydrate
(CHO) (>50 percent of energy (E%) from CHO), low-fat (<30 E%) diet approach, which reflected the
understanding of a prudent diet 20 years ago. No attention was paid to glycaemic index (GI), per se,
and, to date, no studies have investigated the role of GI for prevention of type-2 diabetes.
Other dietary prescriptions that produce significant and sustainable weight loss may also be
effective in T2D prevention. Current international recommendations include lower ranges for CHO
intake [16] and a recommendation to choose lower GI foods [17]. A combination of lower CHO (45 E%),
higher protein, together with lower GI, might be the optimal diet for prevention of T2D [18], perhaps
related to sustained weight loss as shown in medium term trials [19]. To date these hypotheses have
not been tested in large trials of long duration [20].
The program for physical activity in the trials described above followed the international public
health recommendations, that is, a total of approximately 150 min per week of moderate-intensity
aerobic activities or 75 min of vigorous intensity activity [10,14]. A question, not examined in
earlier studies, is whether the metabolic responses are different between higher- and lower-intensity
exercise programs. Moderate-intensity exercise relies relatively more on fat oxidation, whereas
vigorous-intensity exercise relies more on CHO oxidation and use of intramuscular substrates [21].
Houmard et al. found that total exercise time, not intensity or exercise energy expenditure, was associated
with the greatest improvement of insulin sensitivity in obese participants [22]. However, the hypothesis
that physical activity with different intensity levels may differentially affect T2D prevention has yet to
be tested in any large-scale intervention.
Since obesity is a strong risk factor for T2D, any successful prevention program should be able
to prevent weight regain in individuals after a significant weight loss. The high heterogeneity of
dietary intervention design prevents firm conclusions being drawn regarding preferred macronutrient
composition [23]. Notably a recent multi-centre trial ‘DiOGenes’ (Diet, Obesity, and Genes) identified a
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composition in preventing weight regain over six months [19] and in a smaller subset over
12 months [24], after two months of rapid weight loss.
Despite the evidence that a lifestyle program combining prudent diet, increased physical activity
and weight loss reduces the risk for T2D in susceptible individuals [12], important details remain
unanswered. These include the long-term effects and sustainability of diets higher in protein with
a lower glycaemic load, combined with the effects of higher intensity exercise. The present paper
describes PREVention of diabetes through lifestyle Intervention and population studies in Europe and
around the World (PREVIEW), a large multi-centre international randomised controlled trial in adults
designed to answer these questions.
2. Methods
2.1. Aims of the Study
The aim is to determine the effects and interactions of two diets and two physical activity
programmes on the prevention of T2D in overweight, pre-diabetic adults, who have undergone a short
period of significant weight loss. Our primary hypothesis is that a higher protein, lower CHO/low GI
diet (based on the DiOGenes study [19]) will be superior in preventing T2D when compared with a
moderate protein, higher CHO/moderate GI diet (based on the DPS and DPP studies [10,14]). We also
hypothesise that high-intensity physical activity will be superior compared to moderate-intensity
physical activity [25].
Each participant receives one of the two dietary programs, and one of the two physical activity
programs, thus, we have four groups (high protein diet and high-intensity physical activity; moderate
protein diet and high-intensity physical activity; high protein diet and moderate-intensity physical
activity; moderate-protein diet and moderate-intensity physical activity). The majority of outcomes
will be analysed by using these four arms. The primary endpoint and statistical power calculations are
based on a two-arm design (diets compared against each other).
2.2. Primary and Secondary Endpoints
The primary endpoint is incidence of T2D in high vs. moderate protein diet measured over a
36-month intervention period, based on the WHO criteria [26] of either (i) oral glucose tolerance test
(OGTT) with fasting plasma glucose (FPG) > 7.0 mmol/L and/or 2-h post prandial (75 g glucose
load) plasma glucose ≥11.1 mmol/L; or (ii) T2D diagnosed by a medical doctor between the clinical
investigation days (CID) of PREVIEW, by using random plasma glucose ≥11.1 mmol/L in the presence
of symptoms of diabetes, OGTT, or glycated haemoglobin (HbA1c). Asymptomatic individuals with
a single abnormal value will have to repeat the test within 2–4 weeks to confirm the T2D diagnosis.
The secondary endpoints include changes in HbA1c, body weight, body mass index (BMI), waist, and
thigh circumference, body composition, insulin sensitivity, including Matsuda Index [27], glucose
tolerance assessed by the area under the curve during OGTT, blood pressure, serum lipids, C-reactive
protein, liver enzymes, perceived quality of life and work ability, habitual well-being, sleep, chronic
stress, and subjective appetite sensations.
Other endpoints assessed by sub-group studies include liver fat content using magnetic resonance
imaging (MRI) and proton magnetic resonance spectroscopy (H-MRS); colorectal cancer risk assessed
from faecal markers; gut microbiome community assessment from faecal collections; maximal
oxygen uptake capacity (VO2 max); urine metabolite profiles using metabolomic techniques and
food reward outcomes.
2.3. Study Setting and Design
The PREVIEW intervention study for adult participants has eight study sites: University of
Copenhagen (Denmark), University of Helsinki (Finland), University of Maastricht (The Netherlands),
University of Nottingham (UK), University of Navarra (Spain), Medical University of Sofia (Bulgaria),
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The 36-month intervention consists of two phases (Figure 1): a two-month period of rapid weight
reduction achieved using a commercial low-calorie diet (about 800 kcal/day), followed by a 34-month
randomised lifestyle (diet and physical activity) intervention phase for weight loss maintenance.
 
Figure 1. PREVIEW intervention: the general study design.
Clinical investigation days (CID) are conducted throughout the intervention, from CID1 (baseline)
to CID7 (end of trial). At CID visits, anthropometry, blood tests, and questionnaires are performed and
collection of completed diet records, accelerometers, and 24-h urine samples is done. Adverse (AE)
and serious adverse events (SAE) and concomitant medications are recorded. In addition, a total of
17 group visits, leaded by instructors, are held throughout the trial to support lifestyle modification.
The CID assessments and group visits are conducted within University settings or associated
Clinics. Participants follow the diet and physical activity counselling advice in a “real-life” setting
without daily supervision from researchers.
2.4. Participants, Recruitment, and Randomisation
The inclusion criteria were: age 25–70 years (from mid-2013 to mid-2014 individuals aged 25–45
and 55–70 years were enrolled, and from mid-2014 onwards additionally age-group 45–54 years);
BMI > 25 kg/m2; pre-diabetes confirmed by an OGTT using the American Diabetes Association
(ADA) criteria (13): (i) increased fasting glucose (IFG), with venous plasma glucose concentration
of 5.6–6.9 mmol/L when fasted; and/or (ii) impaired glucose tolerance (IGT), with venous plasma
glucose concentration of 7.8–11.0 mmol/L at 2 h after oral administration of standard 75 g glucose
dose, and fasting plasma glucose <7.0 mmol/L. The main exclusion criteria were T2D, and any illness
and/or medication with known or potential effect on compliance (e.g., unable to follow the physical
activity program) or the main outcomes. A complete list of inclusion and exclusion criteria is presented
as Supplementary Table S1.
Participants were recruited using multiple methods across the eight study sites, e.g., newspaper
advertisements, newsletters, radio and television advertisements/interviews, and direct contact
with primary and occupational health care providers. Interested individuals were contacted for the
pre-screening. In the interview, inclusion and exclusion criteria were queried, including the Finnish
Diabetes Risk Score [28] assessment. Potential participants were given written and oral information.
Signed informed consent was required prior to commencement of laboratory screening.
The laboratory screening comprised measurements of weight, height, resting blood pressure,
electrocardiography (in those aged 55 years or more), and an OGTT. A fasting blood sample was
collected from the ante-cubital vein for later assessment of full inclusion and exclusion criteria, whilst
glucose concentration was immediately analysed at each study site (HemoCue™, Angelholm, Sweden;
Reflotron™, Roche diagnostics, Switzerland; or EML105 Radiometer, Copenhagen). Participants were
then given a standard glucose drink (75 g glucose, dissolved in 300 mL water), which they had to
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drinks or smoking were allowed and participants were required to remain sedentary during the test.
The 0 and 2 h glucose concentration were used to identify those with pre-diabetes. Potentially eligible
participants had fasting blood samples analysed to assess safety with haemoglobin, creatinine and
alanine (ALT)/aspartate transaminase (AST).
Upon confirmation of eligibility, participants were enrolled into the trial and randomised to one
of the four treatment groups. Randomisation was stratified by gender and age group (25–45, 46–54,
and 55–70 years of age), and sequentially assigned from each stratum to different interventions, hence,
securing an even distribution of gender and age group over the four intervention arms in each centre.
2.5. Description of Interventions
2.5.1. Low-Calorie Diet (LCD)
The trial started with a two-month (eight-week) weight reduction program using a commercial
LCD, with a requirement to lose ≥ 8% initial body weight in order to continue to the weight
maintenance phase. The LCD consisted of 3.4 MJ (800 kcal), 15–20 E% fat, 35–40 E% protein (84
g protein), and 45–50 E% CHO. The daily diet comprised of 4 × 40 g Cambridge Weight Plan® meal
replacement sachets (Cambridge Weight Plan Ltd., Corby, UK), three of which were dissolved in 250
mL low fat milk ,or similar lactose-free alternatives, and one in 250 mL water. Energy-free drinks
were permitted. Moreover, a maximum of 400 g of non-starchy, low-CHO vegetables, such as lettuce,
asparagus, broccoli, celery, cucumber, mushrooms, radish, tomato, and watercress could be consumed.
During the LCD, participants attended group visits at weeks 2, 4, 6, and 8. Body weight,
AE, SAE, and concomitant medications were recorded, LCD sachets dispensed, and dietary and
behavioural instructions given. No specific instructions on physical activity were given during
the LCD weight-reduction phase. Upon completion of the two months (CID2), participants who
failed to reach the target weight reduction (i.e., ≥ 8% of initial body weight) were excluded from
the intervention.
2.5.2. Weight Maintenance Phase: Intervention Diets
The two intervention diets are described in Table 1. The moderate protein (MP) diet is based
on the DPS-dietary advice [14] aiming to reach a moderate protein (15 E%) and higher CHO (55 E%)
macronutrient distribution with at least moderate dietary GI (>56), following current recommendations
for prevention of T2D [17]. The (HP) diet has a higher protein (25 E%) and moderate CHO (45 E%)
distribution with lower dietary GI (<50), based on the most successful weight-loss maintenance diet in
the DiOGenes study [19]. Protein intake is higher and CHO intake is lower than the recommended
range for prevention of T2D [16,17].
Both intervention diets are moderate in fat (30 E%) and the target macronutrient profile and food
choices are supported by evidence for prevention of weight gain and/or T2D [8,23]. Notably, increased
intake of sugar-rich foods or refined grains is not encouraged as a means to reach the higher CHO
level, nor is increased consumption of red meat encouraged within the higher protein diet.
The diets are consumed ad libitum with respect to energy, with no provision of an individual
target for daily energy intake. Self-monitoring of total energy consumption is not required. However,
participants are instructed about controlling portion sizes of specific food types in order to achieve
the macronutrient and GI prescriptions, and in self-monitoring and adjustment of portion sizes in
general, in order to maintain their body weight loss. They are also encouraged to follow a regular meal
pattern. Additional weight reduction is allowed, but without anything other than adherence to the
maintenance diet and physical activity regimens.
The participants are given examples of daily eating plans with foods in appropriate proportions
to reflect the macronutrient and GI requirements of the two interventions. A food-exchange list assists
in self-selected variety, whilst preserving the required macronutrient and GI levels. Cooking books








Nutrients 2017, 9, 632
Table 1. Description of the PREVIEW dietary interventions.
Higher Protein (25 E% a)
Moderate Carbohydrate (45 E%)
Low GI b (≤50) Diet
Moderate Protein (15 E%)
Higher Carbohydrate (55 E%)
Medium GI (≥56) Diet
Comparison between the groups
• Protein intake higher
• Carbohydrate intake lower
• GI lower
• Protein intake lower
• Carbohydrate intake higher
• GI medium
Food items with increased use
(relative to the other group)
• Whole-grain cereals with low GI
• Pasta




• Whole-grain cereals with
moderate/high GI, e.g., bread




• Most fruits and vegetables
• Vegetable oils, margarine
• Red meat (decreased in both)
• Sugar-sweetened beverages (decreased in both)
a E%, percentage of energy; b GI, glycaemic index.
2.5.3. Weight Maintenance Phase: Physical Activity Programmes
The trial has two physical activity interventions with a similar target for energy expenditure
(>4.2 MJ/week, >1000 kcal/week), comprising high-intensity (HI) exercise or moderate-intensity (MI)
exercise, as shown in Table 2. Measured heart rate using a heart rate monitor or wrist palpation,
and/or perceived exertion using the Borg scale [29], are the principal methods of controlling the
intensity. The participants may choose from several exercise options with similar level of metabolic
turnover (energy expenditure divided by resting metabolic rate, i.e., MET values). The specific advice
is based on the U.S. Centres for Disease Control and Prevention (CDC) recommendations of 75 min
high-intensity (HI) or 150 min moderate-intensity (MI) physical activity weekly [30]. We developed a
leaflet and other written instruction materials for the two PA groups. Physical activity is generally not
supervised by the PREVIEW team, but participants are allowed to join supervised exercise groups of
their own choice.
Table 2. Description of the physical activity interventions.
High-Intensity Physical Activity (HI) Moderate-Intensity Physical Activity (MI)
Heart rate • 76–90% HRmax a or 61–80% HRR b • 60–75% HRmax or 45–60% HRR
Examples of activities
(these may vary depending on the
fitness level of the participant)
• Bicycling, vigorous effort
• Strenuous ball games
• Aerobics with very vigorous effort,
e.g., with extra weights
• Jogging > 8 km/h
• Swimming, vigorous effort
• Cross-country skiing
• Bicycling, moderate effort
• Leisurely ball games
• Most conditioning exercises
(aerobic, power yoga, etc.)
• Brisk walking (4–6 km/h)
• Swimming, recreational
• Downhill skiing
Weekly duration (in total) • at least 75 min • at least 150 min
Recommended weekly frequency • 2–3 times • 3–5 times
Daily duration (guideline) • 25–40 min • 30–50 min (may be broken down intoshorter sessions)
Additional exercises
• Muscle conditioning exercises, by using own weight: twice weekly at home,
15–20 min per session.
• Stretching: twice weekly, 15–20 min per session
a HRmax = max heart rate, defined as 220—age (220 in children under 16 years of age); b HRR = heart rate reserve,
defined as the difference between measured resting HR and estimated HRmax.
A critical issue in PREVIEW is that many participants may be morbidly obese (BMI > 40)
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and even risky. We addressed this point during the recruitments by specifically asking about perceived
competence in coping with our program, and by ECG in all volunteers aged >55 years. Moreover,
significant weight reduction (≥ 8% of baseline body weight) during the first two months’ LCD period
will also simultaneously decrease the cardiovascular risks. The flexibility of our exercise program
(only target energy expenditure is specified, the modes of exercise are due to the participant) is also
likely to improve safety and adherence.
2.5.4. Group Visits and the Behavioural Modification Program
Group visits (8–12 individuals), are conducted throughout the three year intervention to deliver
the behaviour modification information in relation to diet and physical activity [31]. There are 17 group
visits, each 1–2 h, with decreasing frequency as the trial progresses. The behaviour modification
programme is developed based on theories and evidence from health psychology and behaviour
change [32–34]. For example, participants’ beliefs about the consequences of behaviour (i.e., outcome
expectancies), their intention to change their behaviour in the long run, and their belief in their ability
to achieve the behaviour change goals (self-efficacy) are relevant predictors of successful behaviour
change. Counsellors may apply respective behaviour change techniques [35] that are scheduled to
common stages of behaviour change [36].
At the beginning of the weight-maintenance phase (i.e., month 2), the participants are instructed
on how to plan, to start, and to follow the physical activity programme. In the group sessions,
the participants are also instructed on basic principles of increasing physical activity and in
motivational and self-regulative behaviour techniques to overcome barriers to exercise and behaviour
modification. Stretching and home-based muscle-conditioning exercises are also supervised in a
group-based session accompanied with written educational material [31].
2.6. Collection of Data and Description of Analyses
Data are collected from biological specimens (blood, urine, faecal), self-administered records
and questionnaires, and an activity-monitoring device (ActiGraph GT3X accelerometer; ActiGraph,
Pensacola, FL, USA) (see Table 3 with a description of timing). The CIDs are scheduled for a specific
week and the aim is to make the measurements as precisely as scheduled. To accommodate as complete
a data collection as possible we allow the following visit windows: month 2: −3 to +5 days; month 6:
±1 weeks; month 12: ±2 weeks; the remaining measurement points: ±4 weeks.
Blood samples are initially stored locally at −80 ◦C, then transported and analysed centrally at
the National Institution for Health and Welfare (THL) in Helsinki, Finland. Diet records are analysed
at each site using local food composition data and software. If available, local GI data for individual
food items are used, and when not available, generic global GI data are used. Accelerometer data are
downloaded at local sites, and collated and analysed centrally at the Swansea University, Wales, UK.
All questionnaires used in PREVIEW were prepared in English, then translated into the local
language in Finland, Denmark, The Netherlands, Spain, and Bulgaria using authorized translators.
A second authorized translator then back-translated the local versions to English, with this iterative
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Table 3. Overview of main data collection methods at different clinical investigation days (CID)
in PREVIEW.
Outcome Data Collection Method Assessment Time-Points (Month)
0 2 6 12 18 24 36
CID1 CID2 CID3 CID4 CID5 CID6 CID7
Glucose tolerance/diagnosis
of T2D
75 g oral glucose






blood specimen × × × × × × ×
Urinary nitrogen 24-h urine collection × × × × ×
Risk markers for colon cancer
(e.g., Short Chain Fatty Acids) 3-day faecal collection
a × ×
Gut microbiota Faecal spot sample a × ×
Weight, height, BMI and
anthropometrics
Weight; height (week 0 and
156); waist and hip
circumference
× × × × × × ×
Body composition
Body composition by DXA,
BodPod or Bioelectrical
impedance (BIA)
× × × × × ×
Blood pressure and resting
heart rate
Resting blood pressure and
heart rate × × × × × × ×
Nutrient intakes, dietary GI
and food consumption 4-day food record × × × × ×
Physical activity
7-day accelerometer,
7-day physical activity log,
Baecke questionnaire
× × × × ×




(listed with references in
Supplementary Table S2)
× × × × × ×





× × × × × ×
Stress and mood
Perceived Stress Scale (PSS),
Profile of Mood
Scale (POMS)
× × × × × ×
Quality of life WHO Quality of Lifequestionnaire x x x x





x x x x
a In a subgroup (n = 250) in Helsinki and Auckland; b In a subgroup (n = 120) in Copenhagen, Maastricht, Navarra
and Nottingham.
2.7. Data Management
All data are stored in a central project database at the University of Copenhagen. The central
database ensures standardized handling and storing of data and the possibility for easy extraction and
delivery of data both within and after the official project period (2013–2018).
Currently, the database receives input from four data sources on a regular basis: (1) All immediate
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the CIDs and entered into OpenClinica server (electronic case report form); (2) data on social-cognitive
determinants of behaviour, on cultural and socio-demographics, as well as socio-economic components,
are collected by the questionnaire delivery platform (QDP), designed for PREVIEW by NetUnion.
The participants enter their own data into the QDP. A paper version of the questionnaires is also
available; (3) physical activity is reported using the Baecke inventory, and an electronic physical activity
log (PAL), designed by Swansea University, University of Stuttgart, and implemented by NetUnion;
(4) the Central Lab at the National Institute for Health and Welfare (THL) enters all laboratory analyses
into the data hub. Data from analyses of the ActiGraph data accelerometers, from food diaries,
and from the maximal oxygen uptake (VO2 max) analyses are imported from all sites.
2.8. Governance and Quality Management
The intervention trial is led by Prof. Fogelholm at the University of Helsinki, in collaboration
with the project coordinator, Prof. Raben at the University of Copenhagen. In this large, international
multi-centre trial, we are collaborating intensively to ensure data collection of high-quality and
consistency of the intervention across all sites.
Specific working groups were formed with relevant site representatives. The purpose of these
working groups is to discuss and agree on questions related to dietary topics, physical activity, data
management, and other methodological and medical issues.
During the recruitment phase, principal investigators from each centre participated in a monthly
teleconference, which continues at regular intervals throughout the intervention.
The core personnel for each site meet annually at a three-day general assembly for the full
PREVIEW consortium. PREVIEW has a website [37] with both public access and a restricted area for
the PREVIEW researchers.
An electronic trial master file with relevant documents has been designed and is maintained by
the University of Copenhagen within the private part of the PREVIEW website. All written study
material is uploaded and made available at the PREVIEW website private area, including the protocol
and amendments, standard operating procedures (SOPs), and instruction materials for the intervention
subjects, in order ensure that comparable methods are followed across individual sites. The SOPs are
reviewed and revised as needed and also new SOPs are prepared, if necessary.
Representatives from each intervention site participated in two training sessions, each of 2–3 days
duration, in 2013. One session focussed on the main study protocol, the CID protocols, and all
outcome measurements (University of Copenhagen). The other session focused on instructor training
in group counselling (behaviour change) methods (University of Stuttgart). Attendees then trained
their local staff.
2.9. Statistical Power and Basic Analyses
The anticipated three-year incidence of T2D in the PREVIEW trial is 21%, based on data from
the Finnish DPS and US DPP [10,11]. The power calculation was derived for comparison of the two
dietary interventions (HP vs. MP).
It was hypothesized that a risk reduction of one quarter (1/4) in the MP group would reduce
the incidence of T2D incidence from 21% to 16%, and that a risk reduction of one half (1/2) in the
HP group would reduce the incidence of T2D from 21% to 10.5%. Consequently, the sample size
required to detect this difference in T2D incidence (16% vs. 10.5%) was at least 649 per diet group or
1298 participants in total (for a two-sided comparison with a power (1-ß) of 80% and p < 0.05), with
a 10% drop-out during the first 10 months from month 2 (CID2) onwards, and another 20% drop-out
between months 12 (CID4) and 36 (CID7). Thus, the number of participants needed for the intervention
was 1802. To allow an estimated drop-out of 25% as a result of failure to lose >8% of initial body weight
during the two-month LCD period, the number of participants required to be enrolled into PREVIEW
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The primary data are analysed statistically using the principle of ‘intention-to-treat’ (ITT cohort)
and also as a completers’ cohort. A ‘completer’ is defined as a participant who has remained in the
trial for the full three year intervention period, or who has been diagnosed with T2D before the end of
the intervention.
The primary outcome in the adults’ trial is incidence of T2D. For statistical analysis assessing the
effect of the two diets on the T2D is a ‘semi-parametric Cox proportional hazards regression model’.
Missing data are addressed using hot-deck imputation. Missing covariate information is addressed
using multiple imputation. Sensitivity analyses (e.g., complete-case analyses without drop-outs) will
be carried out to assess if censoring was informative or non-informative.
For statistical analysis of the continuous secondary outcomes (e.g., blood chemistry, anthropometrics,
etc.) a ‘linear mixed model’ is used. For the categorical outcomes (e.g., sex, educational attainment,
proportion of subjects maintaining a defined weight loss, etc.), the type of statistical analysis is ‘logistic’
or ‘ordinal mixed-effects model’. The parameter of interest is the difference in odds ratio between the
intervention groups. Although the main statistical analyses will be done by using the entire cohort,
one of the most important stratified analyses will use an age-group (e.g., above and below 65 years)
stratification. By comparing older against younger participants we might obtain new insight on
whether dietary protein content in this respect has different effects on, e.g., body composition, weight,
and clinical variables.
2.10. Ethical Issues
The study protocol and amendments were reviewed and approved by local Human Ethics
Committees at all study sites. The work of PREVIEW is carried out in full compliance with the relevant
requirements of the latest version of the Declaration of Helsinki (59th WMA General Assembly, Seoul,
Korea, October 2008), and the ICH-GCP, The International Conference on Harmonisation (ICH) for
Good Clinical Practice to the extent that this is possible and relevant. All participants provided written
informed consent prior to commencing screening procedures in clinic. All information obtained during
the trial is handled according to local regulations and the European Directive 95/46/CE (directive on
protection of individuals with regard to the processing of personal data and on the free movement of
such data). The trial is registered with ClinicalTrials.gov, NCT01777893.
3. Results
As PREVIEW is an on-going trial, only results obtained from participant screening and baseline
phases are presented here. Screening was conducted from June 2013 to February 2015. On average,
35% of the pre-screened individuals were eligible for the laboratory screening. Further, 43% of the
screened participants were found to be eligible for the trial. In total, 2326 overweight, pre-diabetic
adults were enrolled and randomised into the trial. This was 97% of the original pre-specified target
(Figure 2). Approximately half of the participants were 55–70 years at baseline (Table 4).
Baseline characteristics from blood biochemistry and anthropometric assessments are shown
assigned to each intervention group in Table 5. The basic characteristics of the groups are similar.
A notable feature of the participants is that the mean baseline fasting glucose concentration was
approximately at the mid of the eligibility range, whereas the mean 2-h glucose concentration was
at the lower cut-off point. According to the OGTT laboratory data, 1389 (62%) of all participants had
increased fasting glucose at baseline, 506 (23%) had impaired glucose tolerance and 286 (13%) had both
of these pre-diabetic indicators. At baseline (CID1), 25 participants (1%)—who all had been diagnosed
with pre-diabetes at screening—were not diagnosed with pre-diabetes anymore. The prevalence of
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Figure 2. PREVIEW intervention: the subjects’ flowchart.
4. Discussion
To our knowledge, PREVIEW is the first trial of its kind comparing two potentially effective
interventions, a novel higher protein/low GI diet vs. current best practice moderate protein, higher
CHO/moderate GI diet, in order to determine whether there is a more efficient lifestyle strategy to
prevent T2D. Moreover, previous studies have neither used an effective weight-loss phase by LCD as a
start of the intervention, nor a multi-country design.
Our inclusion criteria for “pre-diabetes” differed from the Finnish DPS. Here, IGT was an
unconditional requirement without limits for IFG [14]. In the US DPP, both IGT and IFG were
required [38] and the lower limit for IFG was 5.3 mmol/L (vs. 5.6 mmol/L in PREVIEW). It is unclear
if the differences in diagnostic criteria between these studies have any major effects on the outcome.
In addition to the diagnostic cut-offs, per se, and the distribution of results within the diagnostic criteria
(i.e., above the lower and below the upper cut-off points) may have an effect on the outcome [39].
In PREVIEW, a majority of the subjects were eligible due to higher fasting blood glucose, rather than
impaired glucose tolerance (higher 2-h value). A small proportion (1%) were no longer diagnosed with
pre-diabetes at baseline. This may be explained by change of method (HemoCue™ or Reflotron™ at
screening, or the laboratory assessment at baseline), to normal day-to-day variance in the assessed
variables, or to a change in lifestyle after being accepted as a participant to PREVIEW. For future
studies of T2D prevention, a single measurement of HbA1c, which is becoming the standard clinical
practice in many countries may save both time and costs [40]. Still, there remains some controversy as
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PREVIEW is a much larger trial than both the Finnish DPS (n = 522) [11] and Chinese Da Qing
study (n = 577) [9], although smaller than the DPP (n = 3234) [10]. However, in the DPP a third of
the participants received ‘Metformin’ in addition to dietary advice; hence, the number of participants
without medical treatment, but adhering to lifestyle intervention (diet and physical activity) was
2161, which is similar to PREVIEW. Of the above interventions, the geographical and ethnic variation
is greatest in PREVIEW. The age-range of participants in DPP and DPS was 33–67 years, slightly
narrower than in PREVIEW, but the mean age of participants is similar across the studies (50–55 years).
The large proportion of older participants in PREVIEW, (>55 years), was expected since the risk for
T2D increases with age [2], and due to the growing health consciousness of this age group, many of
whom are retired and have the time to participate in a demanding intervention. The smaller proportion
of middle age-adults is also explained by later initiation of recruitment in this age group, compared
with younger and older participants. In general, finding an adequate number of pre-diabetic subjects
was a real challenge in most countries, given the “hidden” status of this condition. Thus, recruitment
took about three times as long as planned from the beginning of the project.
One major challenge in PREVIEW is related to adherence to the diet and physical activity
programs. The HP-diet is novel and, with the higher protein content, also somewhat outside the current
boundaries of nutritional guidelines [42,43]. Whether the HP diet results in better adherence than the
MP diet with high CHO and whole-grain cereal intakes is one of the key interests in PREVIEW. Nutrient
intakes and food consumption patterns will be assessed in PREVIEW by repeated 4-d diet-records.
The poor accuracy of dietary assessment is well known [44], but it is expected that the difference
in dietary protein and CHO intakes should be sufficiently large to be detected using this method.
Moreover, protein intake is verified using 24 h urinary nitrogen excretion [45].
It may be more difficult to create a verifiable difference for GI than for protein-to-CHO ratio.
Whilst GI values of foods have been shown to provide a good summary of postprandial glycaemia [46],
difficulties in attributing GI values to foods for which there are no validated data available may add
to the variability [47], particularly in a multi-centre intervention such as PREVIEW. In DiOGenes,
the reported observed difference in mean dietary GI was small (56 vs. 60 units) [19] which increases
the requirements of precision.
The physical activity intervention in PREVIEW is not a supervised training programme.
Participants are expected to integrate activity into their daily lives and use local opportunities to
achieve their goals. To improve adherence, there is flexibility with the type of activities chosen.
A combination of measures of physical activity is used to analyse the compliance to the type of
intervention and our methods allow a description of activities that were used to achieve this.
It is probable that the HI-program will be more challenging in the long-term. Warming-up,
cooling-down, muscular conditioning exercises, and stretching are carefully explained to the
participants in order to decrease the risk for injuries. It should be noted that the HI-program in
PREVIEW is not high-intensity interval-training (HIIT). While there are some data on potential
benefits from HIIT on cardiovascular function and glucose metabolism [48], we considered the data on
feasibility and long-term maintenance of this kind of training still too limited.
In addition to good compliance of the programmes, keeping the drop-out rate as low as possible
will be challenging. Frequent contact with the research staff is one way to reduce the drop-out rate.
However, PREVIEW has been planned to study how behavioural change is realized under ‘real-life’
conditions and, hence, the fading visit design where group visits are infrequent during years two and
three of the intervention. Adherence is encouraged through a number of practices, including use of
specific behavioural change techniques [31], such as implementation intentions, or Facebook groups,
one for each randomised group, to promote attendance at group visits and CIDs. In addition, the sites
can also conduct general information lectures, physical activity sessions, and/or send a newsletter to
the participants, once or twice a year.
Compared to DPS and DPP studies, a particular feature of PREVIEW is related to the different
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norms, and socio-economic features. Although the participating countries are well-developed,
considerable variations exist, e.g., regarding food attitudes and habits, as well as traditions of practicing
physical activity.
The unique feature in the PREVIEW intervention is the direct comparison of two potentially
efficacious diet and physical activity intervention programs. Hence, PREVIEW has a clear potential to
identify a recommended optimal diet and physical activity programme to prevent T2D, a programme
which is also suitable across different countries. It is also possible, however, that PREVIEW data will
demonstrate that there are several, equally efficacious alternatives. Clearly, both answers are important
from a public health viewpoint.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/6/632/s1,
Table S1: Inclusion and exclusion criteria in the PREVIEW screening, Table S2: Questionnaires on moderators,
mediators, behaviour, and social environment.
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Abstract: Glucotoxicity and lipotoxicity are key features of type 2 diabetes mellitus, but their
molecular nature during the early stages of the disease remains to be elucidated. We aimed to
characterize glucose and lipid metabolism in insulin-target organs (liver, skeletal muscle, and white
adipose tissue) in a rat model treated with a high-sucrose (HSu) diet. Two groups of 16-week-old male
Wistar rats underwent a 9-week protocol: HSu diet (n = 10)—received 35% of sucrose in drinking
water; Control (n = 12)—received vehicle (water). Body weight, food, and beverage consumption
were monitored and glucose, insulin, and lipid profiles were measured. Serum and liver triglyceride
concentrations, as well as the expression of genes and proteins involved in lipid biosynthesis were
assessed. The insulin-stimulated glucose uptake and isoproterenol-stimulated lipolysis were also
measured in freshly isolated adipocytes. Even in the absence of obesity, this rat model already
presented the main features of prediabetes, with fasting normoglycemia but reduced glucose tolerance,
postprandial hyperglycemia, compensatory hyperinsulinemia, as well as decreased insulin sensitivity
(resistance) and hypertriglyceridemia. In addition, impaired hepatic function, including altered
gluconeogenic and lipogenic pathways, as well as increased expression of acetyl-coenzyme A
carboxylase 1 and fatty acid synthase in the liver, were observed, suggesting that liver glucose
and lipid dysmetabolism may play a major role at this stage of the disease.
Keywords: high-sucrose diet; prediabetes; glucose; lipid; metabolism; hypertriglyceridemia
1. Introduction
Type 2 diabetes mellitus (T2DM) has become an epidemic of noncommunicable diseases, with
415 million people worldwide currently living with diabetes [1]. According to the International
Diabetes Federation, about 5 million people died from DM in 2015 and the estimates indicate that
there will be about 642 million people living with DM by 2040. In addition, there are about 318 million
adults with impaired glucose tolerance (IGT), which puts them at high risk for the disease.
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Prediabetes (or intermediate hyperglycemia) already displays metabolic alterations and is a
high risk state for developing T2DM. According to the American Diabetes Association, prediabetes is
distinguished by having impaired fasting glucose (IFG) (100–125 mg/dL glucose), IGT (140–199 mg/dL
glucose 2 h after a 75-g oral glucose tolerance test), and glycated hemoglobin (HbA1c) levels between
5.7–6.4%. The prevalence of prediabetes is rapidly increasing with over 470 million people projected
with prediabetes by 2030 [2]. This likely anticipates increased morbidity, mortality, and healthcare
costs in the near future with DM management. Thus, preventing the progression of IGT and/or IFG to
T2DM is the most rational and effective way to combat the DM epidemic and lessen healthcare costs.
However, before we can succeed, we need to unravel glucose and lipid metabolism at this stage of
the disease.
Diets enriched in sugars including the intake of sugar-sweetened beverages have been consistently
linked to the increased risk of hypertriglyceridemia, obesity, T2DM, and cardiovascular disease [3].
A central feature of T2DM is hyperglycemia, as a result of excessive hepatic glucose production, insulin
resistance, and deficient secretion of pancreatic insulin. An often overlooked feature is the relationship
between glucose and lipids, whose fluxes are indeed closely interlinked through the intersection of
metabolic pathways at the acetyl-CoA formation [4]. Impairment of one pathway can indirectly have
a major impact on another [4,5]. Molecular and metabolic abnormalities in insulin action, such as
peripheral tissues (muscle, liver, and adipose tissues) insulin resistance, together with minor defects in
insulin secretion, can be clearly identified before the development of obesity or hyperglycemia. These
factors contribute to the increased fatty acid influx into the liver and muscle causing accumulation
of toxic lipid metabolites. Particularly, chronically increased levels of plasma nonesterified fatty
acids (NEFA) and triglyceride (TG)-rich lipoproteins impair lipid metabolism, a process referred to as
lipotoxicity [6]. Furthermore, when the NEFA supply exceeds metabolic capacity, lipids accumulate in
peripheral tissues, such as liver and muscle, inducing organ dysfunction [6]. Several recent lines of
evidence show that the typical dyslipidemia in T2DM patients, characterized by elevated TGs, low high
density lipoprotein cholesterol (HDL-c), and the predominance of small-dense low density lipoprotein
(LDL) particles, may not only be the consequence of diabetes but may also cause disturbances
of glucose metabolism. In fact, hypertriglyceridemia leads to elevated levels of free fatty acids
(FFAs), which contribute to insulin resistance and β-cell dysfunction, putatively by impairing the
molecular mechanisms linking insulin receptors with glucose transporters, as well as by directly
damaging β-cells. Moreover, hypertriglyceridemia and elevated FFAs can contribute to inflammation,
which boosts insulin resistance and β-cell dysfunction [4–7]. In addition, low HDL-c could also
influence low-grade inflammation and affect glucose metabolism, thus contributing to diabetes [8].
Collectively, lipotoxicity and glucotoxicity are associated to the progression of DM and its micro- and
macrovascular complications [5,9]. However, the nature of glucose and lipid deregulation in the
prediabetic state remains to be elucidated.
Therefore, we aim to evaluate glucose and lipid metabolism in a prediabetic rat model, induced
by a high-sucrose (HSu) diet [10,11], focusing on the main insulin-target organs: liver, skeletal muscle,
and white adipose tissue.
2. Materials and Methods
2.1. Animals and Diets
Male Wistar rats (16 week-old; Charles River Laboratories, Barcelona, Spain) were housed,
two per cage, under controlled conditions (12 h light/dark cycle schedule and controlled temperature
(22 ± 1 ◦C) and humidity). After an adaptation period of 1 week, rats were randomly divided into two
groups (2 animals per cage) and submitted to a 9-week protocol: (1) control—receiving tap water as
vehicle; (2) Hsu—receiving 35% sucrose (S0389; Sigma-Aldrich, St. Louis, MO, USA) in the drinking
water. All animals were fed standard rat chow, containing 60% of carbohydrates, 16.1% of protein,
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during fasting periods). Body weight, food, and beverage consumption were monitored every two days
and presented as weekly variation per rat (which is the mean of the two rats per cage). All experiments
were conducted in accordance with the European Union (EU) Legislation for the protection of animals
used for scientific purposes “Animals (Scientific Procedures) Act”, Directive 2010/63/EU, and with
the National and Local Authorities, under authorization of the Organ Responsible for Animal Welfare
of Faculty of Medicine of Coimbra University (07/2016).
2.2. Chemicals
Collagenase type II was from Roche (Lisbon, Portugal). D-[[14C(U)]-glucose (250 mCi/mmol/L)
was from Scopus Research BV (Wageningen, The Netherlands). Human insulin, Actrapid, was kindly
supplied by Novo Nordisk A/S (Paço de Arcos, Portugal). N-heptane was from Merck-&-Co., Inc.
(Whitehouse Station, NJ, USA). Optiphase Hisafe was from PerkinElmer, Inc. (Waltham, MA, USA).
RNeasy® MiniKits were from QIAGEN Sciences (Germantown, MD, USA). High Capacity cDNA
Reverse Transcriptase kits were from Applied Biosystems (Forest City, CA, USA). PCR primers were
designed using Beacon Designer software and synthesized by IDT-Integrated DNA Technologies, Inc.
(BVBA, Leuven, Belgium). SYBRGreen Supermix was from Quanta Biosciences (Gaithersburg, MA,
USA). All other reagents were from Sigma (St. Louis, MO, USA). ECF reagent was from GE Healthcare
(Little Chalfont, UK).
2.3. Metabolic Characterization
Metabolic characterization was performed as previously described [10] and is detailed in the
supplemental material. This included a glucose tolerance test (GTT), an insulin tolerance test (ITT),
fasting insulin levels, and insulin resistance (evaluated by the homeostatic model assessment of insulin
resistance HOMA-IR index), as well as serum TG to HDL-c ratio (TG/HDL-c), TG-glucose (TyG)
index, as well as fed and fasted alanine aminotransferase [6] and aspartate aminotransferase (AST)
assessment. Caloric intake was calculated based on the daily food intake, and in HSu-treated animals,
the energy related to sucrose consumption was also calculated.
2.4. Blood and Tissues Collection
After a 9-week treatment, blood and tissues (liver, skeletal muscle—from the posterior thigh of the
rat leg—and epididymal adipose tissue) were snap frozen and stored at −80 ◦C. Details are available
in the supplemental material.
2.5. Liver Pathology and Triglyceride Content
Liver TG were extracted and quantified as previously reported [12]. Briefly, 50 mg of liver samples
were homogenized in 0.5 mL of chlorophorm/methanol (2:1) and incubated for 3 h with agitation
at 4 ◦C. 300 μL of milliQ water were then added to the homogenate and centrifuged (13,000 rpm for
20 min, room temperature). The organic phase was transferred to a clean Eppendorf tube, allowed to
evaporate at 4 ◦C, and finally stored at −20 ◦C. Liver TG quantification was performed with a specific
commercial kit from Spinreact. Colorimetric determination was performed in a spectrophotometer
(SPECTRAmax PLUS384, Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 505 nm or
490 nm after TG resuspension in 500 μL of chloroform. Intensity of the formed color was proportional
to TG concentration in each sample. Oil red O staining of liver frozen sections was performed to
evaluate lipid deposition, according to previously described methodology [13]. Liver pathology was
assessed by hematoxylin and eosin (H&E) in paraffin-embedded sections fixed with paraformaldehyde
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2.6. Cell Size and Weight, Glucose Uptake, and Lipolysis in Isolated Epididymal Adipocytes
Epididymal adipocyte size and weight, insulin-stimulated D-[[14C(U)]-glucose uptake, and
isoproterenol-stimulated lipolysis in isolated adipocytes were performed as previously described [14,15].
Briefly, for the insulin-stimulated glucose uptake, the isolated adipocytes were diluted ten times and
were stimulated or not with human insulin (1000 μU/mL), for 10 min, at 37 ◦C, in a shaking water-bath.
Subsequently, 0.86 μM D-[[14C(U)]-glucose was added to the medium and the accumulation of glucose
followed for 30 min. The cell suspension was then transferred to pre-chilled tubes, containing silicone
oil, allowing cells to be separated from the buffer by centrifugation. Cell-associated radioactivity was
determined by liquid scintillation counting, which allowed us to calculate the rate of transmembranar
glucose transport, according to the formula: cellular clearance of medium glucose = (c.p.m. cells ×
volume)/(c.p.m. medium × cell number × time).
For isoproterenol-stimulated lipolysis, the isolated adipocytes were diluted ten times and were
incubated in the presence or absence of insulin (1000 μU/mL), in a shaking water bath, at 37 ◦C,
for 60 min. The medium was also supplemented or not with isoproterenol (1 μM). Following incubation,
cells were separated from the medium by centrifugation and glycerol levels were measured in the
medium using an assay kit (Zen Bio, Inc., Research Triangle Park, NC, USA). Further details are
available in the supplemental material.
2.7. Liver, Skeletal Muscle, and Adipose Tissue Gene and Protein Expression
Total RNA from liver, skeletal muscle, and epididymal adipose tissue was extracted, and cDNA
synthesis and relative mRNA levels for glucose transporter-1(Glut1), -2 (Slc2a2), and -4 (Glut4),
phosphoenolpyruvate carboxykinase (Pepck), glucose-6-phosphatase (G6pc), acetyl-CoA carboxylase 1
(Acc1), fatty acid synthase (Fasn), diglyceride acyltransferase (Dgat1), carbohydrate-responsive
element-binding protein (Mlxipl/Chrebp), sterol regulatory element-binding transcription factor 1
(Srebf1), and hormone-sensitive lipase (Hsl) were measured (by real time-PCR), as previously
described [16]. Protein extraction and Western blot analysis of GLUT1, GLUT2, GLUT4, PEPCK, G6PC,
ACC1, FASN, DGAT1, ChREBP, SREBP, and HSL were performed as previously described [14,15].
The supplemental material details the protocols and lists the primer sequences (Table S1) and antibodies
(Table S2) used.
2.8. Statistical Analysis
Results were expressed as mean ± standard error of the mean, using GraphPad Prism, version 6
(GraphPad Software, San Diego, CA, USA). Student’s t-test for normally distributed data or the Mann
Whitney test for non-normally distributed data were performed when two groups were considered.
One-way or two-way ANOVA, followed by Tukey post hoc test, for multiple comparisons, was used
as appropriate. Repeated measures ANOVA, followed by the Tukey post-hoc test, was used to assess
the differences between groups and between basal and insulin-stimulated glucose uptake. Differences
were considered significant when * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, or **** p ≤ 0.0001.
3. Results
3.1. HSu Diet Increases Beverage Consumption and Caloric Intake, Maintaining Body Weight
During 9 weeks of treatment, the body weight evolution was identical in HSu-treated and control
rats (Figure 1A). However, HSu-treated animals had a higher beverage (35% sucrose) consumption but
a lower food ingestion (Figure 1B,C). This behavior translated to an increased total caloric intake, mainly
from carbohydrates, with a lower calorie consumption from proteins and lipids, when compared with
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Figure 1. Evolution of body weight (A), beverage (B) and food (C) intake, as well as total caloric
consumption (D) and caloric intake related with carbohydrates (E), protein (F), and lipids (G),
throughout the 9 weeks of treatment. Control (n = 12) and HSu (n = 10). ** p < 0.01, *** p < 0.001,
**** p < 0.0001.
3.2. HSu Diet Increases Serum Triglyceride Levels and Impairs Liver Function
The serum TG content in HSu-treated rats was significantly higher than in control animals in
the fed state. Also, fed HSu-treated rats presented higher TG concentrations than in fasted HSu
animals (Figure 2A). However, no significant differences were found in liver TG levels (Figure 2B).
Regardless of the nutritional status (fasted or fed), serum ALT levels were reduced in the HSu-treated
rats (Figure 2C); however, no significant differences were found in serum AST levels (Figure 2D).
In addition, the liver weight/body weight ratio was increased in HSu-treated animals (Figure 2E).
Despite markers of impaired liver function, no changes in liver structure were found when
analyzed by H&E histology (Figure 3(A1,A2)). Oil red O staining showed a slight deposition of lipids
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Figure 2. Serum (A) and liver (B) triglyceride (TG) content, serum alanine aminotransferase (ALT) (C)
and aspartate aminotransferase (AST) (D) levels, as well as liver weight/body weight ratio (E) at the
end of treatment. Control (n = 12) and HSu (n = 10). * p < 0.05, ** p < 0.01, *** p < 0.001.
 
Figure 3. Liver (A1,A2) Hematoxylin and Eosin (H&E) staining (×200) and (B1,B2) Oil red O staining
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3.3. HSu Diet Impairs Glucose Tolerance and Causes Insulin Resistance
Although both groups showed similar fasting glucose levels (Figure 4A,C,E), the HSu-treated
rats had significantly slower glucose excursion during a GTT (2 g/kg body weight of glucose),
compared to control animals (Figure 4A,B), revealing glucose intolerance. Blood glucose levels were
significantly elevated in the HSu-treated rats, 120 min after an insulin injection (0.75 U/kg body weight
of insulin) (Figure 4C,D). In addition, serum fasting insulin concentration was significantly elevated
in HSu-treated animals (Figure 4F). Moreover, TG/HDL-c ratio, TyG and HOMA-IR indexes, known
markers of insulin resistance, were significantly elevated in the HSu-treated rats, compared to the
controls (Figure 4G–I).
Figure 4. Glucose tolerance test (GTT) and area under the curve (A,B), insulin tolerance test (ITT)
and area under the curve (C,D), fasting glucose (E) and insulin (F) levels, as well as insulin resistance
markers: triglycerides to high density lipoprotein cholesterol (TG/HDL-c) ratio (G), triglyceride
glucose (TyG) index (H) and homeostatic model assessment of insulin resistance (HOMA-IR) index
(I) at the end of treatment. Control (n = 12) and HSu (n = 10). * p < 0.05, ** p < 0.01, *** p < 0.001, and
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3.4. HSu Diet Increases Fat Mass While the Insulin-Stimulated Glucose Uptake in Adipocytes Is Impaired
The epididymal fat pad weight/body weight ratio was significantly higher in the HSu-treated
rats when compared to the controls (Figure 5A), while fat cell diameter and weight were unchanged
between the groups (Figure 5C,D). Insulin-stimulated glucose uptake was measured in freshly isolated
adipocytes. Basal glucose uptake was not significantly different between groups (p > 0.05). Adipocytes
responded to the stimulatory effect of insulin in the uptake of glucose in both groups (Control − Basal
= 20.31 ± 2.59 vs. Insulin = 35.88 ± 4.22, p < 0.001; HSu − Basal = 8.55 ± 1.09 vs. Insulin = 17.48 ± 1.16,
p < 0.001); however, the insulin-stimulated glucose uptake was significantly reduced in adipocytes
from HSu-treated rats compared to the controls (17.48 ± 1.16 vs. 35.88 ± 4.22, p < 0.01, respectively)
(Figure 5B).
Figure 5. Epididymal fat pad weight/bw ratio (A), insulin-stimulated D-[[14C(U)]-glucose uptake in
isolated adipocytes (B), and adipocyte diameter (C) and weight (D) at the end of treatment. Control
(n = 12) and HSu (n = 10). ** p < 0.01, *** p < 0.001.
3.5. HSu Diet Decreased GLUT1 but Increased G6Pase Levels in Liver
The gene and protein levels of mediators of glucose uptake and gluconeogenesis were quantified
in liver, skeletal muscle (posterior thigh of the leg), and epididymal adipose tissue. There were no
changes in glucose transporter gene levels in all tissues, in the fed state (Figure 6A). Moreover, GLUT1
protein levels were reduced in HSu-treated rats versus controls, with no change in GLUT2 expression,
in the liver. In addition, no differences were found in either GLUT1 or GLUT4 protein levels in skeletal
muscle or epididymal adipose tissue. To assess hepatic gluconeogenesis, PEPCK and G6Pase gene and
protein levels were evaluated. While there was no alteration in gene expression, there was a significant















Figure 6. (A) Glucose transporters. (B) Gluconeogenesis. Gene and protein levels of glucose
transporters (A) in liver, skeletal muscle (posterior thigh of the leg), and epididymal adipose tissue.
Gene and protein levels of mediators of hepatic gluconeogenesis (B). Control (n = 12) and HSu (n = 10).
* p ≤ 0.05.
3.6. HSu Diet Increases Hepatic Lipid Biosynthesis, without Alterations in Lipolysis
Gene and protein levels of ACC1, FASN, and DGAT1, that play a major role in lipid biosynthesis
in the liver and in fat, were analyzed, together with SREBP and ChREBP. Increased protein levels
of ACC1, FASN, and SREBP were observed in the liver of HSu-treated animals, without changes
in gene levels (Figure 7A). In addition, in adipose tissue, both gene and protein levels for ChREBP
were increased in the HSu-treated rats, without further changes on the other measured mediators
(Figure 7A).
Isoproterenol-stimulated lipolysis was performed to measure TG hydrolysis into glycerol and
free fatty acids, and to evaluate the antilipolytic effect of insulin in isolated adipocytes (Figure 7(B1)).
Both groups responded similarly to the stimulatory effect of isoproterenol (Control: 0.66 ± 0.11;
HSu: 0.50 ± 0.08) versus basal (Control: 0.30 ± 0.03; HSu: 0.22 ± 0.03) and insulin levels (Control:
0.34 ± 0.04; HSu: 0.24 ± 0.03). Even though there is a tendency for an antilipolytic effect of insulin
after isoproterenol stimulation (Control: 0.50 ± 0.05; HSu: 0.39 ± 0.05), it does not reach significance.

























Figure 7. (A) Lipid biosynthesis. (B1,B2) Lipolysis. (B1) Isoproterenol-stimulated lipolysis. (B2) Hormone-
sensitive lipase gene and protein. Gene and protein levels of mediators of lipid biosynthesis (A) in
liver and epididymal adipose tissue. Isoproterenol-stimulated lipolysis (B1) and HSL gene and protein
levels (B2) in epididymal adipose tissue. Control (n = 12) and HSu (n = 10). * p ≤ 0.05, ** p < 0.01, and
*** p < 0.001.
4. Discussion
The novel findings from this study indicate that a high-sugar diet induces early glucose and lipid
dysmetabolism, in the absence of weight gain, only after 9 weeks of treatment. HSu-treated animals
developed impaired insulin-stimulated glucose uptake and reduced insulin sensitivity (resistance),
together with decreased GLUT1 but increased G6Pase protein levels in the liver. These metabolic
changes are paralleled by fed hyperglycemia and hypertriglyceridemia.
Throughout the 9-week treatment, the HSu-treated group had lower food consumption but
higher beverage (35% sucrose) and caloric intake, while maintaining body weight, as previously
described [17–19]. Similar body weight might have been maintained due to: first, differences in
digestion and absorption may have modified the amount of ‘bioavailable’ energy, affecting the actual
positive energy balance; second, the composition of weight gain (fat mass and lean mass) might
be different, as the energy cost of protein deposition is higher than that of adipose tissue. In fact,
we observed that HSu-treated animals have a greater adiposity translated by an increased epididymal
fat pad weight/body weight ratio. Moreover, dietary protein content was suggested to be a critical
determinant of weight gain during ad libitum feeding [20].
This prediabetic animal model presented low food intake, which is enriched in 16.1% protein, and
increased fluid intake of sucrose-enriched water, in agreement with previous studies [18]. This means
that HSu-treated animals ingested a smaller amount of protein and a greater amount of carbohydrates,
which can be translated by higher fat mass and smaller lean mass, which allowed the maintenance
of body weight. This suggestion might be further confirmed by performing an in vivo non-invasive
ecographic magnetic resonance imaging (Echo-MRI) analysis to assess whole body fat, lean, free water,
and total water masses.
Indeed, epididymal fat pad weight/body weight ratio was significantly higher in HSu-treated
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carbohydrate consumption in Western diets [21]. In fact, high-sucrose diets may increase adiposity by
stimulating liver lipogenesis [22].
After 9 weeks of treatment, the HSu-treated group had higher serum TG levels, in agreement
with previous reports [18,23–25], together with increased lipid deposition in the hepatic tissue, viewed
by the Oil Red O staining. In addition, ALT levels were significantly reduced in HSu-treated rats,
while a significant increase in the liver weight/body weight ratio was observed, suggesting altered
liver function, without liver lesion at this stage of impaired metabolism. The strongest hypothesis to
explain the reduced liver function and ALT low levels is malnutrition or an altered nutritional pattern.
This prediabetes model had lower food consumption (constituted by 16.1% protein) and increased
fluid intake (sucrose-enriched water). Thus, the low serum ALT levels, indicative of liver dysfunction,
observed in the HSu-treated rats might be caused by a diet poor in essential nutrients/macromolecules
(including proteins and lipids), i.e., malnutrition.
This prediabetes model presented impaired glucose homeostasis. Already at the early stages of the
disease, there were initial metabolic deregulations, evidenced by alterations in glucose tolerance during
the GTT and ITT, as well as the glucose and insulin levels, indicative of insulin resistance, in agreement
with other studies [18,26,27]. At this stage, although fasting glucose levels are maintained within
normal values (normoglycemia), due to compensatory hyperinsulinemia, there is already some degree
of glucose intolerance and peripheral insulin resistance, in agreement with other reports [18,28–30].
Insulin resistance was demonstrated not only by the increased HOMA-IR index but also by
augmented TG/HDL-c ratio and the TyG index, which have previously been used as surrogate
measures of impaired insulin sensitivity in obese adolescents with normoglycemia, in prediabetes, as
well as in T2DM [31].
In an attempt to explain the glucose, insulin, and lipid dysmetabolism in this model at the
prediabetic stage, we assessed possible alterations in glucose and lipid metabolism in fat. Accordingly
with previous studies [18], the HSu diet increased fat mass, which is closely linked to the development
of severe peripheral IR and prediabetes [32,33]. Moreover, under the fed state, the HSu diet impaired
insulin-induced glucose uptake in isolated adipocytes, confirming that visceral adiposity is strongly
associated with impaired glucose uptake and IR [34]. Additionally, under IGT, adipocytes are resistant
to insulin, and its effectiveness may be impaired, contributing to postprandial hyperglycemia in
prediabetic states. Furthermore, the decrease in hepatic GLUT1 in the HSu-treated rats might be
mediated by the hyperinsulinemia observed in this animal model [35], although supplementary
confirmation of this hypothesis could be achieved by evaluating GLUT1 expression under fasting
conditions. On the other hand, both GLUT2 (in the liver) and GLUT4 protein levels (in the
adipose tissue and skeletal muscle), were unchanged. The translocation of both GLUT2 and GLUT4
to the plasma membrane is mediated by insulin; however, under IR conditions, this process is
impaired [36,37], leading to decreased insulin-stimulated glucose uptake in hepatocytes (mostly
by GLUT2), while increasing postprandial blood glucose levels. Even though we did not measure
translocation of glucose transporters in this study, it may be possible that these processes are impaired,
thus also contributing to the increased postprandial blood glucose levels.
Another factor that may also be contributing to the postprandial hyperglycemia observed in this
animal model is that high sucrose consumption increased gluconeogenesis, as previously reported [38].
However, under IGT and/or IR conditions, the derangement of hepatic glucose handling, indicated by
changes in GLUT1 and G6Pase may at least in part lead to postprandial hyperglycemia in prediabetic
states [39]. Furthermore, in this animal model of IR, insulin may not inhibit the de novo glucose
production by the liver, leading therefore to elevated gluconeogenesis, resulting in elevated blood
glucose levels in the fed state, as previously reported [35], as well as altered glucose tolerance during
a GTT.
Furthermore, the HSu diet increased liver lipid biosynthesis. Our results show that ACC1 and
FASN enzymes, as well as the transcription factor SREBP expression levels were increased in the liver
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that was observed might explain the hypertriglyceridemia present in this prediabetic animal model.
In addition, high sucrose consumption may also be contributing to hypertriglyceridemia due to the
increased ChREBP gene and protein levels observed in fat [45]. However, the HSu diet did not induce
changes in the isoproterenol-stimulated lipolysis in isolated adipocytes, and the HSL protein levels
were not different. HSL lipolytic activity is regulated by reversible phosphorylation on five critical
residues [46]. Therefore the absence of alterations in lipolysis suggest that HSL phosphorylation
was not changed by the HSu diet. Finally, insulin did not show a significant antilipolytic effect at
these insulin concentrations. However, it is important to note that we used supra-physiological
insulin concentrations (1000 μU/mL), in order to evoke a sustained respond to study the impact of
the treatment. Testing physiological insulin concentrations are warranted in both control and HSu
animals in future research. In addition, there are other aspects for the forthcoming studies that could
consolidate this model, namely lipid profiling of FPLC-separated lipoprotein fractions, quantification
of FFA levels, as well as the estimation of VLDL secretion. Furthermore, the impact of the HSu diet on
leptin serum levels and on leptin receptor expression would be of interest.
Overall, our study shows that nine week of HSu-diet, which mimics at least in part Western
diets [10,11,47], can lead to impaired hepatic glucose and lipid metabolism, typical features of
T2DM, already present in this prediabetic model, even in the absence of obesity. This animal
model of diet-induced prediabetes shows reduced glucose tolerance, postprandial hyperglycemia,
hyperinsulinemia, reduced insulin sensitivity (resistance), and hypertriglyceridemia, together with
impaired gluconeogenesis and lipogenesis (Figure 8).
Figure 8. A molecular model describing insulin resistance and prediabetes development after a
HSu diet. HSu diet increases serum triglyceride (TG) accumulation and triggers liver lipogenesis,
inducing hypertriglyceridemia and interfering with liver function. However, no alterations were
observed in lipolysis. The HSu diet alters hepatic proteins involved in basal glucose uptake and
gluconeogenesis and impairs the insulin-stimulated glucose uptake in adipocytes, leading to impaired
glucose homeostasis and increased IR markers. Legend: Apolipoprotein; CE—Cholesterol
ester; IDL—Intermediate-density protein; LDL—Low-density lipoprotein; LDL—Lipoprotein lipase;








Nutrients 2017, 9, 638
This study should be viewed as an important wake up call for the lifestyle that the general
population have been gradually adopting, by consuming large amounts of simple sugars in soft
drinks [48]. Importantly, exaggerated consumption of these drinks has been associated with an
increased risk for T2DM development by about 26% if the average intake is one/two cans a day, or
even more [49]. This feeding behavior is one of the main causes of the uncontrolled increase of IR,
T2DM, and associated complications, such as coronary heart disease [50,51].
5. Conclusions
This animal model of prediabetes induced by high-sucrose consumption presents liver glucose
and lipid dysmetabolism. It is expected that new insights of impaired metabolism at this early stage
of the disease might contribute to disclosing new therapeutic targets and strategies to counteract
prediabetes and hinder the natural course of T2DM progression.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/6/638/s1,
Supplemental methods; Table S1: Primer sequences for RT-PCR; Table S2: Antibodies used for Western blotting.
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Abstract: Nuts and dried fruit are essential foods in the Mediterranean diet. Their frequent
consumption has been associated with the prevention and/or the management of such metabolic
conditions as type 2 diabetes (T2D), metabolic syndrome and cardiovascular diseases. Several
previous reviews of epidemiological studies and clinical trials have evaluated the associations of
nuts and/or dried fruit with various metabolic disorders. However, no reviews have focused on the
mechanisms underlying the role of nuts and/or dried fruit in insulin resistance and T2D. This review
aims to report nut and dried-fruit nutritional interventions in animals and humans, and to focus on
mechanisms that could play a significant role in the prevention and treatment of insulin resistance
and T2D.
Keywords: diabetes; nuts; dried fruits; insulin resistance; mechanisms; clinical trials
1. Introduction
Nuts and traditional dried fruit (i.e., with no added sugar) are key food categories in the
Mediterranean diet and other regional diets [1]. Several prospective studies, clinical trials and research
in animals have reported beneficial effects after nut consumption [2]. However, the benefits of dried
fruits (DF), mainly raisins, have been less explored [3].
Over time, food consumption has varied. More than 30 years ago, the consumption of nuts and DF
was discouraged because of their high fat and sugar content, respectively. However, at the beginning
of the 1990s, several randomized clinical trials (RCT) and animal experiments demonstrated their
potential beneficial effect on cardiovascular diseases (CVD). Nuts and DF contain various macro and
micronutrients together with other important bioactive compounds that may synergically contribute to
modulate specific metabolic diseases such as hypercholesterolemia, hypertension and type 2 diabetes
(T2D) (reviewed in [3,4]). Even so, the specific role of nuts and DF in the development and progression
of insulin resistance (IR) and T2D are still controversial.
In this review, we focus on the role of nuts and DF in the prevention and treatment of T2D.
We summarize published in vivo, in vitro, epidemiological and clinical studies, and we review the
potential mechanisms that could explain the beneficial role of nut consumption on glucose and insulin
metabolism, both of which are altered in T2D and in other glucose-impaired states. Given that the
present article is not a systematic review, we may not have identified some studies and publication
bias should be acknowledged. However, all authors independently conducted the literature search.
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1.1. Nuts and Dried Fruits: The Concept
1.1.1. Nuts
Nuts have been part of the human diet since prehistoric times [5,6]. They are an independent
food group and are one of the cornerstones of the Mediterranean diet (MedDiet) [7]. According to the
botanical definition, a nut is simply a dried fruit with one seed (rarely two) in which the ovary walls
are very hard (stony or woody) at maturity, and the seed is unattached or free within the ovary wall.
However, the word “nut” is commonly used to refer to any large, oily kernel in a shell that can be eaten
as food. In this review, we use the term “nuts” to refer to almonds, Brazil nuts, cashews, hazelnuts,
macadamias, peanuts, pecans, pine nuts, pistachios and walnuts. Although peanuts are actually
classified as legumes because of their similar nutrient composition and their proven cardiovascular
health benefits, they are commonly regarded as being a nut.
1.1.2. Dried Fruits
To extend their shelf life, fresh fruits are processed by various techniques to become DFs [3].
Dried fruits are a concentrated form of fresh fruits with a lower moisture content. Fruits can be dried
whole (e.g., apricots, berries and grapes), in halves, or in slices (e.g., kiwis, mangoes and papayas).
In this form, they are easy to store and distribute, they can be available throughout the year, and they
are a healthier alternative to salty or sugary snacks. Apples, apricots, currants, dates, figs, peaches,
pears, prunes, and raisins are referred to as “conventional” or “traditional” DFs. Meanwhile, such
fruits as blueberries, cranberries, cherries, strawberries and mangoes are commonly infused with
different types of sugar solution (or fruit juice) concentrate before drying [8] so are not included in
the aforementioned category. Moreover, we have also excluded dried tomato because although it is
botanically a berry-type fruit, it is culinary considered a vegetable and it shares nutrient composition
with this food category.
1.2. Nutritional Composition of Nuts and Dried Fruits
Nuts and DFs are a matrix of important bioactive compounds such as Vitamins (Vitamin E, niacin,
choline and/or folic acid), minerals (magnesium, potassium, calcium and/or phosphorus), phenolic
compounds, carotenoids and/or phytosterols [9]. Importantly, some nuts and DFs are among the
50 foods with the highest antioxidant capacity [10] and are also a known source of bioactive compounds,
including plant sterols [11]. Pistachios are particularly rich in β-carotenes which have been widely
associated with a protective T2D role [12,13]. In addition, pistachios are the only nuts that contain
significant amounts of lutein and zeaxanthin [9]. Sun-dried raisins retain the minerals and most of
the phytochemicals and antioxidants of the grape, including its resveratrol [14,15]. In fact, sun-drying
enhances the antioxidant content of raisins. Because of the dehydration process, phytonutrients
are more concentrated in raisins than in grapes. However, the concentration of some compounds is
decreased by the sun-drying process in DFs and by dry roasting techniques in nuts [9]. Polyphenols and
tocopherols from nuts and DF have proved to be rapidly accessible in the stomach, thus maximizing
the possibility of absorption in the upper small intestine, and contributing to the beneficial relation
between nut and DF consumption and health-related outcomes [8,16].
However, their macronutrient compositions are quite different, which means that their energy
contents are also quite different. Nuts contain a high amount of total fat (Range (Re): 43.9–78.8%)
with a high amount of unsaturated fat (monounsaturated fatty acids (MUFA) + polyunsaturated fatty
acids (PUFA), Re: 31.6–62.4%), a relatively low amount of carbohydrates (CHOs) (Re: 11.7–30.2%) and
vegetable protein (Re: 7.9–25.8%) (Table 1).
Conversely, DFs are mainly composed of CHOs (Re: 61.3–72.8%). They have a low content of
protein (Re: 0.17–4.08%) and a fat content of less than 1% (Table 2). Importantly, both foods also contain
a considerable amount of dietary fiber. Overall, their unique and varied nutrient composition makes
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1.3. Diet Quality in the Context of Nut and Dried Fruit Consumption
Epidemiological studies conducted in children and adults have demonstrated a significant positive
association between nut consumption and diet quality [17,18]. Furthermore, the results of a clinical
trial conducted in obese (Ob) subjects (n = 124) showed that the nutritional dietary quality of nut
consumers (reporting to eat 42 g hazelnuts/day for 12 weeks) was remarkably higher than among
other groups consuming chocolate, potato crisps or no additional foods [19]. Moreover, including nuts
in energy-restricted diets reduced attrition and increased weight loss, indicating that nuts enhance
palatability and compliance with diets without compromising health [20].
Several studies have examined the associations of whole fruit or 100% fruit juice [21] with
nutritional or health outcomes such as T2D but there is a lack of studies examining potential links
between DF and diet quality. A prospective study conducted in adult participants (n = 13,292) in
the 1999–2004 National Health and Nutrition Examination Survey (NHANES) demonstrated an
association between DF consumption and diet quality [22]. DF consumption was associated with
improved nutrient intakes, a higher overall diet quality score, and lower body weight (BW)/adiposity
measures [22]. Moreover, in a cross-sectional study in healthy adults (n = 797) from Hong Kong, an
inverse association has been found between the intake of vegetables, legumes, fruits, dried fruits
and Vitamin C and the prevalence of metabolic disorders such as non-alcoholic fatty liver disease
(NAFLD) [23].
The 2015 Dietary Guidelines for Americans included the following three healthy dietary patterns:
a Healthy US-style Pattern, a Healthy Vegetarian Pattern and a Healthy Mediterranean-style pattern.
Fruits, nuts, and seeds play a prominent role in all three of these food-based dietary patterns, which
recommend 350–440 g/day of fruit, and 16–28 g/day of nuts and seeds [24].
2. In Vivo and In Vitro Studies
Even though much of the research on nuts, dried fruits and T2D is based on observational studies
and human trials, some in vitro and in vivo studies also evaluate their modulatory effect on glucose
and insulin metabolism. In this regard, the effect of nuts on glucose and insulin metabolism has
been investigated by evaluating nut extracts [25,26] or nuts as a whole [27–29] mainly in mice or rats.
However, dried fruit has been investigated—like their non-dried counterparts—mainly in in vitro
studies [30–33]. Almost all the research has focused on the extracts from non-edible parts, such as the
shell [34], leaves [35,36], stems [37] and roots [38], and very little on the nut or fruit kernel [27–29,39].
However, this review focuses on those studies evaluating specific nutrients (e.g., polyphenols) or
edible parts in both traditional nuts and dried fruits with outcomes related to glucose metabolism, IR,
and the T2D oxidation/inflammation axis [32,40].
2.1. Nuts
The in vivo studies on nuts and T2D-related parameters are summarized in Table 3. These studies
were mainly performed using extracts from peanuts or walnuts. Peanut oil supplementation for
42 days in diabetes-induced rats significantly reduced glucose and glycated hemoglobin (HbA1c)
concentrations and improved lipid metabolism compared to normal rats [27]. Other researchers
have found similar improvements in glycaemia in genotypes of diabetes in rats fed with peanut oil
extract [41,42] or peanut aqueous extract [25]. In the case of walnuts, a polyphenol-rich walnut extract
(PWE) for 4 weeks significantly decreased urinary 8-hydroxy-2′-deoxyguanosin levels (an in vivo
marker of oxidative stress) and improved serum TG in db/db mice [26]. Moreover, an HFD with a 21.5%
of energy from walnuts tested in mice for 20 weeks significantly reduced TG compared to nut-free
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In vitro assessment of the T2D-related antioxidant and inflammatory capacity of nuts has largely
been conducted by examining the ability of extracts to increase the resistance of human plasma or
low density lipoprotein (LDL) to oxidation. Extracts of walnut [43], almond and almond skins [44,45],
pistachio [46], and hazelnut [47] have been found to increase the lag time oxidation of LDL. However,
little research has focused on their in vitro effects on glucose and insulin metabolism. Specifically,
a hydro-ethanolic extract of cashew nut and its principal compound, anacardic acid, significantly
stimulated glucose uptake in C2C12 muscle cells in a concentration-dependent manner, suggesting
that it may be a potential anti-diabetic nutraceutical [48]. Moreover, cytoprotective activity of pistachio
extracts (methanolic, water or ethyl acetate) against oxidative (reactive oxygen species formation) and
carbonyl stress has also been reported in a T2D model in hepatocytes from rats [49].
2.2. Dried Fruits
Both in vitro and in vivo research has mostly focused on grape. Overman and collaborators
showed that a grape powder extract (GPE) significantly attenuated lipopolysaccharide (LPS)-mediated
inflammation in macrophages and decreased the capacity of LPS-stimulated human macrophages to
inflame adipocytes and cause IR [30]. Moreover, GPE further attenuated tumor necrosis factor-α
(TNF-α) mediated inflammation and IR in primary cultures of human adipocytes [31]. Grape
polyphenol extract modulated in vitro membrane phospholipid fatty acid (FA) composition but also
decreased muscle TG content and increased muscle glucose transporter type 4 (GLUT4) expression
in high-fat-high-sucrose diet-fed rats. Overall, it improved insulin resistance status (i.e., HOMA-IR
parameter) [50]. This is of considerable importance because the accumulation of muscle TG content
and the modification of the muscle phospholipid fatty acid pattern may have an impact on lipid
metabolism and increase the risk of developing T2D [51]. Mice fed with grape skin extract showed
hypoglycaemic and anti-hyperglycaemic effects (independent of an increase in insulin release) but
are probably dependent on an increase in insulin sensitivity resulting from the activation of the
insulin-signaling cascade in skeletal muscle [52]. Furthermore, grape seed aqueous extract protected
the pancreas against oxidative stress, inflammation and apoptosis-induced damage while preserving
pancreatic function at near normal levels in diabetic rats [53].
Other DF extracts have also been evaluated. Treatment with a date fruit extract was effective at
decreasing behavioral, neurophysiological, and pathological alterations induced by diabetes in the
peripheral nerves of streptozotocin (STZ)-induced diabetic rats (well-characterized animal model of
type 1 diabetes) [33]. Moreover, daily consumption of a low- or high-fat diet supplemented with 1%
black currant powder extract (with 32% of anthocyanins) for 8 weeks reduced body weight gain and
improved glucose metabolism [54].
The beneficial effect of fruit juices and fermented grape juice (i.e., wine) have also been an
important focus of research. Schmatz and collaborators investigated the ex vivo effects of a moderate
consumption of red wine (RW) and grape juice (GJ), and the in vitro effects of various substances
(resveratrol, caffeic acid, gallic acid, quercetin and rutin) on STZ-induced diabetic rats. They
demonstrated decreased platelet aggregation in diabetic-induced rats after moderate RW and GJ
consumption for 45 days [55]. Similarly, resveratrol increased the hydrolysis of adenosine triphosphate
(ATP), while quercetin decreased it in platelets [55]. These results were extended using a wine grape
powder supplementation, which prevented hyperglycemia and IR, and reduced oxidative stress in a
rat model of metabolic syndrome (MetS) [56].
Specific compounds found in both nuts and DFs were also further investigated. Quercetin
and trans-resveratrol are plant polyphenols which have showed a significant reduction of IR and
inflammation associated with obesity. Eid et al. showed that quercetin (isolated from lingonberry)
exerted an anti-diabetic activity by stimulating adenosine monophosphate-activated protein kinase
(AMPK) [40]. Moreover, quercetin also enhanced basal glucose uptake in mouse myoblast C2C12
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Importantly, quercetin seems to be as effective as or more effective than resveratrol in attenuating
TNF-α-mediated inflammation and IR in primary human adipocytes and macrophages [32,57].
3. Epidemiological Studies on Nuts
The relationship between the consumption of different food categories and the incidence or
prevalence of metabolic disorders has been explored all over the world. As is shown in Table 4,
numerous epidemiological studies have assessed the associations between nut consumption and T2D.
However, no studies have been published on the link between DF consumption and risk of T2D.
As far as nuts are concerned, several studies have found an inverse association between the
frequency of consumption and the development of this metabolic pathology [58–64]. In the Nurses’
Health Study (NHS) and NHS II cohort, the intake of different types of nut was explored [61,64]. Total
nut, walnut and peanut butter intake were associated with a lower risk of T2D in women. In the NHS
(n = 83,818 female subjects), those with the highest nut consumption (28 g/day; ≥5 days a week) had a
lower relative risk (RR) of developing T2D (0.73 [95% confidence interval (CI), 0.60–0.89]) than those
who never/almost never consume (0.92 [95% CI, 0.85–1.00]) [61]. Results were similar for peanut
butter: the RR was 0.79 (95% CI, 0.68–0.91) in those women who had a higher intake (5 times or more a
week) than those who never/almost never ate peanut butter [61]. After combining NHS and NHS II
cohorts, in a total of 137,953 female subjects, Pan and collaborators found that walnut consumption
was inversely associated with risk of T2D [64].
These results are in line with those of a cross-sectional study of 7,210 subjects at high CV risk
within the context of the PREvención con DIeta MEDiterránea (PREDIMED) study, where the upper
category of nut consumption had a lower prevalence of T2D than the lower category [63]. A recent
prospective study also associated the consumption of nuts—higher than 4 times a week—with a lower
risk of T2D [60]. A cross-sectional study performed in the context of the National Health and Nutrition
Examination Survey (NHANES) established a relation between the homeostatic model assessment
of insulin resistance (HOMA-IR) and tree nut consumption. Decreased insulin resistance and lower
levels of β-cell function markers were found in the nut consumers than the non-consumers [59]. In a
large cohort of the Netherlands Cohort Study (NLCS), the total nut intake was associated to lower T2D
cause-specific mortality in men and women [65].
Even though current evidence shows that nuts have a strong protective effect against the progress of
T2D, especially in women, some epidemiological studies have not identified this relation [66,67]. The latest
systematic review and meta-analysis designed to assess the relation between nut consumption and
risk of cancer and T2D was published in 2015. It included five studies that were linked to T2D. After
pooling data from studies conducted in both genders, it was found that there was no statistically
significant association between nut consumption and risk of developing T2D (RR = 0.98 [95% CI,
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4. Human Clinical Trials
The effect of nut consumption on glucose and insulin metabolism has also been researched in acute
and chronic clinical trials. Acute studies mostly demonstrate a decrease in postprandial glycaemia and
hyperinsulinemia after nut consumption. In contrast, chronic randomized clinical trials designed to
analyze the effects on glucose metabolism provided controversial results.
4.1. Nuts
4.1.1. Acute Clinical Trials on Nuts
Table 5 summarizes various acute clinical studies of nut consumption, most of which focus on
almonds [69–73]. In a randomized crossover trial in healthy subjects, almond intake decreased
postprandial glycaemia and insulinaemia [69]. In a dose-response study conducted in healthy
individuals, almond intake attenuated the postprandial glycaemic response of white bread [70].
In impaired glucose-tolerant subjects, it was observed that the consumption of almonds with a meal also
decreased blood glucose in plasma [71]. In a recent crossover study performed in pre-diabetic subjects,
a preload of almonds decreased postprandial glycaemia [73]. In healthy and diabetic individuals,
Cohen et al. also showed a 30% reduction in postprandial glycaemia after almond consumption
compared with a starchy meal [72].
The effect of pistachio intake on postprandial glycaemia was investigated by Kendall et al. in two
randomized studies. In overweight (Ow) healthy subjects, pistachio consumption was reported to have
a minimal effect on postprandial glycaemia. When pistachios were included in a carbohydrate meal,
the relative glycaemic response (RGR) was attenuated [74]. In a crossover trial with 20 subjects with
MetS, postprandial glycaemia decreased after the consumption of pistachios (85 g) compared to white
bread. In the same study, a peripheral increase in the glucagon-like peptide-1 (GLP-1) concentrations
was also observed after pistachio consumption compared with the consumption of white bread [75].
For peanuts, a randomized crossover trial conducted in 13 healthy subjects reported a decreased
postprandial glycaemic response after the consumption of a breakfast containing 63 g of one of the
following types of peanuts: raw with skin, roasted without skin and ground-roasted without skin [76].
Similarly, in a parallel study conducted in 65 overweight and obese men, peanut consumption reduced
postprandial insulinaemia levels compared to high-oleic peanut consumption [77].
Nut consumption was observed to have similar beneficial effects on glucose and insulin
metabolism in the only study to analyze the effect of a mix of nuts (almonds, macadamias, walnuts,
pistachios, hazelnuts and pecans). In this study conducted in 10 diabetic and 14 non-diabetic subjects,
nut consumption decreased the RGR compared to white bread. Importantly, this study also reported
that nut consumption improved short-term glycaemic control in patients with T2D [74].
In summary, nuts seem to have beneficial postprandial glycaemic effects when consumed alone
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4.1.2. Chronic Clinical Trials on Nuts
Most of the RCTs have compared nut-enriched diets with control diets in order to analyze their
effects on lipid profile, and blood glucose and insulin concentrations as a secondary outcome. However,
some, mainly conducted in subjects with T2D [72,79–84], but also in pre-diabetic [85], hyperlipemic [86],
overweight/obese [87] and healthy individuals [88], were specifically designed to assess changes in
glucose or insulin metabolism after nut consumption (Table 6).
In 2002, Lovejoy and coworkers evaluated the effect of an almond-enriched diet in 20 healthy and
30 T2D subjects in two different studies [79]. Healthy subjects, supplemented with 100 g almonds/day
for 4 weeks and advised to reduce their energy intake by an equivalent amount, did not change their
insulin sensitivity, whereas their body weight increased and their lipid profile improved. In a second
study, subjects with T2D were randomized following a crossover design to one of 4 diets with different
fat contents (25% or 37%) with 10% of fat from almonds or from olive or canola oil, with a minimum
washout of 2 weeks between periods. Fat source (almond vs. oil) or fat level (high fat vs. low fat)
were not observed to have any significant effect on either the glucose or insulin index. In contrast, in a
crossover study conducted in 20 Chinese patients with T2D and mild-hyperlipidemia assigned to either
a control diet (National Cholesterol Education Program (NCEP) step II diet) or an almond-enriched
diet (with almonds replacing the 20% total daily calorie intake) for 4 weeks, a significant decrease in
fasting insulin and glucose concentrations together with an improvement of HOMA-IR were reported
during the almond phase [80]. In a similar crossover study conducted in 48 diabetic patients who
received 50 g/day of pistachios and a pistachio-free diet (12 weeks each period), with an 8-week
washout, a significant improvement in fasting blood glucose (FBG) and HbA1c was observed during
the pistachio consumption, while no changes in HOMA-IR were reported [83]. Recently, Gulati and
coworkers conducted a pre-post intervention study in a group of 50 Asian Indians who consumed 20%
of total energy in the form of whole raw almonds for 24 weeks preceded by a control diet free of nuts.
Although no changes in FBG were observed during the almond consumption, the authors found a
significant reduction in glycosylated hemoglobin, together with an improvement in other T2D risk
factors such as waist circumference or inflammation status [84]. To determine whether the beneficial
effect of nut consumption on glucose and insulin metabolism could also be extended to pre-diabetic
subjects our group conducted a randomized crossover study in 54 pre-diabetic subjects who consumed
a pistachio-supplemented diet (55 g pistachio/day) and a control diet (nut-free diet), each for 4 months
with a 2-week washout period. We found a beneficial effect of pistachio intake on fasting glucose,
insulin, and HOMA-IR. Other cardiometabolic risk markers such as fibrinogen, oxidized LDL, platelet
factor 4 and GLP-1 were also modified appropriately during the consumption of pistachios [85].
Changes in fasting glucose or insulin levels, HOMA-IR and glycosylated hemoglobin have also
been assessed as secondary outcomes in several clinical feeding trials with different designs (parallel,
crossover) and subject characteristics (i.e., healthy, overweight/obese, TD2, MetS), mainly using
walnuts and almonds, and with different intervention lengths (from 2 weeks to 2 years). The results
obtained are controversial. Although most studies found no improvement in glucose/insulin
metabolism [89–103], others reported a significant reduction in FBG levels [89,92,104,105], fasting
insulin or insulin resistance [90,92,106,107] and HbA1c [92]. However, a meta-analysis of RCTs
including 25 trials with a total of 1,650 particpants who were otherwise healthy or had dyslipidaemia,
metabolic syndrome or type 2 diabetes mellitus showed that the consumption of tree nuts led to
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4.2. Dried Fruits
4.2.1. Acute Clinical Trials on Dried Fruits
Less research has been carried out into DFs than into nuts. However, the findings to date point to
a beneficial effect of DFs on postprandial glucose regulation and glycaemic control in T2D subjects.
The putative effect of DFs on postprandial glycaemia and insulinaemia has been studied mainly
using raisins (Table 7). However, some research into dried plums has also been published.
First, in 1989 Rasmussen and coworkers evaluated in healthy and T2D subjects the postprandial
effects of three meals: raw rolled oats, oatmeal porridge, or a mixture of raw rolled oats with raisins,
compared to a control glucose ingestion [109]. The substitution of 25% of the starch meal with raisins
(i.e., simple sugars) did not affect blood glucose or insulin responses. In addition, a similar glucose and
insulin response in both normal and T2D subjects were reported [109]. Other researchers investigated
the postprandial effect of raisins consumed alone. When the GI was investigated in three different
groups (sedentary, aerobically trained or pre-diabetic subjects), no significant differences were found
among groups, even though the GI (55–69) it seemed moderate for aerobically trained adults, and low
(GI, ≤55) for the other groups [110]. Kanellos and collaborators found a moderate GI of raisins in
healthy and T2D subjects [111], whereas Esfahani et al. found that raisins were low-GI and glycaemic
load (GL) foods in healthy subjects [112]. Recently, researchers have found that even though the
same available CHO content from raisins and glucose generated a similar postprandial response,
raisins significantly modulated the levels of GIP, ghrelin and ghrelin/obestatin ratio, with important
implications in terms of appetite regulation and overall insulin secretion [113]. In overweight women,
researchers determined that dried plums had a lower plasma glucose and insulin incremental area
under the curve (IAUC) than an isoenergetic low-fat cookie meal [114].
Overall, results suggest that raisins have a beneficial postprandial glucose and insulin effect, which
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2017, 9, 673
4.2.2. Chronic Clinical Trials on Dried Fruits
The study of the beneficial effects of chronic DF consumption also focuses on raisins (Table 8).
Randomized clinical trials have been conducted in healthy [115], overweight or obese [116,117], T2D
subjects [118,119], or a combination of the three [120]. In a 6-week parallel trial in healthy subjects,
Puglisi et al. included 150 g/day of raisins into subjects’ habitual diet or increased their physical
activity (or combined them both). Neither FPG nor insulin levels were different among groups or
compared to baseline. However, the inflammation status reported by plasma TNF-α significantly
decreased in the raisin intervention [115].
The results for overweight or obese subjects do not show a significant improvement in glucose
or insulin levels after the consumption of raisins [116] or dried plums [117]. However, these studies
are only short (2 weeks) which makes it impossible to analyze the chronic effect. In fact, in a parallel
study conducted in Ow/Ob subjects, comparing raisin consumption (270 Kcal/day) with a snack
(300 Kcal/day) for 12 weeks, researchers [120] found that even though FGP or insulin were not
affected by either intervention, HbA1c levels and postprandial glucose levels had been reduced by
raisin consumption by the end of the trial. This suggests a beneficial effect of raisin consumption on
glycaemic control in Ow/Ob subjects with pre-D. Importantly, raisin intake also improved systolic
blood pressure (SBP) and diastolic blood pressure (DBP) and had a null effect on body weight [120].
Two studies have been conducted in individuals with T2D. A parallel study comparing the
consumption of 36 g of raisins versus the habitual diet free of raisins or grapes for 24 weeks did not
find any change in either body weight or in glycaemic control and lipid profile, but the total antioxidant
capacity increased and the DBP decreased after raisin consumption [118]. Likewise, the consumption
of raisins as a snack (84 g/day, 270 Kcal/day) for 12 weeks significantly reduced the postprandial
glucose response in T2D subjects compared to an alternative snack (300 Kcal/day) for 12 weeks.
A non-significant trend to a reduction in fasting glucose and HbA1c was also observed in the same
group of raisin consumers [119].
The results of DF consumption on glycaemia/insulinaemia point to a beneficial effect. However,
novel acute and long-term RCTs assessing other types of DF should be carried out in order to
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5. Potential Mechanisms Linking Nut and Dried Fruit Consumption to Glucose and Insulin
Metabolism
5.1. Nut- and Dried Fruit-Related Nutrients and Their Role in Glucose and Insulin Metabolism
Fiber Content in Nuts and Dried Fruits
Both nuts and DFs are high in dietary fiber [9]. Diets rich in complex CHO and fiber are
associated with increased insulin sensitivity and reduced plasma insulin levels, promoting better
glycaemic control in diabetic patients [121]. Soluble fiber increases gastric distension, viscosity in the
gastrointestinal tract, and slower absorption of macronutrients [122]. As a consequence, the speed of
CHO absorption and the concentration of postprandial glucose tend to be lower after the ingestion of
fiber-rich foods than foods or meals poor in fibers [123].
Fiber is resistant to enzymatic digestion in the small intestine and thus susceptible to fermentation
by bacteria in the colon. It produces short chain fatty acids (SCFA, e.g., acetate, propionate and butyrate)
which reduce the production of hepatic glucose and stimulate the secretion of GLP-1 [124,125]. Incretins
such as GLP-1 and gastric inhibitory polypeptide (GIP) stimulate the secretion of insulin by β-cells and
promote the proliferation of these cells, favoring the maintenance of normal blood glucose levels [125].
The secretion of GLP-1—which is mainly performed by enteroendocrine L-cells of the gastrointestinal
tract -is partly mediated by monosaccharides, peptides and amino-acids, MUFA and PUFA as well as
by SCFA. Therefore, the positive influence of GLP-1 on blood glucose homeostasis, appetite sensations,
and food intake provides a strong rationale for its therapeutic potential in the nutritional management
of T2D and obesity [126].
Overall fiber contained in nuts and DFs is also able to decrease postprandial glycaemic levels and
this could be a strategy for increasing insulin sensitivity which improves T2D and several other CV
risk factors for chronic diseases [74,127].
Carbohydrate Content—Glycaemic Index of Nuts and Dried Fruits
It should be noted that nuts are relatively low in CHO (approximately 15% of the total energy)
whereas DFs have a high amount of CHO (60–80%). Nuts have a low glycaemic index and therefore
increase the blood glucose level less and require less insulin secretion, thus favoring the control
of T2D. However, because DFs are high in carbohydrates and fiber, their specific GI has been the
object of considerable study. The GI of raisins was first evaluated in three heterogeneous groups of
subjects (aerobically trained, sedentary or pre-diabetic) and was described between 49 and 69, therefore
corresponding to the low-to-moderate GI foods [110]. However, later studies have reported that raisins
are in the low GI category in healthy subjects (a GI of 49.4 and an insulinemic index of 47.1) [15].
This suggests a favorable postprandial glucose and insulin response [112], that could be explained by
the high proportion of fructose that DFs contain.
Overall, the inclusion of both nuts and DFs in a balanced diet may reduce the overall glycaemic
index of the diet, with benefits to glycaemic and insulinemic control in both healthy and T2D
subjects [128].
Fat Content in Nuts
The high content of MUFA and PUFA in nuts seems to enhance the reduction of IR, thus
consequently reducing the risk of developing T2D [129–131]. However, the mechanisms by which
these fatty acids (FA) affect insulin sensitivity are not yet fully understood [132]. It is believed, however,
that the FAs present in the phospholipids of different cell membranes are affected by the type of fatty
acid intake, thus affecting insulin sensitivity. The different unsaturated FAs that are part of the cell
membrane influence the action of insulin via affecting the binding or affinity of insulin to its cellular
receptor [133]. It is hypothesized that a higher unsaturation of FA in the cell membrane facilitates
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In addition, as we have seen, unsaturated fatty acids act through the stimulation of GLP-1 secretion,
thus improving the efficiency of β-cells. SFA and MUFA act on the lipogenic gene expression, while
PUFA inhibit the expression of these genes, partly by binding and activating nuclear receptors, such as
those activated by peroxisome proliferators (PPAR) [131]. It has been suggested that the activation
of PPAR has a therapeutic role in the treatment of T2D, because it induces fatty acid clearance by the
adipose tissue, decreasing its plasma levels and thus increasing insulin sensitivity in the muscle [135].
Mineral Content in Nuts and Dried Fruits
Nuts contain relatively high quantities of different minerals such as potassium, magnesium
and calcium, whereas DF contains more moderate quantities (mainly potassium, magnesium and
boron). Magnesium has been associated with beneficial effects on glycaemic control [136]. Low
magnesium levels have been implicated in IR development [124]. In fact, kidneys lose the ability to
retain magnesium in periods of acute hyperglycemia. It is excreted in the urine, leading to low mineral
blood levels. It has been shown that correcting this depletion improves response and insulin action.
Magnesium deficiency also interferes with the reactions that use or produce ATP, thus altering the
enzyme cascade involved in the CHO metabolism and favoring the development of T2D [137].
Therefore, the minerals present in nuts and DF could explain the relationship observed between
magnesium intake and the lower risk of developing T2D and other chronic diseases [138,139].
Other Bioactive Compounds in Nuts and Dried Fruits
The other bioactive compounds contained in nuts and DF could partially explain their protective
anti-oxidant and anti-inflammatory properties [2] and their implication in glucose and insulin
metabolism (and therefore in T2D). Significant evidence suggests that polyphenol-rich diets have
the ability to protect against diabetes [140]. It appears that anthocyanins (or anthocyanin-rich
foods) are inversely associated to the risk of T2D, but there is no association for other polyphenol
subclasses [141,142]. Dietary polyphenols have some benefits for T2D: they protect pancreatic β-cells
against glucose toxicity and they have anti-inflammatory and anti-oxidant effects, among other
things. Quercetin is a member of the flavonoid class of polyphenols which is abundant in such
foods as fruits, vegetables, nuts and seeds [143]. Several in vitro studies have sought to elucidate
the mechanisms behind the antidiabetic properties of quercetin: for example the inhibition of the
α-amylase and α-glucosidase activities, and the prevention of the lipid peroxidation of pancreatic tissue
homogenates [144]. Moreover, ellagic acid (EA) is another polyphenol which naturally occurs in some
fruits, such as berries (strawberries and red and black raspberries), nuts, and pomegranates [145]. There
is emerging in vitro evidence that EA may ameliorate symptoms of chronic metabolic diseases—by
decreasing chronic inflammation at the expression level—which include dyslipidemia, IR and
T2D [146–148]. Despite the growing amount of information on EA, a definitive mechanism of action
has not been established. This may be attributed to the complexity of EA metabolism, which is
governed by various factors [145].
A growing body of evidence suggests that dietary agents and the non-nutrient components of
fruits, vegetables and nuts can affect epigenetic processes related to T2D [149,150]. Epigenetics
generally refers to heritable and reversible changes affecting gene expression and chromatin
organization that are not due to alterations in the DNA sequence [151,152]. No specific data is available
on the role of nuts and DFs in T2D epigenetics. However, dietary polyphenol resveratrol—most
abundant in the skin of grapes and raisins, but also found in peanuts and cranberries [153]—and other
phytochemicals (e.g., curcumin) have proved to be effective agents against cancer and to act through
epigenetic mechanisms that affect the global epigenome [154,155]. However, future studies are needed
to determine the biological importance of the altered tissue-specific DNA methylation in T2D resulting
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5.2. Cellular and Molecular Mechanisms Linking Nut and Dried Fruit Consumption and the Prevention and/or
Management of T2D/IR
Gene Expression
Some studies have analyzed the effect of nut and DF consumption on changes in the gene
expression of particular cells and/or tissues and its relationship with glucose and insulin metabolism
or T2D. In particular, a crossover study conducted in pre-diabetic subjects consuming pistachio for
4 months reported a downregulation of interleukin-6 (IL-6) and resistin (RETN) genes in leukocytes,
whereas the pistachio diet led to a lower significant increase of solute carrier family 2 member
4 (SLC2A4, codifying GLUT4) [85]. Consistent with this attenuation in the expression of glucose
transporters, leukocytes significantly reduced the uptake of glucose following pistachio consumption,
suggesting a decrease in the cell hyperactivity described in T2D.
To our knowledge no published studies have evaluated gene expression after the consumption of
DF. However, a translational study conducted in 120 healthy young subjects has shown that individuals
in the highest tertile of fruit and vegetable consumption had statistically lower values of the expression
of some pro-inflammatory marker genes such as intercellular adhesion molecule-1 (ICAM-1), IL-6 and
TNF-α, in peripheral blood mononuclear cells (PBMC) [156].
Therefore, these results shed new light on the nutrient-gene interactions in nuts and DFs. However,
further research is needed.
MicroRNAs
The modulatory role of nuts and DF on the expression of genes related to inflammation, oxidative
stress and glucose metabolism can also be mediated by the effect of nutrients on microRNAs.
MicroRNAs (miRNAs) are RNA molecules that belong to a family of small non-coding RNAs with 20
to 25 nucleotides [157,158] that post-transcriptionally and negatively regulate gene expression.
Research into the nutritional modulation of miRNA is still in its infancy and few studies
have assessed whether a specific dietary pattern, food, supplements or a particular nutrient can
influence miRNA levels [159]. In humans, consumption of grape extract rich in resveratrol, and Vitamin
supplementation modulated specific miRNAs towards a healthier status [160]. Similarly, a PUFA-enriched
diet including almonds and walnuts was effective at modifying several miRNAs [161]. More recently,
pistachio consumption in pre-diabetic subjects significantly diminished the levels of miR-375 and
miR-192, both related to the glucose and insulin metabolism [162]. However, there is still much to
discover about the exact mechanisms linking miRNAs with the glucose and insulin metabolism and
the dietary modulation of miRNA expression.
Microbiota and Metabolomic Modulation
In recent years, many studies have pointed out that the gut microbiome might make an important
contribution to the development of insulin resistance and T2D. Several mechanisms related to the
composition of gut microbes—including changes in bowel permeability, endotoxemia and interaction
with bile acids—may contribute to the onset of insulin resistance. On the other hand, it is well
established that long-term dietary patterns and shorter-term dietary variation influence gut microbiota
composition [163]. Many potential prebiotic components can be present in a particular food. For
example, the fermentation of fiber from nuts and DF to beneficial end-products (e.g., butyric acid) and
the biotransformation of phytochemicals (i.e., tocopherols, phytosterols, and phenolic compounds) are
associated with the transition to a healthier microbiota composition [2,164].
There is little information on the putative effect of nuts and DF on microbiota modulation. In fact,
only two publications have evaluated the effect of nut consumption (almonds and pistachios) on
changes in microbiota. Mandalari et al. conducted an in vitro study with almond skins and they
found that almond fiber significantly altered the composition of gut bacteria, specifically Bifidobacteria,
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collaborators carried out two separate crossover feeding trials with nuts and pistachios, and showed
that they both significantly affected microbiota modulation [166]. However, a greater prebiotic effect
was found after pistachio intake. In fact, pistachio increased the number of butyrate-producing
bacteria, which are potentially beneficial, whereas the numbers of Bifidobacteria were not affected by
the consumption of either nut [166].
Recently, dietary polyphenols have been found to be involved in gut microbiota dysbiosis
processes which may lead to a reduction of fat storage, inflammation and IR (reviewed in [167]).
In fact, a cranberry extract also altered the gut microbiome of mice by increasing mucin-degrading
bacteria, a potential link to reverse the dysbiosis and metabolic inflammation underlying T2D [168].
Very few studies have been made on metabolomic modulation after nut and DF intake.
Of the studies that have been made, some have evaluated changes in metabolites after a chronic
consumption of nuts. They showed a modulation in the levels of metabolites such as raffinose,
(12Z)-9,10-dihydroxyoctadec-12-enoate, sucrose, together with some modulations of plasma amino
acids and fatty acids [169], and a modulation of gut-related metabolites and cis-aconitate, an
intermediate of tricarboxylic acid [170], after pistachio consumption.
Therefore, several specific nutrients—together with their synergic effects—in both nuts and DFs
may explain their beneficial role in glucose and insulin metabolism, which helps to prevent or maintain
T2D (Figure 1).
 
Figure 1. Role of nutrients from nuts and dried fruits in glucose and insulin metabolism, and cellular
and molecular mechanisms related to T2D/IR. CHO, carbohydrate; CMF, cellular membrane fluidity;
GI, glycaemic index; IR, insulin resistance; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated
fatty acid; T2D, type 2 diabetes.
6. Concluding Remarks
Undoubtedly, the specific composition of nuts and dried fruits means that they can be used to
efficiently counteract metabolic diseases such as type 2 diabetes. Their unique profile of macronutrients,
micronutrients and other bioactive compounds may explain the beneficial effects observed in clinical
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insulin metabolism and influence T2D have yet to be fully discovered. They contain fiber, fat, minerals
and other bioactive molecules that modulate several gene mechanisms at the cellular and molecular
level. This may explain some of their beneficial effects. However, further basic and translational
research is needed in order to extend their positive health benefits and to find novel mechanisms and
targets to explain their contribution to the management of type 2 diabetes.
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NAFLD non-alcoholic fatty liver disease
NCEP National Cholesterol Education Program
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NHS Nurses’ Health Study
NLCS Netherlands Cohort Study
NS non-significant
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ORAC oxygen radical absorbance capacity
Ow overweight
PBMC peripheral blood mononuclear cell
PF-4 platelet factor-4
PHS Physicians' Health Study
PM post-menopausal
PPAR peroxisome proliferator-activated receptors
pre-D pre-diabetes
PREDIMED PREvención con DIeta MEDiterránea
PUFA polyunsaturated fatty acids
PWE polyphenol-rich walnut extract
Re range
RETN resistin
RCT randomized clinical trial
RGR relative glycaemic responses
RR relative risk
RW red wine
ROS reactive oxygen species
S sedentary
SBP systolic blood pressure
SCCS Southern Community Cohort Study
SCFA short chain fatty acids
SFA saturated fatty acids
SLC2A4 solute carrier family 2 member 4
SMHS Shanghai Men's Health Study
STZ streptozotocin
SWHS Shanghai Women's Health Study




TLGS Tehran Lipid and Glucose Study
TNF-α tumor necrosis factor-α
USDA United States Department of Agriculture
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Abstract: Cardiovascular risk management is an integral part of treatment in Type 2 Diabetes Mellitus
(T2DM), and requires pharmacological as well as nutritional management. We hypothesize that a
systematic assessment of both pharmacological and nutritional management can identify targets for
the improvement of treatment quality. Therefore, we analysed blood pressure (BP) management in
the DIAbetes and LifEstyle Cohort Twente (DIALECT). DIALECT is an observational cohort from
routine diabetes care, performed at the ZGT Hospital (Almelo and Hengelo, The Netherlands).
BP was measured for 15 min with one minute intervals. Sodium and potassium intake was
derived from 24-hour urinary excretion. We determined the adherence to pharmacological and
non-pharmacological guidelines in patients with BP on target (BP-OT) and BP not on target (BP-NOT).
In total, 450 patients were included from August 2009 until January 2016. The mean age was
63 ± 9 years, and the majority was male (58%). In total, 53% had BP-OT. In those with BP-NOT,
pharmacological management was suboptimal (zero to two antihypertensive drugs) in 62% of patients,
and nutritional guideline adherence was suboptimal in 100% of patients (only 8% had a sodium
intake on target, 66% had a potassium intake on target, 3% had a sodium-to-potassium ratio on target,
and body mass index was <30 kg/m2 in 35%). These data show pharmacological undertreatment and
a low adherence to nutritional guidelines. Uncontrolled BP is common in T2DM, and our data show a
window of opportunity for improving BP control, especially in nutritional management. To improve
treatment quality, we advocate to incorporate the integrated monitoring of nutritional management
in quality improvement cycles in routine care.
Keywords: Type 2 diabetes mellitus; blood pressure; pharmacological management; nutrition; dietary
sodium intake
1. Introduction
Type 2 Diabetes Mellitus (T2DM), with an estimated number of 422 million patients worldwide,
is one of the major conditions associated with cardiovascular events and cardiovascular death [1].
Therefore, the prevention of the development and progression of such complications is a main goal in
the treatment of T2DM, and evidence-based recommendations to reach this goal are incorporated in
treatment guidelines. Treatment consists of pharmacological and non-pharmacological management,
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the latter consisting in large part of nutritional guidance. Still, cardiovascular complications develop
in the majority of T2DM patients, demonstrating the large challenge of adequate treatment [2,3]. One
explanation for this could be a failure to reach guideline treatment targets. Indeed, several studies
have shown that targets for blood pressure, glycemic control, and Low Density Lipoprotein (LDL)
cholesterol are not reached in a large number of patients [4–8].
Pharmacological and nutritional management are often studied as separate entities, despite the
fact that both are crucial elements of treatment. We hypothesize that a systematic assessment of both
pharmacological and nutritional management can identify targets for the improvement of treatment
quality. The DIAbetes and LifEstyle Cohort Twente (DIALECT) cohort study was specifically designed
for this purpose. DIALECT is an observational study in T2DM patients in a well-defined region in The
Netherlands, and uses validated and detailed real-world data on nutritional habits, pharmacological
treatment, and current clinical condition. To obtain non-biased data on individual nutrient intake,
24-hour urine collections were used and stored in a biobank to allow for future analyses [9].
We aim to address how well the targets for blood pressure management are reached, and how
this is related to (1) pharmacological management; and (2) nutritional management (i.e., the dietary
intake of salt [10,11], potassium [12,13], body mass index (BMI), and alcohol). Moreover, we assessed
additional nutritional parameters for which no specific counselling was given, but have been shown to
be relevant to cardiovascular risk in diabetic kidney disease (magnesium [14–16] and phosphate [17,18]).
Because the presence of diabetic kidney disease implicates different blood pressure targets, we analysed
patients without and with renal involvement separately.
2. Materials and Methods
2.1. Study Design and Participants
DIALECT is a prospective cohort study in patients with T2DM, performed in the ZGT Hospital,
which is located in Almelo and Hengelo, The Netherlands. It is designed to study pharmacological
and non-pharmacological management in a regional T2DM population treated in a secondary
health care center. All patients with T2DM and aged 18+ years treated in the outpatient clinic of
our hospital were eligible, with the only exclusion criteria being an inability to understand the
informed consent procedure, insufficient knowledge of the Dutch language, or a dependency on renal
replacement therapy.
This paper reports on the DIALECT-1 population, consisting of the first 450 patients, recruited
between September 2009 and January 2016. The inclusion of new patients in DIALECT-2 will be
performed until December 2019, or until the number of 850 is reached. The study is performed
according to the guidelines of good clinical practice and the Declaration of Helsinki. It has been
approved by the local institutional review boards (METC-registration numbers NL57219.044.16 and
1009.68020), and is registered in the Netherlands Trial Register (NTR trial code 5855).
2.2. Study Procedures
Patients were screened for eligibility in the electronic patient file, and subsequently invited for
a study visit. At the clinic, all of the information relevant to the medical condition was recorded in
a database (Figure 1, Supplementary Table S1). Height, weight, and waist and hip circumference
were measured. Body mass index was calculated as weight divided by height squared (kg/m2), and
body surface area was estimated by applying the universally adopted formula of DuBois [19]. Blood
pressure was measured in a supine position by an automated device (Dinamap®; GE Medical systems,
Milwaukee, WI, USA) for 15 min with a one-minute interval. The mean systolic and diastolic pressure
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Figure 1. Patient inclusion and data collection.
Physical activity was assessed using the Short Questionnaire to Asses Health enhancing physical
activity (SQUASH) questionnaire, which was previously validated in [20]. The 24-hour urinary content
of specific substances was measured where possible and appropriate.
Routine laboratory tests were performed in venous blood, including blood count tests, liver
function tests, renal function tests, HbA1c, and cholesterol. The estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula [21]. From samples of a 24-hour urine collection, the following parameters were measured:
sodium, potassium, creatinine, calcium, phosphate, chloride, albumin, protein, urea, and uric acid
excretion. Twenty-four-hour urinary excretion was calculated by multiplying these concentrations with
the volume of the 24-hour urine collection. Creatinine clearance was calculated from the 24-hour urine
creatinine excretion and the plasma creatinine concentration. For the proper collection of the 24-hour
urine sample, patients were instructed to dispose of the first morning void urine, and thereafter collect
all urine in the provided canister until the first morning void urine of the next day. In between voids,
they were instructed to store the canister in a dark cool place, preferably in a refrigerator. A separate
single morning void urine was used to assess the urinary albumin-to-creatinine ratio.
The samples of blood, 24-hour urine collection, and morning void urine were stored in a biobank
at −80 degrees Celsius for additional analyses, as specified in Supplementary Table S1.
2.3. Routine Clinical Care
Diabetes care in the Netherlands is standardised, both in the outpatient clinic and at the general
practitioner. It consists of three to four outpatient clinic visits per year. The development of albuminuria
is assessed yearly using the albumin–creatinine ratio in a single morning void urine. Retinopathy is
assessed at one to two year intervals. Neuropathy is assessed yearly using monofilament and vibration
tests with a tuning fork.
Lifestyle management in T2DM consists of guidance regarding weight loss, increasing physical
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and the adherence to dietary guidelines, including sodium restriction and stimulating an intake of
fruit and vegetables. The frequency of dietary follow-up visits is targeted at the individual goals
and needs of patients depending on personal preferences as well as comorbidity. At each doctor
visit, target HbA1c and blood pressure are monitored, and pharmacological intervention is adjusted
accordingly. Cholesterol levels are monitored yearly. Targets for HbA1c and LDL cholesterol are often
individualized; the general targets are <53 mmol/L and <2.5 mmol/L, respectively.
2.4. Definitions
The blood pressure (BP) targets in our analyses were derived from the international guidelines
for diabetes management, which have been adopted for use in The Netherlands [22,23]. In patients
with diabetic kidney disease, the BP target was set according to the Kidney Diseases Improving
Global Outcomes (KDIGO) guidelines, which are internationally acclaimed guidelines for chronic
kidney disease, and are also applied in The Netherlands [23]. Patients with diabetic kidney disease
without albuminuria (eGFR <60, no albuminuria) had a BP target of ≤140/90 mmHg, while patients
with albuminuria and either an eGFR ≥60 mL/min or an eGFR <60 mL/min had a BP target of
≤130/80 mmHg. For patients with T2DM without diabetic kidney disease, the European Association
for the Study of Diabetes (EASD) guidelines are used, which stipulate a blood pressure (BP) target of
<140/85 mmHg [22]. Accordingly, the patients were grouped by eGFR above or below 60 mL/min
and by the presence of albuminuria. Albuminuria was defined as a 24-hour urinary albumin excretion
>30 mg/day. As the EASD and KDIGO guidelines for those without albuminuria differ slightly, we
performed all of the analyses using the EASD guidelines for those with eGFR <60 and no albuminuria
as well. The results were virtually similar, and for the sake of conciseness, the data is not shown.
The targets for nutritional management were set according to the Dutch guidelines when available.
The target dietary salt intake was ≤6 g/day [24], and the target dietary potassium intake was set
at ≥3.5 g/day, according to best evidence [13]. The target alcohol intake was ≤2 units per day for
women, and ≤3 units per day for men. It should be noted that in 2015, the Health Council of The
Netherlands changed the guidelines for alcohol consumption to zero units per day; however, our
patients were included in the study before the introduction of these new guidelines [25]. The target
BMI was <30 kg/m2. The target for smoking was either no smoking history, or having previously
stopped smoking.
The data on dietary intake of salt, potassium, and proteins were derived from 24-hour urinary
excretion. For this, it is important to realise that the patients in our cohort were assessed under steady
state conditions, in which the net renal excretion of sodium is almost equal to the dietary intake
of sodium, with only approximately 5–10% being excreted by other routes (e.g., sweat or feces) [9].
Therefore, 24-hour urinary sodium excretion is considered the gold standard for the assessment of
sodium intake [9,26], and dietary salt intake was calculated by multiplying the net 24-hour sodium
excretion (in mol/day) with the molar weight of salt (NaCl, 58.44 g/mol). Dietary potassium intake
was calculated from urinary potassium excretion under the assumption of a renal excretion rate of
77% [13,27]. Dietary protein intake was calculated from urinary urea nitrogen excretion using the
Maroni formula [28]. As the renal excretion of magnesium is lower in patients with a low eGFR, dietary
magnesium intake could not be calculated from urinary magnesium excretion with the same formula
(using the assumption of an intestinal absorption of 30%) [16]. Therefore, we present the urinary
daily excretion of magnesium. Also, while no consensus exists to calculate dietary phosphate intake
from the urinary excretion, urinary phosphate excretion does reflect variability in intestinal phosphate
uptake [29,30], so we present the urinary excretion values.
2.5. Statistical Analyses
All of the statistical analyses were performed using Statistical Package for the Social Sciences
(SPSS), version 23.0. Normally distributed data are presented as mean ± standard deviation. Skewed
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number and percentage. First, we divided the population according to the presence of albuminuria
and/or a reduced eGFR (<60 mL/min), as in these groups the target BP is different (<140/85 for
those without diabetic kidney disease, ≤140/90 mmHg for patients without albuminuria and an eGFR
<60 mL/min, and ≤130/80 mmHg for those with albuminuria). Second, we divided the population
into two groups, according to the reached blood pressure. These groups are denoted as “Blood pressure
on target” (BP-OT) and “Blood pressure not on target” (BP-NOT), respectively. The differences between
the groups were analysed using the student t-test, one-way ANOVA, the Mann–Whitney U test, the
Kruskall–Wallis test, and the Chi Square test when appropriate. To perform a multivariate analysis
of the determinants of not on target BP, multivariate logistic regression was used. In order to adjust
for age and gender, the differences in nutritional data among the groups were also determined using
mixed model analyses with Sidak post-hoc tests.
3. Results
Between September 2009 and January 2016, 1082 eligible patients were identified and invited to
participate in the study, of whom 470 were enrolled in the study and performed the baseline visit. The
most common causes for not participating in the study were: No interest in research, and inability
due to co-morbidity (Figure 2). Twenty patients were excluded after the baseline visit, as in closer
analysis their correct diagnosis was Type 1 Diabetes Mellitus instead of Type 2. All of the remaining
450 patients were included in our data analysis.
 
Figure 2. Patient recruitment flowchart.
3.1. Baseline Pharmacological and Nutritional Characteristics
The baseline data are presented in Table 1, by a break-up according to reduced eGFR (<60 mL/min)
and the presence of albuminuria. The mean age of the participants was 63 ± 9 years, and was higher
in the groups with eGFR <60 (Table 1). There were more men (58%) than women, and men were
over-represented in the albuminuria groups (74% and 77% respectively for eGFR ≥60 and <60).
The mean BMI was 32.9 ± 6.2 kg/m2, reflecting a predominantly obese T2DM population, and BMI
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There was no renal involvement in 57% of the patients (eGFR ≥60/Alb−; Table 1). Of all of the
patients, 30% (n = 136) had albuminuria, either with a preserved (n = 85, eGFR ≥60/Alb+) or reduced
renal function (n = 51, eGFR <60/Alb+). Fifty-two patients (12%) had a reduced renal function without
albuminuria (eGFR <60/Alb−). The mean systolic blood pressure was 139 ± 16 mmHg, and the
mean diastolic BP was 76 ± 9 mmHg. Most of the patients (81%) used one or more antihypertensive
drugs. The target BP was reached in 53% of all patients, while 47% had BP not on target. In patients
with albuminuria, 33% and 24% reached the target blood pressure in eGFR ≥60 and in eGFR <60,
respectively (Table 1). Additionally, a blood pressure of ≤140/90 mmHg was reached in 48% and 41% of
albuminuria patients with an eGFR ≥60 and eGFR <60, respectively. The group with albuminuria and
eGFR <60 received the largest number of antihypertensive drugs (3 (2–4) drugs, Table 1). Additionally,
the number of patients with hypertension requiring 4+ drugs was highest in this group (59%, p < 0.001).
In contrast, the antihypertensive drug use in the eGFR ≥60/Alb+ group is not higher than in the
other groups (2 (1–3) drugs). Patients without chronic kidney disease (CKD) (Table 1, group eGFR
≥60/Alb−) most commonly used renin-angiotensin-aldosterone-system inhibition (RAASi) (59%),
followed by β-blockers (39%), and thiazide diuretics (32%). This was different in those with CKD
(groups eGFR ≥60/Alb+, eGFR <60/Alb−, and eGFR <60/Alb+): RAASi (77%), β-blockers (62%),
and Calcium antagonists (31%). There were two patients with an eGFR <60 that used a phosphate
binder, one in the Alb− group, and one in the Alb+ group.
The mean dietary salt intake was high, namely, 10.9 g of salt per day, and was considerably higher
in the groups with preserved eGFR. When adjusting for age and gender, these differences remained
virtually similar (data not shown). In the overall population, only 53 patients (12%) adhered to
the dietary guidelines for dietary salt intake, ≤6 g/day, and in the eGFR ≥60/Alb+ group this
percentage was even lower, i.e., 6%. In total, 8% of patients had a salt intake of ≤5 g/day as
recommended by the WHO. The mean potassium intake was 3.9 ± 1.3 g/day, and 66% of patients had
an intake, as recommended, above 3.5 g/day (Table 1). The mean urinary magnesium excretion was
4.0 ± 2.1 mmol/day, and as expected was lower in patients with an eGFR <60 mL/min than in those
with an eGFR ≥ 60mL/min. The mean urinary phosphate excretion was 27.5 ± 11.6 mmol/day, and
the mean calculated dietary protein intake was 92 ± 27 g/day.
3.2. Pharmacological and Nutritional Management in BP-On Target (BP-OT) and BP-Not On Target
(BP-NOT) Groups
Table 2 shows the patients’ characteristics by a break-up of BT-OT and BP-NOT. Patients with
BP-NOT were more often men (64% vs. 53%, P = 0.018), and had a higher HbA1C (59 ± 12 vs.
56 ± 11 mmol/L, P = 0.031). While the presence of albuminuria was a strong predictor of uncontrolled
BP (46% vs. 17%, p < 0.001), poor BP control was not associated with an eGFR <60 mL/min
(24% vs. 22%).
Patients with BP-OT used loop diuretics more often than those with BP-NOT (Table 2). There
were no other differences in the pharmacological treatment between the BP groups; neither in the
types of prescribed drugs, nor in the total number of prescribed antihypertensive drugs. Surprisingly,
of the patients with BP-NOT, 21% did not use any antihypertensive drug, while 20% used only one,
and 21% used two antihypertensive drugs.
Adherence to the recommended nutritional guidelines by a breakup of BP-OT and BP-NOT is
shown in Figure 3. In both groups, adherence to the recommended lifestyle guidelines was poor, and
the total number of lifestyle targets adhered to did not differ between the groups (3 (2–3) in BP-OT
vs. 3 (2–3) in BP-NOT, p = 0.22). In patients with BP-NOT, 8% had a dietary salt intake below the
recommended 6 g/day, which was lower than those with BP-OT (15%, p = 0.025). Adherence to the
potassium guideline (66% of patients) did not differ among the groups. Only 3% of patients had a
sodium-to-potassium ratio ≤1.0 in both BP groups. There were only three patients (1%) who adhered
to both the recommended intakes of salt and potassium. BMI was ≤30 kg/m2 in 35% of patients, and
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to by 83% and 86% of all patients, and these proportions were not different among the BP groups. We
found no differences in the other nutritional factors between the BP-OT and BP-NOT groups (Table 2).
In the total population, there was only one patient (with BP-OT) who adhered to all of the lifestyle
guidelines simultaneously. There were no differences in lifestyle guidelines adherence between those
with zero to two antihypertensives and those with three-plus antihypertensives.
Table 2. DIALECT-1 pharmacological and nutritional management by a breakup of BP on target/not
on target.
Variable BP On Target BP Not On Target p-Value
Patient characteristics n = 239 n = 210
Age (years) 63 ± 9 63 ± 9 0.36
Male, n (%) 126 (53) 134 (64) 0.02
Years T2DM (years) 11 (7–17) 12 (7–18) 0.26
Serum HbA1C (mmol/mol) 56 ± 11 59 ± 12 0.03
Insulin use, n (%) 149 (62) 136 (65) 0.60
Systolic blood pressure (mmHg) 125 ± 10 149 ± 13 <0.001
Diastolic blood pressure (mmHg) 70 ± 8 80 ± 9 <0.001
eGFR <60, n (%) 53 (22) 51 (24) 0.60
Albuminuria, n (%) 40 (17) 95 (46) <0.001
Pharmacological management
RAASi, n (%) 163 (68) 134 (64) 0.33
β-blockers, n (%) 115 (48) 93 (44) 0.42
Thiazide diuretics, n (%) 71 (30) 66 (31) 0.69
Calcium antagonists, n (%) 50 (21) 52 (25) 0.33
Loop diuretics, n (%) 52 (22) 29 (14) 0.03
Potassium sparing diuretics, n (%) 22 (9) 21 (10) 0.78
Number of antihypertensives 2 (1–3) 2 (1–3) 0.51
No antihypertensive therapy, n (%) 39 (16) 44 (21) 0.85
1 drug, n (%) 47 (20) 42 (20)
2 drugs, n (%) 64 (27) 45 (21)
3 drugs, n (%) 50 (21) 43 (21)
4 drugs, n (%) 29 (12) 27 (13)
5+ drugs, n (%) 10 (4) 9 (4)
Hypertension requiring 4+ drugs, n (%) 39 (16) 79 (38) <0.001
Total number of drugs 7.0 ± 2.6 6.7 ± 2.8 0.30
Non-pharmacological management
BMI (kg/m2) 32.8 ± 5.8 32.9 ± 6.7 0.89
Serum 25 (OH) Vitamin D (nmol/L) 43 ± 20 41 ± 20 0.22
Urinary excretion
Urinary creatinine excretion (mmol/day) 13.6 ± 4.9 14.1 ± 4.7 0.22
Urinary magnesium excretion (mmol/day) 3.9 ± 2.1 4.0 ± 1.9 0.43
Urinary phosphate excretion (mmol/day) 26.9 ± 12.3 28.2 ± 10.7 0.26
Sodium-to-potassium ratio (mmol/mmol) 2.5 ± 1.0 2.5 ± 0.9 0.49
Calculated intake
Dietary salt intake (g/day) 10.7 ± 4.8 11.1 ± 4.4 0.47
Dietary potassium intake (g/day) 3.8 ± 1.3 4.0 ± 1.2 0.15
Dietary protein intake (g/day) 90 ± 29 93 ± 26 0.29
In the multivariate logistic regression analysis, albuminuria and the use of loop diuretics remained
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Figure 3. % Adherence to nutritional guidelines, by a breakup of blood pressure on target/not on
target. Alcohol intake is self-reported, and the target intake was ≤2 units per day for women and
≤3 units per day for men.
4. Discussion
In this paper, we present the blood pressure management of Type 2 diabetes patients (T2DM),
using combined data on pharmacological and nutritional management in a real-life secondary health
care setting. As anticipated, the prevalence of hypertension was high, and 81% of patients were on
antihypertensives. However, BP control was poor, as the target BP was not reached in 47% of patients.
An integrated assessment of pharmacological and nutritional management demonstrated a large
window of opportunity for improving BP control in T2DM, both by intensifying antihypertensive drug
treatment, and increasing nutritional guideline adherence.
The proportion of patients with their blood pressure on target (BP-OT) in our cohort is in line
with findings in other T2DM cohorts [31], as well as diabetic kidney disease cohorts [5,32]. The
proportion was lower than found in T2DM patients treated in the primary care setting, in whom
adequate blood pressure control was found in 85% of patients [33,34], which may well reflect the
referral policy, with more difficult patients being referred to secondary care. In the baseline data of
the LEADER-4 trial (a randomized clinical trial in T2DM patients) [31], where 51% of patients had
BP-NOT, the antihypertensive use was lower than we report, as about 80% of all patients used zero to
two antihypertensive drugs. In diabetic kidney disease studies (i.e., studies with T2DM and either
albuminuria and/or eGFR <60), the antihypertensive drug use is mostly in line with our findings,
with >90% of patients using antihypertensive drugs, and RAASi being the most frequently used
drug [5,32]. In line with our findings, Smits et al. found that RAASi was the most commonly used
class of antihypertensive drugs in a Dutch T2DM cohort in primary care, followed by betablockers and
diuretics [33]. The number of used antihypertensive drugs they report is largely comparable to our
findings, albeit that the use of four to five drugs seems more common in our secondary care cohort.
It should be noted that in these studies regarding BP control in a real world setting, data regarding
nutrient intake is not available.
An important issue when evaluating the pharmacological management of blood pressure is
treatment non-adherence, which reportedly ranges from 31 to 40% in patients with poorly controlled
blood pressure [35,36]. Thus, establishing an infrastructure that allows the monitoring of adherence
would be of great value. Yet, even assuming a drug-treatment non-adherence rate of 40% in our
patients, the non-adherence to lifestyle measures seems to stand out as an additional important target
for intervention.
What can be done to improve BP control in T2DM? Our data, and data from other trials, clearly
show that true therapy-resistant hypertension, defined as hypertension persisting despite three
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in most patients with BP-NOT. The majority of BP-NOT patients (62%) do not use more than two
antihypertensive drugs, illustrating the opportunity for intensifying pharmacological treatment. One
promising option in this regard is the removal of excess extracellular fluid with diuretics, especially in
those patients with a high salt intake.
Our data show that, especially for nutritional management, there is a large window of opportunity
for improvement, as in the total population only one patient adhered to all of the nutritional guidelines
simultaneously. This is highly relevant, since lifestyle interventions have the potential to not only
reduce BP, but to also reduce the overall cardiovascular risk [11,37–40]. Even though dietary counselling
has already been part of their routine care, the mean daily salt intake in our population was almost
11 g/day, roughly twice that of the recommended 6 g/day, and considerably higher than the mean salt
intake in the general Dutch population of 8.5 g/day [41]. Previously, Mente et al demonstrated that for
each 1-gram increment in estimated sodium excretion, blood pressure was 2/1 mmHg higher, where
this slope was more pronounced and steeper in those with hypertension, high-sodium diets (>5g/day),
and older persons [42]. Therefore, the most obvious step to improve non-pharmacological management
would be to reduce dietary salt intake. This is underscored by a previous study, performed in T2DM
patients in the same region, which has shown that, although the aim to reduce dietary salt intake to
<6 g/day was not reached, even a relatively modest reduction in salt intake from 12 to 9 g/day can
reduce blood pressure by 6/3 mmHg and albuminuria by 42% while under RAASi [43]. Furthermore,
reducing salt intake is associated with potentiating the antihypertensive effects of RAASi [44–46].
There is evidence that a combined dietary approach aimed at reducing salt while increasing
potassium intake has the potential to improve cardiovascular risk management [12,47]. However, the
potassium intake in our patients was generally already above the recommended intake of 3.5 g/day.
Therefore, the finding that the sodium-to-potassium ratio was higher than the deemed optimal ratio of
1 mmol/mmol in 97% of patients is primarily determined by high salt intake.
To improve blood pressure control, dietary intervention could also be aimed at reducing body
weight. The mean BMI in our cohort was above 30 kg/m2. While a relationship between obesity and
blood pressure has previously been demonstrated [7,48], we did not find such an association here.
This might be due to the fact that we had few participants with a BMI < 25 kg/m2, and therefore
did not have a large enough dispersion to differentiate between the BP groups. Intentional weight
loss has been associated with beneficial effects, both on BP and on other cardiovascular risk factors
such as LDL cholesterol and glycemic control [49]. Therefore, even though weight loss is notoriously
difficult to achieve, especially in patients on insulin treatment, it should remain a priority in the
non-pharmacological treatment of T2DM, and also in secondary health care centres.
Finally, an association between the intake of magnesium and phosphate and blood pressure has
been reported previously [14,17,18,50,51]. Here, we did not find differences in urinary magnesium
excretion or in urinary phosphate excretion between those with BP-OT and BP-NOT. As the urinary
excretion of magnesium and phosphate is lower in those with a low eGFR, these results might be
misleading. However, the proportion of patients with a low eGFR was similar in both the BP-OT
and BP-NOT groups, making it less likely that differences in the urinary excretion of magnesium and
phosphate between the BP groups were masked by differences in urinary excretion due to a low eGFR.
In the general population, a continuous relationship between lower magnesium excretion and the risk
for hypertension was reported [16]; moreover, patients with a low magnesium intake had a greater
risk of developing ischemic heart disease [52]. While no nutritional recommendations are currently
available for magnesium to stratify adequate/inadequate intake, in our population approximately 28%
of patients had a magnesium excretion below the values associated with ischemic heart disease in the
general population. Regarding phosphate intake, population-based studies as well as studies in CKD
have shown associations with outcome, albeit not equivocal [53,54], and it has been proposed that
excess phosphate intake is a risk factor that is generally overlooked in patients with early stages of
CKD by lack of measurements [55]. While more research is needed on the relation between magnesium
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assess the intake of established nutritional targets such as salt and potassium, can simply be used
to establish a more complete nutritional profile, which could be useful for future improvements in
nutritional studies and counselling.
It should be noted that the adherence to nutritional guidelines was equally poor in the BP-OT
and BP-NOT groups. While in the BP-NOT group there is more urgency to adhere to these guidelines,
namely to correct BP, the adherence to the guidelines in the BP-OT group should not be overlooked.
In regard to salt intake, previously it has been shown that a higher salt intake while under RAASi is
associated with worse cardiovascular outcomes, even independent of BP [46]. Furthermore, as stated
above, intentional weight loss has many benefits that surpass BP management [49], and therefore can
also greatly improve outcomes if BP is already on target. Lastly, in a population-based cohort, low
potassium intake has been associated with the occurrence of chronic kidney disease [56].
The DIALECT study has several strengths, including the use of real-world data from a cohort
representative of secondary health care in T2DM, at least in the context of the Dutch referral health
care setting. Second, we study the integrated role of non-biased data on both pharmacological and
non-pharmacological parameters on BP, which is an important approach, as in cardiovascular risk
management pharmacological and non-pharmacological interventions go hand in hand. Third, through
the use of 24-hour urine collections, we provide objective measurements of dietary intake and several
relevant nutrients.
There are also some limitations. An observational study cannot prove causal relationships. Also,
there is some risk of response bias, although patient characteristics were similar between those who
did and did not participate.
What are the implications of our study? Adequate management equals the sum of measures taken
in combination with compliance. Our data on poor nutritional management do not distinguish between
a lack of adequate nutritional counselling and a lack of compliance. However, it is well established that
sustained lifestyle change is difficult to achieve, demonstrating that currently no modus of adequate
counselling and therefore adequate management exists. The question, therefore, is how to establish
this. Previous well-designed studies, using interventions of intensive nurse practitioner support and
self-management, both did not lead to neither long-standing changes in nutritional habits, nor a
reduction of cardiovascular outcomes [57,58]. As alternative approach, improvement strategies as
tested for pharmacological management could be considered. In particular, it has been shown that the
systematic evaluation of prescription quality as assessed by prescription quality indicators not only
improved pharmacological compliance with guidelines, but also patient outcomes [59]. To the best of
our knowledge, such approaches have never been developed and tested for nutritional management.
As several objective parameters are available, such as the urinary excretion of sodium and potassium,
this would be feasible in routine clinical care. Therefore, to improve blood pressure control, in our
opinion, the use of nutritional quality indicators may have the potential to improve treatment quality
as a whole.
5. Conclusions
Uncontrolled BP is common in T2DM, especially in those with microalbuminuria. An integrated
assessment of pharmacological and nutritional management demonstrated a window of opportunity
for improving BP treatment, especially in nutritional management. We advocate that incorporating the
integrated monitoring of pharmacological and nutritional management in quality control cycles has
the potential to improve treatment quality in T2DM.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/7/709/s1,
Table S1: Data collection in DIALECT.
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Abstract: Adipose tissue (AT) has a modulating role in obesity-induced metabolic complications like
type 2 diabetes mellitus (T2DM) via the production of so-called adipokines such as leptin, adiponectin,
and resistin. The adipokines are believed to influence other tissues and to affect insulin resistance,
liver function, and to increase the risk of T2DM. In this study, we examined the impact of intervention
with the short-chain fatty acid butyrate following a high-fat diet (HFD) on AT function and other
metabolic risk factors associated with obesity and T2DM in mice during mid- and late life. In both
mid- and late adulthood, butyrate reduced HFD-induced adipocyte hypertrophy and elevations in
leptin levels, which were associated with body weight, and cholesterol and triglyceride levels. HFD
feeding stimulated macrophage accumulation primarily in epididymal AT in both mid- and late life
adult mice, which correlated with liver inflammation in late adulthood. In late-adult mice, butyrate
diminished increased insulin levels, which were related to adipocyte size and macrophage content
in epididymal AT. These results suggest that dietary butyrate supplementation is able to counteract
HFD-induced detrimental changes in AT function and metabolic outcomes in late life. These changes
underlie the obesity-induced elevated risk of T2DM, and therefore it is suggested that butyrate has
potential to attenuate risk factors associated with obesity and T2DM.
Keywords: obesity; T2DM; high-fat diet; butyrate; adipose tissue; macrophages; adipokines
1. Introduction
In line with the rise of type 2 diabetes mellitus (T2DM) the global prevalence of obesity has
more than doubled since 1980 [1]. Moreover, obesity is a major risk factor for T2DM, accounting
for 80–85% of the overall risk [2]. Weight or fat loss has the strongest effect on reducing the risk of
developing T2DM [3]. It has been suggested that the relationship between obesity and T2DM exists
already at a young age [4–6]. In addition, obesity is suggested to exaggerate aging processes [7],
and aging is associated with impaired insulin signaling [8], which causes an increase in blood glucose
levels. Over time, high blood glucose concentrations combined with high blood pressure and high
cholesterol levels affect vascular function, and may evolve into cardiovascular disease, kidney failure,
and subsequent cognitive deficits [9,10].
Accumulating evidence suggests that adipose tissue dysfunction—with adipocyte hypertrophy
as a first manifestation—may play a role in the development of obesity-induced metabolic conditions
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that increase the risk for T2DM [11]. Adipocyte hypertrophy results in an elevated recruitment of
macrophages surrounding dead or dying adipocytes, which is referred to as crown-like structures
(CLS)—an important hallmark of adipose tissue dysfunction— [12]. Macrophages are believed to be
major sources of inflammatory cytokines with detrimental effects on insulin signaling in obesity [13].
In addition, adipocyte hypertrophy may lead to the altered production and secretion of adipokines like
leptin, resistin, serum amyloid A (SAA), and adiponectin [14–16]. These adipokines play important
roles in insulin signaling and the development of a chronic low-grade inflammatory state, which is
characteristic for obesity. Overall, amelioration of these obesity-induced and adipose tissue-related
changes may provide an important approach to attenuate the risk of developing T2DM.
There is a growing interest in short-chain fatty acids—such as butyrate—as dietary intervention
for obesity and related metabolic diseases [17,18]. Butyrate is one of the fatty acids produced during
bacterial fermentation in the distal gut of nondigestible carbohydrates like dietary fiber and resistant
starch. Both intake of butyrate and dietary fibers have shown positive effects on body weight and
insulin sensitivity [17,19–22]. In addition, butyrate has anti-inflammatory properties and affects
lipogenesis [17]. A decreased concentration of butyrate-producing bacteria has been observed both
in patients with obesity [23] and T2DM [24]. Butyrate may therefore play an essential role in the
maintenance of an optimal metabolic state.
It is acknowledged that obesity may differentially affect various organs and tissues, like the
brain and cardiovascular system, during midlife as opposed to late life [18,25–27]. Recently, we
demonstrated that butyrate is able to restore high-fat diet (HFD)-induced neuroinflammation and
changes in brain function in low-density-lipoprotein receptor knockout (LDLr-/-).Leiden mice in
mid-adulthood [18]. In addition, mid-adult mice seem to be more susceptible to the development of
HFD-induced cardiovascular damage as compared to late-adult mice [18]. However, it has not been
elucidated whether diet-induced obesity affects adipose tissue function and its metabolic outcomes
differentially during mid- and late adulthood. As follow-up of the previous published study [18],
we investigated in the current study the effects of a therapeutic butyrate intervention on adipose tissue
function and adipokine levels in the context of manifested HFD-induced obesity in both mid- and
late-adult LDLr-/-.Leiden mice.
2. Materials and Methods
2.1. Animals and Diets
The adipose tissues and plasma samples analyzed in this experiment originate from a previously
described study [18]. LDLr-/-.Leiden mice were selected because of their high sensitivity to developing
HFD-induced obesity and subsequent complications like vascular damage and fatty liver [28–30].
Briefly, male LDLr-/-.Leiden mice (TNO Metabolic Health Research, Leiden, The Netherlands) were
housed in individually ventilated cages in a conventional animal room situated in the preclinical
imaging center (PRIME) at the central animal laboratory, Radboudumc Nijmegen, the Netherlands.
A maximum of five mice were housed per cage with ad libitum access to acidified tap water and
food (temperature 21 ◦C; relative humidity 50–60%; light-dark cycle 7 a.m.–7 p.m.). The experiments
were approved by an independent ethical committee on animal care and experimentation (Zeist,
The Netherlands), approval project number DEC3682 [18] and carried out in accordance to the
ARRIVE guidelines [31].
The intervention regimen of the study [18] is schematically presented in Figure 1. A total group of
n = 60 LDLr-/-.Leiden mice were divided into a mid- and late-adult cohort (n = 30 each). Both cohorts
consisted of three diet groups. For the cohort representing mid-adulthood, the first group received a
chow diet from birth until the end of the study (Chow). The second group switched to a HFD at three
months of age (HFD). The third group switched to a HFD when three months old (m.o.) as well, but
this HFD was subsequently enriched with 5% w/w butyrate from seven months of age until the end of
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manner, but mice were switched to HFD at six months of age and butyrate intervention started at 10
months of age (Figure 1b).
Figure 1. Schematic overview of the study design. (a) Mid-adulthood, exposure of the high-fat died
HFD started at 3 m.o. in the HFD and HFDB groups. At 7 months of age, the butyrate intervention
(HFD supplemented with 5% w/w butyrate) started in the HFDB group; (b) Late adulthood, exposure
to the HFD started at 6 months of age in the HFD and HFDB groups, and a butyrate intervention
initiated at 10 months of age in the HFDB group. Body weight (individual) and food intake (cage
level) were monitored weekly. Blood samples were taken after five hours of fasting. At 9 m.o. and 12
m.o., mice were sacrificed and both liver and adipose tissues were harvested. These tissues were
subsequently processed for immunohistochemical staining. B = blood sample collection; HFD =
high-fat diet; HFDB = high fat diet enriched with butyrate; m.o. = months old.
2.2. Plasma Analyses
Blood was collected after five hours of fasting (8 a.m. to 1 p.m.). Plasma cholesterol, triglyceride
and insulin levels were measured using standardized ELISA kits as previously described [18].
Moreover, ELISA kits (Quantikine, R&D systems, Inc., Minneapolis, MN, USA) were used to
define plasma leptin (DY498), adiponectin (DY1119), resistin (DY1069) and interleukin-6 (IL-6;
M6000B) levels. SAA plasma levels were determined by an ELISA kit as well (KMA0021, Invitrogen,
Carlsbad, CA, USA).
2.3. (Immuno)histochemistry
Mice were sacrificed by transcardial perfusion with 0.1 M phosphate buffered saline (PBS) after
being anesthetized with isoflurane (3.5%, Nicholas Primal (I) limited, London, UK), as described in
Arnoldussen et al. [18]. Directly thereafter, the liver and two different adipose tissue depots were
harvested and post-fixed in 4% paraformaldehyde for 24 h. Fat depots seem to be differentially active
and affected by a HFD and, therefore, we dissected in addition subcutaneous (inguinal) and visceral
(epididymal) adipose tissue depots [32,33]. Liver outcomes used for correlation analyses were obtained
from a previous experiment [18].
Both epididymal and inguinal adipose tissues were processed for immunohistochemistry on
5 μm paraffin embedded sections. Briefly, paraffin sections were first deparaffinized in xylene and
rehydrated in a series of ethanol followed by endogenous peroxidase blocking with 0.3% H2O2 in
0.1 M PBS. Antigen retrieval was achieved by treating the tissue in hot 0.05 M sodiumcitrate with a
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(PBS-B), the tissue was incubated overnight at room temperature with primary macrophage (MAC-3)
antibodies (1:100; eBioscience, 14-1072) [34]. Next, sections were incubated with secondary donkey
anti-rat IgG antibodies (1:200; Jackson ImmunoResearch) in 0.1 M PBS-B at room temperature. Staining
was visualized using the ABC method with a Vectastain kit (Vector Laboratories, Burlingame, CA,
USA) and diaminobenzidine imidazole solution as chromogen. Finally, sections were dehydrated in a
series of ethanol, cleared in xylene, and mounted.
Two entire sections per animal were visualized using a VisionTek live digital microscope (Sakura
Finetek, Torrance, CA, USA) at a 10× magnification. Sampling of these sections was carried out with
Adobe Illustrator CC 2016 (Adobe, San Jose, CA, USA) using a template with three randomly placed
artboards (592.7 × 886.2 mm). Adipocyte cell size (μm2) and the number of CLS were determined in a
total of six samples—three samples per section—per animal. Analyses to determine these measures
were performed using CellProfiler [35] version 2.3.0 together with Ilastik version 0.5 [36] for pixel
classification. Separate pipelines and classifiers for epididymal and inguinal adipose tissue analyses
were used. In order to verify the reliability of these relatively novel analyses, we included an established
analysis to determine adipocyte size using ImageJ software as previously described [37]. CLS were
determined based on intensity of the cell edge, and total numbers of CLS per animal were calculated
per 1000 adipocytes.
2.4. Statistical Analyses
A random and blinded selection procedure was maintained throughout the study. Group means
were compared using univariate analysis of variance (ANOVA) with Bonferroni correction for multiple
testing with a statistical program, SPSS 24 (IBM SPSS Statistics 24, IBM Corporation, Armonk, NY,
USA). Parameter correlation tests were performed using Pearson correlations. Nonparametric tests
were used when assumptions of normality and homogeneity of variance were not met. p-values lower
than 0.05 were considered significant. Data are presented as mean ± SEM.
3. Results
3.1. Adipocyte Size
Adipocyte size—measured as area (μm2)—of both epididymal and inguinal adipose tissue depots
were determined to assess morphological adaptations. A HFD increased the average epididymal
adipocyte size in both mid- and late-adult mice (mid: p < 0.001; F(1,18) = 26.05, late: p < 0.02;
F(1,19) = 7.01) (Figure 2a). Butyrate intervention significantly reduced adipocyte size in both age
cohorts (mid: p = 0.001; F(1,18) = 14.95, late: p < 0.02; F(1,18) = 7.14).
Similarly, inguinal adipocyte size was increased by HFD in both mid- and late adulthood
(p = 0.001; mid: F(1,18) = 20.49, late: F(1,19) = 14.25) (Figure 2b). After HFD exposure, inguinal
adipocyte size was reduced due to butyrate intervention in mid-adult mice (p < 0.001; F(1,18) = 25.69),
but not in late-adult mice. Mean inguinal adipocyte size was significantly larger in late adult as
compared to mid-adult high fat diet enriched with butyrate (HFDB) mice (p < 0.01; F(1,18) = 11.28).
In addition, we compared the number of adipocytes as an additional indication of adipose tissue
function. Our analysis indicated that the epididymal adipose tissue contained a lower number of
adipocytes than inguinal adipose tissue. The mean adipocyte number in epididymal adipose tissue
was higher in mid-adult Chow mice as compared to HFD mice (Table 1). Butyrate intervention
increased epididymal adipocyte number solely in mid-adulthood. In both age cohorts, inguinal
adipocyte numbers were significantly higher in Chow mice as opposed to HFD mice (Table 1). Only in












Figure 2. Adipose tissue cell sizes and macrophage infiltration. Mean adipocyte sizes in epididymal
(a) and inguinal (b) adipose tissue depots in both mid- (9 m.o.) and late- (12 m.o.) adult mice.
(c,d) Mean number of crown-like structures (CLS) in epididymal (c) and inguinal (d) adipose tissue.
(e) Representative photomicrographs of epididymal adipose tissue stained with antibodies against
macrophages (MAC-3) in late-adult mice. In addition, a magnification (40×) of a CLS is represented.
These examples are comparable to those observed in mid-adulthood. Data are presented as mean ±
standard error of mean (SEM). * p < 0.05; ** p < 0.01; *** p ≤ 0.001.
In mid- and late adulthood, both epididymal and inguinal adipocyte size were positively
associated with body weight, and cholesterol and triglyceride plasma levels (Tables 2 and 3). In
addition, only inguinal adipocyte size was positively correlated with inguinal adipose tissue weight
(mid: p < 0.01; R = 0.55, late: p < 0.001; R = 0.64). Solely in late adulthood, epididymal adipocyte size
correlated positively with plasma insulin levels (p < 0.01; Table 3).
Moreover, body weight, cholesterol and triglyceride levels revealed significant and positive inter
correlations (Tables 2 and 3). Finally, insulin levels correlated positively with these outcomes in
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Table 1. Adipocyte numbers. Represented are the combined mean numbers of two slides.
Adipocyte Numbers Per 106 μm2 (Mean ± SEM)
Epididymal
Chow vs. HFD
mid 468 ± 34 vs. 376 ± 31 0.05 < p < 0.08 F(1,18) = 3.95
late 452 ± 40 vs. 410 ± 21 p = 0.02 F(1,18) = 6.54
HFD vs. HFDB
mid 376 ± 31 vs. 496 ± 35 ns
late 410 ± 21 vs. 481 ± 47 ns
Inguinal
Chow vs. HFD
mid 665 ± 59 vs. 449 ± 16 p < 0.01 F(1,18) = 12.61
late 659 ± 44 vs. 474 ± 41 p < 0.01 F(1,19) = 9.54
HFD vs. HFDB
mid 449 ± 16 vs. 522 ± 15 p < 0.01 F(1,18) = 11.27
late 474 ± 41 vs. 446 ± 18 ns
ns = not significant.
Table 2. Correlation coefficients among mid-adult mice.
BW Chol Trigl eAS iAS eCLS iCLS Leptin SAA
BW x
Chol 0.80 R + x
Trigl 0.58 R + 0.69 R + x
eAS 0.53 R + 0.64 R + 0.57 R + x
iAS 0.55 R + 0.57 R + 0.37 R + NE x
eCLS 0.53 τb + 0.49 τb + 0.15 τb + 0.24 τb + NE x
iCLS 0.31 τb + 0.29 τb + 0.10 τb + NE 0.37 τb + NE x
Leptin 0.78 R + 0.87 R + 0.62 R + 0.76 R + 0.67 R + 0.52 τb + 0.37 τb + x
SAA 0.56 τb + 0.50 τb + 0.13 τb + 0.17 τb + 0.24 τb + 0.69 τb + 0.28 τb + NE x
Either the Pearson’s (R) or Kendall’s tau (τb) test was used. Not significant. + = positive correlation; Adi =
adiponectin; BW = body weight; Chol = cholesterol; eAS = epididymal adipocyte size; eCLS = epididymal CLS; iAS
= inguinal adipocyte size; iCLS = inguinal CLS; LI = liver inflammation; NE = not estimated; SAA = serum amyloid
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3.2. Inflammation in Adipose Tissue and Liver
To assess the degree of inflammation in adipose tissue, the number of adipocytes infiltrated by
macrophages—known as crown-like structures (CLS)—has been determined. Both mid- and late-adult
mice on HFD showed higher numbers of CLS in epididymal adipose tissue as opposed to Chow-fed
mice (Kruskal Wallis: p < 0.001; mid: χ2(1) = 13.50, late: χ2(1) = 13.02) (Figure 2c). No effects of butyrate
on CLS number in epididymal adipose tissue were observed. In inguinal adipose tissue, the number
of CLS was increased after HFD exposure in both mid- (Kruskal-Wallis: p < 0.01; χ2(1) = 7.30) and
late- (Kruskal-Wallis: p < 0.02; χ2(1) = 6.16) adult mice (Figure 2d). No significant differences in the
number of CLS in inguinal adipose tissue were observed between HFD and HFDB mice (Figure 2d).
As scales differ between Figure 2c,d, caution should be taken when interpreting these results. In
Figure 2e, examples of epididymal adipose tissue stained for macrophages are shown.
In late adulthood, the number of CLS in epididymal adipose tissue correlated significantly with
body weight (p = 0.001), and plasma triglyceride (p < 0.02), cholesterol (p < 0.001) and insulin (p < 0.05)
levels (Table 3). In mid-adulthood, epididymal adipose tissue CLS content showed only significant
correlations with body weight (p < 0.001) and plasma cholesterol levels (p < 0.001) (Table 2).
In addition to CLS in adipose tissue, data including inflammatory aggregates were used [18] to
examine potential relationships to inflammation in the liver, which is another crucial organ regulating
insulin sensitivity. Liver inflammation was increased after HFD exposure only in late-adult mice [18].
No significant changes were observed after butyrate intervention. In this age cohort, the number of
inflammatory aggregates in the liver was positively correlated with the number of CLS in epididymal
adipose tissue (p < 0.001) (Table 3).
3.3. Adipokine Plasma Levels
Adipokine plasma levels were determined at either nine or 12 months of age. HFD exposure
strongly increased leptin plasma levels in both age cohorts (p < 0.001; mid: F(1,18) = 50.10, late:
F(1,19) = 44.87) (Figure 3a). Late-adult HFD-fed mice showed higher leptin levels as compared to
mid-adult mice fed a HFD (p < 0.02; F(1,19) = 7.71). Subsequent butyrate intervention resulted in
reduced plasma leptin levels, almost reaching control levels in Chow mice (p < 0.001; mid: F(1,18)
= 26.49, late: F(1,18) = 32.88). HFD did not affect plasma resistin levels (Figure 3b). Adiponectin
plasma levels were reduced after HFD exposure in late-adult mice (p < 0.001; F(1,19) = 17.57) and were
moderately increased after butyrate intervention (p = 0.053; F(1,18) = 4.29) (Figure 3c). An age effect
was observed in both Chow and HFD animals (p < 0.05; F(1,18) = 4.60 and F(1,19) = 4.55, respectively).
Serum amyloid A (SAA) plasma levels were increased in mice fed a HFD when compared to Chow-fed
mice in both age cohorts (Kruskal-Wallis: p ≤ 0.001; mid: χ2(1) = 10.14, late: χ2(1) = 14.46) (Figure 3d).
Plasma levels of interleukin-6 (IL-6) were below detectable levels in all animals in the absence of
abnormal positive and negative controls.
In both mid- and late adulthood, plasma leptin levels were positively correlated with body weight
(p < 0.001), both epididymal and inguinal adipocyte size (p < 0.001), and epididymal CLS content
(p < 0.001) (Tables 2 and 3). Solely in late-adult mice, plasma leptin levels positively correlated with
insulin levels (p < 0.001) and liver inflammation (p = 0.001) (Table 3). Only in late adulthood plasma
adiponectin levels showed a negative correlation with body weight (p < 0.01), insulin plasma levels (p
< 0.02), and liver inflammation (p < 0.05) (Table 3).
Plasma SAA levels were positively correlated with body weight (mid: p < 0.001, late: p < 0.01) and
the number of CLS in epididymal adipose tissue (p < 0.001) in both mid- and late adulthood (Tables 2
and 3). Whereas, SAA plasma levels were positively correlated with insulin levels (p < 0.05), inguinal
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Figure 3. Adipokine plasma levels. Mean plasma levels of leptin (a), resistin (b), adiponectin (c),
and serum amyloid A (SAA) (d) are represented in both mid- (9 m.o.) and late- (12 m.o.) adult mice as
mean ± SEM. *** p ≤ 0.001; # p = 0.053.
4. Discussion
This study describes the detrimental effects of a six-month HFD exposure in mid-adult and
late-adult mice, and examined potential health effects of butyrate administered during the last two
months of HFD feeding. In this study, HFD exposure caused adipocyte hypertrophy and inflammation,
as well as an increase in the plasma levels of proinflammatory adipokines (leptin, SAA) in mid- and
late life. Butyrate attenuated HFD-evoked effects, though the effects of butyrate varied in mice that
were exposed to HFD in mid-life as compared to late life.
In our study, HFD treatment increased body weight and adiposity, and subsequent butyrate
intervention diminished these changes in the LDLr-/-.Leiden mice [18]. Moreover, these changes were
observed without significant differences in calorie intake, suggesting that energy intake was similar
between the dietary interventions. Other rodent research has shown that a HFD increases body weight
and adiposity [38–40], and similar effects of butyrate have been reported in obese mice [38,41]. The
LDLr-/-.Leiden mouse model was chosen for this study because of its high sensitivity to develop
vascular complications and obesity when fed a HFD even with modest fat content. We found that 12
m.o. LDLr-/-.Leiden mice on standard Chow show a disposition towards pronounced weight gain and
are approximately 32% heavier than Chow-fed male C57BL/6 mice of the same age [42], supporting
the obesity-prone condition of the model chosen. It is unclear why these mice are susceptible to obesity
development, and comparative molecular analysis to C57BL/6 mice have not been made. In our
experimental design, a control group of wild-type mice was not included due to restrictions in mice per
experiment and time. Therefore, a generalization of the results cannot be made, the more so because
the interaction between the LDLr-/- genotype and HFD are still not fully understood. A detailed
comparison with wild-type mice and other obesity models would be required to elucidate the role of
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In a previous study, insulin levels were significantly increased in late-adult mice after HFD
feeding, whereas no changes in glucose levels were observed [18]. Plasma insulin levels are extremely
high due to the experimental conditions employed in this disease model (>20 ng/mL) and much
higher than in wild-type mice fed the same diet (<5 ng/mL) [18,30], indicating insulin resistance
but no overt T2DM because glucose levels are not elevated and seem to be controlled. Interestingly,
butyrate supplementation restored insulin levels to values found in Chow-fed mice, suggesting an
improvement in insulin signaling [18]. Previous research described similar effects of butyrate on insulin
levels and sensitivity in HFD-fed mice [38,43]. It is not clear whether this effect of butyrate is mediated
by improvement of insulin signaling in liver, in peripheral organs, or both. It is possible that both
organs are involved, given the time frame in which insulin resistance develops under the conditions
employed. For instance, a time resolved clamp study using C57BL/6 mice that were treated with the
same HFD as used in the current study showed that the adipose tissue develops insulin resistance
after about six to 12 weeks of HFD feeding [44]. Second, the development of insulin resistance in the
liver requires longer periods of HFD feeding (about 24 weeks), i.e., a period that is comparable to the
duration of HFD exposure herein [44].
Even in the absence of obesity, metabolic dysfunction in adipose tissue induced by adipocyte
hypertrophy has consistently been related to insulin resistance and may serve as a predictor for
T2DM [45,46]. We observed increased adipocyte size in both epididymal and inguinal adipose tissue
depots after HFD feeding. Adipocyte hypertrophy was reduced by butyrate with the exception of
inguinal adipose tissue in late-adult mice. Epididymal adipocyte sizes were associated with insulin
levels in late adulthood suggesting that epididymal, as opposed to inguinal, adipose tissue may be
important in mediating the effects on insulin. Previous studies have demonstrated the significant
role of visceral fat in mediating insulin sensitivity in rats [47,48], which may be attributed to the
higher degree of metabolic activity of visceral fat as opposed to subcutaneous fat [16,49,50]. The
beneficial effects of butyrate on adipocyte size in epididymal adipose tissue have been demonstrated
before [51]. Although our knowledge about the exact mechanisms is incomplete, it is likely that
butyrate may reverse adipocyte hypertrophy by promoting fatty acid oxidation in adipose tissue [38].
In particular, butyrate may induce a shift from lipid synthesis to utilization resulting in decreased
fat storage in white adipose tissue [43]. Our data confirm this hypothesis as adipocyte sizes were
significantly associated with both cholesterol and triglyceride levels. Dyslipidemia is a regularly
observed condition in T2DM patients [52]. HFD-induced elevations in cholesterol and triglycerides
were diminished by butyrate in LDLr-/-.Leiden mice [18], suggesting a mitigation of hyperlipidemia
that is not related to enhanced clearance, suggesting effects on very-low-density lipoprotein (VLDL)
production. For instance, butyrate may affect hyperlipidemia as it can induce a switch from lipid
synthesis to utilization [53]. Unfortunately, our study is limited with respect to functional analyses such
as glucose transport, insulin signaling, lipogenesis, and adipogenesis in adipose tissue. Therefore, it
would be valuable to investigate these aspects in future studies. The effects of butyrate supplementation
on key regulators of adipogenesis in mid-adult versus late-adult mice may provide insight into the
pathways by which butyrate may modulate adiposity. It has been shown that butyrate may reduce
body weight and improve insulin sensitivity via the modulation of peroxisome proliferator-activated
receptor-γ (PPAR-γ) [43], which is a key regulator of adipogenesis [54]. Consistent with this, we
recently showed that specific activation of PPAR-γ in adipose tissue attenuates CLS development and,
related to this, the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis [55].
Anti-inflammatory effects in adipose tissue may attenuate the release of inflammatory mediators and
may also affect the development of diseases in other organs such as the liver [56,57]. A notion which is
further supported by the coordinated and interactive expression of inflammatory genes in adipose
tissue and liver during metabolic overload [58].
It is well established that a correlative and causative relation exists between chronic inflammation
and both insulin resistance and T2DM in humans and rodents [13,59]. More specifically, a reduction of
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by reducing the expression of inflammatory cytokines in adipose tissue [11]. As shown in the present
study, HFD feeding results in increased macrophage infiltration mainly in epididymal adipose tissue
associated with body weight and insulin levels. Epididymal adipose tissue was characterized by an
abundance of CLS, whereas CLS were almost absent in inguinal adipose tissue, which is consistent
with previous studies investigating adipose tissue inflammation of various adipose tissue depots in
the context of their expandability and maximal storage capacity [30,57]. It is possible that visceral
fat may excrete higher amounts of inflammatory proteins and fatty acids affecting insulin signaling,
and that macrophages play an important role in this [56,60]. CLS formation in epididymal adipose
tissue was not affected by butyrate supplementation in mid-adult mice, whereas a mean reduction of
almost 33% was observed in late-adult mice. Consistent with the inflammatory cross-talk between
epidydimal adipose tissue and liver, medial lobular inflammation was not affected in mid-adult mice,
whereas the number of inflammatory aggregates in the liver was reduced by 44% after dietary butyrate
intervention in late-adult mice [18]. Furthermore, liver inflammation in late-adult mice, indicated
by inflammatory aggregates in the medial lobe [18], correlated significantly with the number of CLS
in epididymal adipose tissue in this study. It is not known via which pathways butyrate can affect
inflammation, and future studies may examine the expression of inflammatory mediators at tissue
level, in both adipose tissue and the liver. In addition, mechanistic studies examining the expression of
transcription factors, such as nuclear factor κB, support the notion that the activation of inflammatory
processes in adipose tissue and liver are necessary.
Both the increase in pro-inflammatory and the reduction in anti-inflammatory adipokine secretion
by adipose tissue can contribute to systemic and tissue-specific inflammation. In this study, HFD
exposure results in increased levels of leptin and serum amyloid A (SAA). These findings are
accompanied by a reduction in adiponectin in late adulthood, whereas it remains unclear why
adiponectin was not affected by HFD or butyrate treatment in mid-adult mice. An exaggerated
metabolic load in adipocytes and inflammatory state may underlie the effects of a HFD on leptin,
adiponectin, and SAA levels [16]. Both leptin and SAA are suggested to be pro-inflammatory
adipokines, whereas adiponectin has anti-inflammatory properties [61]. Leptin contributes to the
inflammatory state in obesity by modulating TNF-α and activating macrophages [62], and butyrate
reduced leptin levels in mid-adult and late-adult mice. Leptin can also affect insulin sensitivity by
modulating pancreatic β-cells [60]. It thereby contributes to the observed reduction in plasma insulin
by butyrate in late-adult mice the more, because butyrate reduced leptin levels nearly to those of
Chow-fed mice. Our finding that leptin levels were significantly related to insulin levels in late-adult
mice further supports this notion. Although current evidence for the role of SAA in insulin signaling is
contradictory [63–65], SAA levels have been correlated with insulin resistance and T2DM [66], which
may be related to the pro-inflammatory properties of SAA [14]. Interestingly, adiponectin plasma
levels were only affected by HFD feeding in late-adult mice. It is possible that the circulating SAA is
mainly released from adipose tissue and that butyrate reduced CLS only in adipose tissue of late-adult
mice. Low adiponectin levels may add to an impaired insulin signaling via polarization towards
M1 macrophages in adipose tissue [67]. Butyrate intervention reduced changes in both leptin and
adiponectin levels, which may in part be attributed to its effect on adipocyte size and its differential
effects on CLS, i.e., adipose tissue inflammation, in mid-and late-adult mice.
5. Conclusions
This study provides evidence that dietary supplementation with butyrate constitutes a strategy
to counteract features of HFD-induced adipose tissue dysfunction and accompanying metabolic
disturbances. These metabolic adaptations often affect insulin signaling and may therefore indicate
an increased risk of developing T2DM. Late-adult mice are particularly sensitive to HFD-evoked
metabolic risk factors and adaptations. The findings of the current study provide novel insights about
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interventions with butyrate may constitute means to ameliorate the risk of developing metabolic
disorders such as T2DM in people with obesity.
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